Pharmaceutical Schedule - effective 1 August 2012 (text extract)

This is the text extract for Pharmaceutical Schedule - effective 1 August 2012 , browse documents here.

Pharmaceutical Management Agency

August 2012

New Zealand Pharmaceutical Schedule

Only

annually for hard copy Schedule and Updates

$55

www. schedule. co.nz

today

to receive electronic and/or hard copy

August 2012

Volume 19 Number 2

Editors: Kaye Wilson, Rebecca Bloor & Donna Jennings email: schedule@pharmac.govt.nz Telephone +64 4 460 4990 Facsimile +64 4 460 4995 Level 9, 40 Mercer Street PO Box 10 254 Wellington Freephone Information Line 0800 66 00 50 (9am – 5pm weekdays) Circulation Published each April, August and December. Changes to the contents are published in monthly updates. Accessible in an electronic format at no cost from the Health Professionals section of the PHARMAC website www.pharmac.govt.nz You can register to have an electronic version of the Pharmaceutical Schedule (link to PDF copy) emailed to your nominated email address each month. Alternatively there is a nominal charge for an annual subscription to the printed Schedule publications. To access either of these subscriptions visit our subscription website www.schedule.co.nz. Production Typeset automatically from XML and TEX. XML version of the Schedule available from www.pharmac.govt.nz/schedule/pub/archive/ Programmers Anrik Drenth & John Geering email: texschedule@pharmac.govt.nz c Pharmaceutical Management Agency ISSN 1179-3686 pdf ISSN 1172-9376 print This work is licensed under the Creative Commons Attribution 3.0 New Zealand licence. In essence, you are free to copy, distribute and adapt it, as long as you attribute the work to PHARMAC and abide by the other licence terms. To view a copy of this licence, visit: creativecommons.org/licenses/by/3.0/nz/. Attribution to PHARMAC should be in written form and not by reproduction of the PHARMAC logo. While care has been taken in compiling this Schedule, PHARMAC takes no responsibility for any errors or omissions, and shall not be liable for any consequences arising there from.

Introducing PHARMAC

Section A Section B

General Rules 13 Alimentary Tract & Metabolism 26

Blood & Blood Forming Organs 40 Cardiovascular System 48 Dermatologicals 58 Genito Urinary System 70 Hormone Preparations – Systemic 76 Infections – Agents For Systemic Use 83 Musculoskeletal System 102 Nervous System 119 Oncology Agents & Immunosuppressants 147 Respiratory System & Allergies 168 Sensory Organs 176 Various 180

Section C Extemporaneous Compounds (ECPs) 181 Section D Section E

Special Foods 188 Practitioner’s Supply Orders 209 Rural Areas 213

Section F Section G

Dispensing Period Exemptions 214 Safety Cap Medicines 216 Index 219

Introducing PHARMAC

PHARMAC, the Pharmaceutical Management Agency, is a Crown entity established pursuant to the New Zealand Public Health and Disability Act 2000 (The Act). The primary objective of PHARMAC is to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided. The PHARMAC Board consists of up to ﬁve members appointed by the Minister of Health. All decisions relating to PHARMAC’s operation are made by or under the authority of the Board. In particular, Board members decide on the strategic direction of PHARMAC and may decide which community pharmaceuticals should be subsidised and at what levels, and determine national prices for some pharmaceuticals to be purchased by and used in DHB Hospitals, and whether or not special conditions are to be applied to such purchases. Members of the PHARMAC Board Stuart McLauchlan Kura Denness David Kerr Anne Kolbe Jens Mueller Decisions taken by the PHARMAC Board members, or made under the authority of the Board, incorporate a balanced view of the needs of prescribers and patients. The aim is to achieve long-term gains and efﬁcient ways of making pharmaceuticals available to the community and for DHB Hospitals to purchase them. The following attend PHARMAC’s Board meetings as observers G Murray Georgel, CE MidCentral DHB G Kate Russell, Chair Consumer Advisory Committee G Carl Burgess, Chair Pharmacology and Therapeutics Advisory Committee (PTAC) The functions of PHARMAC are to perform the following, within the amount of funding provided to it in the Pharmaceutical Budget or to DHBs from their own budgets for the use of pharmaceuticals in their hospitals, as applicable, and in accordance with its annual plan and any directions given by the Minister (Section 103 of the Crown Entities Act): a) to maintain and manage a pharmaceutical schedule that applies consistently throughout New Zealand, including determining eligibility and criteria for the provision of subsidies; b) to manage incidental matters arising out of (a), including in exceptional circumstances providing for subsidies for the supply of pharmaceuticals not on the pharmaceutical schedule; c) to engage as it sees ﬁt, but within its operational budget, in research to meet its objectives as set out in Section 47(a) of the Act; d) to promote the responsible use of pharmaceuticals; e) to manage the purchasing of any or all pharmaceuticals, whether used either in a hospital or outside it, on behalf of DHBs; f) any other functions given to PHARMAC by or under any enactment or authorised by the Minister. The policies and criteria set out in the Pharmaceutical Schedule and PHARMAC’s Operating Policies and Procedures arise out of, and are designed to help PHARMAC achieve and perform, PHARMAC’s objective and functions under the Act. However PHARMAC may, having regard to its public law obligations, depart from the strict application of those policies and criteria in certain exceptional cases where it considers this necessary or appropriate in the proper exercise of its statutory discretion and to give effect to its objective and functions, particularly with respect to: G Determining eligibility and criteria for the provision of subsidies; and G In exceptional circumstances providing for subsidies for the supply of pharmaceuticals not on the Pharmaceutical Schedule. Decision Criteria PHARMAC updates the Pharmaceutical Schedule at regular intervals to notify prescribers, pharmacists, hospital managers and patients of changes to Community Pharmaceutical subsidies and the prices for Hospital Pharmaceuticals. In making decisions about amendments to the Pharmaceutical Schedule, PHARMAC is guided by its Operating Policies and Procedures, as amended or supplemented from time to time. PHARMAC takes into account the following criteria when making decisions about Community Pharmaceuticals: G the health needs of all eligible people within New Zealand (eligible deﬁned by the Government’s then current rules of eligibility); G the particular health needs of M¯ ori and Paciﬁc peoples; a G the availability and suitability of existing medicines, therapeutic medical devices and related products and related things; G the clinical beneﬁts and risks of pharmaceuticals; G the cost-effectiveness of meeting health needs by funding pharmaceuticals rather than using other publicly funded health and disability support services; G the budgetary impact (in terms of the pharmaceutical budget and the Government’s overall health budget) of any changes to the Pharmaceutical Schedule; G the direct cost to health service users;

the Government’s priorities for health funding, as set out in any objectives notiﬁed by the Crown to PHARMAC, or in PHARMAC’s Funding Agreement, or elsewhere; and G such other criteria as PHARMAC thinks ﬁt. PHARMAC will carry out appropriate consultation when it intends to take any such “other criteria” into account. The Operating Policies and Procedures, including any supplements, also describe the way in which PHARMAC determines the level of subsidy or purchase price payable for each Community Pharmaceutical or Hospital Pharmaceutical, respectively. The decision criteria for Hospital Pharmaceuticals are set out in the hospital supplement to the Operating Policies and Procedures and in the introductory part of Section H of the Pharmaceutical Schedule. Copies of PHARMAC’s Operating Policies and Procedures and of any applicable supplements are available on the PHARMAC website (www.pharmac.govt.nz), or on request.

PHARMAC and the Pharmaceutical Schedule:

PHARMAC manages the national Pharmaceutical Schedule, which lists: G Pharmaceuticals available in the community and subsidised by the Government with funding from the Pharmaceutical Budget; and G some Pharmaceuticals purchased by DHBs for use in their hospitals, and includes those Hospital Pharmaceuticals for which national prices have been negotiated by PHARMAC. In the community approximately 1848 Pharmaceuticals are subsidised by the Government. Most are available to all eligible people within New Zealand on prescription by a medical doctor. Some are listed with guidelines or conditions such as ‘only if prescribed for a dialysis patient’ or ‘Special Authority - Retail Pharmacy’, to ensure that Pharmaceuticals are used by those people who are most likely to beneﬁt from them. Pharmaceuticals provided to patients for use while in DHB hospitals are not covered by Sections A to G of the Pharmaceutical Schedule. Section H of the Pharmaceutical Schedule is not a comprehensive list of Pharmaceuticals that are used within the DHB Hospitals. Section H of the Pharmaceutical Schedule includes Pharmaceuticals that can be purchased at a national price by DHBs for use in their hospitals. These are referred to as National Contract Pharmaceuticals. A list of Discretionary Community Supply Pharmaceuticals, in Section H of the Pharmaceutical Schedule, identiﬁes those products that currently are not subsidised from the Pharmaceutical Budget as Community Pharmaceuticals in Sections A to G of the Pharmaceutical Schedule but which DHBs can at their discretion fund for use in the community from their own budgets Hospital Pharmaceuticals in the Community approval.

PHARMAC’s clinical advisors Pharmacology and Therapeutics Advisory Committee (PTAC) PHARMAC works closely with the Pharmacology and Therapeutics Advisory Committee (PTAC), an expert medical committee which provides independent advice to PHARMAC on health needs and the clinical beneﬁts of particular pharmaceuticals for use in the community and/or in DHB Hospitals. The committee members are all senior, practising clinicians. The chair of PTAC sits with the PHARMAC Board in an advisory capacity. PTAC helps decide which community pharmaceuticals are to be subsidised from public monies by making recommendations to PHARMAC. Part of the role of PTAC is to review whether Community Pharmaceuticals already listed on the Schedule should continue to receive Government funds. The resources freed up can be used to subsidise other community pharmaceuticals with a greater therapeutic worth. PHARMAC may obtain clinical advice from PTAC in relation to national purchasing strategies for Hospital Pharmaceuticals. There may be additional specialist hospital representatives on PTAC subcommittees, or additional PTAC subcommittees, where PHARMAC considers this necessary. PTAC members are: Carl Burgess Howard Wilson Chris Cameron Melissa Copland Stuart Dalziel Ian Hosford Sisira Jayathissa George Laking Dee Mangin Graham Mills Mark Weatherall MBChB, MD, MRCP (UK), FRACP, FRCP, physician/clinical pharmacologist, Chair BSc, PhD, MB, BS, Dip Obst, FRNZCGP, FRAGCP Deputy Chair MBChB, FRACP, MClin Pharm PhD, BPharm(Hons), RegPharmNZ, FNZCP MBChB, PhD, FRACP MBChB, FRANZCP, psychiatrist MMedSc (Clin Epi), MMBS, MD, MRCP (UK), FRCP (Edin), FRACP, FAFPHM, Dip Clin Epi, Dip OHP, Dip HSM, MBS PhD, MD, FRACP MBChB, DPH, RNZCGP MBChB, MTropHlth, MD, FRACP, infectious disease specialist and general physician BA, MBChB, MApplStats, FRACP

Contact PTAC C/- PTAC Secretary, Pharmaceutical Management Agency, PO Box 10 254, WELLINGTON, Email: PTAC@pharmac.govt.nz PHARMAC’s consumer advisors Consumer Advisory Committee (CAC) The Consumer Advisory Committee is an advisory committee to the PHARMAC Board. It provides written reports to the Board, and its Chair attends Board meetings as an observer to report on the activities and ﬁndings of the Committee, and to comment on consumer issues. While accountable to the Board, the Committee’s general working relationship is with the staff of PHARMAC. The Committee is made up of people from a range of backgrounds and interests including the health of M¯ ori people, Paciﬁc a peoples, older people, women and mental health. For current membership of the Consumer Advisory Committee, visit our website. The Consumer Advisory Committee can be contacted by email: CAC@pharmac.govt.nz, or you can write to the Consumer Advisory Committee at PHARMAC’s postal address.

The PHARMAC Team The PHARMAC team has a wide range of expertise in health, medicine, economics, commerce, critical analysis, and policy development and implementation. Bridget Macfarlane Programme & Accountability Steffan Crausaz Chief Executive Manager Paul Alexander Health Economist Richard Anderson Network and Systems Janet Mackay Programme & Accountability Administrator Manager Julian Apatu Web Content Leader Rachel Mackay Manager, Schedule and Katie Appleby Panel Co-ordinator Contracts Jason Arnold Team Leader, Analysis Trish Mahoney Contract Manager Diana Beswetherick HR Manager Scott Metcalfe Chief Advisor Population Stephen Boxall Creative Director Medicine / Deputy Medical Lisa Buxton Senior Receptionist Director Davina Carpenter Records Manager Peter Moodie Medical Director Angela Cathro M¯ ori Health Programmes’ a Christina Newman Executive Assistant to Chief Assistant Executive & Board Secretary Christine Chapman Therapeutic Group Manager Hew Norris Analyst Mary Chesterﬁeld High Cost Drugs Co-ordinator Leigh Parish PA to Medical Director / Medical Ian Craigie Manager, Technology and Team Assistant Informantion Kylie Parker Accounts Co-ordinator Andrew Davies Acting Manager, Funding and Marama Parore Manager, Access & Optimal Procurement Use & M¯ ori Health a Natalie Davis Therapeutic Group Manager Chris Peck Analyst Jessica Dougherty Corporate Team Executive Karen Phillips HR Assistant/Payroll Assistant Matthew Poynton Analyst/Health Economist Sean Dougherty Funding Systems Development Rachel Pratt Panel Co-ordinator Manager Dilky Rasiah Deputy Medical Director Anrik Drenth Database Analyst Awhimai Reynolds M¯ ori Health Manager a Kim Ellis Access & Optimal Use Alexander Rodgers Health Economist Co-ordinator Brian Roulston Contract Manager Fiona Rutherford Establishment Manager, Simon England Communications Manager Medical Devices Jackie Evans Senior Therapeutic Group Manager Rico Schoeler Manager, Analysis and Assessment John Geering Systems Architect Anne Glennie Panel Co-ordinator Carsten Schousboe Health Economist Rachel Grocott Senior Health Economist Merryn Simmons PHARMAC Seminar Series Rachel Hargreaves Senior Policy Analyst Co-ordinator Geralt Jones Formulary Researcher Liz Skelley Finance Manager Rochelle Harker PTAC Secretary & Panel Stuart Sorrel Panel Co-ordinator Co-ordinator Jude Urlich Manager, Corporate and Hayden Holmes Panel Co-ordinator (Growth External Relations Hormone/PAH) Jayne Watkins Team Leader, Medical Team Karen Jacobs National Programme Manager, Rachel Werner Health Economist One Heart Many Lives Bryce Wigodsky Policy Analyst Greg Williams Senior Therapeutic Group Donna Jennings Schedule Analyst Manager Marcus Kim Tender Analyst Catherine Kingsbury Funding and Procurement Lisa Williams Legal Counsel Assistant Kaye Wilson Senior Schedule Analyst Stephen Woodruffe Therapeutic Group Manager Geoff Lawn Applications Developer / Team Sue Anne Yee Therapeutic Group Manager Leader IT Michael Young Analyst

Purpose of the Pharmaceutical Schedule

The purpose of the Schedule is to list: G the Community Pharmaceuticals that are subsidised by the Government and to show the amount of the subsidy paid to contractors, as well as the manufacturer’s price (if it differs from the Subsidy) and any access conditions that may apply; and G some Hospital Pharmaceuticals that are purchased and used by DHB Hospitals, including those for which national prices have been negotiated by PHARMAC. The purpose of the Schedule is not to show the ﬁnal cost to Government of subsidising each Community Pharmaceutical or to DHBs in purchasing each Hospital Pharmaceutical since that will depend on any rebate and other arrangements PHARMAC has with the supplier and, for some Hospital Pharmaceuticals, on any logistics arrangements put in place by individual DHB Hospitals.

Finding Information in the Pharmaceutical Schedule

Community Pharmaceuticals For Community Pharmaceuticals, the Schedule is organised in a way to help the reader ﬁnd Community Pharmaceuticals, which may be used to treat similar conditions. To do this, Community Pharmaceuticals are ﬁrst classiﬁed anatomically, originally based on the Anatomical Therapeutic Chemical (ATC) system, and then further classiﬁed under section headings structured for the New Zealand medical system. G Section A lists the General Rules in relation to Community Pharmaceuticals and related products. G Section B lists Community Pharmaceuticals and related products by anatomical classiﬁcation, which are further divided into one or more therapeutic headings. Community Pharmaceuticals used to treat similar conditions are grouped together. G Section C lists the rules in relation to Extemporaneously Compounded Products (ECPs) and Community Pharmaceuticals that will be subsidised when extemporaneously compounded. G Section D lists the rules in relation to Special Foods and the Special Foods that are subsidised. G Section E Part I lists the Community Pharmaceuticals that are subsidised on a Practitioner’s Supply Order (PSO). G Section E Part II lists rural areas for the purpose of PSOs. G Section F lists the Community Pharmaceuticals dispensing period exemptions. G Section G lists the Community Pharmaceuticals eligible for reimbursement of safety cap and related rules. The listings are displayed alphabetically (where practical) within each level of the classiﬁcation system. Each anatomical section contains a series of therapeutic headings, some of which may contain a further classiﬁcation level. Where a Community Pharmaceutical is used in more than one therapeutic area, they may be cross-referenced. The therapeutic headings in the Pharmaceutical Schedule do not necessarily correspond to the therapeutic groups and therapeutic subgroups, which PHARMAC establishes for the separate purpose of determining the level of subsidy to be paid for each Community Pharmaceutical. The index located at the back of the book in which Sections A-G of the Pharmaceutical Schedule are published can be used to ﬁnd page numbers for generic chemical entities, or product brand names.

Hospital Pharmaceuticals

Section H lists Pharmaceuticals that DHBs fund from their own budgets. The Hospital Pharmaceuticals are grouped into the following Parts in Section H: G Part I lists the rules in relation to Hospital Pharmaceuticals. G Part II lists Hospital Pharmaceuticals for which national contracts exist (National Contract Pharmaceuticals). These are listed alphabetically by generic chemical entity name and line item, the relevant Price negotiated by PHARMAC and, if applicable, an indication of whether it has Hospital Supply Status (HSS) and any associated Discretionary Variance (DV) Pharmaceuticals and DV Limit. G Part III lists Discretionary Community Supply Pharmaceuticals, which are not Community Pharmaceuticals, but which a DHB Hospital can, in its discretion, fund for use in the community from its own budget. The index located at the back of the Section H supplement can be used to ﬁnd page numbers for generic chemical entities, or product brand names, for Hospital Pharmaceuticals.

Explaining drug entries

The Pharmaceutical Schedule lists pharmaceuticals subsidised by the Government, the amount of that subsidy paid to contractors, the supplier’s price and the access conditions that may apply. Example

ANATOMICAL HEADING

Subsidy (Manufacturer’s Price) $ Per Fully Brand or Subsidised Generic Manufacturer

Three months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber. Practitioner’s Supply Order Safety cap reimbursed Conditions of and restrictions on prescribing (including Special Authority where it applies) Three months or six months, as applicable, dispensed all-at-once

THERAPEUTIC HEADING CHEMICAL L Presentation, form and strength .........................10.00

100

Brand A Brand B Brand C Brand D Brand or manufacturer’s name Sole subsidised supply product Fully subsidised product Original Pack Subsidy is rounded up to a multiple of whole packs

Presentation - Available on a PSO .....................15.00 ‡ Presentation - Retail pharmacy-specialist ..........18.00 a) Prescriptions must be written by a paediatrician or paediatric cardiologist; or b) on the recommendation of a paediatrician or a paediatric cardiologist CHEMICAL F Presentation, form and strength .........................26 26.53 (35.27)

50 250 ml OP

100 Brand E

Quantity the Subsidy applies to Subsidy paid on a product before mark-ups and GST Manufacturer’s Price if different from Subsidy

Sole Supply Fully Subsidised

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the presriber.

Glossary

Units of Measure gram ..................................................g kilogram...........................................kg international unit ...............................iu microgram....................................... µg milligram .........................................mg millilitre.............................................ml millimole......................................mmol unit.....................................................u

Abbreviations Ampoule ...................................... Amp Granules ......................................Gran Suppository ................................ Supp Capsule ........................................ Cap Infusion............................................Inf Tablet .............................................Tab Cream...........................................Crm Injection ...........................................Inj Tincture.........................................Tinc Device........................................... Dev Linctus .......................................... Linc Trans Dermal Delivery Dispersible................................... Disp Liquid..............................................Liq System.................................. TDDS Effervescent.................................... Eff Long Acting..................................... LA Emulsion..................................... Emul Ointment....................................... Oint Enteric Coated................................EC Sachet ........................................ Sach Gelatinous ..................................... Gel Solution........................................ Soln BSO Bulk Supply Order. CBS Cost Brand Source. There is no set manufacturer’s price, and the Government subsidises the product at the price it is obtained by the pharmacy. CE Compounded Extemporaneously. CPD Cost Per Dose. The Funder (as deﬁned in Part I of the General Rules) cost of a standard dose, without mark-ups or fees and excluding GST. ECP Extemporaneously Compounded Preparation. HSS Hospital Supply Status, the status of being the brand of the relevant Hospital Pharmaceutical listed in Section H Part II as HSS, that DHBs are obliged to purchase subject to any DV Limit for that Hospital Pharmaceutical for the period of hospital supply, as awarded under an agreement between PHARMAC and the relevant pharmaceutical supplier. OP Original Pack – subsidy is rounded up to a multiple at whole packs. PSO Practitioner’s Supply Order. Sole Subsidised Supplier Only brand of this medicine subsidised. XPharm Pharmacies cannot claim subsidy because PHARMAC has made alternative distribution arrangements. L Three months supply may be dispensed at one time if the exempted medicine is endorsed ‘certiﬁed exemption’ by the practitioner. F Three months dispensed all-at-once or, in the case of oral contraceptives, six months dispensed all-at-once, unless medicine is endorsed “close control” or “cc” and the endorsement is initialled by the prescriber. ‡ Safety cap required and subsidised for oral liquid formulations, including extemporaneously compounded preparations. Fully subsidised brand of a given medicine. Brands without the tick are not fully subsidised and may cost the patient a manufacturer’s surcharge. S29 This medicine is an unapproved medication supplied under Section 29 of the Medicines Act 1981. Practitioners prescribing this medication should: a) be aware of and comply with their obligations under Section 29 of the Medicines Act 1981 and otherwise under that Act and the Medicines Regulations 1984; b) be aware of and comply with their obligations under the Health and disability Commissioner’s Code of Consumer Rights, including the requirement to obtain informed consent from the patient (PHARMAC recommends that Practitioners obtain written consent); and c) exercise their own skill, judgement, expertise and discretions, and make their own prescribing decisions with respect to the use of an unapproved Pharmaceutical or a Pharmaceutical for an indication for which it is not approved. Note: Where medicines supplied under Section 29 that are used for emergency situations, patient details required under Section 29 of the Medicines Act may be retrospectively provided to the supplier.

Abbrev. [HP3]

[HP4]

Deﬁnitions Pharmacy Services Agreement Subsidised when dispensed from pharmacies that have a Special Foods Service appended to their Pharmacy Services Agreement by their DHB. Subsidised when dispensed from pharmacies that have the Monitored Therapy Variation (for Clozapine Services)

All other Pharmacy Agreements Available from selected pharmacies that have an exclusive contract to dispense Special Foods. Avaliable from selected pharmacies that have an exclusive contract to dispense ‘Hospital Pharmacy’ [HP4] pharmaceuticals.

Patient costs

Community Pharmaceuitical costs met by the Government Most of the cost of a subsidised prescription Community Pharmaceutical is met by the Government through the Pharmaceutical Budget. The Government pays a subsidy for the Community Pharmaceutical to Contractors, and a fee covering distribution and pharmacy dispensing services. The subsidy paid to Contractors does not necessarily represent the ﬁnal cost to Government of subsidising a particular Community Pharmaceutical. The ﬁnal cost will depend on the nature of PHARMAC’s contractual arrangements with the supplier. Fully subsidised medicines are identiﬁed with a in the product’s Schedule listing. SALBUTAMOL Aerosol inhaler 100 µg per dose ...................................... 3.80 (6.00) Fully subsidised brand Higher priced brand

Pharmaceutical Co-Payments Some Community Pharmaceutical costs are met by the patient. Generally a patient pays a prescription charge. In addition a patient will sometimes pay a manufacturer’s surcharge, after hours service fee and any special packaging fee. PRESCRIPTION CHARGE From 1 September 2008, everyone who is eligible for publicly funded health and disability services should in most circumstances pay only $3 for subsidised medicines. All prescriptions from a public hospital, a midwife and a Family Planning Clinic are covered for $3 co-payments. Prescriptions from the following providers are approved for $3 co-payments on subsidised medicines if they meet the speciﬁed criteria: G After Hours Accident and Medical Services with a DHB or a PHO contract. G Youth Health Clinics with a DHB or a PHO contract. G Dentists who write a prescription that relates to a service being provided under a DHB contract. G Private specialists (for example, opthalmologists and orthopaedics) who write a prescription for a patient receiving a publicly funded service contracted by the DHB. G General practitioners who write a prescription during normal business hours to a person who is not enrolled in the general practice provided the person is eligible for publicly funded health and disability services and the general practice is part of a PHO. G Hospices that have a contract with a DHB. Patients can check whether they are eligible for publicly funded health and disability services by referring to the Eligibility Direction on the Ministry of Health’s website. To check if a medicine is fully subsidised, refer to the Pharmaceutical Schedule on PHARMAC’s website or ask your pharmacist or general practitioner. DHBs have a list of eligible providers in their respective regions. Any provider/prescriber not speciﬁcally listed by a DHB as an approved provider/prescriber should be regarded as not approved. NOTE: Information sourced from Ministry of Health Website, for more information please visit www.moh.govt.nz MANUFACTURER’S SURCHARGE Not all Community Pharmaceuticals are fully subsidised. Although PHARMAC endeavours to fully subsidise at least one Community Pharmaceutical in each therapeutic group, and has contracts with some suppliers to maintain the price of a particular product, manufacturers are able to set their own price to pharmacies. When these prices exceed the subsidy, the pharmacist may recoup the difference from the patient. To estimate the amount a patient will pay on top of the prescription charge, take the difference between the manufacturer’s price and the subsidy, and multiply this by 1.86. The 1.86 factor represents the pharmacy mark-up on the surcharge plus other costs such as GST. Pharmacies charge different mark-ups so this may vary. Manufacturer’s surchage to patient = (price − subsidy) × 1.86 For example, a Community Pharmaceutical with a supplier (ex-manufacturer) cost of $11.00 per pack with a $10.00 subsidy will cost the patient a surchage of $1.86 on top of the prescription charge. The most a patient should pay is therefore $16.86 - being

$15.00 maximum prescription charge, plus $1.86. Hospital Pharmaceutical and Pharmaceutical Cancer Treatment Costs The cost of purchasing Hospital Pharmaceuticals (for use in DHB hospitals and/or in association with Outpatient services provided in DHB hospitals) is met by the relevant DHB hospital Funder from its own budget. Pharmaceutical Cancer Treatments (for use in DHB hospitals and/or in association with Outpatient services provided in DHB hospitals) are funded through the Combined Pharmaceutical Budget. As required by section 23(7) of the Act, in performing any of their functions in relation to the supply of Pharmaceuticals including Pharmaceutical Cancer Treatments, DHBs must not act inconsistently with the Pharmaceutical Schedule. PHARMAC web site PHARMAC has set up an interactive Schedule on the Internet. Other information about PHARMAC is also available on our website. This includes copies of the Annual Review, Annual Report and Annual Plan, as well as information such as the Pharmaceutical Schedule, Pharmaceutical Schedule Updates, National Hospital Pharmaceutical Strategy, other publications and recent press releases.

Special Authority Applications

Special Authority is an application process in which a prescriber requests government subsidy on a Community Pharmaceutical for a particular person. Applications must be submitted to the Ministry of Health by the prescriber for the request to be processed. Subsidy Once approved, the presciber will be provided a Special Authority number which must appear on the prescription. Specialists who make an application must communicate the valid authority number to the prescriber who will be writing the prescriptions. The authority number can provide access to subsidy, increased subsidy, or waive certain restrictions otherwise present on the Community Pharmaceutical. Some approvals are dependent on the availability of funding from the Pharmaceutical Budget. Criteria The criteria for approval of Special Authority applications are included below each Community Pharmaceutical listing, and on the application forms available on PHARMAC’s website. For some Special Authority Community Pharmaceuticals, not all indications that have been approved by Medsafe are subsidised. Criteria for each Special Authority Community Pharmaceutical are updated regularly, based on the decision criteria of PHARMAC. The appropriateness of the listing of a Community Pharmaceutical in the Special Authority category will also be regularly reviewed. Applications for inclusion of further Community Pharmaceuticals in the Special Authority category will generally be made by a pharmaceutical supplier. Special Authority Applications Application forms can be found at www.pharmac.govt.nz. Requests for fax copies should be made to PHARMAC, phone 04 460 4990. Applications are processed by the Ministry of Health, and should be sent to: Ministry of Health Sector Services, Fax: (06) 349 1983 or free fax 0800 100 131 Private Bag 3015, WANGANUI 4540 For enquiries, phone the Ministry of Health Sector Services Call Centre, free phone 0800 243 666 Note: The Ministry of Health can only provide information on Special Authority applications to prescribers and pharmacists. Each application must: G Include the patients name, date of birth and NHI number (codes for AIDS patients’ applications) G Include the practitioner’s name, address and Medical Council registration number G Clearly indicate that the relevant criteria, have been met. G Be signed by the practitioner.

Named Patient Pharmaceutical Assessment policy

The Named Patient Pharmaceutical Assessment (NPPA) Policy is PHARMAC’s process for considering applications about named patients seeking funding for treatments not listed on the Schedule, either at all or for the named patient’s clinical circumstances. For PHARMAC to perform its legislative function of maintaining and managing a Schedule that applies consistently throughout New Zealand, the NPPA Policy will, and must, operate in a way that does not undermine the Schedule decision making process. Together, the Schedule process and the NPPA Policy, ensure there is a pathway for consideration of an individual’s clinical circumstances. If an individual has a set of clinical circumstances not covered by the NPPA Policy, the Schedule decision making process is available. It is not the purpose of the NPPA Policy to provide access to every treatment not listed on the Schedule. There are three main pathways by which named patients can be considered for funding under the NPPA Policy. PHARMAC will exercise its discretion to determine the most appropriate pathway for an application under the NPPA Policy based on the information that is provided. PHARMAC will assess applications that meet the prerequisites described below according to its Decision Criteria before deciding whether to approve applications for funding. The Decision Criteria will be used to assess both the individual clinical circumstances of each NPPA applicant, and the implications of each NPPA funding decision on PHARMAC’s ability to carry out its legislative functions. For more information on NPPA, or to apply, visit the PHARMAC website at http://www.pharmac.govt.nz/ nppa, or call the Panel Coordinators at (04) 9167553 or (04) 9167521. Unusual Clinical Circumstance (UCC) The purpose of the Unusual Clinical Circumstances (UCC) pathway is to provide a process for consideration for funding for named patients whose clinical circumstances are so unusual that PHARMAC is unlikely, for administrative reasons, to consider listing treatments for these circumstances on the Schedule. The prerequisite requirements for UCC consideration are: G The patient has reasonably tried and failed all alternative funded treatments (or alternative treatments have been contraindicated, or there are no other treatments available), or the patient has experienced such serious side effects with all other relevant funded treatments that treatment has been ceased or cannot reasonably be continued; and G The patient is experiencing an indication or set of clinical circumstances that are so unusual that PHARMAC is unlikely to consider listing treatments for these on the Schedule; and G Generally, PHARMAC has not already considered/is not considering, through the Schedule decision making process, the treatment for the patient’s clinical circumstances, or has not considered the treatment at all. Urgent Assessment (UA) The purpose of the Urgent Assessment (UA) pathway is to provide a process for PHARMAC to consider funding treatments for named patients where PHARMAC is also considering or is likely to consider the treatment for Schedule listing, but the patient’s clinical circumstances justify urgent assessment, prior to a decision on Schedule listing. The prerequisite requirements for UA are: G The patient has reasonably tried and failed all alternative funded treatments (or alternative treatments have been contraindicated, or there are no other treatments available), or the patient has experienced such serious side effects with all other relevant funded treatments that treatment has been ceased or cannot reasonably be continued; and G The patient is experiencing an indication or set of clinical circumstances that may be experienced by a population group (either currently or over time); and G The patient has serious clinical circumstances and not receiving the treatment within six to 12 months would lead to either a signiﬁcant deterioration in a serious clinical condition or the patient would miss the opportunity for signiﬁcant improvement in clinical outcome (length or quality of life); and G The treatment has either not been prioritised by PHARMAC, or if it has, PHARMAC has funded the treatment under the NPPA Policy for the same clinical circumstances prior to prioritisation. G PHARMAC has not declined to list, on the Schedule, this treatment for these clinical circumstances. Hospital Pharmaceuticals in the Community (HPC) The purpose of the Hospital Pharmaceuticals in the Community (HPC) pathway is to allow District Health Board hospitals to fund a medicine for a patient in the community if it would be more affordable for the DHB than paying for the treatment that would otherwise need to be provided. PHARMAC’s approval is required for any such funding, given DHBs’ legislative obligation to act consistently with the Schedule. The prerequisite requirements for HPC are: G The patient has reasonably tried and failed all alternative cheaper funded treatments (or these alternative treatments have been contraindicated) or the patient has experienced such serious side effects with all other cheaper relevant funded treatments that treatment has been ceased or cannot reasonably be continued; and G The application is for a DHB hospital to fund a treatment for use in the community for a patient under the care of a DHB hospital clinician (in-patient or out-patient); and G The treatment is not being used to treat a cancer; and G The treatment costs less for the DHB than the most likely alternative intervention or outcome; and G The treatment is being sought for a short-term episode of care (usually a maximum of three months) and is not generally for

the treatment of a chronic condition.

SECTION A: GENERAL RULES

INTRODUCTION

Section A contains the restrictions and other general rules that apply to Subsidies on Community Pharmaceuticals. The amounts payable by the Funder to Contractors are currently determined by: G the quantities, forms, and strengths, of subsidised Community Pharmaceuticals dispensed under valid prescription by each Contractor; G the amount of the Subsidy on the Manufacturer’s Price payable for each unit of the Community Pharmaceuticals dispensed by each Contractor and; G the contractual arrangements between the Contractor and the Funder for the payment of the Contractor’s dispensing services. The Pharmaceutical Schedule shows the level of subsidy payable in respect of each Community Pharmaceutical so that the amount payable by the Government to Contractors, for each Community Pharmaceutical, can be calculated. The Pharmaceutical Schedule also shows the standard price (exclusive of GST) at which a Community Pharmaceutical is supplied ex-manufacturer to wholesalers if it differs from the subsidy. The manufacturer’s surcharge to patients can be estimated using the subsidy and the standard manufacturer’s price as set out in this Schedule. The cost to Government of subsidising each Community Pharmaceutical and the manufacturer’s prices may vary, in that suppliers may provide rebates to other stakeholders in the primary health care sector, including dispensers, wholesalers, and the Government. Rebates are not speciﬁed in the Pharmaceutical Schedule. This Schedule is dated 1 August 2012 and is to be referred to as the Pharmaceutical Schedule Volume 19 Number 2, 2012. Distribution will be from 20 August 2012. This Schedule comes into force on 1 August 2012.

PART I INTERPRETATIONS AND DEFINITIONS

1.1 In this Schedule, unless the context otherwise requires: “90 Day Lot” means the quantity of a Community Pharmaceutical required for the number of days’ treatment covered by the Prescription, being up to 90 consecutive days’ treatment; “180 Day Lot” means the quantity of a Community Pharmaceutical required for the number of days’ treatment covered by the Prescription, being up to 180 consecutive days’ treatment; “Access Exemption Criteria” means the criteria under which patients may receive greater than one Month’s supply of a Community Pharmaceutical covered by Section F Part II (b) subsidised in one Lot. The speciﬁcs of these criteria are conveyed in the Ministry of Health guidelines, which are issued from time to time. The criteria the patient must meet are that they: a) have limited physical mobility; b) live and work more than 30 minutes from the nearest pharmacy by their normal form of transport; c) are relocating to another area; d) are travelling extensively and will be out of town when the repeat prescriptions are due. “Act” means the New Zealand Public Health and Disability Act 2000. “Advisory Committee” means the Pharmaceutical Services Advisory Committee convened by the Ministry of Health under the terms of the Advice Notice issued to Contractors pursuant to Section 88 of the Act. “Alternate Subsidy” means a higher level of subsidy that the Government will pay contractors for a particular community Pharmaceutical dispensed to a person who has either been granted a Special Authority for that pharmaceutical, or where the prescription is endorsed in accordance with the requirements of this Pharmaceutical Schedule. “Annotation” means written annotation of a prescription by a dispensing pharmacist in the pharmacist’s own handwriting following conﬁrmation from the Prescriber if required, and “Annotated” has a corresponding meaning. The Annotation must include the details speciﬁed in the Schedule, including the date the prescriber was contacted (if applicable) and be initialled by the dispensing pharmacist. “Assessed Pharmaceuticals” means the list of Pharmaceuticals set out in Section H Part III of the Schedule, that have been or are being assessed by PHARMAC. “Authority to Substitute” means an authority for the dispensing pharmacist to change a prescribed medicine in accordance with regulation 42(4) of the Medicines Regulations 1984. An authority to substitute letter, which may be used by Practitioners, is available on the ﬁnal page of the Schedule. “Bulk Supply Order” means a written order, on a form supplied by the Ministry of Health, or approved by the Ministry of Health, made by the licensee or manager of an institution certiﬁed to provide hospital care under the Health and Disability

SECTION A: GENERAL RULES

Services (Safety) Act 2001 for the supply of such Community Pharmaceuticals as are expected to be required for the treatment of persons who are under the medical or dental supervision of such a Private Hospital or institution. “Class B Controlled Drug” means a Class B controlled drug within the meaning of the Misuse of Drugs Act 1975. “Community Pharmaceutical” means a Pharmaceutical listed in Sections A to G of the Pharmaceutical Schedule that is subsidised by the Funder from the Pharmaceutical Budget for use in the community. “Contractor” means a person who is entitled to receive a payment from the Crown or a DHB under a notice issued by the Crown or a DHB under Section 88 of the Act or under a contract with the Ministry of Health or a DHB for the supply of Community Pharmaceuticals. “Controlled Drug” means a controlled drug within the meaning of the Misuse of Drugs Act 1975 (other than a controlled drug speciﬁed in Part VI of the Third Schedule to that Act). “Cost, Brand, Source of Supply” means that the Community Pharmaceutical is eligible for Subsidy on the basis of the Contractor’s annotated purchase price, brand, and source of supply. “Dentist” means a person registered with the Dental Council, and who holds a current annual practising certiﬁcate, under the HPCA Act 2003. “Diabetes Nurse Prescriber” means a registered nurse practising in diabetes health who has authority to prescribe speciﬁed diabetes medicines in accordance with regulations made under the Medicines Act 1981, and who is practicing in an approved DHB demonstration site. “Dietitian” means a person registered as a dietitian with the Dietitians Board, and who holds a current annual practicing certiﬁcate under the HPCA Act 2003. “DHB” means an organisation established as a District Health Board by or under Section 19 of the Act. “DHB Hospital” means a DHB, including its hospital or associated provider unit that the DHB purchases Hospital Pharmaceuticals for. “Discretionary Community Supply Pharmaceutical” means the list of Pharmaceuticals set out in Section H Part IV of the Schedule, which may be funded by a DHB Hospital from its own budget for use in the community. “Dispensing Frequency Rule” means the rule in Part IV, Section A of the Pharmaceutical Schedule that deﬁnes patient groups or medicines eligible for more frequent dispensing periods. “Doctor” means a medical Practitioner registered with the Medical Council of New Zealand and, who holds a current annual practising certiﬁcate under the HPCA Act 2003. “DV Limit” means, for a particular Hospital Pharmaceutical with HSS, the National DV Limit or the Individual DV Limit. “DV Pharmaceutical” means a discretionary variance Pharmaceutical, that does not have HSS and which: a) is either listed in Section H Part II of the Schedule as being a DV Pharmaceutical in association with the relevant Hospital Pharmaceutical with HSS; or b) is the same chemical entity, at the same strength, and in the same or a similar presentation or form, as the relevant Hospital Pharmaceutical with HSS, but which is not yet listed as being a DV Pharmaceutical. “Endorsements” - unless otherwise speciﬁed, endorsements should be either handwritten or computer generated by the practitioner prescribing the medication. The endorsement can be written as “certiﬁed condition”, or state the condition of the patient, where that condition is speciﬁed for the Community Pharmaceutical in Section B of the Pharmaceutical Schedule. Where the practitioner writes “certiﬁed condition” as the endorsement, he/she is making a declaration that the patient meets the criteria as set out in Section B of the Pharmaceutical Schedule. “Funder” means the body or bodies responsible, pursuant to the Act, for the funding of pharmaceuticals listed on the Schedule (which may be one or more DHBs and/or the Ministry of Health) and their successors. “GST” means goods and services tax under the Goods and Services Tax Act 1985. “Hospital Care Operator” means a person for the time being in charge of providing hospital care, in accordance with the Health and Disability Services (Safety) Act 2001. “Hospital Pharmaceuticals” means National Contract Pharmaceuticals, DV Pharmaceuticals, Discretionary Community Supply Pharmaceuticals and Assessed Pharmaceuticals. “Hospital Pharmaceuticals in the Community (HPC)” means the pathway under the Named Patient Pharmaceutical Assessment policy to allow District Health Board hospitals to fund a medicine for a patient in the community if this is more affordable for the DHB than paying for the treatment that would otherwise need to be provided. “Hospital Pharmacy” means that the Community Pharmaceutical is not eligible for Subsidy unless it is supplied by a hospital or pharmacy contracted to the Funder to dispense as a hospital pharmacy to an person on the Prescription of a Practitioner. “Hospital Pharmacy-Specialist” means that the Community Pharmaceutical is not eligible for Subsidy unless it is supplied by a hospital or pharmacy contracted to the Funder to dispense as a hospital pharmacy to an Outpatient either: a) on a Prescription signed by a Specialist, or

SECTION A: GENERAL RULES

b) where the treatment with the Community Pharmaceutical has been recommended by a Specialist, on the Prescription of a practitioner which is either: i) endorsed with the words “recommended by [name of specialist and year of authorisation]” and signed by the Practitioner, or ii) annotated by the dispensing pharmacist, following verbal conﬁrmation from the Practitioner of the name of the Specialist and date of recommendation, with the words “recommended by [name of specialist and date of authorisation], conﬁrmed by [practitioner]”. Where the Contractor has an electronic record of such an Endorsement or Annotation from a previous prescription for the same Community Pharmaceutical written by a prescriber for the same patient, they may annotate the prescription accordingly. “As recommended by a Specialist” to be interpreted as: a) follows a substantive consultation with an appropriate Specialist; b) the consultation to relate to the Patient for whom the Prescription is written; c) consultation to mean communication by referral, telephone, letter, facsimile or email; d) except in emergencies consultation to precede annotation of the Prescription; and e) both the specialist and the General Practitioner must keep a written record of the consultation. For the purposes of the deﬁnition it makes no difference whether or not the Specialist is employed by a hospital. “Hospital Pharmacy-Specialist Prescription” means that the Community Pharmaceutical is not eligible for Subsidy unless it is supplied by a hospital or pharmacy contracted to the Funder to dispense as a hospital pharmacy: a) to an Outpatient; and b) on a Prescription signed by a Specialist. For the purposes of this deﬁnition, a “specialist” means a doctor who holds a current annual practicing certiﬁcate and who satisﬁes the criteria set out in paragraphs (a) or (b) or (c) of the deﬁnitions of Specialist below. “HSS” means hospital supply status, the status of being the brand of the relevant Hospital Pharmaceutical listed in Section H Part II as HSS, that DHBs are obliged to purchase subject to any DV Limit for that Hospital Pharmaceutical for the period of hospital supply, as awarded under an agreement between PHARMAC and the relevant pharmaceutical supplier. “In Combination” means that the Community Pharmaceutical is only subsidised when prescribed in combination with another subsidised pharmaceutical as speciﬁed in Section B or C of the Pharmaceutical Schedule. “Individual DV Limit” means, for a particular Hospital Pharmaceutical with HSS and a particular DHB Hospital, the discretionary variance limit, being the speciﬁed percentage of that DHB Hospital’s Total Market Volume up to which that DHB Hospital may purchase DV Pharmaceuticals of that Hospital Pharmaceutical. “Licensed Hospital” means a place or institution that is certiﬁed to provide hospital care within the meaning of the Health and Disability Services (Safety) Act 2001. “Lot” means a quantity of a Community Pharmaceutical supplied in one dispensing. “Manufacturer’s Price” means the standard price at which a Community Pharmaceutical is supplied to wholesalers (excluding GST), as notiﬁed to PHARMAC by the supplier. “Maternity hospital” means that the Community Pharmaceutical is not eligible for Subsidy unless it is supplied pursuant to a Bulk Supply Order to a maternity hospital certiﬁed under the Health and Disability Services (Safety) Act 2001. “Midwife” means a person registered as a midwife with the Midwifery Council, and who holds a current annual practising certiﬁcate under the HPCA Act 2003. “Month” means a period of 30 consecutive days. “Monthly Lot” means the quantity of a Community Pharmaceutical required for the number of days’ treatment covered by the Prescription, being up to 30 consecutive days’ treatment; “Named Patient Pharmaceutical Assessment Advisory Panel” means the panel of clinicians, appointed by the PHARMAC Board, that is responsible for advising, within its Terms of Reference, on Named Patient Pharmaceutical Assessment applications and Exceptional Circumstances renewal applications submitted after 1 March 2012 (EC renewal application form located at http://www.pharmac.govt.nz/healthpros/EC/ECForms) “National Contract Pharmaceutical” means a Hospital Pharmaceutical for which PHARMAC has negotiated a national contract and the Price. “National DV Limit” means, for a particular Hospital Pharmaceutical with HSS, the discretionary variance limit, being the speciﬁed percentage of the Total Market Volume up to which all DHB Hospitals may collectively purchase DV Pharmaceuticals of that Hospital Pharmaceutical. “Not In Combination” means that no Subsidy is available for any Prescription containing the Community Pharmaceutical in combination with other ingredients unless the particular combination of ingredients is separately speciﬁed in Section B or C of the Schedule, and then only to the extent speciﬁed.

SECTION A: GENERAL RULES

“Nurse Prescriber” means a nurse registered with the Nursing Council and who holds a current annual practicing certiﬁcate under the HPCA Act 2003 and who is approved by the Nursing Council, to prescribe speciﬁed prescription medicines relating to his/her scope of practice including, for the avoidance of doubt, a Diabetes Nurse Prescriber. “Optometrist” means a person registered as an optometrist with the Optometrists and Dispensing Opticians Board, who holds a current annual practising certiﬁcate under the HPCA Act 2003, and who is authorised by regulations under the Medicines Act 1981 and approved by the Optometrists and Dispensing Opticians Board to prescribe speciﬁed medicines. “Outpatient” , in relation to a Community Pharmaceutical, means a person who, as part of treatment at a hospital or other institution under the control of a DHB, is prescribed the Community Pharmaceutical for consumption or use in the person’s home. “PCT” means Pharmaceutical Cancer Treatment in respect of which DHB hospital pharmacies and other Contractors can claim Subsidies. “PCT only” means Pharmaceutical Cancer Treatment in respect of which only DHB hospital pharmacies can claim Subsidies. “Penal Institution” means a penal institution, as that term is deﬁned in The Penal Institutions Act 1954; “PHARMAC” means the Pharmaceutical Management Agency established by Section 46 of the Act (PHARMAC). “Pharmaceutical” means a medicine, therapeutic medical device, or related product or related thing listed in Sections B to H of the Schedule. “Pharmaceutical Beneﬁts” means the right of: a) a person; and b) any member under 16 years of age of that person’s family, to have made by the Government on his or her behalf, subject to any conditions for the time being speciﬁed in the Schedule, such payment in respect of any Community Pharmaceutical supplied to that person or family member under the order of a Practitioner in the course of his or her practice. “Pharmaceutical Budget” means the pharmaceutical budget set for PHARMAC by the Crown for the subsidised supply of Community Pharmaceuticals and Pharmaceutical Cancer Treatments including for named patients in exceptional circumstances. “Pharmaceutical Cancer Treatment” means Pharmaceuticals for the treatment of cancer, listed in Sections A to G of the Schedule and identiﬁed therein as a “PCT” or “PCT only” Pharmaceutical that DHBs must provide access to, for use in their hospitals, and/or in association with Outpatient services provided in their DHB Hospitals, in relation to the treatment of cancers. “Practitioner” means a Doctor, a Dentist, a Dietitian, a Midwife, a Nurse Prescriber or an Optometrist as those terms are deﬁned in the Pharmaceutical Schedule. “Practitioner’s Supply Order” means a written order made by a Practitioner on a form supplied by the Ministry of Health, or approved by the Ministry of Health, for the supply of Community Pharmaceuticals to the Practitioner, which the Practitioner requires to ensure medical supplies are available for emergency use, teaching and demonstration purposes, and for provision to certain patient groups where individual prescription is not practicable. “Prescription” means a quantity of a Community Pharmaceutical prescribed for a named person on a document signed by a Practitioner. “Prescription Medicine” means any Pharmaceutical listed in Part I of Schedule 1 of the Medicines Regulations 1984. “Private Hospital” means a hospital certiﬁed under the Health and Disability Services (Safety) Act 2001 that is not owned or operated by a DHB. “Residential Disability Care Institution” means premises used to provide residential disability care in accordance with the Health and Disability Services (Safety) Act 2001. “Rest Home” means premises used to provide rest home care in accordance with the Health and Disability Services (Safety) Act 2001. “Restricted Medicine” means any Pharmaceutical listed in Part II of Schedule 1 of the Medicines Regulations 1984. “Retail Pharmacy-Specialist” means that the Community Pharmaceutical is only eligible for Subsidy if it is either: a) supplied on a Prescription or Practitioner’s Supply Order signed by a Specialist, or, b) in the case of treatment recommended by a Specialist, supplied on a Prescription or Practitioner’s Supply Order and either: i) endorsed with the words “recommended by [name of Specialist and year of authorisation]” and signed by the Practitioner, or ii) Annotated by the dispensing pharmacist, following verbal conﬁrmation from the Practitioner of the name of the Specialist and date of recommendation, with the words “recommended by [name of specialist

SECTION A: GENERAL RULES

and year of authorisation], conﬁrmed by [practitioner]”. Where the Contractor has an electronic record of such an Endorsement or Annotation from a previous prescription for the same Community Pharmaceutical written by a prescriber for the same patient, they may annotate the prescription accordingly. “As recommended by a Specialist” to be interpreted as: a) follows a substantive consultation with an appropriate Specialist; b) the consultation to relate to the Patient for whom the Prescription is written; c) consultation to mean communication by referral, telephone, letter, facsimile or email; d) except in emergencies consultation to precede annotation of the Prescription; and e) both the Specialist and the General Practitioner must keep a written record of consultation. “Retail Pharmacy-Specialist Prescription” means that the Community Pharmaceutical is only eligible for Subsidy if it is supplied on a Prescription, or Practitioner’s Supply Order, signed by a Specialist. For the purposes of this deﬁnition, a “specialist” means a doctor who holds a current annual practicing certiﬁcate and who satisﬁes the criteria set out in paragraphs (a) or (b) or (c) of the deﬁnitions of Specialist below. “Schedule” means this Pharmaceutical Schedule and all its sections and appendices. “Section B” of this Pharmaceutical Schedule means the list of Community Pharmaceuticals eligible for Subsidies included in the Schedule. “Section C” of this Pharmaceutical Schedule means the list of community extemporaneously compounded preparations and galenicals eligible for Subsidies included in the Schedule. “Section D” of this Pharmaceutical Schedule means the list of community special foods eligible for Subsidies included in the Schedule. “Section E Part I” of this Pharmaceutical Schedule means the list of Community Pharmaceuticals eligible for Subsidies and available on a Practitioner’s Supply Order included in the Schedule. “Section E Part II” of this Pharmaceutical Schedule means the list of rural areas for the purpose of community Practitioner’s Supply Orders included in the Schedule. “Section F Part I” of this Pharmaceutical Schedule means the part of Section F relating to the exemption from dispensing in Monthly Lots, and requirement to dispense in 90 Day Lots or 180 Day Lots, as applicable, in respect of the Community Pharmaceuticals referred to in this part of Section F; “Section F Part II” of this Pharmaceutical Schedule means the part of Section F relating to the exemption from dispensing in Monthly Lots in respect of the Community Pharmaceuticals referred to in this part of Section F; “Section G” of this Pharmaceutical Schedule means the list of Community Pharmaceuticals eligible for reimbursement of safety caps. “Section H” of this Pharmaceutical Schedule means the general rules for Hospital Pharmaceuticals and the lists of National Contract Pharmaceuticals and any associated DV Pharmaceuticals, of Discretionary Community Supply Pharmaceuticals and Assessed Pharmaceuticals included in Section H of the Schedule. “Section H Part I” of this Pharmaceutical Schedule means the general rules for Hospital Pharmaceuticals. “Section H Part II” of this Pharmaceutical Schedule means the list of National Contract Pharmaceuticals, the relevant Price, an indication of whether the Pharmaceutical has HSS and any associated DV Pharmaceuticals and DV Limit. “Section H Part III” of this Pharmaceutical Schedule means the list of Discretionary Community Supply Pharmaceuticals. “Special Authority” means that the Community Pharmaceutical or Pharmaceutical Cancer Treatment is only eligible for Subsidy or additional Subsidy for a particular person if an application meeting the criteria speciﬁed in the Schedule has been approved, and the valid Special Authority number is present on the prescription. “Specialist”, in relation to a Prescription, a doctor who holds a current annual practising certiﬁcate and who satisﬁes the criteria set out in paragraphs (a) or (b) or (c) or (d) below: a) i) the doctor is vocationally registered in accordance with the criteria set out by the Medical Council of New Zealand and the HPCA Act 2003 and who has written the Prescription in the course of practising in that area of medicine; and ii) the doctor’s vocational scope of practice is one of those listed below: — anaesthetics, cardiothoracic surgery, dermatology, diagnostic radiology, emergency medicine, general surgery, internal medicine, neurosurgery, obstetrics and gynaecology, occupational medicine, ophthalmology, oral and maxillofacial surgery, otolaryngology head and neck surgery, orthopaedic surgery, paediatric surgery, paediatrics, pathology, plastic and reconstructive surgery, psychological medicine or psychiatry, public health medicine, radiation oncology, rehabilitation medicine, urology and venereology; b) the doctor is recognised by the Ministry of Health as a specialist for the purposes of this Schedule and receives

SECTION A: GENERAL RULES

remuneration from a DHB at a level which that DHB considers appropriate for specialists and who has written that Prescription in the course of practising in that area of medicine; c) the doctor is recognised by the Ministry of Health as a specialist in relation to a particular area of medicine for the purpose of writing Prescriptions and who has written the Prescription in the course of practising in that area of medicine; d) the doctor writes the Prescription on DHB stationery and is appropriately authorised by the relevant DHB to do so. “Subsidy” means the maximum amount that the Government will pay Contractors for a Community Pharmaceutical dispensed to a person eligible for Pharmaceutical Beneﬁts and is different from the cost to Government of subsidising that Community Pharmaceutical. For the purposes of a DHB hospital pharmacy claiming for Pharmaceutical Cancer Treatments, Subsidy refers to any payment made to the DHB hospital pharmacy or service provider to which that pharmacy serves, and does not relate to a speciﬁc payment that might be made on submission of a claim. “Supply Order” means a Bulk Supply Order or a Practitioner’s Supply Order. “Unapproved Indication” means, for a Pharmaceutical, an indication for which it is not approved under the Medicines Act 1981. Practitioners prescribing Pharmaceuticals for Unapproved Indications should be aware of, and comply with, their obligations under Section 25 and/or Section 29 of the Medicines Act 1981 and as set out in Section A: General Rules, Part IV (Miscellaneous Provisions) rule 5.5. “Unusual Clinical Circumstances (UCC)” means the pathway under the Named Patient Pharmaceutical Assessment policy for funding consideration for named patients whose clinical circumstances are so unusual that PHARMAC is unlikely, for administrative reasons, to consider listing treatments for these circumstances on the Schedule. “Urgent Assessment (UA)” means the pathway under the Named Patient P harmaceutical Assessment policy for funding consideration for treatments for named patients where PHARMAC is also considering or is likely to consider the treatment for Schedule listing, but the patient’s clinical circumstances justify urgent assessment, prior to a decision on Schedule listing. 1.2 In addition to the above interpretations and deﬁnitions, unless the content requires otherwise, a reference in the Schedule to: a) the singular includes the plural; and b) any legislation includes a modiﬁcation and re-enactment of, legislation enacted in substitution for, and a regulation, Order in Council, and other instrument from time to time issued or made under that legislation, where that legislation, regulation, Order in Council or other instrument has an effect on the prescribing, dispensing or subsidising of Community Pharmaceuticals.

PART II COMMUNITY PHARMACEUTICALS SUBSIDY

2.1 Community Pharmaceuticals eligible for Subsidy include every medicine, therapeutic medical device or related product, or related thing listed in Sections B to G of the Schedule subject to: 2.1.1 clauses 2.2 of the Schedule; and 2.1.2 clauses 3.1 to 5.4 of the Schedule; and 2.1.3 the conditions (if any) speciﬁed in Sections B to G of the Schedule; 2.2 No claim by a Contractor for payment in respect of the supply of Community Pharmaceuticals will be allowed unless the Community Pharmaceuticals so supplied: 2.2.1 comply with the appropriate standards prescribed by regulations for the time being in force under the Medicines Act 1981; or 2.2.2 in the absence of any such standards, comply with the appropriate standards for the time being prescribed by the British Pharmacopoeia; or 2.2.3 in the absence of the standards prescribed in clauses 2.3.1 and 2.3.2, comply with the appropriate standards for the time being prescribed by the British Pharmaceutical Codex; or 2.2.4 in the absence of the standards prescribed in clauses 2.3.1, 2.3.2 and 2.3.3, are of a grade and quality not lower than those usually applicable to Community Pharmaceuticals intended to be used for medical purposes.

PART III PERIOD AND QUANTITY OF SUPPLY

3.1 Doctors’, Dentists’, Dietitians’, Midwives’, Nurse Prescribers’ and Optometrists’ Prescriptions (other than oral contraceptives)

SECTION A: GENERAL RULES

The following provisions apply to all Prescriptions, other than those for an oral contraceptive, written by a Doctor, Dentist, Dietitian, Midwife, Nurse Prescriber or Optometrist unless speciﬁcally excluded: 3.1.1 For a Community Pharmaceutical other than a Class B Controlled Drug, only a quantity suffcient to provide treatment for a period not exceeding three Months will be subsidised. 3.1.2 For methylphenidate hydrochloride and dexamphetamine sulphate (except for Dentist prescriptions), only a quantity sufﬁcient to provide treatment for a period not exceeding one Month will be subsidised. 3.1.3 For a Class B Controlled Drug: a) other than Dentist prescriptions and methylphenidate hydrochloride and dexamphetamine sulphate, only a quantity: i) sufﬁcient to provide treatment for a period not exceeding 10 days; and ii) which has been dispensed pursuant to a Prescription sufﬁcient to provide treatment for a period not exceeding one Month, will be subsidised. b) for a Dentist prescription only such quantity as is necessary to provide treatment for a period not exceeding ﬁve days will be subsidised. 3.1.4 Subject to clauses 3.1.3 and 3.1.7, for a Doctor, Dentist, Dietitian, Midwife or Nurse Prescriber and 3.1.7 for an Optometrist, where a practitioner has prescribed a quantity of a Community Pharmaceutical sufﬁcient to provide treatment for: a) one Month or less than one Month, but dispensed by the Contractor in quantities smaller than the quantity prescribed, the Community Pharmaceutical will only be subsidised as if that Community Pharmaceutical had been dispensed in a Monthly Lot; b) more than one Month, the Community Pharmaceutical will be subsidised only if it is dispensed: i) in a 90 Day Lot, where the Community Pharmaceutical is a Pharmaceutical covered by Section F Part I of the Pharmaceutical Schedule; or ii) if the Community Pharmaceutical is not a Pharmaceutical referred to in Section F Part I of the Pharmaceutical Schedule, in Monthly Lots, unless: A) the eligible person or his/her nominated representative endorses the back of the Prescription form with a statement identifying which Access Exemption Criterion (Criteria) applies and signs that statement to this effect; or B) both: 1) the Practitioner endorses the Community Pharmaceutical on the Prescription with the words “certiﬁed exemption” written in the Practitioner’s own handwriting, or signed or initialled by the Practitioner; and 2) every Community Pharmaceutical endorsed as “certiﬁed exemption” is covered by Section F Part II of the Pharmaceutical Schedule. 3.1.5 A Community Pharmaceutical is only eligible for Subsidy if the Prescription under which it has been dispensed was presented to the Contractor: a) for a Class B Controlled Drug, within eight days of the date on which the Prescription was written; or b) for any other Community Pharmaceutical, within three Months of the date on which the Prescription was written. 3.1.6 No subsidy will be paid for any Prescription, or part thereof, that is not fulﬁlled within: a) in the case of a Prescription for a total supply of from one to three Months, three Months from the date the Community Pharmaceutical was ﬁrst dispensed; or b) in any other case, one Month from the date the Community Pharmaceutical was ﬁrst dispensed. Only that part of any Prescription that is dispensed within the time frames speciﬁed above is eligible for Subsidy. 3.1.7 If a Community Pharmaceutical: a) is stable for a limited period only, and the Practitioner has endorsed the Prescription with the words “unstable medicine” and has speciﬁed the maximum quantity that may be dispensed at any one time; or b) is stable for a limited period only, and the Contractor has endorsed the Prescription with the words “unstable medicine” and has speciﬁed the maximum quantity that should be dispensed at any one time in all the circumstances of the particular case; or c) is under the Dispensing Frequency Rule, The actual quantity dispensed will be subsidised in accordance with any such speciﬁcation. 3.2 Oral Contraceptives

SECTION A: GENERAL RULES

The following provisions apply to all Prescriptions written by a Doctor, Midwife or Nurse Prescriber for an oral contraceptive: 3.2.1 The prescribing Doctor, Midwife or Nurse Prescriber must specify on the Prescription the period of treatment for which the Community Pharmaceutical is to be supplied. This period must not exceed six Months. 3.2.2 Where the period of treatment speciﬁed in the Prescription does not exceed six Months, the Community Pharmaceutical is to be dispensed: a) in Lots as speciﬁed in the Prescription if the Community Pharmaceutical is under the Dispensing Frequency Rule; or b) where no Lots are speciﬁed, in one Lot sufﬁcient to provide treatment for the period prescribed. 3.2.3 An oral contraceptive is only eligible for Subsidy if the Prescription under which it has been dispensed was presented to the Contractor within three Months of the date on which it was written. 3.2.4 Where a Community Pharmaceutical on a Prescription is under the Dispensing Frequency Rule and a repeat on the Prescription remains unfulﬁlled after six Months from the date the Community Pharmaceutical was ﬁrst dispensed only the actual quantity supplied by the Contractor within this time limit will be eligible for Subsidy. 3.3 Original Packs, and Certain Antibiotics 3.3.1 Notwithstanding clauses 3.1 and 3.3 of the Schedule, if a Practitioner prescribes or orders a Community Pharmaceutical that is identiﬁed as an Original Pack (OP) on the Pharmaceutical Schedule and is packed in a container from which it is not practicable to dispense lesser amounts, every reference in those clauses to an amount or quantity eligible for Subsidy, is deemed to be a reference: a) where an amount by weight or volume of the Community Pharmaceutical is speciﬁed in the Prescription, to the smallest container of the Community Pharmaceutical, or the smallest number of containers of the Community Pharmaceutical, sufﬁcient to provide that amount; and b) in every other case, to the amount contained in the smallest container of the Community Pharmaceutical that is manufactured in, or imported into, New Zealand. 3.3.2 If a Community Pharmaceutical is the liquid oral form of an antibiotic to which a diluent must be added by the Contractor at the time of dispensing and it is prescribed or ordered by a Practitioner in an amount that does not coincide with the amount contained in one or more standard packs of that Community Pharmaceutical, Subsidy will be paid for the amount prescribed or ordered by the Practitioner in accordance with either clause 3.1 or clause 3.3 of the Schedule, and for the balance of any pack or packs from which the Community Pharmaceutical has been dispensed. At the time of dispensing the Contractor must keep a record of the quantity discarded. To ensure wastage is reduced, the Contractor should reduce the amount dispensed to make it equal to the quantity contained in a whole pack where: a) the difference the amount dispensed and the amount prescribed by the Practitioner is less than 10% (eg; if a prescription is for 105 mls then a 100ml pack would be dispensed); and b) in the reasonable opinion of the Contractor the difference would not affect the efﬁcacy of the course of treatment prescribed by the Practitioner. Note: For the purposes of audit and compliance it is an act of fraud to claim wastage and then use the wastage amount for any subsequent prescription. 3.4 Dietitians’ Prescriptions The following provisions apply to every Prescription written by a Dietitian: 3.4.1 Prescriptions written by a Dietitian for a Community Pharmaceutical will only be subsidised where they are for either: a) special foods, as listed in Section D; or b) any other Pharmaceutical that has been identiﬁed in Section D of the Pharmaceutical Schedule as being able to be prescribed by a Dietitian, providing that the products being prescribed are not classiﬁed as Prescription Medicines or Restricted Medicines. 3.4.2 For the purposes of Dietitians prescribing pursuant to this clause 3.5, the prescribing and dispensing of these products is required to be in accordance with regulations 41 and 42 of the Medicines Regulations 1984. 3.5 Diabetes Nurse Prescribers’ Prescriptions The following provisions apply to every Prescription written by a Diabetes Nurse Prescriber: 3.5.1 Prescriptions written by a Diabetes Nurse Prescriber for a Community Pharmaceutical will only be subsidised where they are for either: a) a Community Pharmaceutical classiﬁed as a Prescription Medicine or a Restricted Medicine and which a Diabetes Nurse Prescribers is permitted under regulations to prescribe; or

SECTION A: GENERAL RULES

b) any other Community Pharmaceutical listed below, being an item that has been identiﬁed as being able to be prescribed by a Diabetes Nurse Prescriber, but which is not classiﬁed as a Prescription Medicine or a Restricted Medicine: aspirin, blood glucose diagnostic test meter, blood glucose diagnostic test strip, glucagon hydrochloride inj 1 mg syringe kit, insulin pen needles, insulin syringes disposable with attached needle, ketone blood beta-ketone electrodes test strip, nicotine, sodium nitroprusside test strip, 3.5.2 Any Diabetes Nurse Prescribers’ prescription for a medication requiring a Special Authority will only be subsidised if it is for a repeat prescription (ie after the initial prescription with Special Authority approval was dispensed). Note: A list of Diabetes Nurse Prescribers will be published periodically in the Update of the Pharmaceutical Schedule for the duration of an initial pilot scheme. After this period there will be no approved DHB demonstration sites and hence no Diabetes Nurse Prescribers.

PART IV DISPENSING FREQUENCY RULE

The Pharmaceutical Schedule speciﬁes, for community patients, a default period of supply for each Community Pharmaceutical (a Monthly Lot, 90 Day Lot or for oral contraceptives 180 Day Lot). This Dispensing Frequency rule deﬁnes patient groups or medicines eligible for more frequent dispensing periods; and the conditions that must be met to enable any claim for payment of handling fees for the additional dispensings made. “Frequent Dispensing” means: G for a Community Pharmaceutical referred to in Section F Part I, dispensing in quantities less than one 90 Day Lot (or for oral contraceptives, less than one 180 Day Lot); or G for any other Community Pharmaceutical, where any of 4.1, 4.2 or 4.3 of Part IV apply, dispensing in quantities less than a Monthly Lot NOTE patients who have had more frequent dispensings due to being "intellectually impaired, frail, inﬁrm or unable to manage their medicines" will continue to receive the same frequency of dispensings until they are assessed to see if they are eligible for additional support under the Long-Term Condition (LTC) service. The structure of the remainder fee payment provides funding for pharmacy to continue to provide more frequent dispensings for patients until they are assessed. 4.1 Frequent Dispensings for persons in residential care 4.1.1 Pharmaceuticals can be dispensed in quantities of not less than 28 days to: G any person whose placement in a Residential Disability Care Institution is funded by the Ministry of Health or a DHB; or G a person assessed as requiring long term residential care services and residing in an age related residential care facility; on the request of the person, their agent or caregiver or community residential service provider, provided the following conditions are met: a) the quantity or period of supply to be dispensed at any one time is not less than 28 days’ supply (except under conditions outlined in 4.2.2 below); and b) the prescribing Practitioner or dispensing pharmacist has i) included the name of the patient’s residential placement or facility on the Prescription; and ii) included the patient’s NHI number on the Prescription; and iii) speciﬁed the maximum quantity or period of supply to be dispensed at any one time. 4.1.2 Any person meeting the criteria above who is being initiated onto a new medicine or having their dose changed is able to have their medicine dispensed in accordance with 4.2.2 below. 4.2 Frequent Dispensings for trial periods or safety medicines 4.2.1 If a Pharmacist considers more frequent dispensing is required, this can occur as follows: G For Long Term Condition (LTC) patients dispensing frequency can occur as often as the dispensing pharmacist deems appropriate to meet the patients compliance and adherence needs; G For non-LTC patients the dispensing frequency should be no more often than monthly. If Frequent Dispensing more often than monthly is necessary for non-LTC patients, prescriber approval is required. Verbal approval is acceptable, provided that it is annotated by the pharmacist on the Prescription and dated.

SECTION A: GENERAL RULES

NOTE this rule does not override alternative dispensing frequencies as expressly stated in the Medicines Act, Medicines Regulations, Pharmacy Services Agreement, Pharmaceutical Schedule or under rule 4.2.2 Trial Periods or rule 4.2.3 safety and co-prescribed medicines below. Pharmacy would claim handling fees only on repeats under the above scenarios. Prescribers can request, and pharmacists may dispense a higher frequency of dispensing in the following circumstances: 4.2.2 Trial Periods The Community Pharmaceutical has been prescribed for a patient who requires close monitoring due to recent initiation onto, or dose change for, the Community Pharmaceutical (applicable to the patient’s ﬁrst changed Prescription only); and the prescribing Practitioner has: G endorsed each Community Pharmaceutical on the Prescription clearly with the words “Trial Period”, or “Trial”; and G speciﬁed the maximum quantity or period of supply to be dispensed for each Community Pharmaceutical at any one time. Patients who reside in Penal Institutions are not eligible for Trial Periods. 4.2.3 Safety and co-prescribed medicines a) The Community Pharmaceutical is any of the following: i) a tri-cyclic antidepressant; or ii) an antipsychotic; or iii) a benzodiazepine; or iv) a Class B Controlled Drug; or v) codeine (includes combination products) vi) buprenorphine with naloxone All of the following conditions must be met: The Community Pharmaceutical has been prescribed for a patient who is not a resident in a Penal Institution, or one of the residential placements or facilities referenced in 4.1 above. The prescribing Practitioner has: G Assessed clinical risk and determined the patient requires Frequent Dispensing; and G Speciﬁed the maximum quantity or period of supply to be dispensed for each Community Pharmaceutical at any one time. b) The Community Pharmaceutical is co-prescribed with one of the Community Pharmaceuticals listed in 4.2.3(a) above and has been prescribed for a patient who is not a resident in a Penal Institution, or one of the residential placements or facilities referenced in 4.1 above. The dispensing pharmacist has: G Assessed clinical risk and determined the patient requires Frequent Dispensing; G Annotated the Prescription with the amended dispensing quantity and frequency. 4.3 Frequent Dispensing for Pharmaceutical Supply Management 4.3.1 Frequent Dispensing may be required from time to time to manage stock supply issues or emergency situations. Pharmacists may dispense more frequently than the Schedule would otherwise allow when all of the following conditions are met: a) PHARMAC has approved and notiﬁed pharmacists to annotate Prescriptions for a speciﬁed Community Pharmaceutical(s) “out of stock” without prescriber endorsement for a speciﬁed time; and b) the dispensing pharmacist has: i) clearly annotated each of the approved Community Pharmaceuticals that appear on the Prescription with the words “out of stock” or “OOS”; and ii) initialled the annotation in their own handwriting; and iii) has complied with maximum quantity or period of supply to be dispensed at any one time, as speciﬁed by PHARMAC at the time of notiﬁcation. Note – no claim shall be made to any DHB for subsidised dispensing where dispensing occurs more frequently than speciﬁed by PHARMAC to manage the supply management issue.

SECTION A: GENERAL RULES

PART V MISCELLANEOUS PROVISIONS

5.1 Bulk Supply Orders The following provisions apply to the supply of Community Pharmaceuticals under Bulk Supply Orders: 5.1.1 No Community Pharmaceutical supplied under a Bulk Supply Order will be subsidised unless all the requirements in Section B, C or D of the Schedule applicable to that pharmaceutical are met. 5.1.2 The person who placed the Bulk Supply Order may be called upon by the Ministry of Health to justify the amount ordered. 5.1.3 Class B Controlled Drugs will be subsidised only if supplied under Bulk Supply Orders placed by an institution certiﬁed to provide hospital care under the Health and Disability Services (Safety) Act 2001. 5.1.4 Any order for a Class B Controlled Drug or for buprenorphine hydrochloride must be written on a Special Bulk Supply Order Controlled Drug Form supplied by the Ministry of Health. 5.1.5 Community Pharmaceuticals listed in Part I of the First Schedule to the Medicines Regulations 1984 will be subsidised only if supplied under a Bulk Supply Order placed by an institution certiﬁed to provide hospital care under the Health and Disability Services (Safety) Act 2001 and: a) that institution employs a registered general nurse, registered with the Nursing Council and who holds a current annual practicing certiﬁcate under the HPCA Act 2003; and b) the Bulk Supply Order is supported by a written requisition signed by a Hospital Care Operator. 5.1.6 No Subsidy will be paid for any quantity of a Community Pharmaceutical supplied under a Bulk Supply Order in excess of what is a reasonable monthly allocation for the particular institution, after taking into account stock on hand. 5.1.7 The Ministry of Health may, at any time, by public notiﬁcation, declare that any approved institution within its particular region, is not entitled to obtain supplies of Community Pharmaceuticals under Bulk Supply Orders with effect from the date speciﬁed in that declaration. Any such notice may in like manner be revoked by the Ministry of Health at any time. 5.2 Practitioner’s Supply Orders The following provisions apply to the supply of Community Pharmaceuticals to Practitioners under a Practitioner’s Supply Order: 5.2.1 Subject to clause 5.2.3, a Practitioner may only order under a Practitioner’s Supply Order those Community Pharmaceuticals listed in Section E Part I and only in such quantities as set out in Section E Part I that the Practitioner requires to ensure medical supplies are available for emergency use, teaching and demonstration purposes, and for provision to certain patient groups where individual prescription is not practicable. 5.2.2 Any order for a Class B Controlled Drug or for buprenorphine hydrochloride must be written on a Special Practitioner’s Supply Order Controlled Drug Form supplied by the Ministry of Health. 5.2.3 A Practitioner may order such Community Pharmaceuticals as he or she expects to be required for personal administration to patients under the Practitioner’s care if: a) the Practitioner’s normal practice is in the speciﬁed areas listed in Section E Part II of the Schedule, or if the Practitioner is a locum for a Practitioner whose normal practice is in such an area. b) the quantities ordered are reasonable for up to one Month’s supply under the conditions normally existing in the practice. (The Practitioner may be called on by the Ministry of Health to justify the amounts of Community Pharmaceuticals ordered.) 5.2.4 No Community Pharmaceutical ordered under a Practitioner’s Supply order will be eligible for Subsidy unless: a) the Practitioner’s Supply Order is made on a form supplied for that purpose by the Ministry of Health, or approved by the Ministry of Health and which: i) is personally signed and dated by the Practitioner; and ii) sets out the Practitioner’s address; and iii) sets out the Community Pharmaceuticals and quantities, and; b) all the requirements of Sections B and C of the Schedule applicable to that pharmaceutical are met. 5.2.5 The Ministry of Health may, at any time, on the recommendation of an Advisory Committee appointed by the Ministry of Health for that purpose, by public notiﬁcation, declare that a Practitioner speciﬁed in such a notice is not entitled to obtain supplies of Community Pharmaceuticals under Practitioner’s Supply Orders until such time as the Ministry of Health notiﬁes otherwise. 5.3 Retail Pharmacy and Hospital Pharmacy-Specialist Restriction

SECTION A: GENERAL RULES

The following provisions apply to Prescriptions for Community Pharmaceuticals eligible to be subsidised as “Retail Pharmacy-Specialist” and “Hospital Pharmacy-Specialist”: 5.3.1 Record Keeping It is expected that a record will be kept by both the General Practitioner and the Specialist of the fact of consultation and enough of the clinical details to justify the recommendation. This means referral by telephone will need to be followed up by written consultation. 5.3.2 Expiry The recommendation expires at the end of two years and can be renewed by a further consultation. 5.3.3 The circulation by Specialists of the circumstances under which they are prepared to recommend a particular Community Pharmaceutical is acceptable as a guide. It must however be followed up by the procedure in subclauses 5.3.1 and 5.3.2, for the individual Patient. 5.3.4 The use of preprinted forms and named lists of Specialists (as circulated by some pharmaceutical companies) is regarded as inappropriate. 5.3.5 The Rules for Retail Pharmacy-Specialist and Hospital Pharmacy-Specialist will be audited as part of the Ministry of Health’s routine auditing procedures. 5.4 Pharmaceutical Cancer Treatments 5.4.1 DHBs must provide access to Pharmaceutical Cancer Treatments for the treatment of cancers in their DHB hospitals, and/or in association with Outpatient services provided in their DHB hospitals. 5.4.2 DHBs must only provide access to Pharmaceuticals for the treatment of cancer that are listed as Pharmaceutical Cancer Treatments in Sections A to G of the Schedule, provided that DHBs may provide access to an unlisted pharmaceutical for the treatment of cancer where that unlisted pharmaceutical: a) has Named Patient Pharmaceutical Assessment (NPPA) approval; b) is being used as part of a bona ﬁde clinical trial which has Ethics Committee approval; c) is being used and funded as part of a paediatric oncology service; or d) was being used to treat the patient in question prior to 1 July 2005. 5.4.3 A DHB hospital pharmacy that holds a claiming agreement for Pharmaceutical Cancer Treatements with the Funder may claim a Subsidy for a Pharmaceutical Cancer Treatment marked as “PCT” or “PCT only” in Sections A to G of this Schedule subject to that Pharmaceutical Cancer Treatment being dispensed in accordance with: a) Part 1; b) clauses 2.1 to 2.3; c) clauses 3.1 to 3.4; and d) clause 5.4, of Section A of the Schedule 5.4.4 A Contractor (other than a DHB hospital pharmacy) may only claim a Subsidy for a Pharmaceutical Cancer Treatment marked as “PCT” in Sections A to G of the Schedule subject to that Pharmaceutical Cancer Treatment being dispensed in accordance with the rules applying to Sections A to G of the Schedule. 5.4.5 Some indications for Pharmaceutical Cancer Treatments listed in the Schedule are Unapproved Indications. Some of these formed part of the October 2001 direction from the Minister of Health as to pharmaceuticals and indications for which DHBs must provide funding. As far as reasonably practicable, these Unapproved Indications are marked in the Schedule. However, PHARMAC makes no representation and gives no guarantee as to the accuracy of this information. Practitioners prescribing Pharmaceutical Cancer Treatments for such Unapproved Indications should: a) be aware of and comply with their obligations under sections 25 and 29 of the Medicines Act 1981, as applicable, and otherwise under the Medicines Act and the Medicines Regulations 1984; b) be aware of and comply with their obligations under the Health and Disability Comissioner’s Code of Consumer Rights, including the requirement to obtain informed consent from the patient (PHARMAC recommends that Practitioners obtain written consent); and c) exercise their own skill, judgement, expertise and discretion, and make their own prescribing decisions with respect to the use of an unapproved Pharmaceutical Cancer Treatment or a Pharmaceutical Cancer Treatment for an Unapproved Indication. 5.5 Practitioners prescribing unapproved Pharmaceuticals Practitioners should, where possible, prescribe Pharmaceuticals that are approved under the Medicines Act 1981. However, the access criteria under which a Pharmaceutical is listed on the Pharmaceutical Schedule may:

SECTION A: GENERAL RULES

a) in some case, explicitly permit Government funded access to a Pharmaceutical that is not approved under the Medicines Act 1981 or for an Unapproved Indication; or b) not explicitly preclude Government funded access to a Pharmaceutical when it is used for an Unapproved Indication; Accordingly, if Practitioners are planning on prescribing an unapproved Pharmaceutical or a Pharmaceutical for an Unapproved Indication, Practitioners should: a) be aware of and comply with their obligations under sections 25 and 29 of the Medicines Act 1981, as applicable, and otherwise under that Act and the Medicines Regulations 1984; b) be aware of and comply with their obligations under the Health and Disability Commissioner’s Code of Consumer Rights, including the requirement to obtain informed consent from the patient (PHARMAC recommends that Practitioners obtain written consent); and c) exercise their own skill, judgment, expertise and discretion, and make their own prescribing decisions with respect to the use of an unapproved Pharmaceutical or a Pharmaceutical for an Unapproved Indication. Practitioners should be aware that simply by listing a Pharmaceutical on the Pharmaceutical Schedule PHARMAC makes no representations about whether that Pharmaceutical has any form of approval or consent under, or whether the supply or use of the Pharmaceutical otherwise complies with, the Medicines Act 1981. Further, the Pharmaceutical Schedule does not constitute an advertisement, advertising material or a medical advertisement as deﬁned in the Medicines Act or otherwise. 5.6 Substitution Where a Practitioner has prescribed a brand of a Community Pharmaceutical that has no Subsidy or has a Manufacturer’s Price that is greater than the Subsidy and there is an alternative fully subsidised Community Pharmaceutical available, a Contractor may dispense the fully subsidised Community Pharmaceutical, unless either or both of the following circumstances apply: a) there is a clinical reason why substitution should not occur; or b) the prescriber has marked the prescription with a statement such as ‘no brand substitution premitted’ Such an Authority to Substitute is valid whether or not there is a ﬁnancial implication for the Pharmaceutical Budget. When dispensing a subsidised alternative brand, the Contractor must annotate and sign the prescription and inform the patient of the brand change. 5.7 Alteration to Presentation of Pharmaceutical Dispensed A Contractor, when dispensing a subsidised Community Pharmaceutical, may alter the presentation of a Pharmaceutical dispensed to another subsidised presentation but may not alter the dose, frequency and/or total daily dose. This may only occur when it is not practicable for the contractor to dispense the requested presentation. If the change will result in additional cost to the DHBs, then annotation of the prescription by the dispensing pharmacist must occur stating the reason for the change, and the Contractor must initial the change for the purposes of Audit. 5.8 Conﬂict in Provisions If any rules in Sections B-G of this Schedule conﬂict with the rules in Section A, the rules in Sections B-G apply.

SECTION B: ALIMENTARY TRACT AND METABOLISM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

Antacids and Antiﬂatulants Antacids and Reﬂux Barrier Agents

ALGINIC ACID Sodium alginate 225 mg and magnesium alginate 87.5 mg per sachet .................................................................................... 4.50

Gaviscon Infant

CALCIUM CARBONATE WITH AMINOACETIC ACID F Tab 420 mg with aminoacetic acid 180 mg – Higher subsidy of $6.30 per 100 tab with Endorsement........................................ 3.00 100 (6.30) Titralac Additional subsidy by endorsement is available for pregnant women. The prescription must be endorsed accordingly. SIMETHICONE F Oral liq aluminium hydroxide 200 mg with magnesium hydroxide 200 mg and activated simethicone 20 mg per 5 ml ............... 1.50 500 ml (4.26) Mylanta P SODIUM ALGINATE F Tab 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg - peppermint ﬂavour ....................................... 1.80 (8.60) F Oral liq 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg per 10 ml ........................................................ 1.50 (4.95)

60 Gaviscon Double Strength 500 ml Acidex

Phosphate Binding Agents

ALUMINIUM HYDROXIDE F Tab 600 mg .......................................................................................12.56 100

Alu-Tab

Antidiarrhoeals Agents Which Reduce Motility

DIPHENOXYLATE HYDROCHLORIDE WITH ATROPINE SULPHATE F Tab 2.5 mg with atropine sulphate 25 µg ...........................................3.90 LOPERAMIDE HYDROCHLORIDE – Up to 30 cap available on a PSO F Tab 2 mg .............................................................................................8.95 F Cap 2 mg ............................................................................................8.95 100 400 400

Diastop Nodia Diamide Relief

Rectal and Colonic Anti-inﬂammatories

BUDESONIDE Cap 3 mg – Special Authority see SA1155 on the next page – Retail pharmacy ................................................................... 166.50

Entocort CIR

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

ALIMENTARY TRACT AND METABOLISM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

¾SA1155 Special Authority for Subsidy Initial application — (Crohn’s disease) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Mild to moderate ileal, ileocaecal or proximal Crohn’s disease; and 2 Any of the following: 2.1 Diabetes; or 2.2 Cushingoid habitus; or 2.3 Osteoporosis where there is signiﬁcant risk of fracture; or 2.4 Severe acne following treatment with conventional corticosteroid therapy; or 2.5 History of severe psychiatric problems associated with corticosteroid treatment; or 2.6 History of major mental illness (such as bipolar affective disorder) where the risk of conventional corticosteroid treatment causing relapse is considered to be high; or 2.7 Relapse during pregnancy (where conventional corticosteroids are considered to be contraindicated). Initial application — (collagenous and lymphocytic colitis (microscopic colitis)) from any relevant practitioner. Approvals valid for 6 months where patient has a diagnosis of microscopic colitis (collagenous or lymphocytic colitis) by colonoscopy with biopsies. Initial application — (gut Graft versus Host disease) from any relevant practitioner. Approvals valid for 6 months where patient has a gut Graft versus Host disease following allogenic bone marrow transplantation*. Note: Indication marked with * is an Unapproved Indication. Renewal from any relevant practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is beneﬁting from treatment. Note: Clinical trials for Entocort CIR use beyond three months demonstrated no improvement in relapse rate. HYDROCORTISONE ACETATE Rectal foam 10%, CFC-Free (14 applications) .................................23.00 21.1 g OP Colifoam MESALAZINE Tab 400 mg .......................................................................................49.50 Tab EC 500 mg .................................................................................49.50 Tab long-acting 500 mg ....................................................................59.05 Enema 1 g per 100 ml ......................................................................44.12 Suppos 500 mg ................................................................................22.80 Suppos 1 g .......................................................................................50.96 OLSALAZINE Tab 500 mg .......................................................................................59.86 Cap 250 mg ......................................................................................31.51 SODIUM CROMOGLYCATE Cap 100 mg ......................................................................................89.21 SULPHASALAZINE F Tab 500 mg – For sulphasalazine oral liquid formulation refer, page 182 .................................................................................... 11.68 F Tab EC 500 mg .................................................................................12.89 100 100 100 7 20 28 100 100 100

Asacol Asamax Pentasa Pentasa Asacol Pentasa Dipentum Dipentum Nalcrom

100 100

Salazopyrin Salazopyrin EN

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

ALIMENTARY TRACT AND METABOLISM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

Antihaemorrhoidals Corticosteroids

FLUOCORTOLONE CAPROATE WITH FLUOCORTOLONE PIVALATE AND CINCHOCAINE Oint 950 µg, with ﬂuocortolone pivalate 920 µg, and cinchocaine hydrochloride 5 mg per g ............................................. 6.35 30 g OP Suppos 630 µg, with ﬂuocortolone pivalate 610 µg, and cinchocaine hydrochloride 1 mg ....................................................... 2.66 12 HYDROCORTISONE WITH CINCHOCAINE Oint 5 mg with cinchocaine hydrochloride 5 mg per g ......................15.00 Suppos 5 mg with cinchocaine hydrochloride 5 mg per g ..................9.90 30 g OP 12

Ultraproct Ultraproct Proctosedyl Proctosedyl

Antispasmodics and Other Agents Altering Gut Motility

ATROPINE SULPHATE F Inj 600 µg, 1 ml – Up to 5 inj available on a PSO.............................52.00 HYOSCINE N-BUTYLBROMIDE F Tab 10 mg ...........................................................................................1.48 F Inj 20 mg, 1 ml – Up to 5 inj available on a PSO ................................9.57 MEBEVERINE HYDROCHLORIDE F Tab 135 mg .......................................................................................18.00 50 20 5 90

AstraZeneca Gastrosoothe Buscopan Colofac

Antiulcerants Antisecretory and Cytoprotective

MISOPROSTOL F Tab 200 µg .......................................................................................52.70 120

Cytotec

Helicobacter Pylori Eradication

CLARITHROMYCIN Tab 500 mg – Subsidy by endorsement ............................................10.95 14 Apo-Clarithromycin a) Maximum of 14 tab per prescription b) Subsidised only if prescribed for helicobacter pylori eradication and prescription is endorsed accordingly. Note: the prescription is considered endorsed if clarithromycin is prescribed in conjunction with a proton pump inhibitor and either amoxycillin or metronidazole.

H2 Antagonists

CIMETIDINE – Only on a prescription F Tab 200 mg .........................................................................................5.00 (7.50) F Tab 400 mg .......................................................................................10.00 (12.00) FAMOTIDINE – Only on a prescription F Tab 20 mg ...........................................................................................8.10 F Tab 40 mg .........................................................................................11.35 100 Apo-Cimetidine 100 Apo-Cimetidine 250 250

Famox Famox

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

ALIMENTARY TRACT AND METABOLISM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

RANITIDINE HYDROCHLORIDE – Only on a prescription F Tab 150 mg .........................................................................................6.79 F Tab 300 mg .........................................................................................9.34 F Oral liq 150 mg per 10 ml ...................................................................5.92 F Inj 25 mg per ml, 2 ml .........................................................................8.75

250 250 300 ml 5

Arrow-Ranitidine Arrow-Ranitidine Peptisoothe Zantac

Proton Pump Inhibitors

LANSOPRAZOLE F Cap 15 mg ..........................................................................................3.27 3.50 F Cap 30 mg ..........................................................................................4.34 4.65 OMEPRAZOLE For omeprazole suspension refer, page 185 F Cap 10 mg ..........................................................................................2.91 F Cap 20 mg ..........................................................................................3.78 F Cap 40 mg ..........................................................................................5.57 F Powder – Only in combination .........................................................42.50 Only in extemporaneously compounded omeprazole suspension. F Inj 40 mg ...........................................................................................28.65 PANTOPRAZOLE F Tab 20 mg ...........................................................................................1.23 F Tab 40 mg ...........................................................................................1.54 F Inj 40 mg .............................................................................................6.50 28 28

Lanzol Relief Solox Lanzol Relief Solox

90 90 90 5g 5

Omezol Relief Omezol Relief Omezol Relief Midwest Dr Reddy’s

Omeprazole

28 28 1

Dr Reddy’s

Pantoprazole

Dr Reddy’s

Pantoprazole

Pantocid IV

Site Protective Agents

SUCRALFATE Tab 1 g ..............................................................................................35.50 (48.28) 120 Carafate

Diabetes Hyperglycaemic Agents

GLUCAGON HYDROCHLORIDE Inj 1 mg syringe kit – Up to 5 kit available on a PSO........................32.00 1

Glucagen Hypokit

Insulin - Short-acting Preparations

INSULIN NEUTRAL L Inj human 100 u per ml .....................................................................25.26 L Inj human 100 u per ml, 3 ml ............................................................42.66 10 ml OP 5

Actrapid Humulin R Actrapid Penﬁll Humulin R

Insulin - Intermediate-acting Preparations

INSULIN ASPART L Inj 100 iu per ml, 3 ml preﬁlled pen ...................................................52.15 5

NovoMix 30 FlexPen

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

ALIMENTARY TRACT AND METABOLISM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

INSULIN ISOPHANE L Inj human 100 u per ml .....................................................................17.68 L Inj human 100 u per ml, 3 ml ............................................................29.86 INSULIN ISOPHANE WITH INSULIN NEUTRAL L Inj human with neutral insulin 100 u per ml ......................................25.26 L Inj human with neutral insulin 100 u per ml, 3 ml .............................42.66

10 ml OP 5

Humulin NPH Protaphane Humulin NPH Protaphane Penﬁll Humulin 30/70 Mixtard 30 Humulin 30/70 PenMix 30 PenMix 40 PenMix 50

10 ml OP 5

INSULIN LISPRO WITH INSULIN LISPRO PROTAMINE L Inj lispro 25% with insulin lispro protamine 75% 100 u per ml, 3 ml ............................................................................................52.15 L Inj lispro 50% with insulin lispro protamine 50% 100 u per ml,3 ml ...............................................................................................52.15

5 5

Humalog Mix 25 Humalog Mix 50

Insulin - Long-acting Preparations

INSULIN GLARGINE L Inj 100 u per ml, 10 ml ......................................................................63.00 L Inj 100 u per ml, 3 ml ........................................................................94.50 L Inj 100 u per ml, 3 ml disposable pen ...............................................94.50 1 5 5

Lantus Lantus Lantus SoloStar

Insulin - Rapid Acting Preparations

INSULIN ASPART L Inj 100 u per ml, 3 ml ........................................................................51.19 L Inj 100 u per ml, 10 ml ......................................................................30.03 INSULIN GLULISINE L Inj 100 u per ml, 10 ml ......................................................................27.03 L Inj 100 u per ml, 3 ml ........................................................................46.07 L Inj 100 u per ml, 3 ml disposable pen ...............................................46.07 INSULIN LISPRO L Inj 100 u per ml, 10 ml ......................................................................34.92 L Inj 100 u per ml, 3 ml ........................................................................59.52 5 1 1 5 5 10 ml OP 5

NovoRapid Penﬁll NovoRapid Apidra Apidra Apidra SoloStar Humalog Humalog

Alpha Glucosidase Inhibitors

ACARBOSE F Tab 50 mg .........................................................................................16.50 F Tab 100 mg .......................................................................................26.70 90 90

Glucobay Glucobay

Oral Hypoglycaemic Agents

GLIBENCLAMIDE F Tab 5 mg .............................................................................................5.00 GLICLAZIDE F Tab 80 mg .........................................................................................17.60 GLIPIZIDE F Tab 5 mg .............................................................................................3.50

fully subsidised [HP4] refer page 9

100 500 100

Daonil Apo-Gliclazide Minidiab

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

ALIMENTARY TRACT AND METABOLISM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

METFORMIN HYDROCHLORIDE F Tab immediate-release 500 mg ..........................................................8.09 12.30 F Tab immediate-release 850 mg ..........................................................6.67 10.10 PIOGLITAZONE – Special Authority see SA0959 below – Retail pharmacy F Tab 15 mg ...........................................................................................1.50 F Tab 30 mg ...........................................................................................2.50 F Tab 45 mg ...........................................................................................3.50

500 1,000 250 500 28 28 28

Apotex Apo-Metformin Apotex Apo-Metformin Pizaccord Pizaccord Pizaccord

¾SA0959 Special Authority for Subsidy Initial application — (Patients with type 2 diabetes) from any relevant practitioner. Approvals valid without further renewal unless notiﬁed for applications meeting the following criteria: Either: 1 Patient has not achieved glycaemic control on maximum doses of metformin or a sulphonylurea or where either or both are contraindicated or not tolerated; or 2 Patient is on insulin.

Diabetes Management Ketone Testing

KETONE BLOOD BETA-KETONE ELECTRODES – Maximum of 20 strip per prescription Test strip – Not on a BSO...................................................................7.07 10 strip OP SODIUM NITROPRUSSIDE – Maximum of 50 strip per prescription F Test strip – Not on a BSO...................................................................6.00 14.14

Freestyle Optium

Ketone

50 strip OP

Accu-Chek

Ketur-Test

Ketostix

Blood Glucose Testing

BLOOD GLUCOSE DIAGNOSTIC TEST METER – Subsidy by endorsement a) Maximum of 1 meter per prescription b) 1) A diagnostic blood glucose test meter is subsidised for patients who begin insulin or sulphonylurea therapy after 1 March 2005 or is prescribed for a pregnant woman with diabetes. 2) Only one meter per patient. No further prescriptions will be subsidised. The prescription must be endorsed accordingly. Meter ..................................................................................................6.00 1 CareSens POP 9.00 CareSens II FreeStyle Lite Freestyle Optium On Call Advanced 19.00 Accu-Chek Performa

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

ALIMENTARY TRACT AND METABOLISM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

BLOOD GLUCOSE DIAGNOSTIC TEST STRIP The number of test strips available on a prescription is restricted to 50 unless: 1) Prescribed with insulin or a sulphonylurea but are on a different prescription and the prescription is endorsed accordingly; or 2) Prescribed on the same prescription as insulin or a sulphonylurea in which case the prescription is deemed to be endorsed; or 3) Prescribed for a pregnant woman with diabetes and endorsed accordingly. SensoCard blood glucose test strips are subsidised only if prescribed for a patient who is severely visually impaired and is using a SensoCard Plus Talking Blood Glucose Monitor. Blood glucose test strips ..................................................................21.65 50 test OP Accu-Chek Performa FreeStyle Lite Freestyle Optium 26.20 SensoCard Blood glucose test strips × 50 and lancets × 5 ...............................19.10 50 test OP On Call Advanced 19.60 CareSens

Insulin Syringes and Needles

Subsidy is available for disposable insulin syringes, needles, and pen needles if prescribed on the same form as the one used for the supply of insulin or when prescribed for an insulin patient and the prescription is endorsed accordingly. INSULIN PEN NEEDLES – Maximum of 100 dev per prescription F 29 g × 12.7 mm ..................................................................................3.15 30 B-D Micro-Fine 10.50 100 B-D Micro-Fine ABM 11.75 SC Proﬁ-Fine F 31 g × 5 mm .....................................................................................11.75 100 B-D Micro-Fine SC Proﬁ-Fine F 31 g × 6 mm .....................................................................................10.50 100 ABM 11.75 Fine Ject 10.50 (26.00) NovoFine F 31 g × 8 mm .......................................................................................3.15 30 B-D Micro-Fine 10.50 100 B-D Micro-Fine ABM 11.75 SC Proﬁ-Fine F 32 g × 4 mm .....................................................................................10.50 100 B-D Micro-Fine (SC Proﬁ-Fine 29 g × 12.7 mm to be delisted 1 December 2012) (SC Proﬁ-Fine 31 g × 5 mm to be delisted 1 December 2012) (Fine Ject 31 g × 6 mm to be delisted 1 December 2012) (SC Proﬁ-Fine 31 g × 8 mm to be delisted 1 December 2012)

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

ALIMENTARY TRACT AND METABOLISM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

INSULIN SYRINGES, DISPOSABLE WITH ATTACHED NEEDLE – Maximum of 100 dev per prescription F Syringe 0.3 ml with 29 g × 12.7 mm needle ....................................13.00 100 ABM 1.30 10 (1.99) B-D Ultra Fine 13.00 100 B-D Ultra Fine DM Ject F Syringe 0.3 ml with 31 g × 8 mm needle .........................................13.00 100 ABM 1.30 10 (1.99) B-D Ultra Fine II 13.00 100 B-D Ultra Fine II DM Ject F Syringe 0.5 ml with 29 g × 12.7 mm needle ....................................13.00 100 ABM 1.30 10 (1.99) B-D Ultra Fine 13.00 100 B-D Ultra Fine DM Ject F Syringe 0.5 ml with 31 g × 8 mm needle .........................................13.00 100 ABM 1.30 10 (1.99) B-D Ultra Fine II 13.00 100 B-D Ultra Fine II DM Ject F Syringe 1 ml with 29 g × 12.7 mm needle .......................................13.00 100 ABM 1.30 10 (1.99) B-D Ultra Fine 13.00 100 B-D Ultra Fine DM Ject F Syringe 1 ml with 31 g × 8 mm needle ............................................13.00 100 ABM 1.30 10 (1.99) B-D Ultra Fine II 13.00 100 B-D Ultra Fine II DM Ject (DM Ject Syringe 0.3 ml with 29 g × 12.7 mm needle to be delisted 1 December 2012) (DM Ject Syringe 0.3 ml with 31 g × 8 mm needle to be delisted 1 December 2012) (DM Ject Syringe 0.5 ml with 29 g × 12.7 mm needle to be delisted 1 December 2012) (DM Ject Syringe 0.5 ml with 31 g × 8 mm needle to be delisted 1 December 2012) (DM Ject Syringe 1 ml with 29 g × 12.7 mm needle to be delisted 1 December 2012) (DM Ject Syringe 1 ml with 31 g × 8 mm needle to be delisted 1 December 2012)

Digestives Including Enzymes

PANCREATIC ENZYME Cap EC 10,000 BP u lipase, 9,000 BP u amylase and 210 BP u protease ..................................................................... 34.93 Cap EC 25,000 BP u lipase, 18,000 BP u amylase, 1,000 BP u protease .................................................................. 94.38 Cap EC 25,000 BP u lipase, 22,500 BP u amylase, 1,250 BP u protease .................................................................. 94.40

100 100 100

Creon 10000 Creon Forte Panzytrat

URSODEOXYCHOLIC ACID – Special Authority see SA1188 on the next page – Retail pharmacy Brand switch fee payable - see page 180 for details Cap 250 mg – For ursodeoxycholic acid oral liquid formulation refer, page 182..................................................................... 71.50 100 Ursosan

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

ALIMENTARY TRACT AND METABOLISM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

¾SA1188 Special Authority for Subsidy Initial application — (Pregnancy/Cirrhosis) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: Either: 1 Patient diagnosed with cholestasis of pregnancy; or 2 Both: 2.1 Primary biliary cirrhosis conﬁrmed by antimitochondrial antibody titre (AMA) > 1:80, and raised cholestatic liver enzymes with or without raised serum IgM or, if AMA is negative, by liver biopsy; and 2.2 Patient not requiring a liver transplant (bilirubin > 170umol/l; decompensated cirrhosis). Note: Liver biopsy is not usually required for diagnosis but is helpful to stage the disease. Initial application — (Haematological Transplant) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Patient at risk of veno-occlusive disease or has hepatic impairment and is undergoing conditioning treatment prior to allogenic stem cell or bone marrow transplantation; and 2 Treatment for up to 13 weeks. Renewal — (Pregnancy/Cirrhosis) from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is beneﬁting from treatment. Note: Ursodeoxycholic acid is not an appropriate therapy for patients requiring a liver transplant (bilirubin > 170 micromol/l; decompensated cirrhosis). These patients should be referred to an appropriate transplant centre. Treatment failure – doubling of serum bilirubin levels, absence of a signiﬁcant decrease in ALP or ALT and AST, development of varices, ascites or encephalopathy, marked worsening of pruritus or fatigue, histological progression by two stages, or to cirrhosis, need for transplantation.

Laxatives Bulk-forming Agents

MUCILAGINOUS LAXATIVES – Only on a prescription F Dry ......................................................................................................6.02 F Sugar Free .........................................................................................3.31 (10.60) (Mucilax Sugar Free to be delisted 1 September 2012) MUCILAGINOUS LAXATIVES WITH STIMULANTS F Dry ......................................................................................................2.41 (8.72) 6.02 (17.32) 500 g OP 275 g OP

Konsyl-D

Mucilax

200 g OP Normacol Plus 500 g OP Normacol Plus

Faecal Softeners

DOCUSATE SODIUM – Only on a prescription F Cap 50 mg ..........................................................................................2.57 F Cap 120 mg ........................................................................................3.48 F Enema conc 18% ...............................................................................5.40 DOCUSATE SODIUM WITH SENNOSIDES F Tab 50 mg with total sennosides 8 mg ...............................................6.38 POLOXAMER – Only on a prescription Not funded for use in the ear. F Oral drops 10% ...................................................................................3.78 100 100 100 ml OP 200

Laxofast 50 Laxofast 120 Coloxyl Laxsol

30 ml OP

Coloxyl

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

ALIMENTARY TRACT AND METABOLISM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

Osmotic Laxatives

GLYCEROL F Suppos 3.6 g – Only on a prescription ...............................................6.00 LACTULOSE – Only on a prescription F Oral liq 10 g per 15 ml ........................................................................7.68 MACROGOL 3350 – Special Authority see SA0891 below – Retail pharmacy Powder 13.125 g, sachets – Maximum of 60 sach per prescription ...................................................................................... 18.14 20 1,000 ml

PSM Laevolac

Movicol

¾SA0891 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid for 6 months where the patient has problematic constipation requiring intervention with a per rectal preparation despite an adequate trial of other oral pharmacotherapies including lactulose where lactulose is not contraindicated. Renewal from any relevant practitioner. Approvals valid for 12 months where the patient is compliant and is continuing to gain beneﬁt from treatment. SODIUM ACID PHOSPHATE – Only on a prescription Enema 16% with sodium phosphate 8% ............................................2.50 1 Fleet Phosphate Enema SODIUM CITRATE WITH SODIUM LAURYL SULPHOACETATE – Only on a prescription Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml ............................................................................................ 25.00 50

Micolette

Stimulant Laxatives

BISACODYL – Only on a prescription F Tab 5 mg .............................................................................................4.99 F Suppos 5 mg ......................................................................................3.00 F Suppos 10 mg ....................................................................................3.00 DANTHRON WITH POLOXAMER – Only on a prescription Note: Only for the prevention or treatment of constipation in the terminally ill. Oral liq 25 mg with poloxamer 200 mg per 5 ml .................................9.50 Oral liq 75 mg with poloxamer 1 g per 5 ml ......................................13.95 SENNA – Only on a prescription F Tab, standardised ...............................................................................0.43 (1.72) 2.17 (6.16) 200 6 6

Lax-Tab Dulcolax Dulcolax

300 ml 300 ml 20

Pinorax Pinorax Forte

Senokot 100 Senokot

Metabolic Disorder Agents Gaucher’s Disease

IMIGLUCERASE – Special Authority see SA0473 on the next page – Retail pharmacy Inj 40 iu per ml, 200 iu vial ...........................................................1,072.00 1 Inj 40 iu per ml, 400 iu vial ...........................................................2,144.00 1

Cerezyme Cerezyme

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

ALIMENTARY TRACT AND METABOLISM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

¾SA0473 Special Authority for Subsidy Special Authority approved by the Gaucher’s Treatment Panel Notes: Subject to a budgetary cap. Applications will be considered and approved subject to funding availability. Application details may be obtained from PHARMAC’s website http://www.pharmac.govt.nz or: The Co-ordinator, Gaucher’s Treatment Panel Phone: (04) 460 4990 PHARMAC, PO Box 10 254 Facsimile: (04) 916 7571 Wellington Email: gaucherpanel@pharmac.govt.nz

Mouth and Throat Agents Used in Mouth Ulceration

BENZYDAMINE HYDROCHLORIDE Soln 0.15% .........................................................................................3.60 (8.50) 9.00 (17.01) CHLORHEXIDINE GLUCONATE Mouthwash 0.2% ................................................................................3.87 CHOLINE SALICYLATE WITH CETALKONIUM CHLORIDE F Adhesive gel 8.7% with cetalkonium chloride 0.01% .........................2.06 (5.62) SODIUM CARBOXYMETHYLCELLULOSE With pectin and gelatin paste ...........................................................17.20 1.52 (3.60) 4.55 (7.90) With pectin and gelatin powder ..........................................................8.48 (10.95) TRIAMCINOLONE ACETONIDE 0.1% in Dental Paste USP ..................................................................4.34 200 ml Difﬂam 500 ml Difﬂam 200 ml OP 15 g OP Bonjela 56 g OP 5 g OP 15 g OP Orabase 28 g OP Stomahesive 5 g OP

Rivacol

Stomahesive

Orabase

Oracort

Oropharyngeal Anti-infectives

AMPHOTERICIN B Lozenges 10 mg .................................................................................5.86 MICONAZOLE Oral gel 20 mg per g ...........................................................................8.70 NYSTATIN Oral liq 100,000 u per ml ....................................................................3.19 20 40 g OP 24 ml OP

Fungilin Daktarin Nilstat

Other Oral Agents

For folinic mouthwash, pilocarpine oral liquid or saliva substitute formula refer, page 185 HYDROGEN PEROXIDE F Soln 10 vol – Maximum of 200 ml per prescription.............................1.28 100 ml THYMOL GLYCERIN F Compound, BPC .................................................................................9.15 500 ml

PSM PSM

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

ALIMENTARY TRACT AND METABOLISM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

Vitamins

Alpha tocopheryl acetate is available fully subsidised for speciﬁc patients at the Medical Director of PHARMAC’s discretion. Refer to PHARMAC website www.pharmac.govt.nz for the “Alpha tocopheryl acetate information sheet and application form”.

Vitamin A

VITAMIN A WITH VITAMINS D AND C F Soln 1000 u with Vitamin D 400 u and ascorbic acid 30 mg per 10 drops ................................................................................4.50

10 ml OP

Vitadol C

Vitamin B

HYDROXOCOBALAMIN F Inj 1 mg per ml, 1 ml – Up to 6 inj available on a PSO .......................5.10 PYRIDOXINE HYDROCHLORIDE a) No more than 100 mg per dose b) Only on a prescription F Tab 25 mg – No patient co-payment payable .....................................2.20 F Tab 50 mg .........................................................................................12.16 THIAMINE HYDROCHLORIDE – Only on a prescription F Tab 50 mg ...........................................................................................5.62 VITAMIN B COMPLEX F Tab, strong, BPC ................................................................................4.70 3

ABM

Hydroxocobalamin

90 500 100 500

PyridoxADE Apo-Pyridoxine Apo-Thiamine B-PlexADE

Vitamin C

ASCORBIC ACID a) No more than 100 mg per dose b) Only on a prescription F Tab 100 mg .......................................................................................13.80

500

Vitala-C

Vitamin D

ALFACALCIDOL F Cap 0.25 µg ......................................................................................26.32 F Cap 1 µg ...........................................................................................87.98 F Oral drops 2 µg per ml .....................................................................60.68 CALCITRIOL F Cap 0.25 µg ........................................................................................3.03 F Cap 0.5 µg ..........................................................................................5.62 F Oral liq 1 µg per ml ...........................................................................39.40 CHOLECALCIFEROL F Tab 1.25 mg (50,000 iu) – Maximum of 12 tab per prescription .........7.76 100 100 20 ml OP 30 30 10 ml OP 12

One-Alpha One-Alpha One-Alpha Airﬂow Airﬂow Rocaltrol solution Cal-d-Forte

Multivitamin Preparations

MULTIVITAMINS – Special Authority see SA1036 on the next page – Retail pharmacy F Powder ..............................................................................................72.00 200 g OP

Paediatric Seravit

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

ALIMENTARY TRACT AND METABOLISM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

¾SA1036 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid without further renewal unless notiﬁed where the patient has inborn errors of metabolism. Renewal from any relevant practitioner. Approvals valid without further renewal unless notiﬁed where patient has had a previous approval for multivitamins. VITAMINS F Tab (BPC cap strength) ......................................................................8.00 1,000 MultiADE F Cap (fat soluble vitamins A, D, E, K) – Special Authority see SA1002 below – Retail pharmacy .............................................23.40 60 Vitabdeck ¾SA1002 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid without further renewal unless notiﬁed for applications meeting the following criteria: Either: 1 Patient has cystic ﬁbrosis with pancreatic insufﬁciency; or 2 Patient is an infant or child with liver disease or short gut syndrome.

Minerals Calcium

CALCIUM CARBONATE F Tab eff 1.75 g (1 g elemental) .............................................................6.21 F Tab 1.25 g (500 mg elemental) ...........................................................6.38 CALCIUM GLUCONATE F Inj 10%, 10 ml ...................................................................................21.40 30 250 10

Calsource Arrow-Calcium Mayne

Fluoride

SODIUM FLUORIDE F Tab 1.1 mg (0.5 mg elemental) ...........................................................5.00 100

PSM

Iodine

POTASSIUM IODATE F Tab 256 µg (150 µg elemental iodine) ...............................................7.55 90

NeuroKare

Iron

FERROUS FUMARATE F Tab 200 mg (65 mg elemental) ...........................................................4.35 FERROUS FUMARATE WITH FOLIC ACID F Tab 310 mg (100 mg elemental) with folic acid 350 µg ......................4.75 FERROUS SULPHATE F Tab long-acting 325 mg (105 mg elemental) ......................................1.01 (4.26) 5.06 (15.58) F‡ Oral liq 30 mg per 1 ml (6 mg elemental per 1 ml) ...........................10.30 FERROUS SULPHATE WITH FOLIC ACID F Tab long-acting 325 mg (105 mg elemental) with folic acid 350 µg ......................................................................................... 1.80 (4.29) 100 60 30 Ferrograd 150 Ferrograd 500 ml

Ferro-tab Ferro-F-Tabs

Ferodan

30 Ferrograd F

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

ALIMENTARY TRACT AND METABOLISM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

IRON POLYMALTOSE F Inj 50 mg per ml, 2 ml .......................................................................19.90

Ferrum H

Magnesium

For magnesium hydroxide mixture refer, page 185 MAGNESIUM SULPHATE F Inj 49.3%, 5 ml ..................................................................................26.60

Mayne

Zinc

ZINC SULPHATE F Cap 137.4 mg (50 mg elemental) .....................................................11.00 100

Zincaps

Agents Used in the Treatment of Poisonings

CHARCOAL F Oral liq 50 g per 250 ml ....................................................................43.50 a) Up to 250 ml available on a PSO b) Only on a PSO SODIUM CALCIUM EDETATE F Inj 200 mg per ml, 5 ml .....................................................................53.31 (156.71) 250 ml OP

Carbosorb-X

6 Calcium Disodium Versenate

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

BLOOD AND BLOOD FORMING ORGANS

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

Antianaemics Hypoplastic and Haemolytic

¾SA0922 Special Authority for Subsidy Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Both: 1.1 patient in chronic renal failure; and 1.2 Haemoglobin ≤ 100g/L; and 2 Any of the following: 2.1 Both: 2.1.1 patient is not diabetic; and 2.1.2 glomerular ﬁltration rate ≤ 30ml/min; or 2.2 Both: 2.2.1 patient is diabetic; and 2.2.2 glomerular ﬁltration rate ≤ 45ml/min; or 2.3 patient is on haemodialysis or peritoneal dialysis. Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is beneﬁting from treatment. Notes: Erythropoietin beta is indicated in the treatment of anaemia associated with chronic renal failure (CRF) where no cause for anaemia other than CRF is detected and there is adequate monitoring of iron stores and iron replacement therapy. The Cockroft-Gault Formula may be used to estimate glomerular ﬁltration rate (GFR) in persons 18 years and over: GFR (ml/min) (male) = (140 - age) × Ideal Body Weight (kg) / 814 × serum creatinine (mmol/l) GFR (ml/min) (female) = Estimated GFR (male) × 0.85 ERYTHROPOIETIN ALPHA – Special Authority see SA0922 above – Retail pharmacy Inj human recombinant 1,000 iu preﬁlled syringe .............................48.68 6 Eprex Inj human recombinant 2,000 iu, preﬁlled syringe ..........................120.18 6 Eprex Inj human recombinant 3,000 iu, preﬁlled syringe ..........................166.87 6 Eprex Inj human recombinant 4,000 iu, preﬁlled syringe ..........................193.13 6 Eprex Inj human recombinant 5,000 iu, preﬁlled syringe ..........................243.26 6 Eprex Inj human recombinant 6,000 iu, preﬁlled syringe ..........................291.92 6 Eprex Inj human recombinant 10,000 iu, preﬁlled syringe ........................395.18 6 Eprex ERYTHROPOIETIN BETA – Special Authority see SA0922 above – Retail pharmacy Inj 2,000 iu, preﬁlled syringe ...........................................................120.18 Inj 3,000 iu, preﬁlled syringe ...........................................................166.87 Inj 4,000 iu, preﬁlled syringe ...........................................................193.13 Inj 5,000 iu, preﬁlled syringe ...........................................................243.26 Inj 6,000 iu, preﬁlled syringe ...........................................................291.29 Inj 10,000 iu, preﬁlled syringe .........................................................395.18 6 6 6 6 6 6

NeoRecormon NeoRecormon NeoRecormon NeoRecormon NeoRecormon NeoRecormon

Megaloblastic

FOLIC ACID F Tab 0.8 mg ........................................................................................19.80 F Tab 5 mg ...........................................................................................10.21 Oral liq 50 µg per ml .........................................................................24.00 1,000 500 25 ml OP

Apo-Folic Acid Apo-Folic Acid Biomed

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

BLOOD AND BLOOD FORMING ORGANS

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

Antiﬁbrinolytics, Haemostatics and Local Sclerosants

SODIUM TETRADECYL SULPHATE F Inj 0.5% 2 ml .....................................................................................23.20 (45.52) F Inj 1% 2 ml ........................................................................................25.00 (48.98) F Inj 3% 2 ml ........................................................................................28.50 (55.91) TRANEXAMIC ACID Tab 500 mg .......................................................................................32.92 5 Fibro-vein 5 Fibro-vein 5 Fibro-vein 100

Cyklokapron

Vitamin K

PHYTOMENADIONE Inj 2 mg per 0.2 ml – Up to 5 inj available on a PSO..........................8.00 Inj 10 mg per ml, 1 ml – Up to 5 inj available on a PSO .....................9.21 5 5

Konakion MM Konakion MM

Antithrombotic Agents Antiplatelet Agents

ASPIRIN F Tab 100 mg .......................................................................................14.00 CLOPIDOGREL F Tab 75 mg – For clopidogrel oral liquid formulation refer, page 182 ............................................................................................. 16.25 DIPYRIDAMOLE F Tab 25 mg – For dipyridamole oral liquid formulation refer, page 182 ......................................................................................8.36 F Tab long-acting 150 mg ....................................................................11.52 PRASUGREL – Special Authority see SA1201 below – Retail pharmacy Tab 5 mg .........................................................................................108.00 Tab 10 mg .......................................................................................120.00 990

Ethics Aspirin EC

Apo-Clopidogrel

84 60 28 28

Persantin Pytazen SR Efﬁent Efﬁent

¾SA1201 Special Authority for Subsidy Initial application — (coronary angioplasty and bare metal stent) from any relevant practitioner. Approvals valid for 6 months where the patient has undergone coronary angioplasty in the previous 4 weeks and is clopidogrel-allergic*. Initial application — (drug eluting stent) from any relevant practitioner. Approvals valid for 12 months where the patient has had a drug-eluting cardiac stent inserted in the previous 4 weeks and is clopidogrel-allergic*. Initial application — (stent thromobosis) from any relevant practitioner. Approvals valid without further renewal unless notiﬁed where patient has experienced cardiac stent thrombosis whilst on clopidogrel. Renewal — (coronary angioplasty and bare metal stent) from any relevant practitioner. Approvals valid for 6 months where the patient has undergone coronary angioplasty or had a bare metal cardiac stent inserted in the previous 4 weeks and is clopidogrelallergic*. Renewal — (drug eluting stent) from any relevant practitioner. Approvals valid for 12 months where had a drug-eluting cardiac stent inserted in the previous 4 weeks and is clopidogrel-allergic*. Note: * Clopidogrel allergy is deﬁned as a history of anaphylaxis, urticaria, generalised rash or asthma (in non-asthmatic patients) developing soon after clopidogrel is started and is considered unlikely to be caused by any other treatment.

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

BLOOD AND BLOOD FORMING ORGANS

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

Heparin and Antagonist Preparations

ENOXAPARIN SODIUM – Special Authority see SA1174 below – Retail pharmacy Inj 20 mg ...........................................................................................37.24 Inj 40 mg ...........................................................................................49.69 Inj 60 mg ...........................................................................................74.91 Inj 80 mg ...........................................................................................99.86 Inj 100 mg .......................................................................................125.06 Inj 120 mg .......................................................................................155.40 Inj 150 mg .......................................................................................177.60 10 10 10 10 10 10 10

Clexane Clexane Clexane Clexane Clexane Clexane Clexane

¾SA1174 Special Authority for Subsidy Initial application — (Pregnancy or Malignancy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: Either: 1 Low molecular weight heparin treatment is required during a patients pregnancy; or 2 For the treatment of venous thromboembolism where the patient has a malignancy. Initial application — (Venous thromboembolism other than in pregnancy or malignancy) from any relevant practitioner. Approvals valid for 1 month for applications meeting the following criteria: Any of the following: 1 For the short-term treatment of venous thromboembolism prior to establishing a therapeutic INR with oral anti-coagulant treatment; or 2 For the prophylaxis and treatment of venous thromboembolism in high risk surgery; or 3 To enable cessation/re-establishment of existing oral anticoagulant treatment pre/post surgery; or 4 For the prophylaxis and treatment of venous thromboembolism in Acute Coronary Syndrome surgical intervention; or 5 To be used in association with cardioversion of atrial ﬁbrillation. Renewal — (Pregnancy or Malignancy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: Either: 1 Low molecular weight heparin treatment is required during a patient’s pregnancy; or 2 For the treatment of venous thromboembolism where the patient has a malignancy. Renewal — (Venous thromboembolism other than in pregnancy or malignancy) from any relevant practitioner. Approvals valid for 1 month where low molecular weight heparin treatment or prophylaxis is required for a second or subsequent event (surgery, ACS, cardioversion, or prior to oral anti-coagulation). HEPARIN SODIUM Inj 1,000 iu per ml, 5 ml ....................................................................13.36 10 Mayne 66.80 50 Mayne 11.44 10 Pﬁzer 46.30 50 Pﬁzer Inj 1,000 iu per ml, 35 ml ..................................................................16.00 1 Mayne Inj 5,000 iu per ml, 1 ml ....................................................................14.20 5 Mayne Inj 5,000 iu per ml, 5 ml ..................................................................118.50 50 Pﬁzer Inj 25,000 iu per ml, 0.2 ml .................................................................9.50 5 Mayne HEPARINISED SALINE F Inj 10 iu per ml, 5 ml .........................................................................32.50 PROTAMINE SULPHATE F Inj 10 mg per ml, 5 ml .......................................................................22.40 (95.87) 50 10 Artex

Pﬁzer

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

BLOOD AND BLOOD FORMING ORGANS

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

Oral Anticoagulants

DABIGATRAN Cap 75 mg – No more than 2 cap per day .....................................148.00 Cap 110 mg ....................................................................................148.00 Cap 150 mg ....................................................................................148.00 RIVAROXABAN – Special Authority see SA1066 below – Retail pharmacy Tab 10 mg .......................................................................................153.00 306.00 60 60 60 15 30

Pradaxa Pradaxa Pradaxa Xarelto Xarelto

¾SA1066 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid for 5 weeks for applications meeting the following criteria: Either: 1 For the prophylaxis of venous thromboembolism following a total hip replacement; or 2 For the prophylaxis of venous thromboembolism following a total knee replacement. Note: Rivaroxaban is only currently indicated and subsidised for up to 5 weeks therapy for prophylaxis of venous thromboembolism following a total hip replacement and up to 2 weeks therapy for prophylaxis of venous thromboembolism following a total knee replacement. Renewal from any relevant practitioner. Approvals valid for 5 weeks where prophylaxis for venous thromboembolism is required for patients following a subsequent total hip or knee replacement. WARFARIN SODIUM Note: Marevan and Coumadin are not interchangeable. F Tab 1 mg .............................................................................................3.46 50 Coumadin 5.69 100 Marevan F Tab 2 mg .............................................................................................4.31 50 Coumadin F Tab 3 mg .............................................................................................8.00 100 Marevan F Tab 5 mg .............................................................................................5.93 50 Coumadin 9.64 100 Marevan

Fluids and Electrolytes Intravenous Administration

DEXTROSE F Inj 50%, 10 ml – Up to 5 inj available on a PSO...............................19.50 F Inj 50%, 90 ml – Up to 5 inj available on a PSO...............................11.25 POTASSIUM CHLORIDE F Inj 75 mg per ml, 10 ml .....................................................................55.00 SODIUM BICARBONATE Inj 8.4%, 50 ml ..................................................................................19.95 a) Up to 5 inj available on a PSO b) Not in combination Inj 8.4%, 100 ml ................................................................................20.50 a) Up to 5 inj available on a PSO b) Not in combination 5 1 50 1

Biomed Biomed AstraZeneca Biomed Biomed

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

BLOOD AND BLOOD FORMING ORGANS

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

SODIUM CHLORIDE Not funded for use as a nasal drop. Only funded for nebuliser use when in conjunction with an antibiotic intended for nebuliser use. Inf 0.9% – Up to 2000 ml available on a PSO ....................................3.06 500 ml Baxter 4.06 1,000 ml Baxter Only if prescribed on a prescription for renal dialysis, maternity or post-natal care in the home of the patient, or on a PSO for emergency use. (500 ml and 1,000 ml packs) Inj 23.4%, 20 ml ................................................................................31.25 5 Biomed For Sodium chloride oral liquid formulation refer Standard Formulae, page 185 Inj 0.9%, 5 ml – Up to 5 inj available on a PSO................................10.85 50 Multichem 15.50 Pﬁzer Inj 0.9%, 10 ml – Up to 5 inj available on a PSO..............................11.50 50 Multichem 15.50 Pﬁzer Inj 0.9%, 20 ml ....................................................................................4.72 6 Pharmacia 11.79 30 Pharmacia 8.41 20 Multichem TOTAL PARENTERAL NUTRITION (TPN) – Retail pharmacy-Specialist Infusion .............................................................................................CBS WATER 1) On a prescription or Practitioner’s Supply Order only when on the same form Schedule requiring a solvent or diluent; or 2) On a bulk supply order; or 3) When used in the extemporaneous compounding of eye drops. Puriﬁed for inj, 5 ml – Up to 5 inj available on a PSO .......................10.25 Puriﬁed for inj, 10 ml – Up to 5 inj available on a PSO .....................11.25 Puriﬁed for inj, 20 ml – Up to 5 inj available on a PSO .......................6.50 1 OP

TPN

as an injection listed in the Pharmaceutical

50 50 20

Multichem Multichem Multichem

Oral Administration

CALCIUM POLYSTYRENE SULPHONATE Powder ............................................................................................169.85 COMPOUND ELECTROLYTES Powder for soln for oral use 4.4 g – Up to 10 sach available on a PSO...................................................................................... 1.12 DEXTROSE WITH ELECTROLYTES Soln with electrolytes ..........................................................................6.60 300 g OP

Calcium Resonium

5 1,000 ml OP

Electral Pedialyte Bubblegum

6.75 POTASSIUM BICARBONATE Tab eff 315 mg with sodium acid phosphate 1.937 g and sodium bicarbonate 350 mg ......................................................82.50 For phosphate supplementation POTASSIUM CHLORIDE F Tab eff 548 mg (14 m eq) with chloride 285 mg (8 m eq) ...................5.26 (11.85) F Tab long-acting 600 mg ......................................................................7.42 SODIUM BICARBONATE Cap 840 mg ........................................................................................8.52

Pedialyte - Fruit Pedialyte - Plain

100

Phosphate-Sandoz

60 Chlorvescent 200 100

Span-K Sodibic

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

BLOOD AND BLOOD FORMING ORGANS

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

SODIUM POLYSTYRENE SULPHONATE Powder ..............................................................................................89.10

450 g OP

Resonium-A

Lipid Modifying Agents Fibrates

BEZAFIBRATE F Tab 200 mg .........................................................................................9.75 F Tab long-acting 400 mg ......................................................................5.70 GEMFIBROZIL F Tab 600 mg .......................................................................................14.00 90 30 60

Fibalip Bezalip Retard Lipazil

Other Lipid Modifying Agents

ACIPIMOX F Cap 250 mg ......................................................................................18.75 NICOTINIC ACID F Tab 50 mg ...........................................................................................4.17 F Tab 500 mg .......................................................................................16.54 30 100 100

Olbetam Apo-Nicotinic Acid Apo-Nicotinic Acid

Resins

CHOLESTYRAMINE WITH ASPARTAME Sachets 4 g with aspartame .............................................................19.25 (52.68) COLESTIPOL HYDROCHLORIDE Sachets 5 g .......................................................................................20.00 50 Questran-Lite 30

Colestid

HMG CoA Reductase Inhibitors (Statins)

Prescribing Guidelines Treatment with HMG CoA Reductase Inhibitors (statins) is recommended for patients with dyslipidaemia and an absolute 5 year cardiovascular risk of 15% or greater. ATORVASTATIN – See prescribing guideline above F Tab 10 mg ...........................................................................................2.52 90 Zarator 2.90 30 Dr Reddy’s Atorvastatin 18.32 Lipitor F Tab 20 mg ...........................................................................................4.17 90 Zarator 4.36 30 Dr Reddy’s Atorvastatin 26.70 Lipitor F Tab 40 mg ...........................................................................................6.51 30 Dr Reddy’s Atorvastatin 7.32 90 Zarator 37.02 30 Lipitor F Tab 80 mg ...........................................................................................9.67 30 Dr Reddy’s Atorvastatin 16.23 90 Zarator 110.50 30 Lipitor

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

BLOOD AND BLOOD FORMING ORGANS

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

PRAVASTATIN – See prescribing guideline on the preceding page F Tab 20 mg ...........................................................................................5.44 F Tab 40 mg ...........................................................................................9.28 SIMVASTATIN – See prescribing guideline on the preceding page F Tab 10 mg ...........................................................................................1.40 F Tab 20 mg ...........................................................................................1.95 F Tab 40 mg ...........................................................................................3.18 F Tab 80 mg ...........................................................................................9.31

30 30 90 90 90 90

Cholvastin Cholvastin Arrow-Simva 10mg Arrow-Simva 20mg Arrow-Simva 40mg Arrow-Simva 80mg

Selective Cholesterol Absorption Inhibitors

EZETIMIBE – Special Authority see SA1045 below – Retail pharmacy Tab 10 mg .........................................................................................45.90 30

Ezetrol

¾SA1045 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and 2 Patient’s LDL cholesterol is 2.0 mmol/litre or greater; and 3 Any of the following: 3.1 The patient has rhabdomyolysis (deﬁned as muscle aches and creatine kinase more than 10 × normal) when treated with one statin; or 3.2 The patient is intolerant to both simvastatin and atorvastatin; or 3.3 The patient has not reduced their LDL cholesterol to less than 2.0 mmol/litre with the use of the maximal tolerated dose of atorvastatin. Notes: A patient who has failed to reduce their LDL cholesterol to < 2.0 mmol/litre with the use of a less potent statin should use a more potent statin prior to consideration being given to the use of non-statin therapies. Other treatment options including ﬁbrates, resins and nicotinic acid should be considered after failure of statin therapy. If a patient’s LDL cholesterol cannot be calculated because the triglyceride level is too high then a repeat test should be performed and if the LDL cholesterol again cannot be calculated then it can be considered that the LDL cholesterol is greater than 2.0 mmol/litre. Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is beneﬁting from treatment. EZETIMIBE WITH SIMVASTATIN – Special Authority see SA1046 below – Retail pharmacy Tab 10 mg with simvastatin 10 mg ...................................................48.90 30 Vytorin Tab 10 mg with simvastatin 20 mg ...................................................51.60 30 Vytorin Tab 10 mg with simvastatin 40 mg ...................................................55.20 30 Vytorin Tab 10 mg with simvastatin 80 mg ...................................................60.60 30 Vytorin

¾SA1046 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 year; and 2 Patient’s LDL cholesterol is 2.0 mmol/litre or greater; and 3 The patient has not reduced their LDL cholesterol to less than 2.0 mmol/litre with the use of the maximal tolerated dose of atorvastatin. Notes: A patient who has failed to reduce their LDL cholesterol to ≤ 2.0 mmol/litre with the use of a less potent statin should use a more potent statin prior to consideration being given to the use of non-statin therapies. Other treatment options including ﬁbrates, resins and nicotinic acid should be considered after failure of statin therapy. continued. . .

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

BLOOD AND BLOOD FORMING ORGANS

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

continued. . . If a patient’s LDL cholesterol cannot be calculated because the triglyceride level is too high then a repeat test should be performed and if the LDL cholesterol again cannot be calculated then it can be considered that the LDL cholesterol is greater than 2.0 mmol/litre. Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is beneﬁting from treatment.

Iron Overload

DEFERIPRONE – Special Authority see SA1042 below – Retail pharmacy Tab 500 mg .....................................................................................533.17 Oral liq 100 mg per 1 ml .................................................................266.59 100 250 ml OP

Ferriprox Ferriprox

¾SA1042 Special Authority for Subsidy Initial application only from a relevant specialist. Approvals valid without further renewal unless notiﬁed where the patient has been diagnosed with chronic transfusional iron overload due to congenital inherited anaemia. Note: For the purposes of this Special Authority, a relevant specialist is deﬁned as a haematologist. DESFERRIOXAMINE MESYLATE F Inj 500 mg .........................................................................................99.00 10 Mayne

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

CARDIOVASCULAR SYSTEM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

Alpha Adrenoceptor Blockers

DOXAZOSIN MESYLATE F Tab 2 mg .............................................................................................8.23 F Tab 4 mg ...........................................................................................12.40 PHENOXYBENZAMINE HYDROCHLORIDE F Cap 10 mg ..........................................................................................7.82 26.05 PHENTOLAMINE MESYLATE F Inj 10 mg per ml, 1 ml ......................................................................17.97 (31.65) (Regitine Inj 10 mg per ml, 1 ml to be delisted 1 January 2013) PRAZOSIN HYDROCHLORIDE F Tab 1 mg .............................................................................................5.53 F Tab 2 mg .............................................................................................7.00 F Tab 5 mg ...........................................................................................11.70 TERAZOSIN HYDROCHLORIDE F Tab 1 mg .............................................................................................1.50 F Tab 2 mg .............................................................................................0.80 F Tab 5 mg .............................................................................................1.00 500 500 30 100 5 Regitine

Apo-Doxazosin Apo-Doxazosin Dibenyline S29 Dibenyline S29

100 100 100 28 28 28

Apo-Prazo Apo-Prazo Apo-Prazo Arrow Arrow Arrow

Agents Affecting the Renin-Angiotensin System ACE Inhibitors

CAPTOPRIL F Tab 12.5 mg ........................................................................................2.00 F Tab 25 mg ...........................................................................................2.40 F Tab 50 mg ...........................................................................................3.50 F‡ Oral liq 5 mg per ml ..........................................................................94.99 Oral liquid restricted to children under 12 years of age. CILAZAPRIL F Tab 0.5 mg ..........................................................................................0.95 F Tab 2.5 mg ..........................................................................................6.18 F Tab 5 mg .............................................................................................9.84 ENALAPRIL F Tab 5 mg .............................................................................................1.98 F Tab 10 mg ...........................................................................................2.44 F Tab 20 mg – For enalapril oral liquid formulation refer, page 182 ............................................................................................... 3.24 LISINOPRIL F Tab 5 mg .............................................................................................1.19 F Tab 10 mg ...........................................................................................1.36 F Tab 20 mg ...........................................................................................1.63 100 100 100 95 ml OP

m-Captopril m-Captopril m-Captopril Capoten

30 90 90 90 90 90 30 30 30

Zapril Zapril Zapril Arrow-Enalapril Arrow-Enalapril Arrow-Enalapril Arrow-Lisinopril Arrow-Lisinopril Arrow-Lisinopril

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

CARDIOVASCULAR SYSTEM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

PERINDOPRIL Perindopril will be funded to the level of the ex-manufacturer price listed in the Schedule for patients who were taking these ACE inhibitors for the treatment of congestive heart failure prior to 1 June 1998. The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certiﬁed condition" or an appropriate description of the patient such as "congestive heart failure", "CHF", "congestive cardiac failure" or "CCF". Deﬁnition of Congestive Heart Failure At the request of some prescribers the PTAC Cardiovascular subcommittee has provided a deﬁnition of congestive heart failure for the purposes of the funding of the manufacturer’s surcharge: "Clinicians should use their clinical judgement. Existing patients would be eligible for the funding of the surcharge if the patient shows signs and symptoms of congestive heart failure, and requires or has in the past required concomitant treatment with a diuretic. The deﬁnition could also be considered to include patients post myocardial infarction with an ejection fraction of less than 40%." F Tab 2 mg – Higher subsidy of $18.50 per 30 tab with Endorsement.....................................................................................3.00 30 (18.50) Coversyl F Tab 4 mg – Higher subsidy of $25.00 per 30 tab with Endorsement.....................................................................................4.05 30 (25.00) Coversyl QUINAPRIL F Tab 5 mg .............................................................................................1.60 F Tab 10 mg ...........................................................................................1.75 F Tab 20 mg ...........................................................................................2.35 30 30 30

Accupril Accupril Accupril

TRANDOLAPRIL Trandolapril will be funded to the level of the ex-manufacturer price listed in the Schedule for patients who were taking these ACE inhibitors for the treatment of congestive heart failure prior to 1 June 1998. The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certiﬁed condition" or an appropriate description of the patient such as "congestive heart failure", "CHF", "congestive cardiac failure" or "CCF". Deﬁnition of Congestive Heart Failure At the request of some prescribers the PTAC Cardiovascular subcommittee has provided a deﬁnition of congestive heart failure for the purposes of the funding of the manufacturer’s surcharge: "Clinicians should use their clinical judgement. Existing patients would be eligible for the funding of the surcharge if the patient shows signs and symptoms of congestive heart failure, and requires or has in the past required concomitant treatment with a diuretic. The deﬁnition could also be considered to include patients post myocardial infarction with an ejection fraction of less than 40%." F Cap 1 mg – Higher subsidy of $18.67 per 28 cap with Endorsement.....................................................................................3.06 28 (18.67) Gopten F Cap 2 mg – Higher subsidy of $27.00 per 28 cap with Endorsement.....................................................................................4.43 28 (27.00) Gopten

ACE Inhibitors with Diuretics

CILAZAPRIL WITH HYDROCHLOROTHIAZIDE F Tab 5 mg with hydrochlorothiazide 12.5 mg .......................................5.36 ENALAPRIL WITH HYDROCHLOROTHIAZIDE F Tab 20 mg with hydrochlorothiazide 12.5 mg .....................................3.32 (8.70) QUINAPRIL WITH HYDROCHLOROTHIAZIDE F Tab 10 mg with hydrochlorothiazide 12.5 mg .....................................3.37 F Tab 20 mg with hydrochlorothiazide 12.5 mg .....................................4.57 28 30 Co-Renitec 30 30

Inhibace Plus

Accuretic 10 Accuretic 20

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

CARDIOVASCULAR SYSTEM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

Angiotension II Antagonists

CANDESARTAN – Special Authority see SA1223 below – Retail pharmacy F Tab 4 mg .............................................................................................4.13 1.38 (12.00) F Tab 8 mg .............................................................................................6.10 2.03 (12.00) F Tab 16 mg .........................................................................................10.18 3.39 (14.50) F Tab 32 mg .........................................................................................17.66 5.89 (24.00) (Atacand Tab 4 mg to be delisted 1 November 2012) (Atacand Tab 8 mg to be delisted 1 November 2012) (Atacand Tab 16 mg to be delisted 1 November 2012) (Atacand Tab 32 mg to be delisted 1 November 2012) 90 30 90 30 90 30 90 30

Candestar

Atacand

Candestar

Atacand

Candestar

Atacand

Candestar

Atacand

¾SA1223 Special Authority for Subsidy Initial application — (ACE inhibitor intolerance) from any relevant practitioner. Approvals valid without further renewal unless notiﬁed for applications meeting the following criteria: Either: 1 Patient has persistent ACE inhibitor induced cough that is not resolved by ACE inhibitor retrial (same or new ACE inhibitor); or 2 Patient has a history of angioedema. Initial application — (Unsatisfactory response to ACE inhibitor) from any relevant practitioner. Approvals valid without further renewal unless notiﬁed where patient is not adequately controlled on maximum tolerated dose of an ACE inhibitor. LOSARTAN F Tab 12.5 mg ........................................................................................2.88 90 Lostaar F Tab 25 mg ...........................................................................................3.20 90 Lostaar F Tab 50 mg ...........................................................................................5.22 90 Lostaar Tab 50 mg with hydrochlorothiazide 12.5 mg .....................................4.89 30 Arrow-Losartan & Hydrochlorothiazide F Tab 100 mg .........................................................................................8.68 90 Lostaar

Antiarrhythmics

For lignocaine hydrochloride refer to NERVOUS SYSTEM, Anaesthetics, Local, page 119 AMIODARONE HYDROCHLORIDE L Tab 100 mg – Retail pharmacy-Specialist ........................................18.65 30 L Tab 200 mg – Retail pharmacy-Specialist ........................................30.52 Inj 50 mg per ml, 3 ml – Up to 5 inj available on a PSO ...................60.84 DIGOXIN F Tab 62.5 µg – Up to 30 tab available on a PSO .................................6.67 F Tab 250 µg – Up to 30 tab available on a PSO ................................14.52 F‡ Oral liq 50 µg per ml .........................................................................16.60 30 10 240 240 60 ml

Aratac Cordarone-X Aratac Cordarone-X Cordarone-X Lanoxin PG Lanoxin Lanoxin

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

CARDIOVASCULAR SYSTEM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

DISOPYRAMIDE PHOSPHATE L Cap 100 mg ......................................................................................15.00 (23.87) L Cap 150 mg ......................................................................................26.21 FLECAINIDE ACETATE – Retail pharmacy-Specialist L Tab 50 mg .........................................................................................45.82 L Tab 100 mg – For ﬂecainide acetate oral liquid formulation refer, page 182 ........................................................................... 80.92 L Cap long-acting 100 mg ...................................................................45.82 L Cap long-acting 200 mg ...................................................................80.92 Inj 10 mg per ml, 15 ml .....................................................................52.45 PROPAFENONE HYDROCHLORIDE – Retail pharmacy-Specialist L Tab 150 mg .......................................................................................40.90

100 Rythmodan 100 60 60 30 30 5 50

Rythmodan Tambocor Tambocor Tambocor CR Tambocor CR Tambocor Rytmonorm

Antihypotensives

MIDODRINE – Special Authority see SA0934 below – Retail pharmacy Tab 2.5 mg ........................................................................................53.00 Tab 5 mg ...........................................................................................79.00 100 100

Gutron Gutron

¾SA0934 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Disabling orthostatic hypotension not due to drugs; and 2 Patient has tried ﬂudrocortisone (unless contra-indicated) with unsatisfactory results; and 3 Patient has tried non pharmacological treatments such as support hose, increased salt intake, exercise, and elevation of head and trunk at night. Notes: Treatment should be started with small doses and titrated upwards as necessary. Hypertension should be avoided, and the usual target is a standing systolic blood pressure of 90 mm Hg. Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is beneﬁting from treatment.

Beta Adrenoceptor Blockers

ATENOLOL F Tab 50 mg ...........................................................................................5.56 11.12 F Tab 100 mg .........................................................................................9.12 18.24 (Atenolol Tablet USP Tab 50 mg to be delisted 25 November 2012) (Atenolol Tablet USP Tab 100 mg to be delisted 25 November 2012) BISOPROLOL FUMARATE Tab 2.5 mg ..........................................................................................3.88 Tab 5 mg .............................................................................................4.74 Tab 10 mg ...........................................................................................9.18 CARVEDILOL F Tab 6.25 mg ......................................................................................21.00 F Tab 12.5 mg ......................................................................................27.00 F Tab 25 mg – For carvedilol oral liquid formulation refer, page 182 ............................................................................................. 33.75 CELIPROLOL F Tab 200 mg .......................................................................................19.00

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

500 1,000 500 1,000

Mylan Atenolol Atenolol Tablet USP Mylan Atenolol Atenolol Tablet USP

30 30 30 30 30 30 180

Bosvate Bosvate Bosvate Dilatrend Dilatrend Dilatrend Celol 51

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

CARDIOVASCULAR SYSTEM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

LABETALOL F Tab 50 mg ...........................................................................................8.23 F Tab 100 mg – For labetalol oral liquid formulation refer, page 182 .............................................................................................10.06 F Tab 200 mg .......................................................................................17.55 F Inj 5 mg per ml, 20 ml .......................................................................59.06 (88.60) METOPROLOL SUCCINATE F Tab long-acting 23.75 mg ...................................................................0.96 (7.50) F Tab long-acting 47.5 mg .....................................................................1.41 (7.50) F Tab long-acting 95 mg ........................................................................2.42 (7.50) F Tab long-acting 190 mg ......................................................................4.66 (7.50) (Myloc CR Tab long-acting 23.75 mg to be delisted 1 September 2012) (Betaloc CR Tab long-acting 23.75 mg to be delisted 1 September 2012) (Myloc CR Tab long-acting 47.5 mg to be delisted 1 September 2012) (Betaloc CR Tab long-acting 47.5 mg to be delisted 1 September 2012) (Myloc CR Tab long-acting 95 mg to be delisted 1 September 2012) (Betaloc CR Tab long-acting 95 mg to be delisted 1 September 2012) (Myloc CR Tab long-acting 190 mg to be delisted 1 September 2012) (Betaloc CR Tab long-acting 190 mg to be delisted 1 September 2012) METOPROLOL TARTRATE F Tab 50 mg – For metoprolol tartrate oral liquid formulation refer, page 182 ...........................................................................16.00 F Tab 100 mg .......................................................................................21.00 F Tab long-acting 200 mg ....................................................................18.00 F Inj 1 mg per ml, 5 ml .........................................................................24.00 NADOLOL F Tab 40 mg .........................................................................................14.97 F Tab 80 mg .........................................................................................22.19 PINDOLOL F Tab 5 mg .............................................................................................5.40 F Tab 10 mg ...........................................................................................9.19 F Tab 15 mg .........................................................................................13.80

100 100 100 5

Hybloc Hybloc Hybloc

Trandate

Metoprolol - AFT CR Myloc CR

Betaloc CR

Metoprolol - AFT CR Myloc CR

Betaloc CR

Metoprolol - AFT CR Myloc CR

Betaloc CR

Metoprolol - AFT CR Myloc CR

Betaloc CR

100 60 28 5 100 100 100 100 100

Lopresor Lopresor Slow-Lopresor Lopresor Apo-Nadolol Apo-Nadolol Apo-Pindolol Apo-Pindolol Apo-Pindolol

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

CARDIOVASCULAR SYSTEM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

PROPRANOLOL F Tab 10 mg ...........................................................................................3.55 3.65 F Tab 40 mg ...........................................................................................4.65

100

Cardinol ApoPropranolol S29

100

ApoPropranolol S29

F Cap long-acting 160 mg ...................................................................16.06 (Cardinol Tab 40 mg to be delisted 1 December 2012) SOTALOL F Tab 80 mg – For sotalol oral liquid formulation refer, page 182 .........27.50 F Tab 160 mg .......................................................................................10.50 F Inj 10 mg per ml, 4 ml .......................................................................65.39 TIMOLOL MALEATE F Tab 10 mg .........................................................................................10.55

100

Cardinol Cardinol LA

500 100 5 100

Mylan Mylan Sotacor Apo-Timol

Calcium Channel Blockers Dihydropyridine Calcium Channel Blockers (DHP CCBs)

AMLODIPINE F Tab 2.5 mg ..........................................................................................2.45 F Tab 5 mg – For amlodipine oral liquid formulation refer, page 182 ...............................................................................................2.65 F Tab 10 mg ...........................................................................................4.15 FELODIPINE F Tab long-acting 2.5 mg .......................................................................2.90 F Tab long-acting 5 mg ..........................................................................3.10 10.73 F Tab long-acting 10 mg ........................................................................4.60 15.60 ISRADIPINE F Cap long-acting 2.5 mg ......................................................................7.50 F Cap long-acting 5 mg .........................................................................7.85 NIFEDIPINE F Tab long-acting 10 mg ......................................................................17.72 F Tab long-acting 20 mg ........................................................................7.30 F Tab long-acting 30 mg ........................................................................8.56 5.50 (19.90) F Tab long-acting 60 mg ......................................................................12.28 8.00 (29.50) 100 100 100 30 30 90 30 90 30 30 60 100 30

Apo-Amlodipine Apo-Amlodipine Apo-Amlodipine Plendil ER Plendil ER Felo 5 ER Plendil ER Felo 10 ER Dynacirc-SRO Dynacirc-SRO Adalat 10 Nyefax Retard Adeﬁn XL Arrow-Nifedipine XR

Adalat Oros

Adeﬁn XL Arrow-Nifedipine XR

Adalat Oros

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

CARDIOVASCULAR SYSTEM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

Other Calcium Channel Blockers

DILTIAZEM HYDROCHLORIDE F Tab 30 mg ...........................................................................................4.60 F Tab 60 mg – For diltiazem hydrochloride oral liquid formulation refer, page 182....................................................................... 8.50 F Cap long-acting 120 mg .....................................................................4.34 F Cap long-acting 180 mg .....................................................................6.50 F Cap long-acting 240 mg .....................................................................8.67 100 100 30 30 30

Dilzem Dilzem Cardizem CD Cardizem CD Cardizem CD Pexsig

PERHEXILINE MALEATE – Special Authority see SA0256 below – Retail pharmacy F Tab 100 mg .......................................................................................62.90 100

¾SA0256 Special Authority for Subsidy Initial application only from a cardiologist or general physician. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Refractory angina; and 2 Patient is already on maximal anti-anginal therapy. Renewal only from a cardiologist or general physician. Approvals valid for 2 years where the treatment remains appropriate and the patient is beneﬁting from treatment. VERAPAMIL HYDROCHLORIDE F Tab 40 mg ...........................................................................................7.01 100 Isoptin F Tab 80 mg – For verapamil hydrochloride oral liquid formulation refer, page 182.....................................................................11.74 100 Isoptin F Tab long-acting 120 mg ....................................................................15.20 250 Verpamil SR F Tab long-acting 240 mg ....................................................................25.00 250 Verpamil SR F Inj 2.5 mg per ml, 2 ml – Up to 5 inj available on a PSO ....................7.54 5 Isoptin

Centrally Acting Agents

CLONIDINE F TDDS 2.5 mg, 100 µg per day – Only on a prescription ..................23.30 F TDDS 5 mg, 200 µg per day – Only on a prescription .....................32.80 F TDDS 7.5 mg, 300 µg per day – Only on a prescription ..................41.20 CLONIDINE HYDROCHLORIDE F Tab 150 µg .......................................................................................33.00 F Inj 150 µg per ml, 1 ml ......................................................................15.45 METHYLDOPA F Tab 125 mg .......................................................................................14.25 F Tab 250 mg .......................................................................................15.10 F Tab 500 mg .......................................................................................23.15 4 4 4 100 5 100 100 100

Catapres-TTS-1 Catapres-TTS-2 Catapres-TTS-3 Catapres Catapres Prodopa Prodopa Prodopa

Diuretics Loop Diuretics

BUMETANIDE F Tab 1 mg ...........................................................................................16.36 F Inj 500 µg per ml, 4 ml ........................................................................7.95 100 5

Burinex Burinex

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

CARDIOVASCULAR SYSTEM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

FUROSEMIDE F Tab 40 mg – Up to 30 tab available on a PSO..................................10.25 F Tab 500 mg .......................................................................................25.00 F‡ Oral liq 10 mg per ml ........................................................................10.66 F Infusion 10 mg per ml, 25 ml ............................................................48.14 F Inj 10 mg per ml, 2 ml – Up to 5 inj available on a PSO .....................1.30

1,000 50 30 ml OP 5 5

Diurin 40 Urex Forte Lasix Lasix Frusemide-Claris

Potassium Sparing Diuretics

AMILORIDE ‡ Oral liq 1 mg per ml ..........................................................................30.00 SPIRONOLACTONE F Tab 25 mg ...........................................................................................4.60 F Tab 100 mg .......................................................................................15.15 ‡ Oral liq 5 mg per ml ..........................................................................30.00 25 ml OP 100 100 25 ml OP

Biomed Spirotone Spirotone Biomed

Potassium Sparing Combination Diuretics

AMILORIDE WITH FRUSEMIDE F Tab 5 mg with frusemide 40 mg .........................................................8.63 AMILORIDE WITH HYDROCHLOROTHIAZIDE F Tab 5 mg with hydrochlorothiazide 50 mg ..........................................5.00 28 50

Frumil Moduretic

Thiazide and Related Diuretics

BENDROFLUAZIDE F Tab 2.5 mg – Up to 150 tab available on a PSO.................................6.48 May be supplied on a PSO for reasons other than emergency. F Tab 5 mg .............................................................................................9.95 CHLOROTHIAZIDE ‡ Oral liq 50 mg per ml ........................................................................26.00 CHLORTHALIDONE F Tab 25 mg ...........................................................................................8.00 INDAPAMIDE F Tab 2.5 mg ..........................................................................................2.95 500 500

ArrowBendroﬂuazide

25 ml OP 50 90

Biomed Hygroton Dapa-Tabs

Nitrates

GLYCERYL TRINITRATE F Tab 600 µg – Up to 100 tab available on a PSO ................................8.00 F Aerosol spray, 400 µg per dose – Up to 250 dose available on a PSO......................................................................................4.45 F TDDS 5 mg .......................................................................................16.56 F TDDS 10 mg .....................................................................................19.50 ISOSORBIDE MONONITRATE F Tab 20 mg .........................................................................................17.10 F Tab long-acting 40 mg ........................................................................7.50 F Tab long-acting 60 mg ........................................................................3.94 100 OP 250 dose OP 30 30 100 30 90

Lycinate Glytrin Nitroderm TTS Nitroderm TTS Ismo 20 Corangin Duride

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

CARDIOVASCULAR SYSTEM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

Sympathomimetics

ADRENALINE Inj 1 in 1,000, 1 ml – Up to 5 inj available on a PSO ..........................4.98 5.25 Inj 1 in 10,000, 10 ml – Up to 5 inj available on a PSO ....................27.00 49.00 ISOPRENALINE HYDROCHLORIDE F Inj 200 µg per ml, 1 ml ......................................................................36.80 (135.00) 5 5 10 25 Isuprel

Aspen Adrenaline Mayne Mayne Aspen Adrenaline

Vasodilators

AMYL NITRITE F Ampoule, 0.3 ml crushable ...............................................................62.92 (73.40) HYDRALAZINE F Inj 20 mg per ml, 1 ml .......................................................................25.90 OXYPENTIFYLLINE Tab 400 mg .......................................................................................36.94 (42.26) PAPAVERINE HYDROCHLORIDE F Inj 12 mg per ml, 10 ml .....................................................................73.12 12 Baxter 5 50 Trental 400 5

Apresoline

Mayne

Endothelin Receptor Antagonists

¾SA0967 Special Authority for Subsidy Special Authority approved by the Pulmonary Arterial Hypertension Panel Notes: Application details may be obtained from PHARMAC’s website http://www.pharmac.govt.nz or: The Coordinator, PAH Panel PHARMAC, PO Box 10-254, WELLINGTON Tel: (04) 916 7512, Fax: (04) 974 4858, Email: PAH@pharmac.govt.nz AMBRISENTAN – Special Authority see SA0967 above – Retail pharmacy Tab 5 mg ......................................................................................4,585.00 Tab 10 mg ....................................................................................4,585.00 BOSENTAN – Special Authority see SA0967 above – Retail pharmacy Tab 62.5 mg .................................................................................4,585.00 Tab 125 mg ..................................................................................4,585.00 30 30 60 60

Volibris Volibris Tracleer Tracleer

Phosphodiesterase Type 5 Inhibitors

¾SA1086 Special Authority for Subsidy Special Authority approved by the Pulmonary Arterial Hypertension Panel Notes: Application details may be obtained from PHARMAC’s website http://www.pharmac.govt.nz or: The Coordinator, PAH Panel PHARMAC, PO Box 10-254, WELLINGTON Tel: (04) 916 7512, Fax: (04) 974 4858, Email: PAH@pharmac.govt.nz

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

CARDIOVASCULAR SYSTEM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

SILDENAFIL – Special Authority see SA1086 on the preceding page – Retail pharmacy Tab 25 mg .........................................................................................39.00 4 Tab 50 mg .........................................................................................43.50 4 Tab 100 mg – For sildenaﬁl oral liquid formulation refer, page 182 ............................................................................................. 47.00 4

Viagra Viagra Viagra

Prostacyclin Analogues

¾SA0969 Special Authority for Subsidy Special Authority approved by the Pulmonary Arterial Hypertension Panel Notes: Application details may be obtained from PHARMAC’s website http://www.pharmac.govt.nz or: The Coordinator, PAH Panel PHARMAC, PO Box 10-254, WELLINGTON Tel: (04) 916 7512, Fax: (04) 974 4858, Email: PAH@pharmac.govt.nz ILOPROST – Special Authority see SA0969 above – Retail pharmacy Nebuliser soln 10 µg per ml, 2 ml ................................................1,185.00 30

Ventavis

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

DERMATOLOGICALS

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

Antiacne Preparations

For systemic antibacterials, refer to INFECTIONS, Antibacterials, page 83 ADAPALENE a) Maximum of 30 g per prescription b) Only on a prescription Crm 0.1% .........................................................................................22.89 Gel 0.1% ...........................................................................................22.89 ISOTRETINOIN – Special Authority see SA0955 below – Retail pharmacy Cap 10 mg ........................................................................................48.48 Cap 20 mg ........................................................................................69.70

30 g OP 30 g OP 180 180

Differin Differin Oratane Oratane

¾SA0955 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 Patient has had an adequate trial on other available treatments and has received an inadequate response from these treatments or these are contraindicated; and 2 Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice; and 3 Applicant has an up to date knowledge of the treatment options for acne and is aware of the safety issues around isotretinoin and is competent to prescribe isotretinoin; and 4 Either: 4.1 Patient is female and has been counselled and understands the risk of teratogenicity if isotretinoin is used during pregnancy and the applicant has ensured that the possibility of pregnancy has been excluded prior to the commencement of the treatment and that the patient is informed that she must not become pregnant during treatment and for a period of one month after the completion of the treatment; or 4.2 Patient is male. Note: Applicants are recommended to either have used or be familiar with using a decision support tool accredited by their professional body. Renewal from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 Patient has had an adequate trial on other available treatments and has received an inadequate response from these treatments or these are contraindicated; and 2 Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice; and 3 Applicant has an up to date knowledge of the treatment options for acne and is aware of the safety issues around isotretinoin and is competent to prescribe isotretinoin; and 4 Either: 4.1 Patient is female and has been counselled and understands the risk of teratogenicity if isotretinoin is used during pregnancy and the applicant has ensured that the possibility of pregnancy has been excluded prior to the commencement of the treatment and that the patient is informed that she must not become pregnant during treatment and for a period of one month after the completion of the treatment; or 4.2 Patient is male. Note: Applicants are recommended to either have used or be familiar with using a decision support tool accredited by their professional body. TRETINOIN Crm 0.5 mg per g – Maximum of 50 g per prescription ....................13.90 50 g OP ReTrieve

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

DERMATOLOGICALS

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

Antibacterials Topical

For systemic antibacterials, refer to INFECTIONS, Antibacterials, page 83 FUSIDIC ACID Crm 2% .............................................................................................3.25 a) Maximum of 15 g per prescription b) Only on a prescription c) Not in combination Oint 2% ..............................................................................................3.25 a) Maximum of 15 g per prescription b) Only on a prescription c) Not in combination HYDROGEN PEROXIDE F Crm 1% ..............................................................................................8.56 MUPIROCIN Oint 2% ...............................................................................................6.60 (9.26) a) Only on a prescription b) Not in combination SILVER SULPHADIAZINE Crm 1% ............................................................................................12.30 a) Up to 250 g available on a PSO b) Not in combination

15 g OP

Foban

15 g OP

Foban

10 g OP 15 g OP

Crystacide

Bactroban

50 g OP

Flamazine

Antifungals Topical

For systemic antifungals, refer to INFECTIONS, Antifungals, page 88 AMOROLFINE a) Only on a prescription b) Not in combination Nail soln 5% ......................................................................................37.86 (61.87) CICLOPIROX OLAMINE a) Only on a prescription b) Not in combination Nail soln 8% ......................................................................................19.85 Soln 1% ..............................................................................................4.36 (11.54) CLOTRIMAZOLE F Crm 1% ..............................................................................................0.54 a) Only on a prescription b) Not in combination F Soln 1% ..............................................................................................4.36 (7.55) a) Only on a prescription b) Not in combination

5 ml OP Loceryl

3 g OP 20 ml OP

Batrafen

20 g OP

Clomazol

20 ml OP Canesten

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

DERMATOLOGICALS

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

ECONAZOLE NITRATE Crm 1% ..............................................................................................1.00 (7.48) a) Only on a prescription b) Not in combination Foaming soln 1%, 10 ml sachets ........................................................9.89 (17.23) a) Only on a prescription b) Not in combination MICONAZOLE NITRATE F Crm 2% ..............................................................................................0.46 a) Only on a prescription b) Not in combination F Lotn 2% ..............................................................................................4.36 (10.03) a) Only on a prescription b) Not in combination F Tinct 2% ..............................................................................................4.36 (12.10) a) Only on a prescription b) Not in combination NYSTATIN Crm 100,000 u per g ..........................................................................1.00 (7.90) a) Only on a prescription b) Not in combination

20 g OP Pevaryl

3 Pevaryl

15 g OP

Multichem

30 ml OP Daktarin

15 g OP Mycostatin

Antipruritic Preparations

CALAMINE a) Only on a prescription b) Not in combination Crm, aqueous, BP ..............................................................................2.78 Lotn, BP ............................................................................................16.70 CROTAMITON a) Only on a prescription b) Not in combination Crm 10% ............................................................................................3.48

100 g 2,000 ml

healthE API

20 g OP

Itch-Soothe

MENTHOL – Only in combination Only in combination with aqueous cream, 10% urea cream, wool fat with mineral oil lotion, 1% hydrocortisone with wool fat and mineral oil lotion, and glycerol, parafﬁn and cetyl alcohol lotion Crystals ..............................................................................................6.50 25 g PSM 6.92 MidWest 29.60 100 g MidWest

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

DERMATOLOGICALS

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

Corticosteroids Topical

For systemic corticosteroids, refer to CORTICOSTEROIDS AND RELATED AGENTS, page 76

Corticosteroids - Plain

BETAMETHASONE DIPROPIONATE Crm 0.05% .........................................................................................2.96 (6.91) 8.97 (18.36) Crm 0.05% in propylene glycol base ..................................................4.33 (13.83) Oint 0.05% ..........................................................................................2.96 (6.51) 8.97 (17.11) Oint 0.05% in propylene glycol base ..................................................4.33 (13.83) BETAMETHASONE VALERATE F Crm 0.1% ...........................................................................................3.20 F Oint 0.1% ............................................................................................3.20 F Lotn 0.1% .........................................................................................10.05 CLOBETASOL PROPIONATE F Crm 0.05% .........................................................................................3.48 F Oint 0.05% ..........................................................................................3.48 CLOBETASONE BUTYRATE Crm 0.05% .........................................................................................5.38 (7.09) 16.13 (22.00) DIFLUCORTOLONE VALERATE Crm 0.1% ...........................................................................................8.97 (15.86) Fatty oint 0.1% ....................................................................................8.97 (15.86) 15 g OP Diprosone 50 g OP Diprosone 30 g OP Diprosone OV 15 g OP Diprosone 50 g OP Diprosone 30 g OP Diprosone OV 50 g OP 50 g OP 50 ml OP 30 g OP 30 g OP 30 g OP Eumovate 100 g OP Eumovate 50 g OP Nerisone 50 g OP Nerisone

Beta Cream Beta Ointment Betnovate Dermol Dermol

HYDROCORTISONE F Crm 1% – Only on a prescription .......................................................3.75 100 g 14.00 500 g F Powder – Only in combination .........................................................44.00 25 g Up to 5% in a dermatological base (not proprietary Topical Corticosteriod – Plain) with galenicals. Refer, page 181 HYDROCORTISONE BUTYRATE Lipocream 0.1% ..................................................................................2.30 30 g OP 6.85 100 g OP Oint 0.1% ............................................................................................6.85 100 g OP Milky emul 0.1% .................................................................................6.85 100 ml OP

Pharmacy Health Pharmacy Health ABM

or without other dermatological

Locoid Lipocream Locoid Lipocream Locoid Locoid Crelo

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

DERMATOLOGICALS

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

HYDROCORTISONE WITH WOOL FAT AND MINERAL OIL Lotn 1% with wool fat hydrous 3% and mineral oil – Only on a prescription................................................................................ 9.95 METHYLPREDNISOLONE ACEPONATE Crm 0.1% ...........................................................................................4.95 Oint 0.1% ............................................................................................4.95 MOMETASONE FUROATE Crm 0.1% ...........................................................................................1.78 3.42 Oint 0.1% ............................................................................................1.78 3.42 Lotn 0.1% ...........................................................................................7.35 TRIAMCINOLONE ACETONIDE Crm 0.02% .........................................................................................6.63 Oint 0.02% ..........................................................................................6.69

250 ml 15 g OP 15 g OP 15 g OP 45 g OP 15 g OP 45 g OP 30 ml OP 100 g OP 100 g OP

DP Lotn HC Advantan Advantan m-Mometasone m-Mometasone m-Mometasone m-Mometasone Elocon Aristocort Aristocort

Corticosteroids - Combination

BETAMETHASONE VALERATE WITH CLIOQUINOL – Only on a prescription Crm 0.1% with clioquinol 3% ..............................................................3.49 (4.90) Oint 0.1% with clioquinol 3% ..............................................................3.49 (4.90) BETAMETHASONE VALERATE WITH FUSIDIC ACID Crm 0.1% with fusidic acid 2% ...........................................................3.49 (10.45) a) Maximum of 15 g per prescription b) Only on a prescription HYDROCORTISONE WITH MICONAZOLE – Only on a prescription F Crm 1% with miconazole nitrate 2% ...................................................2.10 15 g OP Betnovate-C 15 g OP Betnovate-C 15 g OP Fucicort

15 g OP

Micreme H Pimafucort Pimafucort

HYDROCORTISONE WITH NATAMYCIN AND NEOMYCIN – Only on a prescription Crm 1% with natamycin 1% and neomycin sulphate 0.5% ................2.79 15 g OP Oint 1% with natamycin 1% and neomycin sulphate 0.5% .................2.79 15 g OP TRIAMCINOLONE ACETONIDE WITH GRAMICIDIN, NEOMYCIN AND NYSTATIN Crm 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 µg per g – Only on a prescription................. 3.49 15 g OP (6.60)

Viaderm KC

Disinfecting and Cleansing Agents

CHLORHEXIDINE GLUCONATE – Subsidy by endorsement a) No more than 500 ml per month b) Only if prescribed for a dialysis patient and the prescription is endorsed accordingly. F Handrub 1% with ethanol 70% ...........................................................4.60 500 ml F Soln 4% ..............................................................................................5.90 500 ml

healthE Orion

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

DERMATOLOGICALS

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

TRICLOSAN – Subsidy by endorsement a) Maximum of 500 ml per prescription b) a) Only if prescribed for a patient identiﬁed with Methicillin-resistant Staphylococcus aureus (MRSA) prior to elective surgery in hospital and the prescription is endorsed accordingly; or b) Only if prescribed for a patient with recurrent Staphylococcus aureus infection and the prescription is endorsed accordingly Soln 1% ..............................................................................................4.50 500 ml OP Pharmacy Health 5.90 healthE

Barrier Creams and Emollients Barrier Creams

ZINC AND CASTOR OIL F Oint BP ...............................................................................................3.83 500 g

Multichem

Emollients

AQUEOUS CREAM F Crm .....................................................................................................1.96 CETOMACROGOL F Crm BP ...............................................................................................3.15 EMULSIFYING OINTMENT F Oint BP ...............................................................................................3.04 OIL IN WATER EMULSION F Crm .....................................................................................................2.80 UREA F Crm 10% ............................................................................................3.07 WOOL FAT WITH MINERAL OIL – Only on a prescription F Lotn hydrous 3% with mineral oil ........................................................1.40 (3.50) 5.60 (9.54) 1.40 (4.53) 5.60 (11.95) (20.53) 1.40 (7.73) 5.60 (23.91) 500 g 500 g 500 g 500 g 100 g OP 250 ml OP Hydroderm Lotion 1,000 ml Hydroderm Lotion 250 ml OP DP Lotion 1,000 ml DP Lotion Alpha-Keri Lotion 250 ml OP BK Lotion 1,000 ml BK Lotion

AFT PSM AFT healthE Fatty Cream Nutraplus

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

DERMATOLOGICALS

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

Other Dermatological Bases

PARAFFIN White soft – Only in combination .......................................................3.58 500 g (7.78) IPW 20.20 2,500 g IPW 3.58 500 g (8.69) PSM Only in combination with a dermatological galenical or as a diluent for a proprietary Topical Corticosteroid – Plain.

Minor Skin Infections

POVIDONE IODINE Oint 10% .............................................................................................3.27 a) Maximum of 100 g per prescription b) Only on a prescription Antiseptic soln 10% ............................................................................0.19 (4.45) 1.28 (8.25) 6.20 1.28 (4.20) 6.20 Skin preparation, povidone iodine 10% with 30% alcohol ..................1.63 (3.65) 10.00 Skin preparation, povidone iodine 10% with 70% alcohol ..................1.63 (6.04) 8.13 (18.63) 25 g OP

Betadine

15 ml Betadine 100 ml Betadine 500 ml 100 ml 500 ml 100 ml 500 ml 100 ml 500 ml Orion

Betadine

Riodine

Betadine Skin Prep

Orion

Parasiticidal Preparations

GAMMA BENZENE HEXACHLORIDE Crm 1% ..............................................................................................3.50 50 g OP

Benhex

IVERMECTIN – Special Authority see SA1225 below – Retail pharmacy Tab 3 mg – Up to 100 tab available on a PSO..................................17.20 4 Stromectol 1) PSO for institutional use only. Must be endorsed with the name of the institution for which the PSO is required and a valid Special Authority for patient of that institution. 2) Ivermectin available on BSO provided the BSO includes a valid Special Authority for a patient of the institution. 3) For the purposes of subsidy of ivermectin, institution means age related residential care facilities, disability care facilities or penal institutions. ¾SA1225 Special Authority for Subsidy Initial application — (Scabies) from any relevant practitioner. Approvals valid for 1 month for applications meeting the following criteria: Both: 1 Applying clinician has discussed the diagnosis of scabies with a dermatologist, infectious disease physician or clinical microbiologist; and 2 Either: 2.1 Both: continued. . .

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

DERMATOLOGICALS

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

continued. . . 2.1.1 The patient is in the community; and 2.1.2 Any of the following: 2.1.2.1 Patient has a severe scabies hyperinfestation (Crusted/ Norwegian scabies); or 2.1.2.2 The community patient is physically or mentally unable to comply with the application instructions of topical therapy; or 2.1.2.3 The patient has previously tried and failed to clear infestation using topical therapy; or 2.2 All of the following: 2.2.1 The Patient is a resident in an institution; and 2.2.2 All residents of the institution with scabies or at risk of carriage are to be treated for scabies concurrently; and 2.2.3 Any of the following: 2.2.3.1 Patient has a severe scabies hyperinfestation (Crusted/ Norwegian scabies); or 2.2.3.2 The patient is physically or mentally unable to comply with the application instructions of topical therapy; or 2.2.3.3 Previous topical therapy has been tried and failed to clear the infestation. Note: Ivermectin is no more effective than topical therapy for treatment of standard scabies infestation. Initial application — (Other parasitic infections) only from an infectious disease specialist, clinical microbiologist or dermatologist. Approvals valid for 1 month for applications meeting the following criteria: Any of the following: 1 Filaricides; or 2 Cutaneous larva migrans (creeping eruption); or 3 Strongyloidiasis. Renewal — (Scabies) from any relevant practitioner. Approvals valid for 1 month for applications meeting the following criteria: Both: 1 Applying clinician has discussed the diagnosis of scabies with a dermatologist, infectious disease physician or clinical microbiologist; and 2 Either: 2.1 Both: 2.1.1 The patient is in the community; and 2.1.2 Any of the following: 2.1.2.1 Patient has a severe scabies hyperinfestation (Crusted/ Norwegian scabies); or 2.1.2.2 The community patient is physically or mentally unable to comply with the application instructions of topical therapy; or 2.1.2.3 The patient has previously tried and failed to clear infestation using topical therapy; or 2.2 All of the following: 2.2.1 The Patient is a resident in an institution; and 2.2.2 All residents of the institution with scabies or at risk of carriage are to be treated for scabies concurrently; and 2.2.3 Any of the following: 2.2.3.1 Patient has a severe scabies hyperinfestation (Crusted/ Norwegian scabies); or 2.2.3.2 The patient is physically or mentally unable to comply with the application instructions of topical therapy; or 2.2.3.3 Previous topical therapy has been tried and failed to clear the infestation. Note: Ivermectin is no more effective than topical therapy for treatment of standard scabies infestation. Renewal — (Other parasitic infections) only from an infectious disease specialist, clinical microbiologist or dermatologist. Approvals valid for 1 month for applications meeting the following criteria: Any of the following: 1 Filaricides; or 2 Cutaneous larva migrans (creeping eruption); or 3 Strongyloidiasis.

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

DERMATOLOGICALS

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

MALATHION Liq 0.5% ..............................................................................................3.79 Shampoo 1% ......................................................................................2.83 PERMETHRIN Crm 5% ..............................................................................................4.20 Lotn 5% ..............................................................................................3.24

200 ml OP 30 ml OP 30 g OP 30 ml OP

A-Lices A-Lices Lyderm A-Scabies

Psoriasis and Eczema Preparations

ACITRETIN – Special Authority see SA0954 below – Retail pharmacy Cap 10 mg ........................................................................................35.95 38.66 Cap 25 mg ........................................................................................83.11 85.40 100 60 60 100

Neotigason Novatretin Novatretin Neotigason

¾SA0954 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice; and 2 Applicant has an up to date knowledge of the treatment options for psoriasis and of disorders of keratinisation and is aware of the safety issues around acitretin and is competent to prescribe acitretin; and 3 Either: 3.1 Patient is female and has been counselled and understands the risk of teratogenicity if acitretin is used during pregnancy and the applicant has ensured that the possibility of pregnancy has been excluded prior to the commencement of the treatment and that the patient is informed that she must not become pregnant during treatment and for a period of two years after the completion of the treatment; or 3.2 Patient is male. Renewal from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice; and 2 Applicant has an up to date knowledge of the treatment options for psoriasis and of disorders of keratinisation and is aware of the safety issues around acitretin and is competent to prescribe acitretin; and 3 Either: 3.1 Patient is female and has been counselled and understands the risk of teratogenicity if acitretin is used during pregnancy and the applicant has ensured that the possibility of pregnancy has been excluded prior to the commencement of the treatment and that the patient is informed that she must not become pregnant during treatment and for a period of two years after the completion of the treatment; or 3.2 Patient is male. BETAMETHASONE DIPROPIONATE WITH CALCIPOTRIOL Oint 500 µg with calcipotriol 50 µg ...................................................26.12 30 g OP Daivobet Topical gel 500 µg with calcipotriol 50 µg ........................................26.12 30 g OP Daivobet CALCIPOTRIOL Crm 50 µg per g ...............................................................................16.00 45.00 Oint 50 µg per g ...............................................................................20.20 45.00 Soln 50 µg per ml .............................................................................16.00 33.79 30 g OP 100 g OP 30 g OP 100 g OP 30 ml OP 60 ml OP

Daivonex Daivonex Daivonex Daivonex Daivonex Daivonex

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

DERMATOLOGICALS

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

COAL TAR Soln BP – Only in combination ........................................................12.95 200 ml Midwest Up to 10 % Only in combination with a dermatological base or proprietary Topical Corticosteriod – Plain, refer, page 181 With or without other dermatological galenicals. COAL TAR WITH ALLANTOIN, MENTHOL, PHENOL AND SULPHUR Soln 5% with sulphur 0.5%, menthol 0.75%, phenol 0.5% and allantoin crm 2.5% .......................................................................3.43 30 g OP (4.35) Egopsoryl TA 6.59 75 g OP (8.00) Egopsoryl TA COAL TAR WITH SALICYLIC ACID AND SULPHUR Soln 12% with salicylic acid 2% and sulphur 4% oint .........................7.95 40 g OP

Coco-Scalp

SALICYLIC ACID Powder – Only in combination .........................................................18.88 250 g PSM 1) Only in combination with a dermatological base or proprietary Topical Corticosteroid – Plain or collodion ﬂexible, refer, page 181 2) With or without other dermatological galenicals. 3) Maximum 20 g or 20 ml per prescription when prescribed with white soft parafﬁn or collodion ﬂexible. SULPHUR Precipitated – Only in combination ....................................................6.35 100 g Midwest 1) Only in combination with a dermatological base or proprietary Topical Corticosteroid – Plain, refer, page 181 2) With or without other dermatological galenicals. TAR WITH TRIETHANOLAMINE LAURYL SULPHATE AND FLUORESCEIN – Only on a prescription F Soln 2.3% with triethanolamine lauryl sulphate and ﬂuorescein sodium .................................................................................3.05 500 ml Pinetarsol 5.82 1,000 ml Pinetarsol

Scalp Preparations

BETAMETHASONE VALERATE F Scalp app 0.1% ..................................................................................7.22 CLOBETASOL PROPIONATE F Scalp app 0.05% ................................................................................6.36 HYDROCORTISONE BUTYRATE Scalp lotn 0.1% ...................................................................................3.65 KETOCONAZOLE Shampoo 2% ......................................................................................3.08 a) Maximum of 100 ml per prescription b) Only on a prescription 100 ml OP 30 ml OP 100 ml OP 100 ml OP

Beta Scalp Dermol Locoid Sebizole

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

DERMATOLOGICALS

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

Sunscreens

SUNSCREENS, PROPRIETARY – Subsidy by endorsement Only if prescribed for a patient with severe photosensitivity secondary to a deﬁned clinical condition and the prescription is endorsed accordingly. Crm .....................................................................................................2.55 100 g OP (5.89) Hamilton Sunscreen Lotn ....................................................................................................2.55 100 ml OP Marine Blue Lotion SPF 30+ 5.10 200 ml OP Marine Blue Lotion SPF 30+ 3.19 125 ml OP (6.94) Aquasun 30+

Wart Preparations

For salicylic acid preparations refer to PSORIASIS AND ECZEMA PREPARATIONS, page 66 IMIQUIMOD – Special Authority see SA0923 below – Retail pharmacy Crm 5% ............................................................................................62.00 12

Aldara

¾SA0923 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria: Any of the following: 1 The patient has external anogenital warts and podophyllotoxin has been tried and failed (or is contraindicated); or 2 The patient has external anogenital warts and podophyllotoxin is unable to be applied accurately to the site; or 3 The patient has conﬁrmed superﬁcial basal cell carcinoma where other standard treatments, including surgical excision, are contraindicated or inappropriate. Notes: Superﬁcial basal cell carcinoma G Surgical excision remains ﬁrst-line treatment for superﬁcial basal cell carcinoma as it has a higher cure rate than imiquimod and allows histological assessment of tumour clearance. G Imiquimod has not been evaluated for the treatment of superﬁcial basal cell carcinoma within 1 cm of the hairline, eyes, nose, mouth or ears. G Imiquimod is not indicated for recurrent, invasive, inﬁltrating, or nodular basal cell carcinoma. External anogenital warts G Imiquimod is only indicated for external genital and perianal warts (condyloma acuminata). Renewal from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria: Any of the following: 1 Inadequate response to initial treatment for anogenital warts; or 2 New conﬁrmed superﬁcial basal cell carcinoma where other standard treatments, including surgical excision, are contraindicated or inappropriate; or 3 Inadequate response to initial treatment for superﬁcial basal cell carcinoma. Note: Every effort should be made to biopsy the lesion to conﬁrm that it is a superﬁcial basal cell carcinoma. PODOPHYLLOTOXIN Soln 0.5% .........................................................................................33.60 3.5 ml OP Condyline a) Maximum of 3.5 ml per prescription b) Only on a prescription

Other Skin Preparations Antineoplastics

FLUOROURACIL SODIUM Crm 5% ............................................................................................26.49 20 g OP

Efudix

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

DERMATOLOGICALS

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

Topical Analgesia

For aspirin & chloroform application refer, page 185 CAPSAICIN – Subsidy by endorsement Subsidised only if prescribed for post-herpetic neuralgia or diabetic peripheral neuropathy and the prescription is endorsed accordingly. Crm 0.075% .....................................................................................12.50 45 g OP Zostrix HP

Wound Management Products

MAGNESIUM SULPHATE F Paste ..................................................................................................2.98 (4.90) 80 g PSM

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

GENITO-URINARY SYSTEM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

Contraceptives - Non-hormonal Condoms

CONDOMS F 49 mm – Up to 144 dev available on a PSO......................................1.11 13.36 12 144

F 52 mm – Up to 144 dev available on a PSO.....................................13.36

144

F 52 mm extra strength – Up to 144 dev available on a PSO..............13.36 F 53 mm – Up to 144 dev available on a PSO.......................................1.11 13.36 1.11 13.36

144 12 144 12 144

F 53 mm (chocolate) – Up to 144 dev available on a PSO....................1.11 13.36 F 53 mm (strawberry) – Up to 144 dev available on a PSO ..................1.11 13.36 F 53 mm extra strength – Up to 144 dev available on a PSO................1.11 13.36 F 54 mm, shaped – Up to 144 dev available on a PSO.........................1.12 (1.24) 13.36 (14.84) F 55 mm – Up to 144 dev available on a PSO.....................................13.36 F 56 mm – Up to 144 dev available on a PSO.......................................1.11 13.36

12 144 12 144 12 144 12 144

Gold Knight Gold Knight MarquisTantiliza Shield 49 Marquis Selecta Marquis Sensolite Marquis Supalite Marquis Protecta Shield Blue Shield Blue Gold Knight Gold Knight Marquis Black Marquis Titillata Gold Knight Gold Knight Gold Knight Gold Knight Gold Knight Gold Knight

Lifestyles Flared Lifestyles Flared

144 12 144

Marquis Conforma Gold Knight Gold Knight Durex Extra Safe Durex Select

Flavours

F 56 mm, shaped – Up to 144 dev available on a PSO.........................1.11 13.36 F 60 mm – Up to 144 dev available on a PSO.....................................13.36 (Gold Knight 49 mm to be delisted 1 October 2012)

12 144 144

Durex Conﬁdence Durex Conﬁdence Shield XL

Contraceptive Devices

DIAPHRAGM – Up to 1 dev available on a PSO One of each size is permitted on a PSO. F 65 mm ...............................................................................................42.90 F 70 mm ...............................................................................................42.90 F 75 mm ...............................................................................................42.90 F 80 mm ...............................................................................................42.90

1 1 1 1

Ortho All-ﬂex Ortho All-ﬂex Ortho All-ﬂex Ortho All-ﬂex

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

GENITO-URINARY SYSTEM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

INTRA-UTERINE DEVICE a) Up to 40 dev available on a PSO b) Only on a PSO F IUD ...................................................................................................39.50

Multiload Cu 375 Multiload Cu 375 SL

Contraceptives - Hormonal Combined Oral Contraceptives

¾SA0500 Special Authority for Alternate Subsidy Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Either: 1.1 Patient is on a Social Welfare beneﬁt; or 1.2 Patient has an income no greater than the beneﬁt; and 2 Has tried at least one of the fully funded options and has been unable to tolerate it. Renewal from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Patient is on a Social Welfare beneﬁt; or 2 Patient has an income no greater than the beneﬁt. Notes: The approval numbers of Special Authorities approved after 1 November 1999 are interchangeable between Mercilon and Marvelon. The additional subsidy will fund Mercilon and Marvelon up to the manufacturer’s price for each of these products as identiﬁed on the Schedule at 1 November 1999. Special Authorities approved before 1 November 1999 remain valid until the expiry date and can be renewed providing that women are still either: G on a Social Welfare beneﬁt; or G have an income no greater than the beneﬁt. The approval numbers of Special Authorities approved before 1 November 1999 are interchangeable for products within the combined oral contraceptives and progestogen-only contraceptives groups, except Loette and Microgynon 20 ED ETHINYLOESTRADIOL WITH DESOGESTREL F Tab 20 µg with desogestrel 150 µg ....................................................6.62 63 (16.50) Mercilon 21 a) Higher subsidy of $13.80 per 63 tab with Special Authority see SA0500 above b) Up to 63 tab available on a PSO F Tab 20 µg with desogestrel 150 µg and 7 inert tab ............................6.62 84 (16.50) Mercilon 28 a) Higher subsidy of $13.80 per 84 tab with Special Authority see SA0500 above b) Up to 84 tab available on a PSO F Tab 30 µg with desogestrel 150 µg ....................................................6.62 63 (16.50) Marvelon 21 a) Higher subsidy of $13.80 per 63 tab with Special Authority see SA0500 above b) Up to 63 tab available on a PSO F Tab 30 µg with desogestrel 150 µg and 7 inert tab ............................6.62 84 (16.50) Marvelon 28 a) Higher subsidy of $13.80 per 84 tab with Special Authority see SA0500 above b) Up to 84 tab available on a PSO

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

GENITO-URINARY SYSTEM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

ETHINYLOESTRADIOL WITH LEVONORGESTREL F Tab 50 µg with levonorgestrel 125 µg and 7 inert tab – Up to 84 tab available on a PSO............................................................ 9.45 84 Microgynon 50 ED F Tab 30 µg with levonorgestrel 150 µg ................................................6.62 63 (16.50) Microgynon 30 a) Higher subsidy of $15.00 per 63 tab with Special Authority see SA0500 on the preceding page b) Up to 63 tab available on a PSO F Tab 30 µg with levonorgestrel 150 µg and 7 inert tab – Up to 84 tab available on a PSO............................................................ 2.45 84 Ava 30 ED (6.62) Levlen ED (6.62) Monofeme (14.49) Nordette 28 (16.50) Microgynon 30 ED (Levlen ED Tab 30 µg with levonorgestrel 150 µg and 7 inert tab to be delisted 1 September 2012) (Monofeme Tab 30 µg with levonorgestrel 150 µg and 7 inert tab to be delisted 1 September 2012) (Nordette 28 Tab 30 µg with levonorgestrel 150 µg and 7 inert tab to be delisted 1 September 2012) (Microgynon 30 ED Tab 30 µg with levonorgestrel 150 µg and 7 inert tab to be delisted 1 September 2012) ETHINYLOESTRADIOL WITH NORETHISTERONE F Tab 35 µg with norethisterone 1 mg – Up to 63 tab available on a PSO...................................................................................... 6.62 F Tab 35 µg with norethisterone 1 mg and 7 inert tab – Up to 84 tab available on a PSO............................................................ 6.62 F Tab 35 µg with norethisterone 500 µg – Up to 63 tab available on a PSO...................................................................................... 6.62 F Tab 35 µg with norethisterone 500 µg and 7 inert tab – Up to 84 tab available on a PSO............................................................ 6.62

63 84 63 84

Brevinor 1/21 Brevinor 1/28 Brevinor 21 Norimin

NORETHISTERONE WITH MESTRANOL F Tab 1 mg with mestranol 50 µg and 7 inert tab ..................................6.62 84 (13.80) Norinyl-1/28 a) Higher subsidy of $13.80 per 84 tab with Special Authority see SA0500 on the preceding page b) Up to 84 tab available on a PSO

Combined Oral Contraceptives - Other

ETHINYLOESTRADIOL WITH LEVONORGESTREL F Tab 20 µg with levonorgestrel 100 µg and 7 inert tab – Up to 84 tab available on a PSO............................................................ 2.95 6.62 (16.50) (16.50)

Ava 20 ED

Loette Microgynon 20 ED

Progestogen-only Contraceptives

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

GENITO-URINARY SYSTEM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

continued. . . Renewal from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Patient is on a Social Welfare beneﬁt; or 2 Patient has an income no greater than the beneﬁt. Notes: The approval numbers of Special Authorities approved after 1 November 1999 are interchangeable between Mercilon and Marvelon. The additional subsidy will fund Mercilon and Marvelon up to the manufacturer’s price for each of these products as identiﬁed on the Schedule at 1 November 1999. Special Authorities approved before 1 November 1999 remain valid until the expiry date and can be renewed providing that women are still either: G on a Social Welfare beneﬁt; or G have an income no greater than the beneﬁt. The approval numbers of Special Authorities approved before 1 November 1999 are interchangeable for products within the combined oral contraceptives and progestogen-only contraceptives groups, except Loette and Microgynon 20 ED LEVONORGESTREL F Tab 30 µg ...........................................................................................6.62 84 (16.50) Microlut a) Higher subsidy of $13.80 per 84 tab with Special Authority see SA0500 on the preceding page b) Up to 84 tab available on a PSO F Subdermal implant (2 × 75 mg rods) .............................................133.65 1 Jadelle MEDROXYPROGESTERONE ACETATE F Inj 150 mg per ml, 1 ml syringe – Up to 5 inj available on a PSO .........7.15 NORETHISTERONE F Tab 350 µg – Up to 84 tab available on a PSO ..................................6.00 1 84

Depo-Provera Noriday 28

Emergency Contraceptives

LEVONORGESTREL F Tab 1.5 mg ........................................................................................12.50 a) Up to 5 tab available on a PSO b) Maximum of 2 tab per prescription 1

Postinor-1

Antiandrogen Oral Contraceptives

Prescribers may code prescriptions “contraceptive” (code “O”) when used as indicated for contraception. The period of supply and prescription charge will be as per other contraceptives, as follows: G $3.00 prescription charge (patient co-payment) will apply. G prescription may be written for up to six months supply. Prescriptions coded in any other way are subject to the non contraceptive prescription charges, and the non-contraceptive period of supply. ie. Prescriptions may be written for up to three months supply. CYPROTERONE ACETATE WITH ETHINYLOESTRADIOL F Tab 2 mg with ethinyloestradiol 35 µg and 7 inert tabs ......................3.89 84 Ginet 84

Gynaecological Anti-infectives

ACETIC ACID WITH HYDROXYQUINOLINE AND RICINOLEIC ACID Jelly with glacial acetic acid 0.94%, hydroxyquinoline sulphate 0.025%, glycerol 5% and ricinoleic acid 0.75% with applicator .....................................................................................8.43 (24.00)

100 g OP Aci-Jel

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

GENITO-URINARY SYSTEM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

CLOTRIMAZOLE F Vaginal crm 1% with applicators .........................................................1.30 F Vaginal crm 2% with applicators .........................................................2.50 MICONAZOLE NITRATE F Vaginal crm 2% with applicator ..........................................................2.75 (3.70) NYSTATIN Vaginal crm 100,000 u per 5 g with applicator(s) ...............................4.71

35 g OP 20 g OP 40 g OP

Clomazol Clomazol

Micreme 75 g OP

Nilstat

Myometrial and Vaginal Hormone Preparations

ERGOMETRINE MALEATE Inj 500 µg per ml, 1 ml – Up to 5 inj available on a PSO..................31.00 OESTRIOL F Crm 1 mg per g with applicator ..........................................................6.30 F Pessaries 500 µg ...............................................................................6.53 OXYTOCIN – Up to 5 inj available on a PSO Inj 5 iu per ml, 1 ml .............................................................................5.94 Inj 10 iu per ml, 1 ml ...........................................................................7.48 Inj 5 iu with ergometrine maleate 500 µg per ml, 1 ml .....................11.13 5 15 g OP 15 5 5 5

DBL Ergometrine Ovestin Ovestin Syntocinon Syntocinon Syntometrine

Pregnancy Tests - hCG Urine

PREGNANCY TESTS - HCG URINE a) Up to 200 test available on a PSO b) Only on a PSO Cassette ...........................................................................................22.80

40 test OP

Innovacon hCG One

Step Pregnancy Test

Urinary Agents

For urinary tract Infections refer to INFECTIONS, Antibacterials, page 97

5-Alpha Reductase Inhibitors

FINASTERIDE – Special Authority see SA0928 below – Retail pharmacy F Tab 5 mg .............................................................................................5.10 30

Rex Medical

¾SA0928 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid without further renewal unless notiﬁed for applications meeting the following criteria: Both: 1 Patient has symptomatic benign prostatic hyperplasia; and 2 Either: 2.1 The patient is intolerant of non-selective alpha blockers or these are contraindicated; or 2.2 Symptoms are not adequately controlled with non-selective alpha blockers. Note: Patients with enlarged prostates are the appropriate candidates for therapy with ﬁnasteride.

Alpha-1A Adrenoreceptor Blockers

TAMSULOSIN HYDROCHLORIDE – Special Authority see SA1032 on the next page – Retail pharmacy F Cap 400 µg .........................................................................................5.98 30 Tamsulosin-Rex

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

GENITO-URINARY SYSTEM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

¾SA1032 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid without further renewal unless notiﬁed for applications meeting the following criteria: Both: 1 Patient has symptomatic benign prostatic hyperplasia; and 2 The patient is intolerant of non-selective alpha blockers or these are contraindicated.

Other Urinary Agents

OXYBUTYNIN F Tab 5 mg ...........................................................................................44.79 F Oral liq 5 mg per 5 ml .......................................................................50.40 POTASSIUM CITRATE Oral liq 3 mmol per ml – Special Authority see SA1083 below – Retail pharmacy ..................................................................... 30.00 500 473 ml

Apo-Oxybutynin Apo-Oxybutynin

200 ml OP

Biomed

¾SA1083 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 The patient has recurrent calcium oxalate urolithiasis; and 2 The patient has had more than two renal calculi in the two years prior to the application. Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is beneﬁtting from the treatment. SODIUM CITRO-TARTRATE F Grans eff 4 g sachets .........................................................................2.71 28 Ural SOLIFENACIN SUCCINATE – Special Authority see SA0998 below – Retail pharmacy Tab 5 mg ...........................................................................................56.50 30 Tab 10 mg .........................................................................................56.50 30

Vesicare Vesicare

¾SA0998 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid without further renewal unless notiﬁed where the patient has overactive bladder and a documented intolerance of oxybutynin.

Detection of Substances in Urine

ORTHO-TOLIDINE F Compound diagnostic sticks ...............................................................7.50 (8.25) TETRABROMOPHENOL F Blue diagnostic strips .........................................................................7.02 (13.92) 50 test OP Hemastix 100 test OP Albustix

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

Anabolic Agents

NANDROLONE DECANOATE – Retail pharmacy-Specialist Inj 50 mg per ml, 1 ml ......................................................................21.16 (Deca-Durabolin Orgaject

S29

Deca-Durabolin

Orgaject S29

Inj 50 mg per ml, 1 ml to be delisted 1 January 2013)

Corticosteroids and Related Agents for Systemic Use

BETAMETHASONE SODIUM PHOSPHATE WITH BETAMETHASONE ACETATE F Inj 3.9 mg with betamethasone acetate 3 mg per ml, 1 ml ...............19.20 (33.60) 5 Celestone Chronodose

DEXAMETHASONE F Tab 1 mg – Retail pharmacy-Specialist ..............................................5.87 100 Up to 30 tab available on a PSO F Tab 4 mg – Retail pharmacy-Specialist ..............................................8.16 100 Up to 30 tab available on a PSO Oral liq 1 mg per ml – Retail pharmacy-Specialist ...........................45.00 25 ml OP Oral liq prescriptions: 1) Must be written by a Paediatrician or Paediatric Cardiologist; or 2) On the recommendation of a Paediatrician or Paediatric Cardiologist. DEXAMETHASONE SODIUM PHOSPHATE Dexamethasone sodium phosphate injection will not be funded for oral use. F Inj 4 mg per ml, 1 ml – Up to 5 inj available on a PSO .....................21.50 5 F Inj 4 mg per ml, 2 ml – Up to 5 inj available on a PSO .....................31.00 5 FLUDROCORTISONE ACETATE F Tab 100 µg .......................................................................................14.32 HYDROCORTISONE F Tab 5 mg .............................................................................................8.35 F Tab 20 mg – For hydrocortisone oral liquid formulation refer, page 182 ....................................................................................20.95 F Inj 50 mg per ml, 2 ml .........................................................................3.99 a) Up to 5 inj available on a PSO b) Only on a PSO METHYLPREDNISOLONE – Retail pharmacy-Specialist F Tab 4 mg ...........................................................................................60.00 F Tab 100 mg .....................................................................................166.52 METHYLPREDNISOLONE ACETATE Inj 40 mg per ml, 1 ml .........................................................................6.70 METHYLPREDNISOLONE ACETATE WITH LIGNOCAINE Inj 40 mg per ml with lignocaine 1 ml .................................................7.50 100 100 100 1

Douglas Douglas Biomed

Hospira Hospira Florinef Douglas Douglas Solu-Cortef

100 20 1 1

Medrol Medrol Depo-Medrol Depo-Medrol with

Lidocaine

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

METHYLPREDNISOLONE SODIUM SUCCINATE – Retail pharmacy-Specialist Inj 40 mg per ml, 1 ml .........................................................................7.50 151.40 Inj 62.5 mg per ml, 2 ml ....................................................................18.50 412.59 Inj 500 mg .........................................................................................18.00 Inj 1 g ................................................................................................37.50 PREDNISOLONE SODIUM PHOSPHATE F Oral liq 5 mg per ml – Up to 30 ml available on a PSO ......................9.95 Restricted to children under 12 years of age. PREDNISONE F Tab 1 mg ...........................................................................................10.68 F Tab 2.5 mg ........................................................................................12.09 F Tab 5 mg – Up to 30 tab available on a PSO....................................11.09 F Tab 20 mg .........................................................................................29.03 TETRACOSACTRIN F Inj 250 µg .......................................................................................177.18 F Inj 1 mg per ml, 1 ml .........................................................................29.56 TRIAMCINOLONE ACETONIDE Inj 10 mg per ml, 1 ml .......................................................................21.90 Inj 40 mg per ml, 1 ml .......................................................................53.79

1 25 1 25 1 1 30 ml OP

Solu-Medrol Solu-Medrol Solu-Medrol Solu-Medrol Solu-Medrol Solu-Medrol Redipred

500 500 500 500 10 1 5 5

Apo-Prednisone Apo-Prednisone Apo-Prednisone Apo-Prednisone Synacthen Synacthen Depot Kenacort-A Kenacort-A40

Sex Hormones Non Contraceptive Androgen Agonists and Antagonists

CYPROTERONE ACETATE – Retail pharmacy-Specialist Tab 50 mg .........................................................................................18.80 Tab 100 mg .......................................................................................34.25 TESTOSTERONE Transdermal patch, 2.5 mg per day ..................................................80.00 TESTOSTERONE CYPIONATE – Retail pharmacy-Specialist Inj long-acting 100 mg per ml, 10 ml ................................................76.50 TESTOSTERONE ESTERS – Retail pharmacy-Specialist Inj 250 mg per ml, 1 ml .....................................................................12.98 TESTOSTERONE UNDECANOATE – Retail pharmacy-Specialist Cap 40 mg ........................................................................................31.17 79.92 50 50 60 1 1 60 100

Siterone Siterone Androderm Depo-Testosterone Sustanon Ampoules Andriol Testocaps Arrow-Testosterone

Hormone Replacement Therapy - Systemic

¾SA1018 Special Authority for Alternate Subsidy Initial application from any relevant practitioner. Approvals valid for 5 years for applications meeting the following criteria: Any of the following: 1 acute or signiﬁcant liver disease - where oral oestrogens are contraindicated as determined by a gastroenterologist or general physician. The applicant must keep written conﬁrmation from such a specialist with the patient’s record; or 2 oestrogen induced hypertension requiring antihypertensive therapy - documented evidence must be kept on ﬁle that raised blood pressure levels or inability to control blood pressure adequately occurred post oral oestrogens; or continued. . .

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

continued. . . 3 hypertriglyceridaemia - documented evidence must be kept on ﬁle that triglyceride levels increased to at least 2 × normal triglyceride levels post oral oestrogens; or 4 Somatropin co-therapy - patient is being prescribed somatropin with subsidy provided under a valid approval issued under Special Authority. Note: Prescriptions with a valid Special Authority (CHEM) number will be reimbursed at the level of the lowest priced TDDS product within the speciﬁed dose group. Renewal from any relevant practitioner. Approvals valid for 5 years where the treatment remains appropriate and the patient is beneﬁting from treatment, or the patient remains on subsidised somatropin co-therapy. Prescribing Guideline HRT should be taken at the lowest dose for the shortest period of time necessary to control symptoms. Patients should be reviewed 6 monthly in line with the updated NZGG “Evidence-based Best Practice Guideline on Hormone Replacement Therapy March 2004”.

Oestrogens

OESTRADIOL – See prescribing guideline above F Tab 1 mg .............................................................................................4.12 28 OP (10.55) Estrofem F Tab 2 mg .............................................................................................4.12 28 OP (10.55) Estrofem F TDDS 25 µg per day .........................................................................3.01 8 (10.86) Estradot a) Higher subsidy of $10.86 per 8 patch with Special Authority see SA1018 on the preceding page b) No more than 2 patch per week c) Only on a prescription F TDDS 3.9 mg (releases 50 µg of oestradiol per day) ........................4.12 4 (13.18) Climara 50 (32.50) Femtran 50 a) Higher subsidy of $13.18 per 4 patch with Special Authority see SA1018 on the preceding page b) No more than 1 patch per week c) Only on a prescription F TDDS 50 µg per day .........................................................................4.12 8 (13.18) Estradot 50 µg a) Higher subsidy of $13.18 per 8 patch with Special Authority see SA1018 on the preceding page b) No more than 2 patch per week c) Only on a prescription F TDDS 7.8 mg (releases 100 µg of oestradiol per day) ......................7.05 4 (16.14) Climara 100 (35.00) Femtran 100 a) Higher subsidy of $16.14 per 4 patch with Special Authority see SA1018 on the preceding page b) No more than 1 patch per week c) Only on a prescription F TDDS 100 µg per day .......................................................................7.05 8 (16.14) Estradot a) Higher subsidy of $16.14 per 8 patch with Special Authority see SA1018 on the preceding page b) No more than 2 patch per week c) Only on a prescription OESTRADIOL VALERATE – See prescribing guideline above F Tab 1 mg .............................................................................................8.24 56 Progynova F Tab 2 mg .............................................................................................8.24 56 Progynova

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

OESTROGENS – See prescribing guideline on the preceding page F Conjugated, equine tab 300 µg ..........................................................3.01 (11.48) F Conjugated, equine tab 625 µg ..........................................................4.12 (11.48)

28 Premarin 28 Premarin

Progestogens

MEDROXYPROGESTERONE ACETATE – See prescribing guideline on the preceding page F Tab 2.5 mg ..........................................................................................3.09 30 F Tab 5 mg ...........................................................................................13.06 100 F Tab 10 mg ...........................................................................................6.85 30

Provera Provera Provera

Progestogen and Oestrogen Combined Preparations

OESTRADIOL WITH NORETHISTERONE – See prescribing guideline on the preceding page F Tab 1 mg with 0.5 mg norethisterone acetate .....................................5.40 28 OP (14.52) F Tab 2 mg with 1 mg norethisterone acetate ........................................5.40 28 OP (14.52) F Tab 2 mg with 1 mg norethisterone acetate (10), and 2 mg oestradiol tab (12) and 1 mg oestradiol tab (6) ............................5.40 28 OP (14.52)

Kliovance Kliogest

Trisequens

OESTROGENS WITH MEDROXYPROGESTERONE – See prescribing guideline on the preceding page F Tab 625 µg conjugated equine with 2.5 mg medroxyprogesterone acetate tab (28) ................................................................5.40 28 OP (22.96) Premia 2.5 Continuous F Tab 625 µg conjugated equine with 5 mg medroxyprogesterone acetate tab (28) ................................................................5.40 28 OP (22.96) Premia 5 Continuous

Other Oestrogen Preparations

ETHINYLOESTRADIOL F Tab 10 µg .........................................................................................17.60 OESTRIOL F Tab 2 mg .............................................................................................7.00 100

NZ Medical and

Scientiﬁc

Ovestin

Other Progestogen Preparations

LEVONORGESTREL F Levonorgestrel - releasing intrauterine system 20 µg/24 hr – Special Authority see SA0782 on the next page – Retail pharmacy ................................................................................. 269.50

Mirena

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

¾SA0782 Special Authority for Subsidy Initial application — (No previous use) only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 The patient has a clinical diagnosis of heavy menstrual bleeding; and 2 The patient has failed to respond to or is unable to tolerate other appropriate pharmaceutical therapies as per the Heavy Menstrual Bleeding Guidelines; and 3 Either: 3.1 serum ferritin level < 16 µg/l (within the last 12 months); or 3.2 haemoglobin level < 120 g/l. Note: Applications are not to be made for use in patients as contraception except where they meet the above criteria. Initial application — (Previous use before 1 October 2002) only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 The patient had a clinical diagnosis of heavy menstrual bleeding; and 2 Patient demonstrated clinical improvement of heavy menstrual bleeding; and 3 Applicant to state date of the previous insertion. Note: Applications are not to be made for use in patients as contraception except where they meet the above criteria. Renewal only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Either: 1.1 Patient demonstrated clinical improvement of heavy menstrual bleeding; or 1.2 Previous insertion was removed or expelled within 3 months of insertion; and 2 Applicant to state date of the previous insertion. MEDROXYPROGESTERONE ACETATE F Tab 100 mg – Retail pharmacy-Specialist ........................................96.50 100 Provera F Tab 200 mg – Retail pharmacy-Specialist ........................................70.50 30 Provera NORETHISTERONE F Tab 5 mg – Up to 30 tab available on a PSO....................................26.50 100

Primolut N

Thyroid and Antithyroid Agents

CARBIMAZOLE F Tab 5 mg ...........................................................................................10.80 100

Neo-Mercazole Synthroid Synthroid Goldshield Synthroid Synthroid Eltroxin Goldshield Synthroid Eltroxin

LEVOTHYROXINE F Tab 25 µg ...........................................................................................3.89 90 43.24 1,000 ‡ Safety cap for extemporaneously compounded oral liquid preparations. F Tab 50 µg ...........................................................................................1.71 28 4.05 90 45.00 1,000 64.28 ‡ Safety cap for extemporaneously compounded oral liquid preparations. F Tab 100 µg .........................................................................................1.78 28 4.21 90 66.78 1,000 ‡ Safety cap for extemporaneously compounded oral liquid preparations. PROPYLTHIOURACIL – Special Authority see SA1199 on the next page – Retail pharmacy Tab 50 mg .........................................................................................35.00 100

PTU S29

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

¾SA1199 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 The patient has hyperthyroidism; and 2 The patient is intolerant of carbimazole or carbimazole is contraindicated. Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is beneﬁtting from the treatment.

Trophic Hormones Growth Hormones

¾SA0755 Special Authority for Subsidy Special Authority approved by the Growth Hormone Committee Notes: Subject to budgetary cap. Applications will be considered and approved subject to funding availability. Application details may be obtained from PHARMAC’s website http://www.pharmac.govt.nz or: NZGHC Coordinator PHARMAC, PO Box 10-254, WELLINGTON Tel: 0800 808 476, Fax: (09) 929 3221, Email: growthhormone@pharmac.govt.nz SOMATROPIN – Special Authority see SA0755 above F Inj cartridge 16 iu (5.3 mg) .............................................................160.00 F Inj cartridge 36 iu (12 mg) ..............................................................360.00 1 1

Genotropin Genotropin

GnRH Analogues

GOSERELIN ACETATE Inj 3.6 mg ........................................................................................166.20 Inj 10.8 mg ......................................................................................443.76 LEUPRORELIN Inj 3.75 mg ......................................................................................221.60 Inj 3.75 mg preﬁlled syringe ...........................................................221.60 Inj 7.5 mg ........................................................................................166.20 Inj 11.25 mg ....................................................................................591.68 Inj 11.25 mg preﬁlled syringe .........................................................591.68 Inj 22.5 mg ......................................................................................443.76 Inj 30 mg .........................................................................................591.68 Inj 30 mg preﬁlled syringe ...........................................................1,109.40 Inj 45 mg .........................................................................................832.05 1 1 1 1 1 1 1 1 1 1 1

Zoladex Zoladex Lucrin Depot Lucrin Depot PDS Eligard Lucrin Depot Lucrin Depot PDS Eligard Eligard Lucrin Depot PDS Eligard

Vasopressin Agonists

DESMOPRESSIN L Nasal drops 100 µg per ml – Retail pharmacy-Specialist ................39.03 L Nasal spray 10 µg per dose – Retail pharmacy-Specialist...............27.48 Inj 4 µg per ml, 1 ml – Special Authority see SA0090 below – Retail pharmacy ..................................................................... 67.18 2.5 ml OP 6 ml OP

Minirin DesmopressinPH&T

Minirin

¾SA0090 Special Authority for Subsidy Initial application only from a relevant specialist. Approvals valid for 2 years where the patient cannot use desmopressin nasal spray or nasal drops. Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is beneﬁting from treatment.

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

Other Endocrine Agents

CABERGOLINE Tab 0.5 mg – Maximum of 2 tab per prescription; can be waived by Special Authority see SA1031 below........................... 6.25 25.00 16.50 66.00

2 8 2 8

Dostinex Dostinex Arrow-Cabergoline Arrow-Cabergoline

¾SA1031 Special Authority for Waiver of Rule Initial application only from an obstetrician, endocrinologist or gynaecologist. Approvals valid without further renewal unless notiﬁed where the patient has pathological hyperprolactinemia. Renewal only from an obstetrician, endocrinologist or gynaecologist. Approvals valid without further renewal unless notiﬁed where the patient has previously held a valid Special Authority which has expired and the treatment remains appropriate and the patient is beneﬁting from treatment. CLOMIPHENE CITRATE Tab 50 mg .........................................................................................29.84 10 Serophene DANAZOL – Retail pharmacy-Specialist Cap 100 mg ......................................................................................68.33 Cap 200 mg ......................................................................................97.83 GESTRINONE – Retail pharmacy-Specialist Cap 2.5 mg ....................................................................................101.87 (Dimetriose Cap 2.5 mg to be delisted 1 December 2012) METYRAPONE Cap 250 mg – Retail pharmacy-Specialist .....................................238.00 100 100 8 OP

Azol Azol Dimetriose

Metopirone

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

INFECTIONS - AGENTS FOR SYSTEMIC USE

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

Anthelmintics

MEBENDAZOLE – Only on a prescription Tab 100 mg .......................................................................................24.19 Oral liq 100 mg per 5 ml .....................................................................2.18 (7.17) 24 15 ml

De-Worm

Vermox

Antibacterials

a) For anti-infective eye preparations, refer to SENSORY ORGANS, page 176 b) For topical antibacterials, refer to DERMATOLOGICALS, page 59

Cephalosporins and Cephamycins

CEFACLOR MONOHYDRATE Cap 250 mg .....................................................................................24.57 Grans for oral liq 125 mg per 5 ml ......................................................3.53 (Cefaclor Sandoz Cap 250 mg to be delisted 1 October 2012) 100 100 ml

Cefaclor Sandoz Ranbaxy-Cefaclor Ranbaxy-Cefaclor

CEFAZOLIN SODIUM – Subsidy by endorsement Only if prescribed for dialysis or cystic ﬁbrosis patient and the prescription is endorsed accordingly. Inj 500 mg ...........................................................................................3.99 5 AFT Inj 1 g ..................................................................................................3.99 5 AFT CEFOXITIN SODIUM – Retail pharmacy-Specialist – Subsidy by endorsement Only if prescribed for dialysis or cystic ﬁbrosis patient and the prescription is endorsed accordingly. Inj 1 g ................................................................................................55.00 5 Mayne CEFTRIAXONE SODIUM – Subsidy by endorsement a) Up to 5 inj available on a PSO b) Subsidised only if prescribed for a dialysis or cystic ﬁbrosis patient, or the treatment of conﬁrmed ciproﬂoxacin-resistant gonorrhoea, or the treatment of suspected meningitis in patients who have a known allergy to penicillin, and the prescription or PSO is endorsed accordingly. Inj 500 mg ...........................................................................................2.70 1 Veracol Inj 1 g ................................................................................................10.49 5 Aspen Ceftriaxone CEFUROXIME AXETIL – Subsidy by endorsement Only if prescribed for prophylaxis of endocarditis and the prescription is endorsed accordingly. Tab 250 mg .......................................................................................29.40 50 Zinnat CEFUROXIME SODIUM Inj 250 mg – Maximum of 3 inj per prescription; can be waived by endorsement.......................................................................... 20.97 10 Mayne Waiver by endorsement must state that the prescription is for dialysis or cystic ﬁbrosis patient. Inj 750 mg – Maximum of 1 inj per prescription; can be waived by endorsement............................................................................6.96 5 m-Cefuroxime Waiver by endorsement must state that the prescription is for dialysis or cystic ﬁbrosis patient. Inj 1.5 g – Retail pharmacy-Specialist – Subsidy by endorsement..............................................................................................2.65 1 Mylan 4.04 Zinacef Only if prescribed for dialysis or cystic ﬁbrosis patient and the prescription is endorsed accordingly.

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

INFECTIONS - AGENTS FOR SYSTEMIC USE

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

CEPHALEXIN MONOHYDRATE Cap 500 mg ........................................................................................8.90 Grans for oral liq 125 mg per 5 ml ......................................................8.50 Grans for oral liq 250 mg per 5 ml ....................................................11.50

20 100 ml 100 ml

Cephalexin ABM Cefalexin Sandoz Cefalexin Sandoz

Macrolides

AZITHROMYCIN Tab 500 mg – Subsidy by endorsement; can be waived by Special Authority see SA1130 below............................................ 5.95 2 OP Arrow-Azithromycin a) Up to 8 tab available on a PSO b) Maximum of 2 tab per prescription; can be waived by Special Authority see SA1130 below c) Subsidised only if prescribed for patients with uncomplicated urethritis or cervicitis proven or presumed to be due to chlamydia trachomatis and their sexual contacts and prescription or PSO is endorsed accordingly; can be waived by Special Authority see SA1130. Grans for oral liq 200 mg per 5 ml – Subsidy by endorsement..........13.20 15 ml Zithromax 1) Maximum of 5 days per prescription; and 2) The patient is less than one year old; and 3) Either i) Patient has pertussis and this has been notiﬁed to the Medical Ofﬁcer of Health; or ii) Patient has had direct contact with a notiﬁed case of pertussis and requires prophylaxis; and 4) The prescription is endorsed accordingly (note treatment and prophylaxis of pertussis are unapproved indications). ¾SA1130 Special Authority for Waiver of Rule Initial application — (Cystic Fibrosis) only from a respiratory specialist or paediatrician. Approvals valid without further renewal unless notiﬁed for applications meeting the following criteria: All of the following: 1 The applicant is part of multidisciplinary team experienced in the management of cystic ﬁbrosis; and 2 The patient has been deﬁnitively diagnosed with cystic ﬁbrosis*; and 3 The patient has chronic infection with Pseudomonas aeruginosa or Pseudomonas related gram negative organisms as deﬁned by two positive respiratory tract cultures at least three months apart*; and 4 The patient has negative cultures for non-tuberculous mycobacteria. Notes: Caution is advised if using azithromycin as an antibiotic in the treatment of cystic ﬁbrosis patients with pneumonia. Testing for non-tuberculosis mycobacteria should occur annually. Initial application — (bronchiolitis obliterans syndrome) only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: All of the following: 1 Patient has received a lung transplant; and 2 Azithromycin is to be used for prophylaxis of bronchiolitis obliterans syndrome*; and 3 The applicant is experienced in managing patients who have received a lung transplant. Renewal — (bronchiolitis obliterans syndrome) only from a relevant specialist. Approvals valid without further renewal unless notiﬁed for applications meeting the following criteria: Both: 1 The patient remains well and free from bronchiolits obliterans syndrome*; and 2 The applicant is experienced in managing patients who have received a lung transplant. Note: Indications marked with * are Unapproved Indications CLARITHROMYCIN – Maximum of 500 mg per prescription; can be waived by Special Authority see SA1131 on the next page Tab 250 mg .........................................................................................4.19 14 Apo-Clarithromycin Grans for oral liq 125 mg per 5 ml ....................................................23.12 70 ml Klacid

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

INFECTIONS - AGENTS FOR SYSTEMIC USE

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

¾SA1131 Special Authority for Waiver of Rule Initial application — (Mycobacterial infections) only from a respiratory specialist, infectious disease specialist or paediatrician. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Atypical mycobacterial infection; or 2 Mycobacterium tuberculosis infection where there is drug-resistance or intolerance to standard pharmaceutical agents. Renewal — (Mycobacterial infections) only from a respiratory specialist, infectious disease specialist or paediatrician. Approvals valid for 2 years where the treatment remains appropriate and the patient is beneﬁting from treatment. ERYTHROMYCIN ETHYL SUCCINATE Tab 400 mg – Up to 30 tab available on a PSO................................16.95 100 E-Mycin Grans for oral liq 200 mg per 5 ml – Up to 200 ml available on a PSO......................................................................................4.35 100 ml E-Mycin Grans for oral liq 400 mg per 5 ml – Up to 200 ml available on a PSO......................................................................................5.85 100 ml E-Mycin ERYTHROMYCIN LACTOBIONATE Inj 1 g ................................................................................................10.93 ERYTHROMYCIN STEARATE Tab 250 mg – Up to 30 tab available on a PSO................................14.95 (22.29) Tab 500 mg .......................................................................................29.90 (44.58) ROXITHROMYCIN Tab 150 mg .........................................................................................7.48 Tab 300 mg .......................................................................................14.40 1 100 ERA 100 ERA 50 50

Erythrocin IV

ArrowRoxithromycin

Penicillins

AMOXYCILLIN Cap 250 mg – Up to 30 cap available on a PSO..............................16.18 Cap 500 mg ......................................................................................26.50 Grans for oral liq 125 mg per 5 ml – Up to 200 ml available on a PSO......................................................................................1.55 Grans for oral liq 250 mg per 5 ml – Up to 200 ml available on a PSO......................................................................................1.10 Drops 125 mg per 1.25 ml ..................................................................4.00 Inj 250 mg .........................................................................................12.96 Inj 500 mg .........................................................................................15.08 Inj 1 g – Up to 5 inj available on a PSO............................................21.94 500 500 100 ml 100 ml 30 ml OP 10 10 10

Alphamox Alphamox Ospamox Ospamox Ospamox Paediatric

Drops

Ibiamox Ibiamox Ibiamox

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

INFECTIONS - AGENTS FOR SYSTEMIC USE

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

AMOXYCILLIN CLAVULANATE Tab amoxycillin 500 mg with potassium clavulanate 125 mg – Up to 30 tab available on a PSO .............................................12.55 100 Curam Duo 26.00 Synermox Grans for oral liq amoxycillin 125 mg with potassium clavulanate 31.25 mg per 5 ml – Up to 200 ml available on a PSO.............................................................................................. 2.20 100 ml Curam Grans for oral liq amoxycillin 250 mg with potassium clavulanate 62.5 mg per 5 ml – Up to 200 ml available on a PSO.............................................................................................. 3.85 100 ml Curam (Synermox Tab amoxycillin 500 mg with potassium clavulanate 125 mg to be delisted 1 December 2012) BENZATHINE BENZYLPENICILLIN Inj 1.2 mega u per 2.3 ml – Up to 5 inj available on a PSO............315.00 BENZYLPENICILLIN SODIUM (PENICILLIN G) Inj 600 mg – Up to 5 inj available on a PSO.....................................11.50 FLUCLOXACILLIN SODIUM Cap 250 mg – Up to 30 cap available on a PSO..............................22.00 32.00 Cap 500 mg ......................................................................................74.00 110.00 Grans for oral liq 125 mg per 5 ml – Up to 200 ml available on a PSO...................................................................................... 2.49 Grans for oral liq 250 mg per 5 ml – Up to 200 ml available on a PSO...................................................................................... 3.25 Inj 250 mg .........................................................................................10.86 Inj 500 mg .........................................................................................11.32 Inj 1 g – Up to 5 inj available on a PSO............................................14.28 PHENOXYMETHYLPENICILLIN (PENICILLIN V) Cap potassium salt 250 mg – Up to 30 cap available on a PSO .........9.71 Cap potassium salt 500 mg ..............................................................11.70 Grans for oral liq 125 mg per 5 ml – Up to 200 ml available on a PSO...................................................................................... 1.68 Grans for oral liq 250 mg per 5 ml – Up to 200 ml available on a PSO...................................................................................... 1.78 PROCAINE PENICILLIN Inj 1.5 mega u – Up to 5 inj available on a PSO.............................123.50 10 10 250 500

Bicillin LA Sandoz Staphlex AFT Staphlex AFT AFT AFT Flucloxin Flucloxin Flucloxin Cilicaine VK Cilicaine VK AFT AFT Cilicaine

100 ml 100 ml 10 10 10 50 50 100 ml 100 ml 5

Tetracyclines

DOXYCYCLINE HYDROCHLORIDE F Tab 50 mg – Up to 30 tab available on a PSO....................................2.90 (6.00) F Tab 100 mg – Up to 30 tab available on a PSO..................................7.95 MINOCYCLINE HYDROCHLORIDE F Tab 50 mg ...........................................................................................5.79 (12.05) F Cap 100 mg ......................................................................................19.32 (52.04) 30 Doxy-50 250 60 Mino-tabs 100 Minomycin

Doxine

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

INFECTIONS - AGENTS FOR SYSTEMIC USE

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

Other Antibiotics

For topical antibiotics, refer to DERMATOLOGICALS, page 59 CIPROFLOXACIN Tab 250 mg – Up to 5 tab available on a PSO....................................2.20 Tab 500 mg – Up to 5 tab available on a PSO....................................3.00 Tab 750 mg – Retail pharmacy-Specialist ..........................................5.15 CLINDAMYCIN Cap hydrochloride 150 mg – Maximum of 4 cap per prescription; can be waived by endorsement - Retail pharmacy Specialist ......................................................................................9.90 Inj phosphate 150 mg per ml, 4 ml – Retail pharmacySpecialist .................................................................................. 160.00 CO-TRIMOXAZOLE F Tab trimethoprim 80 mg and sulphamethoxazole 400 mg – Up to 30 tab available on a PSO ................................................ 20.97 F Oral liq trimethoprim 40 mg and sulphamethoxazole 200 mg per 5 ml – Up to 200 ml available on a PSO................................2.15

28 28 28

Cipﬂox Cipﬂox Cipﬂox

16 10

Clindamycin ABM Dalacin C

500 100 ml

Trisul Deprim

COLISTIN SULPHOMETHATE – Retail pharmacy-Specialist – Subsidy by endorsement Only if prescribed for dialysis or cystic ﬁbrosis patient and the prescription is endorsed accordingly. Inj 150 mg .........................................................................................65.00 1 Colistin-Link FUSIDIC ACID Tab 250 mg – Retail pharmacy-Specialist ........................................34.50 12 Fucidin Inj 500 mg sodium fusidate per 10 ml – Retail pharmacySpecialist – Subsidy by endorsement......................................... 12.87 1 (17.80) Fucidin Only if prescribed for a dialysis or cystic ﬁbrosis patient and the prescription is endorsed accordingly. GENTAMICIN SULPHATE Inj 10 mg per ml, 1 ml – Subsidy by endorsement ..............................8.56 5 Mayne Only if prescribed for a dialysis or cystic ﬁbrosis patient or for prophylaxis of endocarditis and the prescription is endorsed accordingly. Inj 40 mg per ml, 2 ml – Subsidy by endorsement ..............................6.50 10 Pﬁzer Only if prescribed for a dialysis or cystic ﬁbrosis patient or for prophylaxis of endocarditis and the prescription is endorsed accordingly. LINCOMYCIN – Retail pharmacy-Specialist Inj 300 mg per ml, 2 ml .....................................................................80.00 5 Lincocin MOXIFLOXACIN – Special Authority see SA1065 below – Retail pharmacy No patient co-payment payable Tab 400 mg .......................................................................................52.00

Avelox

¾SA1065 Special Authority for Subsidy Initial application only from a respiratory specialist or infectious disease specialist. Approvals valid for 1 year for applications meeting the following criteria: Either: 1 Both: 1.1 Active tuberculosis*; and 1.2 Any of the following: 1.2.1 Documented resistance to one or more ﬁrst-line medications; or continued. . .

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

INFECTIONS - AGENTS FOR SYSTEMIC USE

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

continued. . . 1.2.2 Suspected resistance to one or more ﬁrst-line medications (tuberculosis assumed to be contracted in an area with known resistance), as part of regimen containing other second-line agents; or 1.2.3 Impaired visual acuity (considered to preclude ethambutol use); or 1.2.4 Signiﬁcant pre-existing liver disease or hepatotoxicity from tuberculosis medications; or 1.2.5 Signiﬁcant documented intolerance and/or side effects following a reasonable trial of ﬁrst-line medications; or 2 Mycobacterium avium-intracellulare complex not responding to other therapy or where such therapy is contraindicated.*. Note: Indications marked with * are Unapproved Indications (refer to Section A: General Rules, Part I (Interpretations and Deﬁnitions) and Part IV (Miscellaneous Provisions) rule 4.6). Renewal only from a respiratory specialist or infectious disease specialist. Approvals valid for 1 year where the treatment remains appropriate and the patient is beneﬁting from treatment. TOBRAMYCIN Inj 40 mg per ml, 2 ml – Subsidy by endorsement ............................29.32 5 DBL Tobramycin Only if prescribed for dialysis or cystic ﬁbrosis patient and the prescription is endorsed accordingly. TRIMETHOPRIM F Tab 300 mg – Up to 30 tab available on a PSO..................................8.94 50 TMP VANCOMYCIN HYDROCHLORIDE – Subsidy by endorsement Only if prescribed for a dialysis or cystic ﬁbrosis patient or in the treatment of pseudomembranous colitis or for prophylaxis of endocarditis and the prescription is endorsed accordingly. Inj 500 mg ...........................................................................................3.58 1 Mylan

Antifungals

a) For topical antifungals refer to DERMATOLOGICALS, page 59 b) For topical antifungals refer to GENITO URINARY, page 73 FLUCONAZOLE Cap 50 mg – Retail pharmacy-Specialist ...........................................4.77 28 Ozole Cap 150 mg – Subsidy by endorsement .............................................0.91 1 Ozole a) Maximum of 1 cap per prescription; can be waived by endorsement - Retail pharmacy - Specialist b) Patient has vaginal candida albicans and the practitioner considers that a topical imidazole (used intra-vaginally) is not recommended and the prescription is endorsed accordingly; can be waived by endorsement - Retail pharmacy - Specialist. Cap 200 mg – Retail pharmacy-Specialist .......................................13.34 28 Ozole Powder for oral suspension 10 mg per ml – Special Authority see SA1148 below – Retail pharmacy ......................................34.56 35 ml Diﬂucan ¾SA1148 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid for 6 weeks for applications meeting the following criteria: Both: 1 Patient requires prophlaxis for, or treatment of systemic candidiasis; and 2 Patient is unable to swallow capsules. Renewal from any relevant practitioner. Approvals valid for 6 weeks for applications meeting the following criteria: Both: 1 Patient requires prophlaxis for, or treatment of systemic candidiasis; and 2 Patient is unable to swallow capsules. ITRACONAZOLE – Retail pharmacy-Specialist Cap 100 mg ........................................................................................4.25 15 Itrazole KETOCONAZOLE Tab 200 mg – Retail pharmacy-Specialist ........................................38.12 NYSTATIN Tab 500,000 u ...................................................................................14.16 Cap 500,000 u ..................................................................................12.81

fully subsidised [HP4] refer page 9

30 50 50

Nizoral Nilstat Nilstat

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

INFECTIONS - AGENTS FOR SYSTEMIC USE

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

TERBINAFINE F Tab 250 mg – For terbinaﬁne oral liquid formulation refer, page 182 ......................................................................................1.78

Dr Reddy’s

Terbinaﬁne

Antimalarials

HYDROXYCHLOROQUINE SULPHATE F Tab 200 mg .......................................................................................22.50 100

Plaquenil

Antitrichomonal Agents

METRONIDAZOLE Tab 200 mg – Up to 30 tab available on a PSO................................10.45 Tab 400 mg .......................................................................................18.15 Oral liq benzoate 200 mg per 5 ml ...................................................25.00 Suppos 500 mg ................................................................................24.48 ORNIDAZOLE Tab 500 mg .......................................................................................16.50 100 100 100 ml 10 10

Trichozole Trichozole Flagyl-S Flagyl Arrow-Ornidazole

Antituberculotics and Antileprotics

Note: There is no co-payment charge for all pharmaceuticals listed in the Antituberculotics and Antileprotics group regardless of immigration status. DAPSONE – No patient co-payment payable Tab 25 mg .........................................................................................95.00 100 Dapsone Tab 100 mg .....................................................................................110.00 100 Dapsone ETHAMBUTOL HYDROCHLORIDE – No patient co-payment payable Tab 100 mg .......................................................................................48.01 Tab 400 mg .......................................................................................49.34 ISONIAZID – Retail pharmacy-Specialist No patient co-payment payable F Tab 100 mg .......................................................................................20.00 F Tab 100 mg with rifampicin 150 mg ..................................................90.04 F Tab 150 mg with rifampicin 300 mg ................................................179.57 PYRAZINAMIDE – Retail pharmacy-Specialist No patient co-payment payable F Tab 500 mg – For pyrazinamide oral liquid formulation refer, page 182 .................................................................................... 59.00 RIFABUTIN – Retail pharmacy-Specialist No patient co-payment payable F Cap 150 mg – For rifabutin oral liquid formulation refer, page 182 ........................................................................................... 213.19 RIFAMPICIN – Retail pharmacy-Specialist No patient co-payment payable F Tab 600 mg .....................................................................................114.40 F Cap 150 mg ......................................................................................58.66 F Cap 300 mg ....................................................................................122.36 F Oral liq 100 mg per 5 ml ...................................................................12.66 56 56

Myambutol Myambutol

100 100 100

PSM Riﬁnah Riﬁnah

100

AFT-Pyrazinamide

Mycobutin

30 100 100 60 ml

Rifadin Rifadin Rifadin Rifadin

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

INFECTIONS - AGENTS FOR SYSTEMIC USE

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

Antivirals

For eye preparations refer to Eye Preparations, Anti-Infective Preparations, page 176

Hepatitis B Treatment

ADEFOVIR DIPIVOXIL – Special Authority see SA0829 below – Retail pharmacy Tab 10 mg .......................................................................................670.00 30

Hepsera

¾SA0829 Special Authority for Subsidy Initial application only from a gastroenterologist or infectious disease specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 Patient has conﬁrmed Hepatitis B infection (HBsAg+); and Documented resistance to lamivudine, deﬁned as: 2 Patient has raised serum ALT (> 1 × ULN); and 3 Patient has HBV DNA greater than 100,000 copies per mL, or viral load ≥ 10 fold over nadir; and 4 Detection of M204I or M204V mutation; and 5 Either: 5.1 Both: 5.1.1 Patient is cirrhotic; and 5.1.2 adefovir dipivoxil to be used in combination with lamivudine; or 5.2 Both: 5.2.1 Patient is not cirrhotic; and 5.2.2 adefovir dipivoxil to be used as monotherapy. Renewal only from a gastroenterologist or infectious disease specialist. Approvals valid for 2 years where in the opinion of the treating physician, treatment remains appropriate and patient is beneﬁting from treatment. Notes: Lamivudine should be added to adefovir dipivoxil if a patient develops documented resistance to adefovir dipivoxil, deﬁned as: i) raised serum ALT (> 1 × ULN); and ii) HBV DNA greater than 100,000 copies per mL, or viral load ≥ 10 fold over nadir; and iii) Detection of N236T or A181T/V mutation. Adefovir dipivoxil should be stopped 6 months following HBeAg seroconversion for patients who were HBeAg+ prior to commencing adefovir dipivoxil. The recommended dose of adefovir dipivoxil is no more than 10mg daily. In patients with renal insufﬁciency adefovir dipivoxil dose should be reduced in accordance with the datasheet guidelines. Adefovir dipivoxil should be avoided in pregnant women and children. ENTECAVIR – Special Authority see SA0977 below – Retail pharmacy Tab 0.5 mg ......................................................................................400.00 30 Baraclude ¾SA0977 Special Authority for Subsidy Initial application only from a gastroenterologist or infectious disease specialist. Approvals valid without further renewal unless notiﬁed for applications meeting the following criteria: All of the following: 1 Patient has conﬁrmed Hepatitis B infection (HBsAg positive for more than 6 months); and 2 Patient is Hepatitis B nucleoside analogue treatment-naive; and 3 Entecavir dose 0.5 mg/day; and 4 Either: 4.1 ALT greater than upper limit of normal; or 4.2 Bridging ﬁbrosis or cirrhosis (Metavir stage 3 or greater) on liver histology; and 5 Either: continued. . .

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

INFECTIONS - AGENTS FOR SYSTEMIC USE

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

continued. . . 5.1 HBeAg positive; or 5.2 patient has ≥ 2,000 IU HBV DNA units per ml and ﬁbrosis (Metavir stage 2 or greater) on liver histology; and 6 No continuing alcohol abuse or intravenous drug use; and 7 Not co-infected with HCV, HIV or HDV; and 8 Neither ALT nor AST greater than 10 times upper limit of normal; and 9 No history of hypersensitivity to entecavir; and 10 No previous documented lamivudine resistance (either clinical or genotypic). Notes: G Entecavir should be continued for 6 months following documentation of complete HBeAg seroconversion (deﬁned as loss of HBeAg plus appearance of anti-HBe plus loss of serum HBV DNA) for patients who were HBeAg positive prior to commencing this agent. This period of consolidation therapy should be extended to 12 months in patients with advanced ﬁbrosis (Metavir Stage F3 or F4). G Entecavir should be taken on an empty stomach to improve absorption. LAMIVUDINE – Special Authority see SA0832 below – Retail pharmacy Tab 100 mg .....................................................................................143.00 28 Zefﬁx Oral liq 5 mg per ml ..........................................................................90.00 240 ml Zefﬁx ¾SA0832 Special Authority for Subsidy Initial application only from a gastroenterologist, infectious disease specialist, paediatrician or general physician. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 All of the following: 1.1.1 HBsAg positive for more than 6 months; and 1.1.2 HBeAg positive or HBV DNA positive deﬁned as > 100,000 copies per ml by quantitative PCR at a reference laboratory; and 1.1.3 ALT greater than twice upper limit of normal or bridging ﬁbrosis or cirrhosis (Metavir stage 3 or 4 or equivalent) on liver histology clinical/radiological evidence of cirrhosis; or 1.2 HBV DNA positive cirrhosis prior to liver transplantation; or 1.3 HBsAg positive and have had a liver, kidney, heart, lung or bone marrow transplant; or 1.4 Hepatitis B surface antigen positive (HbsAg) patient who is receiving chemotherapy for a malignancy, or who has received such treatment within the previous two months; and 2 All of the following: 2.1 No continuing alcohol abuse or intravenous drug use; and 2.2 Not coinfected with HCV or HDV; and 2.3 Neither ALT nor AST greater than 10 times upper limit of normal; and 2.4 No history of hypersensitivity to lamivudine; and 2.5 No previous lamivudine therapy with genotypically proven lamivudine resistance. Renewal only from a gastroenterologist, infectious disease specialist, paediatrician or general physician. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: Renewal for patients who have maintained continuous treatment and response to lamivudine 1 All of the following: 1.1 Have maintained continuous treatment with lamivudine; and 1.2 Most recent test result shows continuing biochemical response (normal ALT); and 1.3 HBV DNA <100,00 copies per ml by quantitative PCR at a reference laboratory; or Renewal when given in combination with adefovir dipivoxil for patients with cirrhosis and resistance to lamivudine 2 All of the following: 2.1 Lamivudine to be used in combination with adefovir dipivoxil; and continued. . .

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

INFECTIONS - AGENTS FOR SYSTEMIC USE

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

continued. . . 2.2 Patient is cirrhotic; and Documented resistance to lamivudine, deﬁned as: 2.3 Patient has raised serum ALT (> 1 × ULN); and 2.4 Patient has HBV DNA greater than 100,000 copies per mL, or viral load = 10 fold over nadir; and 2.5 Detection of M204I or M204V mutation; or Renewal when given in combination with adefovir dipivoxil for patients with resistance to adefovir dipivoxil 3 All of the following: 3.1 Lamivudine to be used in combination with adefovir dipivoxil; and Documented resistance to adefovir, deﬁned as: 3.2 Patient has raised serum ALT (> 1 × ULN); and 3.3 Patient has HBV DNA greater than 100,000 copies per mL, or viral load = 10 fold over nadir; and 3.4 Detection of N236T or A181T/V mutation.

Herpesvirus Treatments

ACICLOVIR F Tab dispersible 200 mg .......................................................................1.98 F Tab dispersible 400 mg .......................................................................6.64 F Tab dispersible 800 mg .......................................................................7.38 VALACICLOVIR – Special Authority see SA0957 below – Retail pharmacy Tab 500 mg .....................................................................................102.72 25 56 35 30

Lovir Lovir Lovir Valtrex

¾SA0957 Special Authority for Subsidy Initial application — (recurrent genital herpes) from any medical practitioner. Approvals valid for 12 months where the patient has genital herpes with 2 or more breakthrough episodes in any 6 month period while treated with aciclovir 400 mg twice daily. Renewal — (recurrent genital herpes) from any medical practitioner. Approvals valid for 12 months where the treatment remains appropriate and the patient is beneﬁting from treatment. Initial application — (ophthalmic zoster) from any medical practitioner. Approvals valid without further renewal unless notiﬁed where the patient has previous history of ophthalmic zoster and the patient is at risk of vision impairment. Initial application — (CMV prophylaxis) from any medical practitioner. Approvals valid for 3 months where the patient has undergone organ transplantation.

Hepatitis B/ HIV/AIDS Treatment

TENOFOVIR DISOPROXIL FUMARATE – Subsidy by endorsement; can be waived by Special Authority see SA1047 below Endorsement for treatment of HIV/AIDS: Prescription is deemed to be endorsed if tenofovir disoproxil fumarate is co-prescribed with another anti-retroviral subsidised under Special Authority SA1025 and the prescription is annotated accordingly by the Pharmacist or endorsed by the prescriber. Note: Tenofovir disoproxil fumarate prescribed under endorsement for the treatment of HIV/AIDS is included in the count of up to 4 subsidised antiretrovirals for the purposes of Special Authority SA1025, page 93 Tab 300 mg .....................................................................................531.00 30 Viread ¾SA1047 Special Authority for Waiver of Rule Initial application — (Conﬁrmed Hepatitis B) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid without further renewal unless notiﬁed for applications meeting the following criteria: Either: 1 All of the following: 1.1 Patient has conﬁrmed Hepatitis B infection (HBsAg positive for more than 6 months); and 1.2 Patient has had previous lamivudine, adefovir or entecavir therapy; and 1.3 HBV DNA greater than 20,000 IU/mL or increased ≥ 10 fold over nadir; and 1.4 Any of the following: continued. . .

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

INFECTIONS - AGENTS FOR SYSTEMIC USE

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

continued. . . 1.4.1 Lamivudine resistance - detection of M204I/V mutation; or 1.4.2 Adefovir resistance - detection of A181T/V or N236T mutation; or 1.4.3 Entecavir resistance - detection of relevant mutations including I169T, L180M T184S/A/I/L/G/C/M, S202C/G/I, M204V or M250I/V mutation; or 2 Patient is either listed or has undergone liver transplantation for HBV. Initial application — (Pregnant) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 4 months for applications meeting the following criteria: Both: 1 Patient is HBsAg positive and pregnant; and 2 Either: 2.1 HBV DNA > 20,000 IU/mL and ALT > ULN; or 2.2 HBV DNA > 100 million IU/mL and ALT normal. Renewal — (Conﬁrmed Hepatitis B following funded tenofovir treatment for pregnancy within the previous two years) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid without further renewal unless notiﬁed for applications meeting the following criteria: Either: 1 All of the following: 1.1 Patient has conﬁrmed Hepatitis B infection (HBsAg positive for more than 6 months); and 1.2 Patient has had previous lamivudine, adefovir or entecavir therapy; and 1.3 HBV DNA greater than 20,000 IU/mL or increased ≥ 10 fold over nadir; and 1.4 Any of the following: 1.4.1 Lamivudine resistance - detection of M204I/V mutation; or 1.4.2 Adefovir resistance - detection of A181T/V or N236T mutation; or 1.4.3 Entecavir resistance - detection of relevant mutations including I169T, L180M T184S/A/I/L/G/C/M, S202C/G/I, M204V or M250I/V mutation; or 2 Patient is either listed or has undergone liver transplantation for HBV. Renewal — (Subsequent Pregnancy) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 4 months for applications meeting the following criteria: Both: 1 Patient is HBsAg positive and pregnant; and 2 Either: 2.1 HBV DNA > 20,000 IU/mL and ALT > ULN; or 2.2 HBV DNA > 100 million IU/mL and ALT normal. Notes: G Tenofovir disoproxil fumarate should be stopped 6 months following HBeAg seroconversion for patients who were HBeAg positive prior to commencing this agent and 6 months following HBsAg seroconversion for patients who were HBeAg negative prior to commencing this agent. G The recommended dose of Tenofovir disoproxil fumarate for the treatment of all three indications is 300 mg once daily. G In patients with renal insufﬁciency (calculated creatinine clearance less than 50ml/min), Tenofovir disoproxil fumarate dose should be reduced in accordance with the approved Medsafe datasheet guidelines. G Tenofovir disoproxil fumarate is not approved for use in children.

Antiretrovirals

¾SA1025 Special Authority for Subsidy Initial application — (Conﬁrmed HIV/AIDS) only from a named specialist. Approvals valid without further renewal unless notiﬁed for applications meeting the following criteria: Both: 1 Conﬁrmed HIV infection; and continued. . .

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

INFECTIONS - AGENTS FOR SYSTEMIC USE

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

continued. . . 2 Any of the following: 2.1 Symptomatic patient; or 2.2 Patient aged 12 months and under; or 2.3 Both: 2.3.1 Patient aged 1 to 5 years; and 2.3.2 Any of the following: 2.3.2.1 CD4 counts < 1000 cells/mm3 ; or 2.3.2.2 CD4 counts < 0.25 × total lymphocyte count; or 2.3.2.3 Viral load counts > 100000 copies per ml; or 2.4 Both: 2.4.1 Patient aged 6 years and over; and 2.4.2 CD4 counts < 350 cells/mm3 . Notes: Tenofovir disoproxil fumarate prescribed under endorsement for HIV/AIDS is included in the count of up to 4 subsidised antiretrovirals. Subsidies for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals. Renewal — (Conﬁrmed HIV/AIDS) only from a named specialist. Approvals valid without further renewal unless notiﬁed where the treatment remains appropriate and the patient is beneﬁting from treatment. Initial application — (Prevention of maternal transmission) only from a named specialist. Approvals valid for 1 year for applications meeting the following criteria: Either: 1 Prevention of maternal foetal transmission; or 2 Treatment of the newborn for up to eight weeks. Notes: Tenofovir disoproxil fumarate prescribed under endorsement for HIV/AIDS is included in the count of up to 4 subsidised antiretrovirals. Subsidies for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals. Some antiretrovirals are unapproved or contraindicated for this indication. Practitioners prescribing these medications should exercise their own skill, judgement, expertise and discretion, and make their own prescribing decisions with respect to the use of a Pharmaceutical for an indication for which it is not approved or contraindicated. Initial application — (post-exposure prophylaxis following non-occupational exposure to HIV) only from a named specialist. Approvals valid for 4 weeks for applications meeting the following criteria: Both: 1 Treatment course to be initiated within 72 hours post exposure; and 2 Either: 2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person. Notes: Tenofovir disoproxil fumarate prescribed under endorsement for HIV/AIDS is included in the count of up to 4 subsidised antiretrovirals. Subsidies for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals. Renewal — (second or subsequent post-exposure prophylaxis) only from a named specialist. Approvals valid for 4 weeks for applications meeting the following criteria: Both: 1 Treatment course to be initiated within 72 hours post exposure; and 2 Either: continued. . .

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

INFECTIONS - AGENTS FOR SYSTEMIC USE

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

continued. . . 2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person. Initial application — (Percutaneous exposure) only from a named specialist. Approvals valid for 6 weeks where the patient has percutaneous exposure to blood known to be HIV positive. Notes: Tenofovir disoproxil fumarate prescribed under endorsement for HIV/AIDS is included in the count of up to 4 subsidised antiretrovirals. Subsidies for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals. Renewal — (Second or subsequent percutaneous exposure) only from a named specialist. Approvals valid for 6 weeks where the patient has percutaneous exposure to blood known to be HIV positive.

Non-nucleosides Reverse Transcriptase Inhibitors

EFAVIRENZ – Special Authority see SA1025 on page 93 – Retail pharmacy Tab 50 mg .......................................................................................158.33 Tab 200 mg .....................................................................................474.99 Tab 600 mg .....................................................................................474.99 ETRAVIRINE – Special Authority see SA1025 on page 93 – Retail pharmacy Tab 100 mg .....................................................................................770.00 NEVIRAPINE – Special Authority see SA1025 on page 93 – Retail pharmacy Tab 200 mg .....................................................................................319.80 Oral suspension 10 mg per ml ........................................................134.55 30 90 30 120 60 240 ml

Stocrin S29 Stocrin Stocrin Intelence Viramune Viramune

Suspension

Nucleosides Reverse Transcriptase Inhibitors

ABACAVIR SULPHATE – Special Authority see SA1025 on page 93 – Retail pharmacy Tab 300 mg .....................................................................................229.00 60 Oral liq 20 mg per ml ........................................................................50.00 240 ml OP

Ziagen Ziagen

ABACAVIR SULPHATE WITH LAMIVUDINE – Special Authority see SA1025 on page 93 – Retail pharmacy Note: Kivexa counts as two anti-retroviral medications for the purposes of the anti-retroviral Special Authority. Tab 600 mg with lamivudine 300 mg ..............................................630.00 30 Kivexa DIDANOSINE [DDI] – Special Authority see SA1025 on page 93 – Retail pharmacy Cap 125 mg ....................................................................................115.05 Cap 200 mg ....................................................................................184.08 Cap 250 mg ....................................................................................230.10 Cap 400 mg ....................................................................................368.16 EMTRICITABINE – Special Authority see SA1025 on page 93 – Retail pharmacy Cap 200 mg ....................................................................................307.20 LAMIVUDINE – Special Authority see SA1025 on page 93 – Retail pharmacy Tab 150 mg .....................................................................................153.60 Oral liq 10 mg per ml ........................................................................50.00 STAVUDINE [D4T] – Special Authority see SA1025 on page 93 – Retail pharmacy Cap 30 mg ......................................................................................377.80 Cap 40 mg ......................................................................................503.80 30 30 30 30 30 60 240 ml OP 60 60

Videx EC Videx EC Videx EC Videx EC Emtriva 3TC 3TC Zerit Zerit Retrovir Retrovir

ZIDOVUDINE [AZT] – Special Authority see SA1025 on page 93 – Retail pharmacy Cap 100 mg ....................................................................................145.00 100 Oral liq 10 mg per ml ........................................................................29.00 200 ml OP

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

INFECTIONS - AGENTS FOR SYSTEMIC USE

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

ZIDOVUDINE [AZT] WITH LAMIVUDINE – Special Authority see SA1025 on page 93 – Retail pharmacy Combivir counts as two anti-retroviral medications for the purposes of the anti-retroviral Special Authority. Tab 300 mg with lamivudine 150 mg ..............................................667.20 60 Combivir

Protease Inhibitors

ATAZANAVIR SULPHATE – Special Authority see SA1025 on page 93 – Retail pharmacy Cap 150 mg ....................................................................................568.34 60 Cap 200 mg ....................................................................................757.79 60 DARUNAVIR – Special Authority see SA1025 on page 93 – Retail pharmacy Tab 400 mg .....................................................................................837.50 Tab 600 mg ..................................................................................1,190.00 INDINAVIR – Special Authority see SA1025 on page 93 – Retail pharmacy Cap 200 mg ....................................................................................519.75 Cap 400 mg ....................................................................................519.75 60 60 360 180

Reyataz Reyataz Prezista Prezista Crixivan Crixivan Kaletra Kaletra Kaletra Norvir Norvir

LOPINAVIR WITH RITONAVIR – Special Authority see SA1025 on page 93 – Retail pharmacy Tab 100 mg with ritonavir 25 mg .....................................................183.75 60 Tab 200 mg with ritonavir 50 mg .....................................................735.00 120 Oral liq 80 mg with ritonavir 20 mg per ml ......................................735.00 300 ml OP RITONAVIR – Special Authority see SA1025 on page 93 – Retail pharmacy Tab 100 mg .......................................................................................43.31 Oral liq 80 mg per ml ......................................................................103.98 30 90 ml OP

Strand Transfer Inhibitors

RALTEGRAVIR POTASSIUM – Special Authority see SA1025 on page 93 – Retail pharmacy Tab 400 mg ..................................................................................1,090.00 60

Isentress

Antiretrovirals - Additional Therapies HIV Fusion Inhibitors

ENFUVIRTIDE – Special Authority see SA0845 below – Retail pharmacy Powder for inj 90 mg per ml × 60 ................................................2,380.00 1

Fuzeon

¾SA0845 Special Authority for Subsidy Initial application only from a named specialist. Approvals valid for 3 months for applications meeting the following criteria: All of the following: 1 Conﬁrmed HIV infection; and 2 Enfuvirtide to be given in combination with optimized background therapy (including at least 1 other antiretroviral drug that the patient has never previously been exposed to) for treatment failure; and 3 Either: 3.1 Patient has evidence of HIV replication, despite ongoing therapy; or 3.2 Patient has treatment-limiting toxicity to previous antiretroviral agents; and 4 Previous treatment with 3 different antiretroviral regimens has failed; and 5 All of the following: 5.1 Previous treatment with a non-nucleoside reverse transcriptase inhibitor has failed; and 5.2 Previous treatment with a nucleoside reverse transcriptase inhibitor has failed; and 5.3 Previous treatment with a protease inhibitor has failed. Renewal only from a named specialist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Evidence of at least a 10 fold reduction in viral load at 12; and 2 The treatment remains appropriate and the patient is beneﬁting from treatment.

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

INFECTIONS - AGENTS FOR SYSTEMIC USE

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

Immune Modulators

Guidelines for the use of interferon in the treatment of hepatitis C: Physicians considering treatment of patients with hepatitis C should discuss cases with a gastroenterologist or an infectious disease physician. All subjects undergoing treatment require careful monitoring for side effects. Patients should be otherwise ﬁt. Hepatocellular carcinoma should be excluded by ultrasound examination and alpha-fetoprotein level. Criteria for Treatment 1) Diagnosis G Anti-HCV positive on at least two occasions with a positive PCR for HCV-RNA and preferably conﬁrmed by a supplementary RIBA test; or G PCR-RNA positive for HCV on at least 2 occasions if antibody negative; or G Anti-HCV positive on at least two occasions with a positive supplementary RIBA test with a negative PCR for HCV RNA but with a liver biopsy consistent with 2(b) following. 2) Establishing Active Chronic Liver Disease G Conﬁrmed HCV infection and serum ALT/AST levels measured on at least three occasions over six months averaging > 1.5 × upper limit of normal. (ALT is the preferable enzyme); or G Liver biopsy showing signiﬁcant inﬂammatory activity (active hepatitis) with or without cirrhosis. This is not a necessary requirement for those patients with coagulopathy. (Some patients have active disease on histology with normal transaminase enzymes). Exclusion Criteria 1) Autoimmune liver disease. (Interferon may exacerbate autoimmune liver disease as well as other autoimmune diseases such as thyroid disease). 2) Pregnancy. 3) Neutropenia (<2.0 × 109 ) and/or thrombocytopenia. 4) Continuing alcohol abuse and/or continuing intravenous drug users. Dosage The current recommended dosage is 3 million units of interferon alpha-2a or interferon alpha-2b administered subcutaneously 3 times a week for 52 weeks (twelve months) Exit Criteria The patient’s response to interferon treatment should be reviewed at either three or four months. Interferon treatment should be discontinued in patients who do not show a substantial reduction (50%) in their mean pre-treatment ALT level at this stage. INTERFERON ALPHA-2A – PCT – Retail pharmacy-Specialist See prescribing guideline above Inj 3 m iu preﬁlled syringe .................................................................31.32 1 Roferon-A Inj 6 m iu preﬁlled syringe .................................................................62.64 1 Roferon-A Inj 9 m iu preﬁlled syringe .................................................................93.96 1 Roferon-A INTERFERON ALPHA-2B – PCT – Retail pharmacy-Specialist See prescribing guideline above Inj 18 m iu, 1.2 ml multidose pen ....................................................187.92 Inj 30 m iu, 1.2 ml multidose pen ....................................................313.20 Inj 60 m iu, 1.2 ml multidose pen ....................................................626.40

1 1 1

Intron-A Intron-A Intron-A

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

INFECTIONS - AGENTS FOR SYSTEMIC USE

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

PEGYLATED INTERFERON ALPHA-2A – Special Authority see SA1134 below – Retail pharmacy See prescribing guideline on the preceding page Inj 135 µg preﬁlled syringe .............................................................362.00 1 Pegasys 1,448.00 4 Pegasys Inj 180 µg preﬁlled syringe .............................................................450.00 1 Pegasys 1,800.00 4 Pegasys Inj 135 µg preﬁlled syringe × 4 with ribavirin tab 200 mg × 112 ....................................................................................... 1,799.68 1 OP Pegasys RBV Combination Pack Inj 135 µg preﬁlled syringe × 4 with ribavirin tab 200 mg × 168 ....................................................................................... 1,975.00 1 OP Pegasys RBV Combination Pack Inj 180 µg preﬁlled syringe × 4 with ribavirin tab 200 mg × 112 ....................................................................................... 2,059.84 1 OP Pegasys RBV Combination Pack Inj 180 µg preﬁlled syringe × 4 with ribavirin tab 200 mg × 168 ....................................................................................... 2,190.00 1 OP Pegasys RBV Combination Pack ¾SA1134 Special Authority for Subsidy Initial application — (chronic hepatitis C - genotype 1, 4, 5 or 6 infection or co-infection with HIV) from any specialist. Approvals valid for 18 months for applications meeting the following criteria: Both: 1 Either: 1.1 Patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection; or 1.2 Patient has chronic hepatitis C and is co-infected with HIV; and 2 Maximum of 48 weeks therapy. Notes: G Consider stopping treatment if there is absence of a virological response (deﬁned as at least a 2-log reduction in viral load) following 12 weeks of treatment since this is predictive of treatment failure. G Consider reducing treatment to 24 weeks if serum HCV RNA level at Week 4 is undetectable by sensitive PCR assay (less than 50IU/ml) AND Baseline serum HCV RNA is less than 400,000IU/ml Initial application — (chronic hepatitis C - genotype 2 or 3 infection without co-infection with HIV) from any specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 Patient has chronic hepatitis C, genotype 2 or 3 infection; and 2 Maximum of 6 months therapy. Initial application — (Hepatitis B) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 18 months for applications meeting the following criteria: All of the following: 1 Patient has conﬁrmed Hepatitis B infection (HBsAg positive for more than 6 months); and 2 Patient is Hepatitis B treatment-naive; and 3 ALT > 2 times Upper Limit of Normal; and 4 HBV DNA < 10 log10 IU/ml; and 5 Either: 5.1 HBeAg positive; or 5.2 serum HBV DNA ≥ 2,000 units/ml and signiﬁcant ﬁbrosis (≥ Metavir Stage F2); and 6 Compensated liver disease; and 7 No continuing alcohol abuse or intravenous drug use; and 8 Not co-infected with HCV, HIV or HDV; and continued. . .

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

INFECTIONS - AGENTS FOR SYSTEMIC USE

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

continued. . . 9 Neither ALT nor AST > 10 times upper limit of normal; and 10 No history of hypersensitivity or contraindications to pegylated interferon; and 11 Maximum of 48 weeks therapy. Notes: G Approved dose is 180 µg once weekly. G The recommended dose of Pegylated Interferon-alpha 2a is 180 µg once weekly. G In patients with renal insufﬁciency (calculated creatinine clearance less than 50ml/min), Pegylated Interferon-alpha 2a dose should be reduced to 135 µg once weekly. G In patients with neutropaenia and thrombocytopaenia, dose should be reduced in accordance with the datasheet guidelines. G Pegylated Interferon-alpha 2a is not approved for use in children.

Urinary Tract Infections

HEXAMINE HIPPURATE F Tab 1 g ..............................................................................................18.40 (38.10) NITROFURANTOIN F Tab 50 mg – For nitrofurantoin oral liquid formulation refer, page 182 .................................................................................... 22.20 F Tab 100 mg .......................................................................................37.50 NORFLOXACIN Tab 400 mg – Maximum of 6 tab per prescription; can be waived by endorsement - Retail pharmacy - Specialist.............. 15.45 100 Hiprex

100 100

Nifuran Nifuran

100

Arrow-Norﬂoxacin

Vaccinations

BACILLUS CALMETTE-GUERIN VACCINE – Hospital pharmacy [Xpharm] For infants at increased risk of tuberculosis. Increased risk is deﬁned as: 1) living in a house or family with a person with current or past history of TB or 2) have one or more household members or carers who within the last 5 years lived in a country with a rate of TB > or equal to 40 per 100,000 for 6 months or longer or 3) during their ﬁrst 5 years will be living 3 months or longer in a country with a rate of TB > or equal to 40 per 100,000 Note a list of countries with high rates of TB are available at www.moh.govt.nz/immunisation or www.bcgatlas.org/index.php. Inj multi-dose vial (10 dose) 0.5 ml .....................................................0.00 1 BCG Vaccine DIPHTHERIA AND TETANUS VACCINE – Hospital pharmacy [Xpharm] For adults aged 45 and 65 years old, and for susceptible individuals. Inj 0.5 ml .............................................................................................0.00

ADT Booster

DIPHTHERIA, TETANUS AND PERTUSSIS VACCINE – Hospital pharmacy [Xpharm] For children aged 11 years old. Inj 0.5 ml .............................................................................................0.00 1 DIPHTHERIA, TETANUS, PERTUSSIS AND POLIO VACCINE – Hospital pharmacy [Xpharm] For children aged 4 years old. Inj 0.5 ml .............................................................................................0.00 1

Boostrix

Infanrix-IPV

DIPHTHERIA, TETANUS, PERTUSSIS, POLIO, HEPATITIS B AND HAEMOPHILUS INFLUENZAE TYPE B VACCINE – Hospital pharmacy [Xpharm] For children aged 6 weeks, 3 months, and 5 months old. 1 Infanrix-hexa Inj 0.5 ml .............................................................................................0.00

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

INFECTIONS - AGENTS FOR SYSTEMIC USE

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

HAEMOPHILUS INFLUENZAE TYPE B VACCINE – Hospital pharmacy [Xpharm] For children aged 15 months old, children aged 0-16 years with functional asplenia, or for patients pre- and post-splenectomy. Inj 0.5 ml .............................................................................................0.00 1 Act-HIB HEPATITIS B VACCINE – Hospital pharmacy [Xpharm] For household or sexual contacts of known hepatitis B carriers, or for children born to mothers who are hepatitis B surface antigen (HBsAg) postive. Inj 0.5 ml .............................................................................................0.00 1 HBvaxPro HUMAN PAPILOMAVIRUS VACCINE – Hospital pharmacy [Xpharm] Three doses over a period of six months for young women aged between 12 and 19 years old. Inj 0.5 ml .............................................................................................0.00 1 Gardasil INFLUENZA VACCINE – Hospital pharmacy [Xpharm] Inj ......................................................................................................90.00 10

Fluarix Fluvax

A) is available 1 March until vaccine supplies are exhausted each year for patients who meet the following criteria, as set by the Ministry of Health: a) all people 65 years of age and over; b) people under 65 years of age with: i) the following cardiovascular disease: 1) ischaemic heart disease, 2) congestive heart disease, 3) rheumatic heart disease, 4) congenital heart disease, or 5) cerebo-vascular disease; ii) the following chronic respiratory disease: 1) asthma, if on a regular preventative therapy, or 2) other chronic respiratory disease with impaired lung function; iii) diabetes; iv) chronic renal disease; v) any cancer, excluding basal and squamous skin cancers if not invasive; vi) the following other conditions: a) autoimmune disease, b) immune suppression, c) HIV, d) transplant recipients, e) neuromuscular and CNS diseases, f) haemoglobinopathies, g) children on long term aspirin, or h) pregnancy. c) people under 18 years of age living within the boundaries of the Canterbury District Health Board. The following conditions are excluded from funding: a) asthma not requiring regular preventative therapy, b) hypertension and/or dyslipidaemia without evidence of end-organ disease, B) Doctors are the only Contractors entitled to claim payment from the Funder for the supply of inﬂuenza vaccine to patients eligible under the above criteria for subsidised immunisation and they may only do so in respect of the inﬂuenza vaccine listed in the Pharmaceutical Schedule. C) Individual DHBs may fund patients over and above the above criteria. The claiming process for these additional patients should be determined between the DHB and Contractor. D) Inﬂuenza Vaccine does not fall within the deﬁnition Community Pharmaceutical as it is not funded directly from the Pharmaceutical Budget. Pharmacists are unable to claim for the dispensing of inﬂuenza vaccine from the Funder.

100

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

INFECTIONS - AGENTS FOR SYSTEMIC USE

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

MEASLES, MUMPS AND RUBELLA VACCINE – Hospital pharmacy [Xpharm] For children aged 15 months and 4 years old or for any individual susceptible to measles, mumps or rubella. Inj 0.5 ml .............................................................................................0.00 1 M-M-R II MENINGOCOCCAL A, C, Y AND W-135 VACCINE – Hospital pharmacy [Xpharm] For patients pre- and post-splenectomy or children aged 0-16 years with functional asplenia. For organisation and community based outbreaks. Inj 0.5 ml .............................................................................................0.00 1 Menomune PNEUMOCOCCAL (PCV13) VACCINE – Hospital pharmacy [Xpharm] For high risk children under the age of 5 and those aged less than 16 years pre- or post-splenectomy or with functional asplenia. Inj 0.5 ml .............................................................................................0.00 1 Prevenar 13 PNEUMOCOCCAL POLYSACCHARIDE VACCINE – Hospital pharmacy [Xpharm] For patients pre- and post-splenectomy or children aged 0-16 years with functional asplenia. Inj 0.5 ml .............................................................................................0.00 1 Pneumovax 23 PNEUMOCOCCAL VACCINE – Hospital pharmacy [Xpharm] For children aged 6 weeks, 3 months, and 5 months, and 15 months old. Inj 0.5 ml .............................................................................................0.00 POLIOMYELITIS VACCINE – Hospital pharmacy [Xpharm] A primary course of three doses for previously unvaccinated individuals. Inj 0.5 ml .............................................................................................0.00

Synﬂorix

IPOL

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

101

MUSCULOSKELETAL SYSTEM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

Anticholinesterases

NEOSTIGMINE Inj 2.5 mg per ml, 1 ml ....................................................................140.00 PYRIDOSTIGMINE BROMIDE L Tab 60 mg .........................................................................................38.90 50 100

AstraZeneca Mestinon

Non-steroidal Anti-inﬂammatory Drugs (NSAIDs)

¾SA1038 Special Authority for Manufacturers Price Note: Subsidy for patients with existing approvals prior to 1 September 2010. Approvals valid without further renewal unless notiﬁed. No new approvals will be granted from 1 September 2010. DICLOFENAC SODIUM F Tab EC 25 mg .....................................................................................1.63 50 Diclofenac Sandoz F Tab 50 mg dispersible – Additional subsidy by Special Authority see SA1038 above – Retail pharmacy ............................. 1.50 20 (8.00) Voltaren D F Tab EC 50 mg .....................................................................................2.13 50 Diclofenac Sandoz F Tab long-acting 75 mg ......................................................................32.80 500 Diclax SR F Tab long-acting 100 mg ....................................................................63.22 500 Diclax SR F Inj 25 mg per ml, 3 ml .......................................................................12.00 5 Voltaren Up to 5 inj available on a PSO F Suppos 12.5 mg .................................................................................1.85 10 Voltaren F Suppos 25 mg ....................................................................................2.22 10 Voltaren F Suppos 50 mg ....................................................................................3.84 10 Voltaren Up to 10 supp available on a PSO F Suppos 100 mg ..................................................................................6.36 10 Voltaren IBUPROFEN – Additional subsidy by Special Authority see SA1038 above – Retail pharmacy F Tab 200 mg .......................................................................................12.75 1,000 F Tab 400 mg .........................................................................................0.77 30 (4.56) F Tab 600 mg .........................................................................................1.15 30 (6.84) F Tab long-acting 800 mg ......................................................................8.12 30 F‡ Oral liq 100 mg per 5 ml .....................................................................2.69 200 ml KETOPROFEN F Cap long-acting 100 mg ...................................................................21.56 F Cap long-acting 200 mg ...................................................................43.12 100 100

Arrowcare

Brufen Brufen

Brufen SR Fenpaed Oruvail SR Oruvail SR

MEFENAMIC ACID – Additional subsidy by Special Authority see SA1038 above – Retail pharmacy F Cap 250 mg ........................................................................................0.50 20 (5.60) Ponstan 1.25 50 (9.16) Ponstan NAPROXEN F Tab 250 mg .......................................................................................23.70 F Tab 500 mg .......................................................................................24.88 F Tab long-acting 750 mg ....................................................................18.00 F Tab long-acting 1,000 mg .................................................................21.00 500 250 90 90

Noﬂam 250 Noﬂam 500 Naprosyn SR 750 Naprosyn SR 1000

102

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

MUSCULOSKELETAL SYSTEM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

SULINDAC – Additional subsidy by Special Authority see SA1038 on the preceding page – Retail pharmacy F Tab 100 mg .........................................................................................2.66 50 (8.55) Aclin F Tab 200 mg .........................................................................................3.36 50 (15.10) Aclin TENOXICAM F Tab 20 mg .........................................................................................23.75 F Inj 20 mg .............................................................................................9.95 TIAPROFENIC ACID F Tab 300 mg .......................................................................................19.26 100 1 60

Tilcotil AFT Surgam

NSAIDs Other

INDOMETHACIN F Suppos 100 mg ...............................................................................14.50 (Arthrexin Suppos 100 mg to be delisted 1 December 2012) MELOXICAM – Special Authority see SA1034 below – Retail pharmacy F Tab 7.5 mg ........................................................................................11.50 30

Arthrexin

Arrow-Meloxicam

¾SA1034 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid without further renewal unless notiﬁed for applications meeting the following criteria: All of the following: 1 The patient has moderate to severe haemophilia with less than or equal to 5% of normal circulating functional clotting factor; and 2 The patient has haemophilic arthropathy; and 3 Pain and inﬂammation associated with haemophilic arthropathy is inadequately controlled by alternative funded treatment options, or alternative funded treatment options are contraindicated.

Antirheumatoid Agents

AURANOFIN Tab 3 mg ...........................................................................................68.99 LEFLUNOMIDE Tab 10 mg .........................................................................................55.00 79.27 Tab 20 mg .........................................................................................76.00 108.60 Tab 100 mg .......................................................................................54.44 PENICILLAMINE Tab 125 mg .......................................................................................61.93 Tab 250 mg .......................................................................................98.98 SODIUM AUROTHIOMALATE Inj 10 mg per 0.5 ml ..........................................................................76.87 Inj 20 mg per 0.5 ml ........................................................................113.17 Inj 50 mg per 0.5 ml ........................................................................217.23 60

Ridaura Ridaura s29 S29 AFT-Leﬂunomide Arava AFT-Leﬂunomide Arava Arava D-Penamine D-Penamine Myocrisin Myocrisin Myocrisin

30 30 3 100 100 10 10 10

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

103

MUSCULOSKELETAL SYSTEM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

Tumour Necrosis Factor (TNF) Inhibitors

ADALIMUMAB – Special Authority see SA1156 below – Retail pharmacy Inj 40 mg per 0.8 ml preﬁlled pen ................................................1,799.92 Inj 40 mg per 0.8 ml preﬁlled syringe ..........................................1,799.92 2 2

HumiraPen Humira

¾SA1156 Special Authority for Subsidy Initial application — (rheumatoid arthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: Either: 1 Both: 1.1 The patient has had an initial Special Authority approval for etanercept for rheumatoid arthritis; and 1.2 Either: 1.2.1 The patient has experienced intolerable side effects from etanercept; or 1.2.2 The patient has received insufﬁcient beneﬁt from etanercept to meet the renewal criteria for etanercept for rheumatoid arthritis; or 2 All of the following: 2.1 Patient has had severe and active erosive rheumatoid arthritis for six months duration or longer; and 2.2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and 2.3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and 2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulphasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and 2.5 Any of the following: 2.5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of cyclosporin; or 2.5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or 2.5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leﬂunomide alone or in combination with oral or parenteral methotrexate; and 2.6 Either: 2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or 2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and 2.7 Either: 2.7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or 2.7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months. Initial application — (Crohn’s disease) only from a gastroenterologist. Approvals valid for 3 months for applications meeting the following criteria: All of the following: 1 Patient has severe active Crohn’s disease; and 2 Any of the following: 2.1 Patient has a Crohn’s Disease Activity Index (CDAI) score of greater than or equal to 300; or 2.2 Patient has extensive small intestine disease affecting more than 50 cm of the small intestine; or 2.3 Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection; or 2.4 Patient has an ileostomy or colostomy, and has intestinal inﬂammation; and continued. . .

104

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

MUSCULOSKELETAL SYSTEM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

continued. . .

3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and 4 Surgery (or further surgery) is considered to be clinically inappropriate. Initial application — (severe chronic plaque psoriasis) only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria: Either: 1 Both: 1.1 The patient has had an initial Special Authority approval for etanercept for severe chronic plaque psoriasis; and 1.2 Either: 1.2.1 The patient has experienced intolerable side effects from etanercept; or 1.2.2 The patient has received insufﬁcient beneﬁt from etanercept to meet the renewal criteria for etanercept for severe chronic plaque psoriasis; or 2 All of the following: 2.1 Either: 2.1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 15, where lesions have been present for at least 6 months from the time of initial diagnosis; or 2.1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and 2.2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, cyclosporin, or acitretin; and 2.3 A PASI assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and 2.4 The most recent PASI assessment is no more than 1 month old at the time of application. Note: "Inadequate response" is deﬁned as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 15, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment. Initial application — (ankylosing spondylitis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: Either: 1 Both: 1.1 The patient has had an initial Special Authority approval for etanercept for ankylosing spondylitis; and 1.2 Either: 1.2.1 The patient has experienced intolerable side effects from etanercept; or 1.2.2 The patient has received insufﬁcient beneﬁt from etanercept to meet the renewal criteria for etanercept for ankylosing spondylitis; or 2 All of the following: 2.1 Patient has a conﬁrmed diagnosis of ankylosing spondylitis for more than six months; and 2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and 2.3 Patient has bilateral sacroiliitis demonstrated by plain radiographs, CT or MRI scan; and 2.4 Patient’s ankylosing spondylitis has not responded adequately to treatment with two or more non-steroidal antiinﬂammatory drugs (NSAIDs), in combination with anti-ulcer therapy if indicated, while patient was undergoing at least 3 months of an exercise regime supervised by a physiotherapist; and 2.5 Either: continued. . .

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

105

MUSCULOSKELETAL SYSTEM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

continued. . .

2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by the following Bath Ankylosing Spondylitis Metrology Index (BASMI) measures: a modiﬁed Schober’s test of less than or equal to 4 cm and lumbar side ﬂexion measurement of less than or equal to 10 cm (mean of left and right); or 2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the following average normal values corrected for age and gender (see Notes); and 2.6 A Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 6 on a 0-10 scale. Notes: The BASDAI must have been determined at the completion of the 3 month exercise trial, but prior to ceasing NSAID treatment. The BASDAI measure must be no more than 1 month old at the time of initial application. Average normal chest expansion corrected for age and gender: 18-24 years - Male: 7.0 cm; Female: 5.5 cm 25-34 years - Male: 7.5 cm; Female: 5.5 cm 35-44 years - Male: 6.5 cm; Female: 4.5 cm 45-54 years - Male: 6.0 cm; Female: 5.0 cm 55-64 years - Male: 5.5 cm; Female: 4.0 cm 65-74 years - Male: 4.0 cm; Female: 4.0 cm 75+ years - Male: 3.0 cm; Female: 2.5 cm Initial application — (psoriatic arthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: Either: 1 Both: 1.1 The patient has had an initial Special Authority approval for etanercept for psoriatic arthritis; and 1.2 Either: 1.2.1 The patient has experienced intolerable side effects from etanercept; or 1.2.2 The patient has received insufﬁcient beneﬁt from etanercept to meet the renewal criteria for etanercept for psoriatic arthritis; or 2 All of the following: 2.1 Patient has had severe active psoriatic arthritis for six months duration or longer; and 2.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and 2.3 Patient has tried and not responded to at least three months of sulphasalazine at a dose of at least 2 g per day or leﬂunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and 2.4 Either: 2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen, tender joints; or 2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and 2.5 Any of the following: 2.5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or 2.5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or 2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months. Renewal — (rheumatoid arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 Either: 1.1 Applicant is a rheumatologist; or continued. . .

106

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

MUSCULOSKELETAL SYSTEM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

continued. . .

1.2 Applicant is a Practitioner and conﬁrms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and 2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and 3 Either: 3.1 Following 3 to 4 months’ initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically signiﬁcant response to treatment in the opinion of the physician; or 3.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically signiﬁcant response to treatment in the opinion of the physician; and 4 Either: 4.1 Adalimumab to be administered at doses no greater than 40 mg every 14 days; or 4.2 Patient cannot take concomitant methotrexate and requires doses of adalimumab higher than 40 mg every 14 days to maintain an adequate response. Renewal — (Crohn’s disease) only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 Either: 1.1 Applicant is a gastroenterologist; or 1.2 Applicant is a Practitioner and conﬁrms that a gastroenterologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and 2 Either: 2.1 Either: 2.1.1 CDAI score has reduced by 100 points from the CDAI score when the patient was initiated on adalimumab; or 2.1.2 CDAI score is 150 or less; or 2.2 Both: 2.2.1 The patient has demonstrated an adequate response to treatment but CDAI score cannot be assessed; and 2.2.2 Applicant to indicate the reason that CDAI score cannot be assessed; and 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days. Renewal — (severe chronic plaque psoriasis) only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 Either: 1.1 Applicant is a dermatologist; or 1.2 Applicant is a Practitioner and conﬁrms that a dermatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and 2 Either: 2.1 Both: 2.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and 2.1.2 Following each prior adalimumab treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-adalimumab treatment baseline value; or 2.2 Both: 2.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and 2.2.2 Either: 2.2.2.1 Following each prior adalimumab treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or continued. . .

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

107

MUSCULOSKELETAL SYSTEM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

continued. . . 2.2.2.2 Following each prior adalimumab treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-adalimumab treatment baseline value; and 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days. Note: A treatment course is deﬁned as a minimum of 12 weeks adalimumab treatment Renewal — (ankylosing spondylitis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 Either: 1.1 Applicant is a rheumatologist; or 1.2 Applicant is a Practitioner and conﬁrms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and 2 Following 12 weeks of adalimumab treatment, BASDAI has improved by 4 or more points from pre-adalimumab baseline on a 10 point scale, or by 50%, whichever is less; and 3 Physician considers that the patient has beneﬁted from treatment and that continued treatment is appropriate; and 4 Adalimumab to be administered at doses no greater than 40 mg every 14 days. Renewal — (psoriatic arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 Either: 1.1 Applicant is a rheumatologist; or 1.2 Applicant is a Practitioner and conﬁrms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and 2 Either: 2.1 Following 3 to 4 months’ initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically signiﬁcant response to treatment in the opinion of the physician; or 2.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically signiﬁcant response to prior adalimumab treatment in the opinion of the treating physician; and 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days. ETANERCEPT – Special Authority see SA1157 below – Retail pharmacy Inj 25 mg .........................................................................................949.96 4 Enbrel Inj 50 mg autoinjector ..................................................................1,899.92 4 Enbrel Inj 50 mg preﬁlled syringe ...........................................................1,899.92 4 Enbrel ¾SA1157 Special Authority for Subsidy Initial application — (juvenile idiopathic arthritis) only from a named specialist or rheumatologist. Approvals valid for 4 months for applications meeting the following criteria: All of the following: 1 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and 2 Patient diagnosed with Juvenile Idiopathic Arthritis (JIA); and 3 Patient has had severe active polyarticular course JIA for 6 months duration or longer; and 4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-20 mg/m2 weekly or at the maximum tolerated dose) in combination with either oral corticosteroids (prednisone 0.25 mg/kg or at the maximum tolerated dose) or a full trial of serial intra-articular corticosteroid injections; and 5 Both: 5.1 Either: 5.1.1 Patient has persistent symptoms of poorly-controlled and active disease in at least 20 swollen, tender joints; or continued. . .

108

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

MUSCULOSKELETAL SYSTEM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

continued. . .

5.1.2 Patient has persistent symptoms of poorly-controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, shoulder, cervical spine, hip; and 5.2 Physician’s global assessment indicating severe disease. Initial application — (rheumatoid arthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: Either: 1 Both: 1.1 The patient has had an initial Special Authority approval for adalimumab for rheumatoid arthritis; and 1.2 Either: 1.2.1 The patient has experienced intolerable side effects from adalimumab; or 1.2.2 The patient has received insufﬁcient beneﬁt from adalimumab to meet the renewal criteria for adalimumab for rheumatoid arthritis; or 2 All of the following: 2.1 Patient has had severe and active erosive rheumatoid arthritis for six months duration or longer; and 2.2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and 2.3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and 2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulphasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and 2.5 Any of the following: 2.5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of cyclosporin; or 2.5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or 2.5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leﬂunomide alone or in combination with oral or parenteral methotrexate; and 2.6 Either: 2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or 2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and 2.7 Either: 2.7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or 2.7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months. Initial application — (severe chronic plaque psoriasis) only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria: Either: 1 Both: 1.1 The patient has had an initial Special Authority approval for adalimumab for severe chronic plaque psoriasis; and 1.2 Either: 1.2.1 The patient has experienced intolerable side effects from adalimumab; or 1.2.2 The patient has received insufﬁcient beneﬁt from adalimumab to meet the renewal criteria for adalimumab for severe chronic plaque psoriasis; or 2 All of the following: 2.1 Either: continued. . .

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

109

MUSCULOSKELETAL SYSTEM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

continued. . . 2.1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 15, where lesions have been present for at least 6 months from the time of initial diagnosis; or 2.1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and 2.2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, cyclosporin, or acitretin; and 2.3 A PASI assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and 2.4 The most recent PASI assessment is no more than 1 month old at the time of application. Note: "Inadequate response" is deﬁned as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 15, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment. Initial application — (ankylosing spondylitis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: Either: 1 Both: 1.1 The patient has had an initial Special Authority approval for adalimumab for ankylosing spondylitis; and 1.2 Either: 1.2.1 The patient has experienced intolerable side effects from adalimumab; or 1.2.2 The patient has received insufﬁcient beneﬁt from adalimumab to meet the renewal criteria for adalimumab for ankylosing spondylitis; or 2 All of the following: 2.1 Patient has a conﬁrmed diagnosis of ankylosing spondylitis present for more than six months; and 2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and 2.3 Patient has bilateral sacroiliitis demonstrated by plain radiographs, CT or MRI scan; and 2.4 Patient’s ankylosing spondylitis has not responded adequately to treatment with two or more non-steroidal antiinﬂammatory drugs (NSAIDs), in combination with anti-ulcer therapy if indicated, while patient was undergoing at least 3 months of an exercise regime supervised by a physiotherapist; and 2.5 Either: 2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by the following Bath Ankylosing Spondylitis Metrology Index (BASMI) measures: a modiﬁed Schober’s test of less than or equal to 4 cm and lumbar side ﬂexion measurement of less than or equal to 10 cm (mean of left and right); or 2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the average normal values corrected for age and gender (see Notes); and 2.6 A Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 6 on a 0-10 scale. Notes: The BASDAI must have been determined at the completion of the 3 month exercise trial, but prior to ceasing NSAID treatment. The BASDAI measure must be no more than 1 month old at the time of initial application. Average normal chest expansion corrected for age and gender: 18-24 years - Male: 7.0 cm; Female: 5.5 cm 25-34 years - Male: 7.5 cm; Female: 5.5 cm 35-44 years - Male: 6.5 cm; Female: 4.5 cm 45-54 years - Male: 6.0 cm; Female: 5.0 cm 55-64 years - Male: 5.5 cm; Female: 4.0 cm continued. . .

110

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

MUSCULOSKELETAL SYSTEM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

continued. . . 65-74 years - Male: 4.0 cm; Female: 4.0 cm 75+ years - Male: 3.0 cm; Female: 2.5 cm Initial application — (psoriatic arthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: Either: 1 Both: 1.1 The patient has had an initial Special Authority approval for adalimumab for psoriatic arthritis; and 1.2 Either: 1.2.1 The patient has experienced intolerable side effects from adalimumab; or 1.2.2 The patient has received insufﬁcient beneﬁt from adalimumab to meet the renewal criteria for adalimumab for psoriatic arthritis; or 2 All of the following: 2.1 Patient has had severe active psoriatic arthritis for six months duration or longer; and 2.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and 2.3 Patient has tried and not responded to at least three months of sulphasalazine at a dose of at least 2 g per day or leﬂunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and 2.4 Either: 2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen, tender joints; or 2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and 2.5 Any of the following: 2.5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or 2.5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or 2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months. Renewal — (juvenile idiopathic arthritis) only from a named specialist, rheumatologist or Practitioner on the recommendation of a named specialist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 Either: 1.1 Applicant is a named specialist or rheumatologist; or 1.2 Applicant is a Practitioner and conﬁrms that a named specialist or rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and 2 Subsidised as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and 3 Either: 3.1 Following 3 to 4 months’ initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician’s global assessment from baseline; or 3.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician’s global assessment from baseline. Renewal — (rheumatoid arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 Either: 1.1 Applicant is a rheumatologist; or 1.2 Applicant is a Practitioner and conﬁrms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and continued. . .

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

111

MUSCULOSKELETAL SYSTEM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

continued. . .

2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and 3 Either: 3.1 Following 3 to 4 months’ initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically signiﬁcant response to treatment in the opinion of the physician; or 3.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically signiﬁcant response to treatment in the opinion of the physician; and 4 Etanercept to be administered at doses no greater than 50 mg every 7 days. Renewal — (severe chronic plaque psoriasis) only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 Either: 1.1 Applicant is a dermatologist; or 1.2 Applicant is a Practitioner and conﬁrms that a dermatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and 2 Either: 2.1 Both: 2.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and 2.1.2 Following each prior etanercept treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-treatment baseline value; or 2.2 Both: 2.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and 2.2.2 Either: 2.2.2.1 Following each prior etanercept treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or 2.2.2.2 Following each prior etanercept treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-treatment baseline value; and 3 Etanercept to be administered at doses no greater than 50 mg every 7 days. Note: A treatment course is deﬁned as a minimum of 12 weeks of etanercept treatment Renewal — (ankylosing spondylitis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 Either: 1.1 Applicant is a rheumatologist; or 1.2 Applicant is a Practitioner and conﬁrms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and 2 Following 12 weeks of etanercept treatment, BASDAI has improved by 4 or more points from pre-treatment baseline on a 10 point scale, or by 50%, whichever is less; and 3 Physician considers that the patient has beneﬁted from treatment and that continued treatment is appropriate; and 4 Etanercept to be administered at doses no greater than 50 mg every 7 days. Renewal — (psoriatic arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 Either: 1.1 Applicant is a rheumatologist; or continued. . .

112

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

MUSCULOSKELETAL SYSTEM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

continued. . . 1.2 Applicant is a Practitioner and conﬁrms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and 2 Either: 2.1 Following 3 to 4 months’ initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically signiﬁcant response to treatment in the opinion of the physician; or 2.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically signiﬁcant response to prior etanercept treatment in the opinion of the treating physician; and 3 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Drugs Affecting Bone Metabolism Alendronate for Osteoporosis

¾SA1039 Special Authority for Subsidy Initial application — (Underlying cause – Osteoporosis) from any relevant practitioner. Approvals valid without further renewal unless notiﬁed for applications meeting the following criteria: Any of the following: 1 History of one signiﬁcant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) ≥ 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score ≤ -2.5) (see Note); or 2 History of one signiﬁcant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or 3 History of two signiﬁcant osteoporotic fractures demonstrated radiologically; or 4 Documented T-Score ≤ -3.0 (see Note); or 5 A 10-year risk of hip fracture ≥ 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or 6 Patient has had a Special Authority approval for zoledronic acid (Underlying cause - Osteoporosis) or raloxifene. Initial application — (Underlying cause – glucocorticosteroid therapy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The patient is receiving systemic glucocorticosteriod therapy (≥ 5 mg per day prednisone equivalents) and has already received or is expected to receive therapy for at least three months; and 2 Any of the following: 2.1 The patient has documented BMD ≥ 1.5 standard deviations below the mean normal value in young adults (i.e. T-Score ≤ -1.5) (see Note); or 2.2 The patient has a history of one signiﬁcant osteoporotic fracture demonstrated radiologically; or 2.3 The patient has had a Special Authority approval for zoledronic acid (Underlying cause - glucocorticosteroid therapy) or raloxifene. Renewal — (Underlying cause was, and remains, glucocorticosteroid therapy) from any relevant practitioner. Approvals valid for 1 year where the patient is continuing systemic glucocorticosteriod therapy (≥ 5 mg per day prednisone equivalents). Renewal — (Underlying cause was glucocorticosteroid therapy but patient now meets the ‘Underlying cause - osteoporosis’ criteria) from any relevant practitioner. Approvals valid without further renewal unless notiﬁed for applications meeting the following criteria: Any of the following: 1 History of one signiﬁcant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) ≥ 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score ≤ -2.5) (see Note); or 2 History of one signiﬁcant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or continued. . .

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

113

MUSCULOSKELETAL SYSTEM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

continued. . . 3 History of two signiﬁcant osteoporotic fractures demonstrated radiologically; or 4 Documented T-Score ≤ -3.0 (see Note); or 5 A 10-year risk of hip fracture ≥ 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or 6 Patient has had a Special Authority approval for zoledronic acid (Underlying cause was glucocorticosteroid therapy but patient now meets the ‘Underlying cause - Osteoporosis’ criteria) or raloxifene. Notes: a) BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable. b) Evidence used by National Institute for Health and Clinical Excellence (NICE) guidance indicates that patients aged 75 years and over who have a history of signiﬁcant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score ≤ -2.5 and, therefore, do not require BMD measurement for treatment with bisphosphonates. c) Osteoporotic fractures are the incident events for severe (established) osteoporosis, and can be deﬁned using the WHO deﬁnitions of osteoporosis and fragility fracture. The WHO deﬁnes severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantiﬁed this as forces equivalent to a fall from a standing height or less. d) In line with the Australian guidelines for funding alendronate, a vertebral fracture is deﬁned as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body. ALENDRONATE SODIUM – Special Authority see SA1039 on the preceding page – Retail pharmacy F Tab 70 mg .........................................................................................22.90 4 Fosamax ALENDRONATE SODIUM WITH CHOLECALCIFEROL – Special Authority see SA1039 on the preceding page – Retail pharmacy F Tab 70 mg with cholecalciferol 5,600 iu ............................................22.90 4 Fosamax Plus

Alendronate for Paget’s Disease

¾SA0949 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Paget’s disease; and 2 Any of the following: 2.1 Bone or articular pain; or 2.2 Bone deformity; or 2.3 Bone, articular or neurological complications; or 2.4 Asymptomatic disease, but risk of complications due to site (base of skull, spine, long bones of lower limbs); or 2.5 Preparation for orthopaedic surgery. Renewal from any relevant practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is beneﬁting from treatment. ALENDRONATE SODIUM – Special Authority see SA0949 above – Retail pharmacy F Tab 40 mg .......................................................................................133.00 30 Fosamax

Other Treatments

CALCITONIN F Inj 100 iu per ml, 1 ml .....................................................................110.00 ETIDRONATE DISODIUM – See prescribing guideline on the next page F Tab 200 mg .......................................................................................15.80 5 100

Miacalcic Arrow-Etidronate

114

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

MUSCULOSKELETAL SYSTEM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

Prescribing Guidelines Etidronate for osteoporosis should be prescribed for 14 days (400 mg in the morning) and repeated every three months. It should not be taken at the same time of the day as any calcium supplementation (minimum dose – 500 mg per day of elemental calcium). Etidronate should be taken at least 2 hours before or after any food or ﬂuid, except water. PAMIDRONATE DISODIUM Inj 3 mg per ml, 5 ml .........................................................................18.75 1 Pamisol Inj 3 mg per ml, 10 ml .......................................................................37.50 1 Pamisol Inj 6 mg per ml, 10 ml .......................................................................75.00 1 Pamisol Inj 9 mg per ml, 10 ml .....................................................................112.50 1 Pamisol RALOXIFENE HYDROCHLORIDE – Special Authority see SA1138 below – Retail pharmacy F Tab 60 mg .........................................................................................53.76 28

Evista

¾SA1138 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid without further renewal unless notiﬁed for applications meeting the following criteria: Any of the following: 1 History of one signiﬁcant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) ≥ 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score ≤ -2.5) (see Notes); or 2 History of one signiﬁcant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or 3 History of two signiﬁcant osteoporotic fractures demonstrated radiologically; or 4 Documented T-Score ≤ -3.0 (see Notes); or 5 A 10-year risk of hip fracture ≥ 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Notes); or 6 Patient has had a prior Special Authority approval for zoledronic acid (Underlying cause - Osteoporosis) or alendronate (Underlying cause - Osteoporosis). Notes: a) BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable. b) Evidence used by the UK National Institute for Health and Clinical Excellence (NICE) in developing its guidance indicates that patients aged 75 years and over who have a history of signiﬁcant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score ≤ -2.5 and, therefore, do not require BMD measurement for raloxifene funding. c) Osteoporotic fractures are the incident events for severe (established) osteoporosis, and can be deﬁned using the WHO deﬁnitions of osteoporosis and fragility fracture. The WHO deﬁnes severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantiﬁed this as forces equivalent to a fall from a standing height or less. d) A vertebral fracture is deﬁned as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body. TERIPARATIDE – Special Authority see SA1139 below – Retail pharmacy Inj 250 µg per ml, 2.4 ml .................................................................490.00 1 Forteo ¾SA1139 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid for 18 months for applications meeting the following criteria: All of the following: 1 The patient has severe, established osteoporosis; and 2 The patient has a documented T-score less than or equal to -3.0 (see Notes); and 3 The patient has had two or more fractures due to minimal trauma; and continued. . .

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

115

MUSCULOSKELETAL SYSTEM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

continued. . . 4 The patient has experienced at least one symptomatic new fracture after at least 12 months’ continuous therapy with a funded antiresorptive agent at adequate doses (see Notes). Notes: a) The bone mineral density (BMD) measurement used to derive the T-score must be made using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable b) Antiresorptive agents and their adequate doses for the purposes of this Special Authority are deﬁned as: alendronate sodium tab 70 mg or tab 70 mg with cholecalciferol 5,600 iu once weekly; raloxifene hydrochloride tab 60 mg once daily; zoledronic acid 5 mg per year. If an intolerance of a severity necessitating permanent treatment withdrawal develops during the use of one antiresorptive agent, an alternate antiresorptive agent must be trialled so that the patient achieves the minimum requirement of 12 months’ continuous therapy. c) A vertebral fracture is deﬁned as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body. d) A maximum of 18 months of treatment (18 cartridges) will be subsidised. ZOLEDRONIC ACID – Special Authority see SA1187 below – Retail pharmacy Soln for infusion 5 mg in 100 ml .....................................................600.00 100 ml Aclasta ¾SA1187 Special Authority for Subsidy Initial application — (Paget’s disease) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 Paget’s disease; and 2 Any of the following: 2.1 Bone or articular pain; or 2.2 Bone deformity; or 2.3 Bone, articular or neurological complications; or 2.4 Asymptomatic disease, but risk of complications; or 2.5 Preparation for orthopaedic surgery; and 3 The patient will not be prescribed more than one infusion in the 12-month approval period. Initial application — (Underlying cause - Osteoporosis) from any relevant practitioner. Approvals valid without further renewal unless notiﬁed for applications meeting the following criteria: Both: 1 Any of the following: 1.1 History of one signiﬁcant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) ≥ 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score ≤ -2.5) (see Note); or 1.2 History of one signiﬁcant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or 1.3 History of two signiﬁcant osteoporotic fractures demonstrated radiologically; or 1.4 Documented T-Score ≤ -3.0 (see Note); or 1.5 A 10-year risk of hip fracture ≥ 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or 1.6 Patient has had a Special Authority approval for alendronate (Underlying cause - Osteoporosis) or raloxifene; and 2 The patient will not be prescribed more than one infusion in a 12-month period. Initial application — (Underlying cause - glucocorticosteroid therapy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The patient is receiving systemic glucocorticosteroid therapy (≥ 5 mg per day prednisone equivalents) and has already received or is expected to receive therapy for at least three months; and continued. . .

116

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

MUSCULOSKELETAL SYSTEM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

continued. . . 2 Any of the following: 2.1 The patient has documented BMD ≥ 1.5 standard deviations below the mean normal value in young adults (i.e. T-Score ≤ -1.5) (see Note); or 2.2 The patient has a history of one signiﬁcant osteoporotic fracture demonstrated radiologically; or 2.3 The patient has had a Special Authority approval for alendronate (Underlying cause - glucocorticosteroid therapy) or raloxifene; and 3 The patient will not be prescribed more than one infusion in the 12-month approval period. Renewal — (Paget’s disease) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 The patient has relapsed (based on increases in serum alkaline phosphatase); or 1.2 The patient’s serum alkaline phosphatase has not normalised following previous treatment with zoledronic acid; or 1.3 Symptomatic disease (prescriber determined); and 2 The patient will not be prescribed more than one infusion in the 12-month approval period. The patient must not have had more than 1 prior approval in the last 12 months. Renewal — (Underlying cause was, and remains, glucocorticosteroid therapy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The patient is continuing systemic glucocorticosteriod therapy (≥ 5 mg per day prednisone equivalents); and 2 The patient will not be prescribed more than one infusion in the 12-month approval period. The patient must not have had more than 1 prior approval in the last 12 months. Renewal — (Underlying cause was glucocorticosteroid therapy but patient now meets the ‘Underlying cause - osteoporosis’ criteria) from any relevant practitioner. Approvals valid without further renewal unless notiﬁed for applications meeting the following criteria: Both: 1 Any of the following: 1.1 History of one signiﬁcant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) ≥ 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score ≤ -2.5) (see Note); or 1.2 History of one signiﬁcant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or 1.3 History of two signiﬁcant osteoporotic fractures demonstrated radiologically; or 1.4 Documented T-Score ≤ -3.0 (see Note); or 1.5 A 10-year risk of hip fracture ≥ 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or 1.6 Patient has had a Special Authority approval for alendronate (Underlying cause was glucocorticosteroid therapy but patient now meets the ‘Underlying cause - Osteoporosis’ criteria) or raloxifene; and 2 The patient will not be prescribed more than one infusion in a 12-month period. Notes: a) BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable. b) Evidence used by National Institute for Health and Clinical Excellence (NICE) guidance indicates that patients aged 75 years and over who have a history of signiﬁcant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score ≤ -2.5 and, therefore, do not require BMD measurement for treatment with bisphosphonates. c) Osteoporotic fractures are the incident events for severe (established) osteoporosis and can be deﬁned using the WHO deﬁnitions of osteoporosis and fragility fracture. The WHO deﬁnes severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces continued. . .

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

117

MUSCULOSKELETAL SYSTEM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

continued. . . that would not ordinarily cause fracture (minimal trauma). The WHO has quantiﬁed this as forces equivalent to a fall from a standing height or less. d) A vertebral fracture is deﬁned as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

Hyperuricaemia and Antigout

ALLOPURINOL F Tab 100 mg .......................................................................................15.90 F Tab 300 mg – For allopurinol oral liquid formulation refer, page 182 ....................................................................................16.75 COLCHICINE F Tab 500 µg .........................................................................................9.60 PROBENECID F Tab 500 mg .......................................................................................55.00 1,000 500 100 100

Apo-Allopurinol Apo-Allopurinol Colgout Probenecid-AFT

Muscle Relaxants

BACLOFEN F Tab 10 mg – For baclofen oral liquid formulation refer, page 182 ............................................................................................... 4.75 DANTROLENE SODIUM F Cap 25 mg ........................................................................................32.96 (65.00) F Cap 50 mg ........................................................................................51.70 (77.00) ORPHENADRINE CITRATE Tab 100 mg .......................................................................................18.54 QUININE SULPHATE F Tab 300 mg .......................................................................................54.06 ‡ Safety cap for extemporaneously compounded oral liquid preparations.

100 100

Pacifen

Dantrium 100 Dantrium 100 500

Norﬂex Q 300

118

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

NERVOUS SYSTEM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

Agents for Parkinsonism and Related Disorders Dopamine Agonists and Related Agents

AMANTADINE HYDROCHLORIDE L Cap 100 mg ......................................................................................38.24 APOMORPHINE HYDROCHLORIDE L Inj 10 mg per ml, 2 ml .....................................................................110.00 BROMOCRIPTINE MESYLATE F Tab 2.5 mg ........................................................................................32.08 F Cap 5 mg ..........................................................................................60.43 ENTACAPONE L Tab 200 mg .....................................................................................116.00 LEVODOPA WITH BENSERAZIDE F Tab dispersible 50 mg with benserazide 12.5 mg .............................10.00 F F F F Cap 50 mg with benserazide 12.5 mg ................................................8.00 Cap 100 mg with benserazide 25 mg ...............................................12.50 Cap long-acting 100 mg with benserazide 25 mg ............................17.00 Cap 200 mg with benserazide 50 mg ...............................................25.00 60 5 100 100 100 100 100 100 100 100

Symmetrel Apomine Apo-Bromocriptine Apo-Bromocriptine Comtan Madopar

Dispersible

Madopar 62.5 Madopar 125 Madopar HBS Madopar 250

LEVODOPA WITH CARBIDOPA F Tab 100 mg with carbidopa 25 mg – For levodopa with carbidopa oral liquid formulation refer, page 182 ............................ 10.00 20.00 F Tab long-acting 200 mg with carbidopa 50 mg .................................47.50 F Tab 250 mg with carbidopa 25 mg ....................................................40.00 LISURIDE HYDROGEN MALEATE L Tab 200 µg .......................................................................................27.50 PERGOLIDE L Tab 0.25 mg ......................................................................................48.00 L Tab 1 mg .........................................................................................170.00 PRAMIPEXOLE HYDROCHLORIDE L Tab 0.125 mg ......................................................................................1.95 L Tab 0.25 mg ........................................................................................2.40 L Tab 0.5 mg ..........................................................................................4.20 ROPINIROLE HYDROCHLORIDE L Tab 0.25 mg ........................................................................................6.20 L Tab 1 mg ...........................................................................................15.95 L Tab 2 mg ...........................................................................................24.95 L Tab 5 mg ...........................................................................................38.00 SELEGILINE HYDROCHLORIDE F Tab 5 mg ...........................................................................................16.06 TOLCAPONE L Tab 100 mg .....................................................................................126.20

50 100 100 100 30 100 100 30 30 30

Sindopa Sinemet Sinemet CR Sinemet Dopergin Permax Permax Dr Reddy’s

Pramipexole

Dr Reddy’s

Pramipexole

Dr Reddy’s

Pramipexole

84 84 84 84 100 100

Ropin Ropin Ropin Ropin Apo-Selegiline Tasmar

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

119

NERVOUS SYSTEM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

Anticholinergics

BENZTROPINE MESYLATE Tab 2 mg .............................................................................................7.99 Inj 1 mg per ml, 2 ml .........................................................................95.00 a) Up to 5 inj available on a PSO b) Only on a PSO ORPHENADRINE HYDROCHLORIDE Tab 50 mg .........................................................................................35.15 PROCYCLIDINE HYDROCHLORIDE Tab 5 mg .............................................................................................7.40 60 5

Benztrop Cogentin

250 100

Disipal Kemadrin

Agents for Essential Tremor, Chorea and Related Disorders

TETRABENAZINE Tab 25 mg .......................................................................................178.00 112

Motetis

Anaesthetics Local

LIGNOCAINE Gel 2%, 10 ml urethral syringe – Subsidy by endorsement...............43.26 10 Pﬁzer a) Up to 5 each available on a PSO b) Subsidised only if prescribed for urethral or cervical administration and the prescription is endorsed accordingly. LIGNOCAINE HYDROCHLORIDE Viscous soln 2% ...............................................................................55.00 200 ml Xylocaine Viscous Inj 1%, 5 ml – Up to 5 inj available on a PSO...................................35.00 50 Xylocaine Inj 2%, 5 ml – Up to 5 inj available on a PSO...................................23.00 50 Xylocaine Inj 1%, 20 ml – Up to 5 inj available on a PSO.................................20.00 5 Xylocaine Inj 2%, 20 ml – Up to 5 inj available on a PSO.................................15.00 5 Xylocaine LIGNOCAINE WITH CHLORHEXIDINE Gel 2% with chlorhexidine 0.05%, 10 ml urethral syringes – Subsidy by endorsement ............................................................43.26 10 Pﬁzer a) Up to 5 each available on a PSO b) Subsidised only if prescribed for urethral or cervical administration and the prescription is endorsed accordingly. LIGNOCAINE WITH PRILOCAINE – Special Authority see SA0906 below – Retail pharmacy Crm 2.5% with prilocaine 2.5% ........................................................45.00 30 g OP EMLA Crm 2.5% with prilocaine 2.5% (5 g tubes) ......................................45.00 5 EMLA ¾SA0906 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid for 2 years where the patient is a child with a chronic medical condition requiring frequent injections or venepuncture. Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is beneﬁting from treatment.

120

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

NERVOUS SYSTEM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

Analgesics

For Anti-inﬂammatory NSAIDS refer to MUSCULOSKELETAL, page 102

Non-opioid Analgesics

ASPIRIN F Tab EC 300 mg ...................................................................................2.00 (8.10) F Tab dispersible 300 mg – Up to 30 tab available on a PSO ...............2.00 NEFOPAM HYDROCHLORIDE Tab 30 mg .........................................................................................23.40 PARACETAMOL F Tab 500 mg – Up to 30 tab available on a PSO..................................9.38 F‡ Oral liq 120 mg per 5 ml .....................................................................2.21 a) Up to 200 ml available on a PSO b) Not in combination F‡ Oral liq 250 mg per 5 ml .....................................................................6.70 a) Up to 100 ml available on a PSO b) Not in combination F Suppos 125 mg ..................................................................................7.49 F Suppos 250 mg ................................................................................14.40 F Suppos 500 mg ................................................................................20.50 TRAMADOL HYDROCHLORIDE Cap 50 mg ..........................................................................................4.95 100 Aspec 300 100 90 1,000 500 ml

Ethics Aspirin Acupan Parafast Ethics Paracetamol Paracare Double

Strength

1,000 ml

20 20 50 100

Panadol Panadol Paracare Arrow-Tramadol

Opioid Analgesics

CODEINE PHOSPHATE – Safety medicine; prescriber may determine dispensing frequency Tab 15 mg ...........................................................................................5.39 100 Tab 30 mg ...........................................................................................8.25 100 Tab 60 mg .........................................................................................17.76 100 DIHYDROCODEINE TARTRATE Tab long-acting 60 mg ......................................................................27.27 FENTANYL a) Only on a controlled drug form b) No patient co-payment payable c) Safety medicine; prescriber may determine dispensing frequency Transdermal patch 12.5 µg per hour ..................................................8.90 Transdermal patch 25 µg per hour .....................................................9.15 Transdermal patch 50 µg per hour ...................................................11.50 Transdermal patch 75 µg per hour ...................................................13.60 Transdermal patch 100 µg per hour .................................................14.50 60

PSM PSM PSM DHC Continus

5 5 5 5 5

Mylan Fentanyl

Patch

Mylan Fentanyl

Patch

Mylan Fentanyl

Patch

Mylan Fentanyl

Patch

Mylan Fentanyl

Patch

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

121

NERVOUS SYSTEM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

FENTANYL CITRATE a) Only on a controlled drug form b) No patient co-payment payable c) Safety medicine; prescriber may determine dispensing frequency Inj 50 µg per ml, 2 ml ..........................................................................4.50 Inj 50 µg per ml, 10 ml ......................................................................11.77

10 10

Boucher and Muir Boucher and Muir

METHADONE HYDROCHLORIDE a) Only on a controlled drug form b) No patient co-payment payable c) Safety medicine; prescriber may determine dispensing frequency d) Extemporaneously compounded methadone will only be reimbursed at the rate of the cheapest form available (methadone powder, not methadone tablets). e) For methadone hydrochloride oral liquid refer, page 185 Tab 5 mg .............................................................................................1.85 10 Methatabs ‡ Oral liq 2 mg per ml ............................................................................5.55 200 ml Biodone ‡ Oral liq 5 mg per ml ............................................................................5.55 200 ml Biodone Forte ‡ Oral liq 10 mg per ml ..........................................................................6.55 200 ml Biodone Extra Forte Inj 10 mg per ml, 1 ml .......................................................................61.00 10 AFT MORPHINE HYDROCHLORIDE a) Only on a controlled drug form b) No patient co-payment payable c) Safety medicine; prescriber may determine dispensing frequency ‡ Oral liq 1 mg per ml ............................................................................8.84 ‡ Oral liq 2 mg per ml ..........................................................................11.62 ‡ Oral liq 5 mg per ml ..........................................................................14.65 ‡ Oral liq 10 mg per ml ........................................................................21.55 MORPHINE SULPHATE a) Only on a controlled drug form b) No patient co-payment payable c) Safety medicine; prescriber may determine dispensing frequency Tab immediate-release 10 mg ............................................................2.80 Tab long-acting 10 mg ........................................................................1.98 Tab immediate-release 20 mg ............................................................5.52 Tab long-acting 30 mg ........................................................................3.15 Tab long-acting 60 mg ........................................................................7.20 Tab long-acting 100 mg ......................................................................7.85 Cap long-acting 10 mg .......................................................................2.22 Cap long-acting 30 mg .......................................................................3.20 Cap long-acting 60 mg .......................................................................6.90 Cap long-acting 100 mg .....................................................................8.05 Inj 5 mg per ml, 1 ml – Up to 5 inj available on a PSO .......................5.51 Inj 10 mg per ml, 1 ml – Up to 5 inj available on a PSO .....................4.79 Inj 15 mg per ml, 1 ml – Up to 5 inj available on a PSO .....................5.01 Inj 30 mg per ml, 1 ml – Up to 5 inj available on a PSO .....................5.30

200 ml 200 ml 200 ml 200 ml

RA-Morph RA-Morph RA-Morph RA-Morph

10 10 10 10 10 10 10 10 10 10 5 5 5 5

Sevredol Arrow-Morphine LA Sevredol Arrow-Morphine LA Arrow-Morphine LA Arrow-Morphine LA m-Eslon m-Eslon m-Eslon m-Eslon DBL Morphine

Sulphate

DBL Morphine

Sulphate

DBL Morphine

Sulphate

DBL Morphine

Sulphate

122

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

NERVOUS SYSTEM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

MORPHINE TARTRATE a) Only on a controlled drug form b) No patient co-payment payable c) Safety medicine; prescriber may determine dispensing frequency Inj 80 mg per ml, 1.5 ml ....................................................................30.00 Inj 80 mg per ml, 5 ml .......................................................................75.00

5 5

Hospira Hospira

OXYCODONE HYDROCHLORIDE a) Only on a controlled drug form b) See prescribing guideline below c) No patient co-payment payable d) Safety medicine; prescriber may determine dispensing frequency Tab controlled-release 5 mg ...............................................................7.51 20 OxyContin Tab controlled-release 10 mg ...........................................................11.14 20 OxyContin Tab controlled-release 20 mg ...........................................................18.93 20 OxyContin Tab controlled-release 40 mg ...........................................................33.29 20 OxyContin Tab controlled-release 80 mg ...........................................................58.03 20 OxyContin Cap 5 mg ............................................................................................2.83 20 OxyNorm Cap 10 mg ..........................................................................................5.58 20 OxyNorm Cap 20 mg ..........................................................................................9.77 20 OxyNorm ‡ Oral liq 5 mg per 5 ml .......................................................................11.20 250 ml OxyNorm Inj 10 mg per ml, 1 ml .......................................................................14.40 5 OxyNorm Inj 10 mg per ml, 2 ml .......................................................................28.80 5 OxyNorm Prescribing Guideline Prescribers should note that oxycodone is signiﬁcantly more expensive than long-acting morphine sulphate and clinical advice suggests that it is reasonable to consider this as a second-line agent to be used after morphine. PARACETAMOL WITH CODEINE – Safety medicine; prescriber may determine dispensing frequency F Tab paracetamol 500 mg with codeine phosphate 8 mg ....................2.70 100 Paracetamol + Codeine (Relieve) PETHIDINE HYDROCHLORIDE a) Only on a controlled drug form b) No patient co-payment payable c) Safety medicine; prescriber may determine dispensing frequency Tab 50 mg ...........................................................................................3.20 10 PSM Tab 100 mg .........................................................................................4.20 10 PSM Inj 50 mg per ml, 1 ml – Up to 5 inj available on a PSO .....................5.51 5 DBL Pethidine Hydrochloride Inj 50 mg per ml, 2 ml – Up to 5 inj available on a PSO .....................5.83 5 DBL Pethidine Hydrochloride

Antidepressants Cyclic and Related Agents

AMITRIPTYLINE – Safety medicine; prescriber may determine dispensing frequency Tab 10 mg ...........................................................................................2.77 50 Tab 25 mg ...........................................................................................1.85 100 Tab 50 mg ...........................................................................................3.60 100

Amirol Amitrip Amitrip

CLOMIPRAMINE HYDROCHLORIDE – Safety medicine; prescriber may determine dispensing frequency Tab 10 mg .........................................................................................12.60 100 Apo-Clomipramine Tab 25 mg ...........................................................................................8.68 100 Apo-Clomipramine

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

123

NERVOUS SYSTEM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

DOTHIEPIN HYDROCHLORIDE – Safety medicine; prescriber may determine dispensing frequency Tab 75 mg .........................................................................................10.50 100 Dopress Cap 25 mg ..........................................................................................6.17 100 Dopress DOXEPIN HYDROCHLORIDE – Safety medicine; prescriber may determine dispensing frequency Cap 10 mg ..........................................................................................6.30 100 Anten Cap 25 mg ..........................................................................................6.86 100 Anten Cap 50 mg ..........................................................................................8.55 100 Anten IMIPRAMINE HYDROCHLORIDE – Safety medicine; prescriber may determine dispensing frequency Tab 10 mg ...........................................................................................5.48 50 Tofranil Tab 25 mg ...........................................................................................8.80 50 Tofranil MAPROTILINE HYDROCHLORIDE – Safety medicine; prescriber may determine dispensing frequency Tab 25 mg .........................................................................................25.06 100 Ludiomil Tab 75 mg .........................................................................................21.01 30 Ludiomil MIANSERIN HYDROCHLORIDE – Special Authority see SA1048 below – Retail pharmacy Tab 30 mg .........................................................................................24.86 30

Tolvon

¾SA1048 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Both: 1.1 Depression; and 1.2 Either: 1.2.1 Co-existent bladder neck obstruction; or 1.2.2 Cardiovascular disease; or 2 Both: 2.1 The patient has a severe major depressive episode; and 2.2 Either: 2.2.1 The patient must have had a trial of two different antidepressants and was unable to tolerate the treatments or failed to respond to an adequate dose over an adequate period of time (usually at least four weeks); or 2.2.2 Both: 2.2.2.1 The patient is currently a hospital in-patient as a result of an acute depressive episode; and 2.2.2.2 The patient must have had a trial of one other antidepressant and either could not tolerate it or failed to respond to an adequate dose over an adequate period of time. Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is beneﬁting from treatment. NORTRIPTYLINE HYDROCHLORIDE – Safety medicine; prescriber may determine dispensing frequency Tab 10 mg ...........................................................................................6.69 100 Norpress Tab 25 mg .........................................................................................14.77 180 Norpress

Monoamine-Oxidase Inhibitors (MAOIs) - Non Selective

PHENELZINE SULPHATE F Tab 15 mg .........................................................................................95.00 TRANYLCYPROMINE SULPHATE F Tab 10 mg .........................................................................................22.94 100 50

Nardil Parnate

124

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

NERVOUS SYSTEM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

Monoamine-Oxidase Type A Inhibitors

MOCLOBEMIDE Note: There is a signiﬁcant cost differential between moclobemide and ﬂuoxetine (moclobemide being about three times more expensive). For depressive syndromes it is therefore more cost-effective to start treatment with ﬂuoxetine ﬁrst before considering prescribing moclobemide. F Tab 150 mg .......................................................................................69.23 500 Apo-Moclobemide F Tab 300 mg .......................................................................................31.33 100 Apo-Moclobemide

Selective Serotonin Reuptake Inhibitors

CITALOPRAM HYDROBROMIDE F Tab 20 mg ...........................................................................................2.34 ESCITALOPRAM F Tab 10 mg ...........................................................................................2.65 F Tab 20 mg ...........................................................................................4.20 84 28 28

Arrow-Citalopram Loxalate Loxalate

FLUOXETINE HYDROCHLORIDE F Tab dispersible 20 mg, scored – Subsidy by endorsement .................2.50 30 Fluox Subsidised by endorsement 1) When prescribed for a patient who cannot swallow whole tablets or capsules and the prescription is endorsed accordingly; or 2) When prescribed in a daily dose that is not a multiple of 20 mg in which case the prescription is deemed to be endorsed. Note: Tablets should be combined with capsules to facilitate incremental 10 mg doses. F Cap 20 mg ..........................................................................................2.70 84 Fluox PAROXETINE HYDROCHLORIDE F Tab 20 mg ...........................................................................................2.38 SERTRALINE F Tab 50 mg ...........................................................................................5.40 F Tab 100 mg .........................................................................................9.60 30 90 90

Loxamine Arrow-Sertraline Arrow-Sertraline

Other Antidepressants

MIRTAZAPINE – Special Authority see SA0994 below – Retail pharmacy Tab 30 mg ...........................................................................................8.78 Tab 45 mg .........................................................................................13.95 30 30

Avanza Avanza

¾SA0994 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 The patient has a severe major depressive episode; and 2 Either: 2.1 The patient must have had a trial of two different antidepressants and was unable to tolerate the treatments or failed to respond to an adequate dose over an adequate period of time (usually at least four weeks); or 2.2 Both: 2.2.1 The patient is currently a hospital in-patient as a result of an acute depressive episode; and 2.2.2 The patient must have had a trial of one other antidepressant and either could not tolerate it or failed to respond to an adequate dose over an adequate period of time. Renewal from any relevant practitioner. Approvals valid for 2 years where the patient has a high risk of relapse (prescriber determined).

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

125

NERVOUS SYSTEM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

VENLAFAXINE – Special Authority see SA1061 below – Retail pharmacy Tab 37.5 mg ......................................................................................12.67 Tab 75 mg .........................................................................................19.00 Tab 150 mg .......................................................................................23.41 Cap 37.5 mg .....................................................................................15.84 Cap 75 mg ........................................................................................31.67 Cap 150 mg ......................................................................................38.82

28 28 28 28 28 28

Arrow-Venlafaxine

Efexor XR Efexor XR Efexor XR

¾SA1061 Special Authority for Subsidy Initial application only from a relevant specialist or vocationally registered general practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 The patient has ’treatment-resistant’ depression; and 2 Either: 2.1 The patient must have had a trial of two different antidepressants and have had an inadequate response from an adequate dose over an adequate period of time (usually at least four weeks); or 2.2 Both: 2.2.1 The patient is currently a hospital in-patient as a result of an acute depressive episode; and 2.2.2 The patient must have had a trial of one other antidepressant and have had an inadequate response from an adequate dose over an adequate period of time. Renewal from any medical practitioner. Approvals valid for 2 years where the patient has a high risk of relapse (prescriber determined).

Antiepilepsy Drugs Agents for Control of Status Epilepticus

CLONAZEPAM – Safety medicine; prescriber may determine dispensing frequency Inj 1 mg per ml, 1 ml .........................................................................19.00 DIAZEPAM – Safety medicine; prescriber may determine dispensing frequency Inj 5 mg per ml, 2 ml – Subsidy by endorsement ...............................9.24 a) Up to 5 inj available on a PSO b) Only on a PSO c) PSO must be endorsed “not for anaesthetic procedures”. Rectal tubes 5 mg – Up to 5 tube available on a PSO .....................25.05 Rectal tubes 10 mg – Up to 5 tube available on a PSO ...................30.50 PARALDEHYDE F Inj 5 ml .........................................................................................1,500.00 PHENYTOIN SODIUM F Inj 50 mg per ml, 2 ml – Up to 5 inj available on a PSO ...................69.24 F Inj 50 mg per ml, 5 ml – Up to 5 inj available on a PSO ...................77.27 5 5

Rivotril Mayne

5 5 5 5 5

Stesolid Stesolid AFT Mayne Mayne

126

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

NERVOUS SYSTEM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

Control of Epilepsy

CARBAMAZEPINE F Tab 200 mg .......................................................................................14.53 F Tab long-acting 200 mg ....................................................................16.98 F Tab 400 mg .......................................................................................34.58 F Tab long-acting 400 mg ....................................................................39.17 F‡ Oral liq 100 mg per 5 ml ...................................................................26.37 100 100 100 100 250 ml

Tegretol Tegretol CR Tegretol Tegretol CR Tegretol Frisium

CLOBAZAM – Safety medicine; prescriber may determine dispensing frequency Tab 10 mg ...........................................................................................9.12 50 ‡ Safety cap for extemporaneously compounded oral liquid preparations. CLONAZEPAM – Safety medicine; prescriber may determine dispensing frequency Tab 500 µg .........................................................................................6.68 100 Tab 2 mg ...........................................................................................12.75 100 ‡ Oral drops 2.5 mg per ml ....................................................................7.38 10 ml OP ETHOSUXIMIDE F Cap 250 mg ......................................................................................32.90 F‡ Oral liq 250 mg per 5 ml ...................................................................13.60 GABAPENTIN – Special Authority see SA1071 below – Retail pharmacy L Cap 100 mg ........................................................................................7.16 L Cap 300 mg – For gabapentin oral liquid formulation refer, page 182 .................................................................................... 11.50 L Cap 400 mg ......................................................................................14.75 200 200 ml 100 100 100

Paxam Paxam Rivotril Zarontin Zarontin Nupentin Nupentin Nupentin

¾SA1071 Special Authority for Subsidy Initial application — (Epilepsy) from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria: Either: 1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or 2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents. Note: "Optimal treatment with other antiepilepsy agents" is deﬁned as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient’s age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance. Initial application — (Neuropathic pain) from any relevant practitioner. Approvals valid for 3 months where the patient has tried and failed, or has been unable to tolerate, treatment with a tricyclic antidepressant. Renewal — (Epilepsy) from any relevant practitioner. Approvals valid without further renewal unless notiﬁed where the patient has demonstrated a signiﬁcant and sustained improvement in seizure rate or severity and/or quality of life. Note: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient’s perspective. Renewal — (Neuropathic pain) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 The patient has demonstrated a marked improvement in their control of pain (prescriber determined); or 2 The patient has previously demonstrated clinical responsiveness to gabapentin and has now developed neuropathic pain in a new site.

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

127

NERVOUS SYSTEM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

GABAPENTIN (NEURONTIN) – Special Authority see SA0973 below – Retail pharmacy L Tab 600 mg .......................................................................................67.50 100 L Cap 100 mg ......................................................................................13.26 100 L Cap 300 mg – For gabapentin (neurontin) oral liquid formulation refer, page 182..................................................................39.76 100 L Cap 400 mg ......................................................................................53.01 100

Neurontin Neurontin Neurontin Neurontin

¾SA0973 Special Authority for Subsidy Notes: Subsidy for patients pre-approved by PHARMAC on 1 August 2009. Approvals valid without further renewal unless notiﬁed. No new approvals will be granted from 1 August 2009. LACOSAMIDE – Special Authority see SA1125 below – Retail pharmacy L Tab 50 mg .........................................................................................25.04 14 Vimpat L Tab 100 mg .......................................................................................50.06 14 Vimpat 200.24 56 Vimpat L Tab 150 mg .......................................................................................75.10 14 Vimpat 300.40 56 Vimpat L Tab 200 mg .....................................................................................400.55 56 Vimpat ¾SA1125 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria: Both: 1 Patient has partial-onset epilepsy; and 2 Seizures are not adequately controlled by, or patient has experienced unacceptable side effects from, optimal treatment with all of the following: sodium valproate, topiramate, levetiracetam and any two of carbamazepine, lamotrigine and phenytoin sodium (see Note). Note: "Optimal treatment" is deﬁned as treatment which is indicated and clinically appropriate for the patient, given in adequate doses for the patient’s age, weight and other features affecting the pharmacokinetics of the drug with good evidence of compliance. Women of childbearing age are not required to have a trial of sodium valproate. Renewal from any relevant practitioner. Approvals valid for 24 months where the patient has demonstrated a signiﬁcant and sustained improvement in seizure rate or severity and/or quality of life compared with that prior to starting lacosamide treatment (see Note). Note: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient’s perspective. LAMOTRIGINE L Tab dispersible 2 mg ...........................................................................6.74 30 Lamictal L Tab dispersible 5 mg ...........................................................................9.64 30 Lamictal 15.00 56 Arrow-Lamotrigine L Tab dispersible 25 mg .......................................................................19.38 56 Logem 20.40 Arrow-Lamotrigine Mogine 29.09 Lamictal L Tab dispersible 50 mg .......................................................................32.97 56 Logem 34.70 Arrow-Lamotrigine Mogine 47.89 Lamictal L Tab dispersible 100 mg .....................................................................56.91 56 Logem Arrow-Lamotrigine 59.90 Mogine 79.16 Lamictal

128

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

NERVOUS SYSTEM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

LEVETIRACETAM Tab 250 mg .......................................................................................24.03 Tab 500 mg – For levetiracetam oral liquid formulation refer, page 182 .................................................................................... 28.71 Tab 750 mg .......................................................................................45.23 PHENOBARBITONE For phenobarbitone oral liquid refer, page 185 F Tab 15 mg .........................................................................................25.00 F Tab 30 mg .........................................................................................26.00 PHENYTOIN SODIUM F Tab 50 mg .........................................................................................42.09 F Cap 30 mg ........................................................................................19.13 F Cap 100 mg ......................................................................................17.21 F‡ Oral liq 30 mg per 5 ml .....................................................................19.16 PRIMIDONE F Tab 250 mg .......................................................................................17.25 SODIUM VALPROATE F Tab 100 mg .......................................................................................13.65 F Tab 200 mg EC .................................................................................27.44 F Tab 500 mg EC .................................................................................52.24 F‡ Oral liq 200 mg per 5 ml ...................................................................20.48 F Inj 100 mg per ml, 4 ml .....................................................................41.50 TOPIRAMATE L Tab 25 mg .........................................................................................11.07 26.04 L Tab 50 mg .........................................................................................18.81 44.26 L Tab 100 mg .......................................................................................31.99 75.25 L Tab 200 mg .......................................................................................55.19 129.85 L Sprinkle cap 15 mg ...........................................................................20.84 L Sprinkle cap 25 mg ...........................................................................26.04 VIGABATRIN – Special Authority see SA1072 below – Retail pharmacy L Tab 500 mg .....................................................................................119.30

60 60 60

Levetiracetam-Rex Levetiracetam-Rex Levetiracetam-Rex

500 500 200 200 200 500 ml 100 100 100 100 300 ml 1 60 60 60 60 60 60 100

PSM PSM Dilantin Infatab Dilantin Dilantin Dilantin Apo-Primidone Epilim Crushable Epilim Epilim Epilim S/F Liquid Epilim Syrup Epilim IV Arrow-Topiramate Topamax Arrow-Topiramate Topamax Arrow-Topiramate Topamax Arrow-Topiramate Topamax Topamax Topamax Sabril

¾SA1072 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria: Both: 1 Either: 1.1 Patient has infantile spasms; or 1.2 Both: 1.2.1 Patient has epilepsy; and 1.2.2 Either: 1.2.2.1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or 1.2.2.2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents; and continued. . .

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

129

NERVOUS SYSTEM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

continued. . . 2 Either: 2.1 Patient is, or will be, receiving regular automated visual ﬁeld testing (ideally before starting therapy and on a 6-monthly basis thereafter); or 2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient’s visual ﬁelds. Notes: “Optimal treatment with other antiepilepsy agents” is deﬁned as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient’s age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance. Vigabatrin is associated with a risk of irreversible visual ﬁeld defects, which may be asymptomatic in the early stages. Renewal from any relevant practitioner. Approvals valid without further renewal unless notiﬁed for applications meeting the following criteria: Both: 1 The patient has demonstrated a signiﬁcant and sustained improvement in seizure rate or severity and or quality of life; and 2 Either: 2.1 Patient is receiving regular automated visual ﬁeld testing (ideally every 6 months) on an ongoing basis for duration of treatment with vigabatrin; or 2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient’s visual ﬁelds. Notes: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient’s perspective. Vigabatrin is associated with a risk of irreversible visual ﬁeld defects, which may be asymptomatic in the early stages.

Antimigraine Preparations

For Anti-inﬂammatory NSAIDS refer to MUSCULOSKELETAL, page 102

Acute Migraine Treatment

ERGOTAMINE TARTRATE WITH CAFFEINE Tab 1 mg with caffeine 100 mg .........................................................31.00 METOCLOPRAMIDE HYDROCHLORIDE WITH PARACETAMOL Tab 5 mg with paracetamol 500 mg ....................................................6.77 RIZATRIPTAN – Brand switch fee payable - see page 180 for details Tab orodispersible 10 mg .................................................................18.00 SUMATRIPTAN Tab 50 mg ...........................................................................................1.55 38.83 Tab 100 mg .........................................................................................1.55 77.66 Inj 12 mg per ml, 0.5 ml – Maximum of 10 inj per prescription .........36.00 100 60 30 4 100 2 100 2 OP

Cafergot Paramax Rizamelt Arrow-Sumatriptan Arrow-Sumatriptan Arrow-Sumatriptan Arrow-Sumatriptan Arrow-Sumatriptan

Prophylaxis of Migraine

For Beta Adrenoceptor Blockers refer to CARDIOVASCULAR SYSTEM, page 51 CLONIDINE HYDROCHLORIDE F Tab 25 µg .........................................................................................19.25 PIZOTIFEN F Tab 500 µg .......................................................................................21.10

100 100

Dixarit Sandomigran

130

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

NERVOUS SYSTEM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

Antinausea and Vertigo Agents

For Antispasmodics refer to ALIMENTARY TRACT, page 28 APREPITANT – Special Authority see SA0987 below – Retail pharmacy Cap 2 × 80 mg and 1 × 125 mg ....................................................116.00

3 OP

Emend Tri-Pack

¾SA0987 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid for 12 months where the patient is undergoing highly emetogenic chemotherapy and/or anthracycline-based chemotherapy for the treatment of malignancy. Renewal from any relevant practitioner. Approvals valid for 12 months where the patient is undergoing highly emetogenic chemotherapy and/or anthracycline-based chemotherapy for the treatment of malignancy. BETAHISTINE DIHYDROCHLORIDE F Tab 16 mg .........................................................................................10.00 84 Vergo 16 CYCLIZINE HYDROCHLORIDE Tab 50 mg ...........................................................................................0.59 CYCLIZINE LACTATE Inj 50 mg per ml, 1 ml .......................................................................14.95 DOMPERIDONE F Tab 10 mg – For domperidone oral liquid formulation refer, page 182 .................................................................................... 11.99 10 5

Nausicalm Nausicalm

100

Motilium Scopoderm TTS

HYOSCINE (SCOPOLAMINE) – Special Authority see SA0939 below – Retail pharmacy Patch 1.5 mg ....................................................................................11.95 2

¾SA0939 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 Control of intractable nausea, vomiting, or inability to swallow saliva in the treatment of malignancy or chronic disease; and 2 Patient cannot tolerate or does not adequately respond to oral anti-nausea agents; and 3 The applicant must specify the underlying malignancy or chronic disease. Renewal from any relevant practitioner. Approvals valid for 1 year where the treatment remains appropriate and the patient is beneﬁting from treatment. HYOSCINE HYDROBROMIDE F Inj 400 µg per ml, 1 ml ........................................................................6.66 5 Mayne METOCLOPRAMIDE HYDROCHLORIDE F Tab 10 mg ...........................................................................................3.95 F Inj 5 mg per ml, 2 ml – Up to 5 inj available on a PSO .......................4.50 ONDANSETRON F Tab 4 mg .............................................................................................5.10 F Tab disp 4 mg .....................................................................................1.70 F Tab 8 mg .............................................................................................1.70 F Tab disp 8 mg .....................................................................................2.00 100 10 30 10 10 10

Metamide Pﬁzer Dr Reddy’s

Ondansetron

Dr Reddy’s

Ondansetron

Dr Reddy’s

Ondansetron

Dr Reddy’s

Ondansetron

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

131

NERVOUS SYSTEM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

PROCHLORPERAZINE F Tab 3 mg buccal .................................................................................5.97 (15.00) F Tab 5 mg – Up to 30 tab available on a PSO....................................16.85 F Inj 12.5 mg per ml, 1 ml – Up to 5 inj available on a PSO ................25.81 F Suppos 25 mg ..................................................................................23.87 PROMETHAZINE THEOCLATE F Tab 25 mg ...........................................................................................1.20 (6.24) TROPISETRON a) Maximum of 6 cap per prescription b) Maximum of 3 cap per dispensing c) Not more than one prescription per month. Cap 5 mg ..........................................................................................77.41

50 Buccastem 500 10 5 10 Avomine

Antinaus Stemetil Stemetil

Navoban

Antipsychotics

Guidelines for the use of atypical antipsychotic agents Diagnosis: Schizophrenia and related psychoses when positive symptoms (delusions, hallucinations and thought disorder) are prominent and/or disabling or when both positive symptoms and negative symptoms (ﬂattened affect, emotional and social withdrawal and poverty of speech) are present. Treatment: Before initiating atypical antipsychotic therapy, physicians should consider whether the patient is likely to respond to and/or tolerate conventional antipsychotic therapy and, where appropriate, trial one or more conventional agent prior to use of an atypical agent.

General

AMISULPRIDE – Safety medicine; prescriber may determine dispensing frequency Tab 100 mg .......................................................................................22.52 30 Tab 200 mg .......................................................................................97.03 60 Tab 400 mg .....................................................................................185.44 60 Oral liq 100 mg per ml ......................................................................55.44 60 ml ARIPIPRAZOLE – Special Authority see SA0920 below – Retail pharmacy Safety medicine; prescriber may determine dispensing frequency Tab 10 mg .......................................................................................123.54 Tab 15 mg .......................................................................................175.28 Tab 20 mg .......................................................................................213.42 Tab 30 mg .......................................................................................260.07

Solian Solian Solian Solian

30 30 30 30

Abilify Abilify Abilify Abilify

¾SA0920 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Patient is suffering from schizophrenia or related psychoses; and 2 Either: 2.1 An effective dose of risperidone or quetiapine has been trialled and has been discontinued, or is in the process of being discontinued, because of unacceptable side effects; or 2.2 An effective dose of risperidone or quetiapine has been trialled and has been discontinued, or is in the process of being discontinued, because of inadequate clinical response. Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is beneﬁting from treatment.

132

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

NERVOUS SYSTEM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

CHLORPROMAZINE HYDROCHLORIDE – Safety medicine; prescriber may determine dispensing frequency Tab 10 mg – Up to 30 tab available on a PSO..................................12.36 100 Largactil Tab 25 mg – Up to 30 tab available on a PSO..................................13.02 100 Largactil Tab 100 mg – Up to 30 tab available on a PSO................................30.61 100 Largactil Inj 25 mg per ml, 2 ml – Up to 5 inj available on a PSO ...................25.66 10 Largactil CLOZAPINE – Hospital pharmacy [HP4] Safety medicine; prescriber may determine dispensing frequency Tab 25 mg .........................................................................................13.37 26.74 6.69 13.37 Tab 50 mg ...........................................................................................8.67 17.33 Tab 100 mg .......................................................................................34.65 69.30 17.33 34.65 Tab 200 mg .......................................................................................34.65 69.30 Suspension 50 mg per ml .................................................................17.33

50 100 50 100 50 100 50 100 50 100 50 100 100 ml

Clozaril Clozaril Clopine Clopine Clopine Clopine Clozaril Clozaril Clopine Clopine Clopine Clopine Clopine Serenace Serenace Serenace Serenace Serenace Nozinan Nozinan Nozinan Lithicarb FC Lithicarb FC Priadel Douglas Dr Reddy’s

Olanzapine

HALOPERIDOL – Safety medicine; prescriber may determine dispensing frequency Tab 500 µg – Up to 30 tab available on a PSO ..................................5.42 100 Tab 1.5 mg – Up to 30 tab available on a PSO...................................8.20 100 Tab 5 mg – Up to 30 tab available on a PSO....................................25.84 100 Oral liq 2 mg per ml – Up to 200 ml available on a PSO ..................19.87 100 ml Inj 5 mg per ml, 1 ml – Up to 5 inj available on a PSO .....................18.74 10 LEVOMEPROMAZINE – Safety medicine; prescriber may determine dispensing frequency Tab 25 mg .........................................................................................16.93 100 Tab 100 mg .......................................................................................43.96 100 Inj 25 mg per ml, 1 ml .......................................................................73.68 10 LITHIUM CARBONATE – Safety medicine; prescriber may determine dispensing frequency Tab 250 mg .......................................................................................34.30 500 Tab 400 mg .......................................................................................12.83 100 Tab long-acting 400 mg ....................................................................19.20 100 Cap 250 mg ........................................................................................9.42 100 OLANZAPINE – Safety medicine; prescriber may determine dispensing frequency Tab 2.5 mg ..........................................................................................2.00 28

Olanzine

(51.07) Tab 5 mg .............................................................................................3.85 Zyprexa 28

Dr Reddy’s

Olanzapine

Olanzine

(101.21) Tab 10 mg ...........................................................................................6.35 Zyprexa 28

Dr Reddy’s

Olanzapine

Olanzine

(204.49) Zyprexa

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

133

NERVOUS SYSTEM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

PERICYAZINE – Safety medicine; prescriber may determine dispensing frequency Tab 2.5 mg ........................................................................................12.49 Tab 10 mg .........................................................................................44.45 QUETIAPINE – Safety medicine; prescriber may determine dispensing frequency Tab 25 mg ...........................................................................................7.00

100 100 60

Neulactil Neulactil Dr Reddy’s

Quetiapine

10.50 Tab 100 mg .......................................................................................14.00

90 60

Seroquel Quetapel Dr Reddy’s

Quetiapine

21.00 Tab 200 mg .......................................................................................24.00

90 60

Seroquel Quetapel Dr Reddy’s

Quetiapine

36.00 Tab 300 mg .......................................................................................40.00

90 60

Seroquel Quetapel Dr Reddy’s

Quetiapine

60.00 RISPERIDONE – Safety medicine; prescriber may determine dispensing frequency Tab 0.5 mg ..........................................................................................3.51

90 60

Seroquel Quetapel Apo-Risperidone Dr Reddy’s

Risperidone

Ridal

1.17 (2.86) Tab 1 mg .............................................................................................6.00 20 Risperdal 60

Apo-Risperidone Dr Reddy’s

Risperidone

Ridal

(16.92) Tab 2 mg ...........................................................................................11.00 Risperdal 60

Apo-Risperidone Dr Reddy’s

Risperidone

Ridal

(33.84) Tab 3 mg ...........................................................................................15.00 Risperdal 60

Apo-Risperidone Dr Reddy’s

Risperidone

Ridal

(50.78) Tab 4 mg ...........................................................................................20.00 Risperdal 60

Apo-Risperidone Dr Reddy’s

Risperidone

Ridal

(67.68) Oral liq 1 mg per ml ..........................................................................18.35 (25.26)

fully subsidised [HP4] refer page 9

Risperdal 30 ml

Apo-Risperidone Risperon

Risperdal

134

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

NERVOUS SYSTEM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

TRIFLUOPERAZINE HYDROCHLORIDE – Safety medicine; prescriber may determine dispensing frequency Tab 1 mg .............................................................................................9.83 100 Stelazine Tab 2 mg ...........................................................................................14.64 100 Stelazine Tab 5 mg ...........................................................................................16.66 100 Stelazine ZIPRASIDONE – Subsidy by endorsement a) Safety medicine; prescriber may determine dispensing frequency b) Ziprasidone is subsidised for patients suffering from schizophrenia or related psychoses after a trial of an effective dose of risperidone or quetiapine that has been discontinued, or is in the process of being discontinued, because of unacceptable side effects or inadequate response, and the prescription is endorsed accordingly. Cap 20 mg ........................................................................................87.88 60 Zeldox Cap 40 mg ......................................................................................164.78 60 Zeldox Cap 60 mg ......................................................................................247.17 60 Zeldox Cap 80 mg ......................................................................................329.56 60 Zeldox ZUCLOPENTHIXOL HYDROCHLORIDE – Safety medicine; prescriber may determine dispensing frequency Tab 10 mg .........................................................................................31.45 100 Clopixol

Depot Injections

FLUPENTHIXOL DECANOATE – Safety medicine; prescriber may determine dispensing frequency Inj 20 mg per ml, 1 ml – Up to 5 inj available on a PSO ...................13.14 5 Fluanxol Inj 20 mg per ml, 2 ml – Up to 5 inj available on a PSO ...................20.90 5 Fluanxol Inj 100 mg per ml, 1 ml – Up to 5 inj available on a PSO .................40.87 5 Fluanxol FLUPHENAZINE DECANOATE – Safety medicine; prescriber may determine dispensing frequency Inj 12.5 mg per 0.5 ml, 0.5 ml – Up to 5 inj available on a PSO .........17.60 5 Modecate Inj 25 mg per ml, 1 ml – Up to 5 inj available on a PSO ...................27.90 5 Modecate Inj 100 mg per ml, 1 ml – Up to 5 inj available on a PSO ...............154.50 5 Modecate HALOPERIDOL DECANOATE – Safety medicine; prescriber may determine dispensing frequency Inj 50 mg per ml, 1 ml – Up to 5 inj available on a PSO ...................28.39 5 Haldol Inj 100 mg per ml, 1 ml – Up to 5 inj available on a PSO .................55.90 5 Haldol Concentrate OLANZAPINE PAMOATE MONOHYDRATE – Special Authority see SA1146 below – Retail pharmacy Safety medicine; prescriber may determine dispensing frequency Inj 210 mg .......................................................................................280.00 1 Zyprexa Relprevv Inj 300 mg .......................................................................................460.00 1 Zyprexa Relprevv Inj 405 mg .......................................................................................560.00 1 Zyprexa Relprevv ¾SA1146 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 The patient has schizophrenia; and 2 The patient has tried but failed to comply with treatment using oral atypical antipsychotic agents; and 3 The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months. Renewal from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria: Either: 1 Both: 1.1 The patient has had less than 12 months’ treatment with olanzapine depot injection; and 1.2 There is no clinical reason to discontinue treatment; or 2 The initiation of olanzapine depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of olanzapine depot injection. Note: The patient should be monitored for post-injection syndrome for at least two hours after each injection.

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

135

NERVOUS SYSTEM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

PIPOTHIAZINE PALMITATE – Safety medicine; prescriber may determine dispensing frequency Inj 50 mg per ml, 1 ml – Up to 5 inj available on a PSO .................178.48 10 Piportil Inj 50 mg per ml, 2 ml – Up to 5 inj available on a PSO .................353.32 10 Piportil RISPERIDONE – Special Authority see SA0926 below – Retail pharmacy Safety medicine; prescriber may determine dispensing frequency Inj 25 mg per 2 ml ...........................................................................175.00 Inj 37.5 mg per 2 ml ........................................................................230.00 Inj 50 mg per 2 ml ...........................................................................280.00

1 1 1

Risperdal Consta Risperdal Consta Risperdal Consta

¾SA0926 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 The patient has schizophrenia or other psychotic disorder; and 2 Has tried but failed to comply with treatment using oral atypical antipsychotic agents; and 3 Has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in last 12 months. Renewal from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria: Either: 1 Both: 1.1 The patient has had less than 12 months treatment with risperidone depot injection; and 1.2 There is no clinical reason to discontinue treatment; or 2 The initiation of risperidone depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of risperidone depot injection. Note: Risperidone depot injection should ideally be used as monotherapy (i.e. without concurrent use of any other antipsychotic medication). In some cases, it may be clinically appropriate to attempt to treat a patient with typical antipsychotic agents in depot injectable form before trialing risperidone depot injection. ZUCLOPENTHIXOL DECANOATE – Safety medicine; prescriber may determine dispensing frequency Inj 200 mg per ml, 1 ml – Up to 5 inj available on a PSO .................19.80 5 Clopixol

Orodispersible Antipsychotics

OLANZAPINE – Safety medicine; prescriber may determine dispensing frequency Orodispersible tab 5 mg .....................................................................6.36 28

Dr Reddy’s

Olanzapine

Orodispersible tab 10 mg ...................................................................8.76

Olanzine-D Dr Reddy’s

Olanzapine

Olanzine-D

Wafer 5 mg .........................................................................................6.36 (102.19) Wafer 10 mg .......................................................................................8.76 (204.37) 28 Zyprexa Zydis 28 Zyprexa Zydis

RISPERIDONE – Special Authority see SA0927 on the next page – Retail pharmacy Safety medicine; prescriber may determine dispensing frequency Orally-disintegrating tablets 0.5 mg ..................................................21.42 28 Orally-disintegrating tablets 1 mg .....................................................42.84 28 28 Orally-disintegrating tablets 2 mg .....................................................85.71

Risperdal Quicklet Risperdal Quicklet Risperdal Quicklet

136

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

NERVOUS SYSTEM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

¾SA0927 Special Authority for Subsidy Initial application — (Acute situations) from any relevant practitioner. Approvals valid for 6 weeks for applications meeting the following criteria: Both: 1 For a non-adherent patient on oral therapy with standard risperidone tablets or risperidone oral liquid; and 2 The patient is under direct supervision for administration of medicine. Initial application — (Chronic situations) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The patient is unable to take standard risperidone tablets or oral liquid, or once stabilized refuses to take risperidone tablets or oral liquid; and 2 The patient is under direct supervision for administration of medicine. Renewal from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The patient is unable to take standard risperidone tablets or oral liquid, or once stabilized refuses to take risperidone tablets or oral liquid; and 2 The patient is under direct supervision for administration of medicine. Note: Risperdal Quicklets cost signiﬁcantly more than risperidone tablets and should only be used where necessary.

Anxiolytics

ALPRAZOLAM – Safety medicine; prescriber may determine dispensing frequency Tab 250 µg .........................................................................................3.15 50 ‡ Safety cap for extemporaneously compounded oral liquid preparations. Tab 500 µg .........................................................................................4.10 50 ‡ Safety cap for extemporaneously compounded oral liquid preparations. Tab 1 mg .............................................................................................7.25 50 ‡ Safety cap for extemporaneously compounded oral liquid preparations. BUSPIRONE HYDROCHLORIDE – Special Authority see SA0863 below – Retail pharmacy Tab 5 mg ...........................................................................................28.00 100 Tab 10 mg .........................................................................................17.00 100

Arrow-Alprazolam Arrow-Alprazolam Arrow-Alprazolam

Paciﬁc Buspirone Paciﬁc Buspirone

¾SA0863 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 For use only as an anxiolytic; and 2 Other agents are contraindicated or have failed. Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is beneﬁting from treatment. DIAZEPAM – Safety medicine; prescriber may determine dispensing frequency Tab 2 mg ...........................................................................................11.44 500 Arrow-Diazepam ‡ Safety cap for extemporaneously compounded oral liquid preparations. Tab 5 mg ...........................................................................................13.71 500 Arrow-Diazepam ‡ Safety cap for extemporaneously compounded oral liquid preparations. LORAZEPAM – Safety medicine; prescriber may determine dispensing frequency Tab 1 mg ...........................................................................................16.42 250 Ativan ‡ Safety cap for extemporaneously compounded oral liquid preparations. Tab 2.5 mg ........................................................................................11.17 100 Ativan ‡ Safety cap for extemporaneously compounded oral liquid preparations.

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

137

NERVOUS SYSTEM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

OXAZEPAM – Safety medicine; prescriber may determine dispensing frequency Tab 10 mg ...........................................................................................5.89 ‡ Safety cap for extemporaneously compounded oral liquid preparations. Tab 15 mg ...........................................................................................8.13 ‡ Safety cap for extemporaneously compounded oral liquid preparations.

100 100

Ox-Pam Ox-Pam

Multiple Sclerosis Treatments

¾SA1062 Special Authority for Subsidy Special Authority approved by the Multiple Sclerosis Treatment Committee Notes: Budget managed by appointed clinicians on the Multiple Sclerosis Treatment Assessments Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (below). Application details may be obtained from PHARMAC’s website http://www.pharmac.govt.nz or: The coordinator Phone: 04 460 4990 Multiple Sclerosis Treatment Assessment Committee Facsimile: 04 916 7571 PHARMAC PO Box 10 254 Email: mstaccoordinator@pharmac.govt.nz Wellington Completed application forms must be sent to the coordinator for MSTAC and will be considered by MSTAC at the next practicable opportunity. Notiﬁcation of MSTAC’s decision will be sent to the patient, the applying clinician and the patient’s GP (if speciﬁed). These agents will NOT be subsidised if dispensed from a community or hospital pharmacy. Regular supplies will be distributed to all approved patients or their clinicians by courier. Prescribers must send quarterly prescriptions for approved patients to the MSTAC coordinator. Only prescriptions for 6 million iu of interferon beta-1-alpha per week, or 8 million iu of interferon beta-1-beta every other day, or 20 mg glatiramer acetate daily will be subsidised. Appeals against MSTAC’s decision and/or the processing of any application may be lodged with the MSTAC coordinator. Concerns that cannot be or have not been adequately addressed by MSTAC will be forwarded to a separate Appeal Committee if necessary. Switching between treatments is permitted within the 12 month approval period without reapproval by MSTAC. The MSTAC coordinator should be notiﬁed of the change and a new prescription provided. Entry Criteria 1) Diagnosis of multiple sclerosis (MS) must be conﬁrmed by a neurologist. Diagnosis should as a rule include MRI conﬁrmation. For patients diagnosed before MRI was widely utilised in New Zealand, conﬁrmation of diagnosis via clinical assessment and laboratory/ancillary data must be provided; and 2) patients must have active relapsing MS (conﬁrmed by MR scan where necessary) with or without underlying progression; and 3) patients must have either: a) EDSS score 2.5 - 5.5 with 2+ relapses: G experienced at least 2 signiﬁcant relapses of MS in the previous 12 months, and G an EDSS score of between 2.5 and 5.5 inclusive; or b) EDSS score 2.0 with 3+ relapses: G experienced at least 3 signiﬁcant relapses of MS in the previous 12 months, and G an EDSS score of 2.0; and 4) Each relapse must: a) be conﬁrmed by a neurologist or general physician (the patient may not necessarily have been seen during the relapse but the neurologist/physician must be satisﬁed that the clinical features were characteristic and met the speciﬁed criteria); b) be associated with characteristic new symptom(s)/sign(s) or substantial worsening of previously experienced symptom(s)/sign(s); continued. . .

138

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

NERVOUS SYSTEM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

continued. . . c) last at least one week; d) follow a period of stability of at least one month; e) be severe enough to change either the EDSS or at least one of the Kurtzke functional systems scores by at least 1 point; f) be distinguishable from the effects of general fatigue; and g) not be associated with a fever (T>37.5◦ C); and 5) applications must be made at least four weeks after the date of the onset of the last known relapse; and 6) patients must have no previous history of lack of response to beta-interferon or glatiramer acetate (see criteria for stopping). 7) applications must be submitted to the Multiple Sclerosis Treatment Assessment Committee (MSTAC) by the patient’s neurologist or a general physician; and 8) patients must agree (via informed consent) to co-operate if as a result of their meeting the stopping criteria, funding is withdrawn. Patients must agree to the collection of clinical data relating to their MS and use of those data by PHARMAC; and 9) patients must agree to allow clinical data to be collected and reviewed by MSTAC annually for each year in which they receive funding for beta-interferon or glatiramer acetate. Stopping Criteria 1) Conﬁrmed progression of disability that is sustained for six months during a minimum of one year of treatment. Progression of disability is deﬁned as any of: a) an increase of 2 EDSS points where starting EDSS was 2.0; or b) an increase of 1.5 EDSS points where starting EDSS was 2.5 or 3.0; or c) an increase of 1 EDSS point where starting EDSS 3.5 or greater; or d) an increase in EDSS score to 6.0 or more; or 2) stable or increasing relapse rate over 12 months of treatment (compared with the relapse rate on starting treatment)(see note); or 3) pregnancy and/or lactation; or 4) within the 12 month approval year, intolerance to interferon beta-1-alpha, and/or interferon beta-1-beta and/or glatiramer acetate; or 5) non-compliance with treatment, including refusal to undergo annual assessment or refusal to allow the results of the assessment to be submitted to MSTAC; or 6) patients may, subject to conclusions drawn from published evidence available at the time, be excluded if they develop a high titre of neutralising anti-bodies to beta-interferon or glatiramer acetate. Note: Patients who have a stable or increasing relapse rate over 12 months of treatment (compared with the relapse rate on starting treatment) and who do not meet any of the other Stopping Criteria at annual review may switch to a different class of funded treatment (i.e. patients may switch from either of the beta-interferons [interferon beta-1-beta or interferon beta-1-alpha] to glatiramer acetate or vice versa). Patients may switch classes of treatment for this reason only once, after which they will be required to stop funded treatment if they meet any of the Stopping Criteria at annual review (including the criterion relating to stable or increasing relapse rate over 12 months of treatment). GLATIRAMER ACETATE – Special Authority see SA1062 on the preceding page Inj 20 mg preﬁlled syringe ...........................................................1,089.25 28 Copaxone INTERFERON BETA-1-ALPHA – Special Authority see SA1062 on the preceding page Inj 6 million iu preﬁlled syringe ....................................................1,425.10 4 Inj 6 million iu per vial ..................................................................1,425.10 4 INTERFERON BETA-1-BETA – Special Authority see SA1062 on the preceding page 15 Inj 8 million iu per 1 ml .................................................................1,322.89

Avonex Avonex Betaferon

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

139

NERVOUS SYSTEM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

Sedatives and Hypnotics

LORMETAZEPAM – Safety medicine; prescriber may determine dispensing frequency Tab 1 mg .............................................................................................3.11 30 (23.50) ‡ Safety cap for extemporaneously compounded oral liquid preparations. MIDAZOLAM – Safety medicine; prescriber may determine dispensing frequency Inj 1 mg per ml, 5 ml .........................................................................10.75 10 (14.73) Inj 5 mg per ml, 3 ml .........................................................................11.90 5 (19.64) NITRAZEPAM – Safety medicine; prescriber may determine dispensing frequency Tab 5 mg .............................................................................................2.00 (4.98) ‡ Safety cap for extemporaneously compounded oral liquid preparations. TEMAZEPAM – Safety medicine; prescriber may determine dispensing frequency Tab 10 mg ...........................................................................................1.27 ‡ Safety cap for extemporaneously compounded oral liquid preparations. TRIAZOLAM – Safety medicine; prescriber may determine dispensing frequency Tab 125 µg .........................................................................................5.10 (7.25) ‡ Safety cap for extemporaneously compounded oral liquid preparations. Tab 250 µg .........................................................................................4.10 (8.70) ‡ Safety cap for extemporaneously compounded oral liquid preparations. ZOPICLONE Tab 7.5 mg ........................................................................................11.90 100 Nitrados

Noctamid

Hypnovel

Pﬁzer

Hypnovel

Pﬁzer

Normison

100 Hypam 100 Hypam

500

Apo-Zopiclone

Stimulants/ADHD Treatments Stimulants/ADHD treatments

ATOMOXETINE – Special Authority see SA0951 below – Retail pharmacy Cap 10 mg ......................................................................................107.03 Cap 18 mg ......................................................................................107.03 Cap 25 mg ......................................................................................107.03 Cap 40 mg ......................................................................................107.03 Cap 60 mg ......................................................................................107.03 Cap 80 mg ......................................................................................139.11 Cap 100 mg ....................................................................................139.11 28 28 28 28 28 28 28

Strattera Strattera Strattera Strattera Strattera Strattera Strattera

¾SA0951 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 Patient has ADHD (Attention Deﬁcit and Hyperactivity Disorder) diagnosed according to DSM-IV or ICD 10 criteria; and 2 Once-daily dosing; and 3 Any of the following: 3.1 Treatment with a subsidised formulation of a stimulant has resulted in the development or worsening of serious adverse reactions or where the combination of subsidised stimulant treatment with another agent would pose an unacceptable medical risk; or continued. . .

140

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

NERVOUS SYSTEM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

continued. . . 3.2 Treatment with a subsidised formulation of a stimulant has resulted in worsening of co-morbid substance abuse or there is a signiﬁcant risk of diversion with subsidised stimulant therapy; or 3.3 An effective dose of a subsidised formulation of a stimulant has been trialled and has been discontinued because of inadequate clinical response; and 4 The patient will not be receiving treatment with atomoxetine in combination with a subsidised formulation of a stimulant, except for the purposes of transitioning from subsidised stimulant therapy to atomoxetine. Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is beneﬁting from treatment. Note: A "subsidised formulation of a stimulant" refers to currently subsidised methylphenidate hydrochloride tablet formulations (immediate-release, sustained-release and extended-release) or dexamphetamine sulphate tablets. DEXAMPHETAMINE SULPHATE – Special Authority see SA1149 below – Retail pharmacy a) Only on a controlled drug form b) Safety medicine; prescriber may determine dispensing frequency Tab 5 mg ...........................................................................................16.50 100 PSM ¾SA1149 Special Authority for Subsidy Initial application — (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria: All of the following: 1 ADHD (Attention Deﬁcit and Hyperactivity Disorder) patients aged 5 years or over; and 2 Diagnosed according to DSM-IV or ICD 10 criteria; and 3 Either: 3.1 Applicant is a paediatrician or psychiatrist; or 3.2 Applicant is a medical practitioner and conﬁrms that a relevant specialist has been consulted within the last 2 years and has recommended treatment for the patient. Initial application — (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 ADHD (Attention Deﬁcit and Hyperactivity Disorder) patients under 5 years of age; and 2 Diagnosed according to DSM-IV or ICD 10 criteria. Initial application — (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the patient suffers from narcolepsy. Renewal — (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is beneﬁting from treatment; and 2 Either: 2.1 Applicant is a paediatrician or psychiatrist; or 2.2 Applicant is a medical practitioner and conﬁrms that a relevant specialist has been consulted within the last 2 years and has recommended treatment for the patient. Renewal — (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months where the treatment remains appropriate and the patient is beneﬁting from treatment. Renewal — (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the treatment remains appropriate and the patient is beneﬁting from treatment.

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

141

NERVOUS SYSTEM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

METHYLPHENIDATE HYDROCHLORIDE – Special Authority see SA1150 below – Retail pharmacy a) Only on a controlled drug form b) Safety medicine; prescriber may determine dispensing frequency Tab immediate-release 5 mg ..............................................................3.20 30 Rubifen Tab immediate-release 10 mg ............................................................3.00 30 Ritalin Rubifen Tab immediate-release 20 mg ............................................................7.85 30 Rubifen Tab sustained-release 20 mg ...........................................................10.95 30 Rubifen SR 50.00 100 Ritalin SR ¾SA1150 Special Authority for Subsidy Initial application — (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria: All of the following: 1 ADHD (Attention Deﬁcit and Hyperactivity Disorder) patients aged 5 years or over; and 2 Diagnosed according to DSM-IV or ICD 10 criteria; and 3 Either: 3.1 Applicant is a paediatrician or psychiatrist; or 3.2 Applicant is a medical practitioner and conﬁrms that a relevant specialist has been consulted within the last 2 years and has recommended treatment for the patient. Initial application — (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 ADHD (Attention Deﬁcit and Hyperactivity Disorder) patients under 5 years of age; and 2 Diagnosed according to DSM-IV or ICD 10 criteria. Initial application — (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the patient suffers from narcolepsy. Renewal — (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is beneﬁting from treatment; and 2 Either: 2.1 Applicant is a paediatrician or psychiatrist; or 2.2 Applicant is a medical practitioner and conﬁrms that a relevant specialist has been consulted within the last 2 years and has recommended treatment for the patient. Renewal — (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months where the treatment remains appropriate and the patient is beneﬁting from treatment. Renewal — (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the treatment remains appropriate and the patient is beneﬁting from treatment. METHYLPHENIDATE HYDROCHLORIDE EXTENDED-RELEASE – Special Authority see SA1151 on the next page – Retail pharmacy a) Only on a controlled drug form b) Safety medicine; prescriber may determine dispensing frequency Tab extended-release 18 mg ............................................................58.96 30 Concerta Tab extended-release 27 mg ............................................................65.44 30 Concerta Tab extended-release 36 mg ............................................................71.93 30 Concerta Tab extended-release 54 mg ............................................................86.24 30 Concerta Cap modiﬁed-release 10 mg ............................................................19.50 30 Ritalin LA Cap modiﬁed-release 20 mg ............................................................25.50 30 Ritalin LA Cap modiﬁed-release 30 mg ............................................................31.90 30 Ritalin LA Cap modiﬁed-release 40 mg ............................................................38.25 30 Ritalin LA

142

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

NERVOUS SYSTEM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

¾SA1151 Special Authority for Subsidy Initial application only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria: All of the following: 1 ADHD (Attention Deﬁcit and Hyperactivity Disorder); and 2 Diagnosed according to DSM-IV or ICD 10 criteria; and 3 Either: 3.1 Applicant is a paediatrician or psychiatrist; or 3.2 Applicant is a medical practitioner and conﬁrms that a relevant specialist has been consulted within the last 2 years and has recommended treatment for the patient; and 4 Either: 4.1 Patient is taking a currently subsidised formulation of methylphenidate hydrochloride (immediate-release or sustainedrelease) which has not been effective due to signiﬁcant administration and/or compliance difﬁculties; or 4.2 There is signiﬁcant concern regarding the risk of diversion or abuse of immediate-release methylphenidate hydrochloride. Renewal only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is beneﬁting from treatment; and 2 Either: 2.1 Applicant is a paediatrician or psychiatrist; or 2.2 Applicant is a medical practitioner and conﬁrms that a relevant specialist has been consulted within the last 2 years and has recommended treatment for the patient. MODAFINIL – Special Authority see SA1126 below – Retail pharmacy Tab 100 mg .......................................................................................72.50 30 Modavigil ¾SA1126 Special Authority for Subsidy Initial application only from a neurologist or respiratory specialist. Approvals valid for 24 months for applications meeting the following criteria: All of the following: 1 The patient has a diagnosis of narcolepsy and has excessive daytime sleepiness associated with narcolepsy occurring almost daily for three months or more; and 2 Either: 2.1 The patient has a multiple sleep latency test with a mean sleep latency of less than or equal to 10 minutes and 2 or more sleep onset rapid eye movement periods; or 2.2 The patient has at least one of: cataplexy, sleep paralysis or hypnagogic hallucinations; and 3 Either: 3.1 An effective dose of a subsidised formulation of methylphenidate or dexamphetamine has been trialled and discontinued because of intolerable side effects; or 3.2 Methylphenidate and dexamphetamine are contraindicated. Renewal only from a neurologist or respiratory specialist. Approvals valid for 24 months where the treatment remains appropriate and the patient is beneﬁting from treatment.

Treatments for Dementia

DONEPEZIL HYDROCHLORIDE F Tab 5 mg .............................................................................................7.71 F Tab 10 mg .........................................................................................14.06 90 90

Donepezil-Rex Donepezil-Rex

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

143

NERVOUS SYSTEM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

Treatments for Opioid Overdose

NALOXONE HYDROCHLORIDE a) Up to 5 inj available on a PSO b) Only on a PSO F Inj 400 µg per ml, 1 ml ......................................................................33.00

Mayne

Treatments for Substance Dependence

BUPRENORPHRINE WITH NALOXONE – Special Authority see SA1203 below – Retail pharmacy a) No patient co-payment payable b) Safety medicine; prescriber may determine dispensing frequency Tab sublingual 2 mg with naloxone 0.5 mg .......................................57.40 28 Suboxone Tab sublingual 8 mg with naloxone 2 mg ........................................166.00 28 Suboxone ¾SA1203 Special Authority for Subsidy Initial application — (Detoxiﬁcation) from any medical practitioner. Approvals valid for 1 month for applications meeting the following criteria: All of the following: 1 Patient is opioid dependent; and 2 Patient is currently engaged with an opioid treatment service approved by the Ministry of Health; and 3 Applicant works in an opioid treatment service approved by the Ministry of Health.. Initial application — (Maintenance treatment) from any medical practitioner. Approvals valid for 12 months for applications meeting the following criteria: All of the following: 1 Patient is opioid dependent; and 2 Patient will not be receiving methadone; and 3 Patient is currently enrolled in an opioid substitution treatment program in a service approved by the Ministry of Health; and 4 Applicant works in an opioid treatment service approved by the Ministry of Health. Renewal — (Detoxiﬁcation) from any medical practitioner. Approvals valid for 1 month for applications meeting the following criteria: All of the following: 1 Patient is opioid dependent; and 2 Patient has previously trialled but failed detoxiﬁcation with buprenorphine with naloxone with relapse back to opioid use and another attempt is planned; and 3 Patient is currently engaged with an opioid treatment service approved by the Ministry of Health; and 4 Applicant works in an opioid treatment service approved by the Ministry of Health. Renewal — (Maintenance treatment) from any medical practitioner. Approvals valid for 12 months for applications meeting the following criteria: All of the following: 1 Patient is or has been receiving maintenance therapy with buprenorphine with naloxone (and is not receiving methadone); and 2 Patient is currently enrolled in an opioid substitution program in a service approved by the Ministry of Health; and 3 Applicant works in an opioid treatment service approved by the Ministry of Health or is a medical practitioner authorised by the service to manage treatment in this patient. Renewal — (Maintenance treatment where the patient has previously had an initial application for detoxiﬁcation) from any medical practitioner. Approvals valid for 12 months for applications meeting the following criteria: All of the following: 1 Patient received but failed detoxiﬁcation with buprenorphine with naloxone; and 2 Maintenance therapy with buprenorphine with naloxone is planned (and patient will not be receiving methadone); and 3 Patient is currently enrolled in an opioid substitution program in a service approved by the Ministry of Health; and 4 Applicant works in an opioid treatment service approved by the Ministry of Health.

144

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

NERVOUS SYSTEM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

BUPROPION HYDROCHLORIDE Tab modiﬁed-release 150 mg ...........................................................65.00 DISULFIRAM Tab 200 mg .......................................................................................24.30

30 100

Zyban Antabuse Naltraccord

NALTREXONE HYDROCHLORIDE – Special Authority see SA0909 below – Retail pharmacy Tab 50 mg .......................................................................................123.00 30

¾SA0909 Special Authority for Subsidy Initial application from any medical practitioner. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Patient is currently enrolled in a recognised comprehensive treatment programme for alcohol dependence; and 2 Applicant works in or with a community Alcohol and Drug Service contracted to one of the District Health Boards or accredited against the New Zealand Alcohol and Other Drug Sector Standard or the National Mental Health Sector Standard. Renewal from any medical practitioner. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Compliance with the medication (prescriber determined); and 2 Any of the following: 2.1 Patient is still unstable and requires further treatment; or 2.2 Patient achieved signiﬁcant improvement but requires further treatment; or 2.3 Patient is well controlled but requires maintenance therapy. The patient must not have had more than 1 prior approval in the last 12 months. NICOTINE Nicotine will not be funded under the Dispensing Frequency Rule in amounts less than 4 weeks of treatment. Patch 7 mg – Up to 28 patch available on a PSO ............................18.13 28 Habitrol Patch 14 mg – Up to 28 patch available on a PSO ..........................18.81 28 Habitrol Patch 21 mg – Up to 28 patch available on a PSO ..........................19.14 28 Habitrol Lozenge 1 mg – Up to 216 loz available on a PSO..........................19.94 216 Habitrol Lozenge 2 mg – Up to 216 loz available on a PSO..........................24.27 216 Habitrol Gum 2 mg (Classic) – Up to 384 piece available on a PSO.............36.47 384 Habitrol Gum 2 mg (Fruit) – Up to 384 piece available on a PSO .................36.47 384 Habitrol Gum 2 mg (Mint) – Up to 384 piece available on a PSO..................36.47 384 Habitrol Gum 4 mg (Classic) – Up to 384 piece available on a PSO.............42.04 384 Habitrol Gum 4 mg (Fruit) – Up to 384 piece available on a PSO .................42.04 384 Habitrol Gum 4 mg (Mint) – Up to 384 piece available on a PSO..................42.04 384 Habitrol VARENICLINE TARTRATE – Special Authority see SA1161 below – Retail pharmacy a) Varenicline will not be funded under the Dispensing Frequency Rule in amounts less than 2 weeks of treatment. b) A maximum of 3 months’ varenicline will be subsidised on each Special Authority approval. Tab 1 mg ...........................................................................................67.74 28 Champix 135.48 56 Champix Tab 0.5 mg × 11 and 1 mg × 14 ......................................................60.48 25 OP Champix ¾SA1161 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid for 5 months for applications meeting the following criteria: All of the following: 1 Short-term therapy as an aid to achieving abstinence in a patient who has indicated that they are ready to cease smoking; and 2 The patient is part of, or is about to enrol in, a comprehensive support and counselling smoking cessation programme, which includes prescriber or nurse monitoring; and 3 Either: continued. . .

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

145

NERVOUS SYSTEM

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

continued. . . 3.1 The patient has tried but failed to quit smoking after at least two separate trials of nicotine replacement therapy, at least one of which included the patient receiving comprehensive advice on the optimal use of nicotine replacement therapy; or 3.2 The patient has tried but failed to quit smoking using bupropion or nortriptyline; and 4 The patient has not used funded varenicline in the last 12 months; and 5 Varenicline is not to be used in combination with other pharmacological smoking cessation treatments and the patient has agreed to this; and 6 The patient is not pregnant; and 7 The patient will not be prescribed more than 3 months’ funded varenicline (see note). Renewal from any relevant practitioner. Approvals valid for 5 months for applications meeting the following criteria: All of the following: 1 Short-term therapy as an aid to achieving abstinence in a patient who has indicated that they are ready to cease smoking; and 2 The patient is part of, or is about to enrol in, a comprehensive support and counselling smoking cessation programme, which includes prescriber or nurse monitoring; and 3 The patient has not used funded varenicline in the last 12 months; and 4 Varenicline is not to be used in combination with other pharmacological smoking cessation treatments and the patient has agreed to this; and 5 The patient is not pregnant; and 6 The patient will not be prescribed more than 3 months’ funded varenicline (see note). The patient must not have had an approval in the past 12 months. Note: a maximum of 3 months’ varenicline will be subsidised on each Special Authority approval.

146

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

Chemotherapeutic Agents Alkylating Agents

BUSULPHAN – PCT – Retail pharmacy-Specialist Tab 2 mg ...........................................................................................59.50 CARBOPLATIN – PCT only – Specialist Inj 10 mg per ml, 5 ml .......................................................................20.00 Inj 10 mg per ml, 15 ml .....................................................................22.50 Inj 10 mg per ml, 45 ml .....................................................................50.00 Inj 10 mg per ml, 100 ml .................................................................105.00 Inj 1 mg for ECP .................................................................................0.15 CARMUSTINE – PCT only – Specialist Inj 100 mg .......................................................................................204.13 Inj 100 mg for ECP .........................................................................204.13 CHLORAMBUCIL – PCT – Retail pharmacy-Specialist Tab 2 mg ...........................................................................................22.35 CISPLATIN – PCT only – Specialist Inj 1 mg per ml, 50 ml .......................................................................15.00 19.00 Inj 1 mg per ml, 100 ml .....................................................................21.00 38.00 Inj 1 mg for ECP .................................................................................0.27 CYCLOPHOSPHAMIDE Tab 50 mg – PCT – Retail pharmacy-Specialist..............................25.71 Inj 1 g – PCT – Retail pharmacy-Specialist.....................................26.70 127.80 Inj 2 g – PCT only – Specialist.........................................................56.90 Inj 1 mg for ECP – PCT only – Specialist ..........................................0.03 IFOSFAMIDE – PCT only – Specialist Inj 1 g ................................................................................................96.00 Inj 2 g ..............................................................................................180.00 Inj 1 mg for ECP .................................................................................0.10 LOMUSTINE – PCT only – Specialist Cap 10 mg ......................................................................................132.59 Cap 40 mg ......................................................................................399.15 MELPHALAN Tab 2 mg – PCT – Retail pharmacy-Specialist................................31.31 Inj 50 mg – PCT only – Specialist....................................................52.15 100 1 1 1 1 1 mg 1 100 mg OP 25 1 1 1 mg 50 1 6 1 1 mg 1 1 1 mg 20 20 25 1

Myleran Carboplatin Ebewe Carboplatin Ebewe Carboplatin Ebewe DBL Carboplatin Carboplatin Ebewe Baxter BiCNU Baxter Leukeran FC Cisplatin Ebewe Mayne Cisplatin Ebewe Mayne Baxter Cycloblastin Endoxan Cytoxan Endoxan Baxter Holoxan Holoxan Baxter CeeNU CeeNU Alkeran Alkeran

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

147

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

OXALIPLATIN – PCT only – Specialist – Special Authority see SA0900 below Inj 50 mg ...........................................................................................15.32 55.00 200.00 Inj 100 mg .........................................................................................25.01 110.00 400.00 Inj 1 mg for ECP .................................................................................0.28

Oxaliplatin Actavis

Oxaliplatin Ebewe Eloxatin Oxaliplatin Actavis

100

1 mg

Oxaliplatin Ebewe Eloxatin Baxter

¾SA0900 Special Authority for Subsidy Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Either: 1 Both: 1.1 The patient has metastatic colorectal cancer; and 1.2 To be used for ﬁrst or second line use as part of a combination chemotherapy regimen; or 2 Both: 2.1 The patient has stage III (Duke’s C) colorectal* cancer; and 2.2 Adjuvant oxaliplatin to be given in combination with a ﬂuoropyrimidine (ﬂuorouracil or capecitabine). Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Either: 1 The patient requires continued therapy; or 2 The tumour has relapsed and requires re-treatment. Note: Indications marked with * are Unapproved Indications, oxaliplatin is indicated for adjuvant treatment of stage III (Duke’s C) colon cancer after complete resection of the primary tumour. THIOTEPA – PCT only – Specialist Inj 15 mg ...........................................................................................CBS 1 Bedford S29 THIO-TEPA S29

Antimetabolites

CALCIUM FOLINATE Tab 15 mg – PCT – Retail pharmacy-Specialist..............................82.45 Inj 3 mg per ml, 1 ml – PCT – Retail pharmacy-Specialist ..............17.10 Inj 50 mg – PCT – Retail pharmacy-Specialist................................24.50 Inj 100 mg – PCT only – Specialist....................................................9.75 Inj 300 mg – PCT only – Specialist..................................................30.00 Inj 1 g – PCT only – Specialist.........................................................90.00 Inj 1 mg for ECP – PCT only – Specialist ..........................................0.10 10 5 5 1 1 1 1 mg

DBL Leucovorin

Calcium

Mayne Calcium Folinate

Ebewe

Calcium Folinate

Ebewe

Calcium Folinate

Ebewe

Calcium Folinate

Ebewe

Baxter

CAPECITABINE – Retail pharmacy-Specialist – Special Authority see SA1049 on the next page Tab 150 mg .....................................................................................115.00 60 Xeloda Tab 500 mg .....................................................................................705.00 120 Xeloda

148

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

¾SA1049 Special Authority for Subsidy Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Any of the following: 1 The patient has advanced gastrointestinal malignancy; or 2 The patient has metastatic breast cancer; or 3 The patient has stage III (Duke’s stage C) colorectal*# cancer and undergone surgery; or 4 Both: 4.1 The patient has stage II (Dukes’ stage B) colorectal* cancer and has undergone surgery; and 4.2 Any of the following: 4.2.1 The patient has stage T4 disease; or 4.2.2 The patient has vascular invasion; or 4.2.3 Fewer than 10 lymph nodes were examined at resection; or 5 All of the following: 5.1 The patient has locally advanced (clinically or radiologically staged T3/T4: N0,1,2) rectal cancer; and 5.2 Surgery is planned; and 5.3 Capecitabine to be given prior to surgery (neoadjuvant); and 5.4 Capecitabine to be given at a maximum dose of 825 mg/m2 twice daily in combination with radiation therapy for a maximum of 6 weeks; or 6 Both: 6.1 The patient has poor venous access or needle phobia*; and 6.2 The patient requires a substitute for single agent ﬂuoropyrimidine*. Note: Indications marked with * are Unapproved Indications, # capecitabine is approved for stage III (Duke’s stage C) colon cancer. Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Either: 1 The patient requires continued therapy; or 2 The tumour has relapsed and requires re-treatment. CLADRIBINE – PCT only – Specialist Inj 2 mg per ml, 5 ml ......................................................................873.00 1 Litak S29 Inj 1 mg per ml, 10 ml ..................................................................5,249.72 7 Leustatin Inj 10 mg for ECP ...........................................................................749.96 10 mg OP Baxter (Litak S29 Inj 2 mg per ml, 5 ml to be delisted 1 December 2012) CYTARABINE Inj 100 mg – PCT – Retail pharmacy-Specialist..............................76.00 80.00 Inj 500 mg – PCT – Retail pharmacy-Specialist..............................18.15 95.36 Inj 1 g – PCT – Retail pharmacy-Specialist.....................................37.00 42.65 Inj 2 g – PCT – Retail pharmacy-Specialist.....................................31.00 34.47 Inj 1 mg for ECP – PCT only – Specialist ..........................................0.27 Inj 100 mg intrathecal syringe for ECP – PCT only – Specialist .........15.20 FLUDARABINE PHOSPHATE – PCT only – Specialist Tab 10 mg .......................................................................................433.50 Inj 50 mg .........................................................................................525.00 1,430.00 Inj 50 mg for ECP ...........................................................................105.00 5 1 5 1 1 10 mg 100 mg OP 20 5 50 mg OP

Pﬁzer Mayne Pﬁzer Mayne Pﬁzer Mayne Pﬁzer Mayne Baxter Baxter Fludara Oral Fludarabine Ebewe Fludara Baxter

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

149

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

FLUOROURACIL SODIUM Inj 50 mg per ml, 10 ml – PCT only – Specialist..............................26.25 Inj 50 mg per ml, 20 ml – PCT only – Specialist................................7.50 Inj 25 mg per ml, 100 ml – PCT only – Specialist............................13.55 Inj 50 mg per ml, 50 ml – PCT only – Specialist..............................18.00 Inj 50 mg per ml, 100 ml – PCT only – Specialist............................34.50 Inj 1 mg for ECP – PCT only – Specialist ..........................................0.77

5 1 1 1 1 100 mg

Fluorouracil Ebewe Fluorouracil Ebewe Mayne Fluorouracil Ebewe Fluorouracil Ebewe Baxter

GEMCITABINE HYDROCHLORIDE – PCT only – Specialist – Special Authority see SA1087 below Inj 1 g ................................................................................................62.50 1 DBL Gemcitabine Gemcitabine Actavis 1000 Gemcitabine Ebewe 349.20 Gemzar Inj 200 mg .........................................................................................12.50 1 Gemcitabine Actavis 200 Gemcitabine Ebewe 78.00 Gemzar Inj 1 mg for ECP .................................................................................0.07 1 mg Baxter ¾SA1087 Special Authority for Subsidy Initial application — (Hodgkin’s Disease) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: All of the following: 1 The patient has Hodgkin’s Disease*; and 2 Any of the following: 2.1 Disease has failed to respond to second line salvage chemotherapy treatment; or 2.2 Disease has relapsed following transplant; or 2.3 The patient is unsuitable for, or intolerant to, second-line salvage chemotherapy or high dose chemotherapy and transplant; and 3 Gemcitabine to be given for a maximum of 6 treatment cycles. Note: Indications marked with a * are Unapproved Indications. Initial application — (T-Cell Lymphoma) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 The patient has T-cell Lymphoma*; and 2 Gemcitabine to be given for a maximum of 6 treatment cycles. Note: Indications marked with a * are Unapproved Indications. Initial application — (Cholangiocarcinoma) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 The patient has locally advanced or metastatic, cholangiocarcinoma*; and 2 Gemcitabine to be given for a maximum of 8 treatment cycles. Notes: Cholangiocarcinoma encompasses epithelial tumours of the hepatobiliary tree, including tumours of bile ducts, ampulla of vater and gallbladder. Indications marked with a * are Unapproved Indications. Initial application — (Pancreatic Cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Either: 1 Both: 1.1 The patient has macroscopically resected (R0) pancreatic carcinoma*; and continued. . .

150

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

continued. . . 1.2 Adjuvant gemcitabine to be administered for a maximum of 6 cycles; or 2 Both: 2.1 The patient has advanced pancreatic carcinoma; and 2.2 The patient is gemcitabine treatment naive. Note: Indications marked with a * are Unapproved Indications. Renewal — (Pancreatic Cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: All of the following: 1 The patient has received gemcitabine for advanced pancreatic carcinoma; and 2 The patient has not received gemcitabine for adjuvant treatment pancreatic carcinoma; and 3 The patient requires continued therapy. Initial application — (Other indications) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Any of the following: 1 1 The patient has non small cell lung carcinoma (stage IIIa, or above); or 2 The patient has advanced malignant mesothelioma; or 3 The patient has ovarian, fallopian tube* or primary peritoneal carcinoma*; or 4 The patient has advanced transitional cell carcinoma of the urothelial tract (locally advanced or metastatic). Note: Indications marked with a * are Unapproved Indications. Renewal — (Other indications) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Either: 1 The patient requires continued therapy; or 2 The tumour has relapsed and requires re-treatment. IRINOTECAN – PCT only – Specialist – Special Authority see SA0878 below Inj 20 mg per ml, 2 ml .......................................................................41.00 1 Camptosar Irinotecan-Rex Inj 20 mg per ml, 5 ml .....................................................................100.00 1 Camptosar Irinotecan-Rex Inj 1 mg for ECP .................................................................................1.04 1 mg Baxter ¾SA0878 Special Authority for Subsidy Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 The patient has metastatic colorectal cancer; and 2 Either: 2.1 To be used for ﬁrst or second line use as part of a combination chemotherapy regimen; or 2.2 As single agent chemotherapy in ﬂuropyrimidine-relapsed disease. Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Either: 1 The patient requires continued therapy; or 2 The tumour has relapsed and requires re-treatment. MERCAPTOPURINE – PCT – Retail pharmacy-Specialist 25 Purinethol Tab 50 mg .........................................................................................47.06

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

151

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

METHOTREXATE F Tab 2.5 mg – PCT – Retail pharmacy-Specialist...............................5.22 F Tab 10 mg – PCT – Retail pharmacy-Specialist..............................40.93 F Inj 2.5 mg per ml, 2 ml – PCT – Retail pharmacy-Specialist ...........23.65 F Inj 25 mg per ml, 2 ml – PCT – Retail pharmacy-Specialist ............48.00 F Inj 25 mg per ml, 20 ml – PCT – Retail pharmacy-Specialist ..........90.00 F Inj 100 mg per ml, 10 ml – PCT – Retail pharmacy-Specialist .........25.00 F Inj 25 mg per ml, 40 ml – PCT – Retail pharmacy-Specialist ..........25.00 F Inj 100 mg per ml, 50 ml – PCT – Retail pharmacy-Specialist .........125.00 F Inj 1 mg for ECP – PCT only – Specialist ..........................................0.10 F Inj 5 mg intrathecal syringe for ECP – PCT only – Specialist............4.73 THIOGUANINE – PCT – Retail pharmacy-Specialist Tab 40 mg .........................................................................................97.16

30 50 5 5 1 1 1 1 1 mg 5 mg OP 25

Methoblastin Methoblastin Mayne Hospira Hospira Methotrexate Ebewe DBL

Methotrexate

S29

Methotrexate Ebewe Baxter Baxter Lanvis

Other Cytotoxic Agents

AMSACRINE – PCT only – Specialist Inj 75 mg ...........................................................................................CBS 6

Amsidine S29

ANAGRELIDE HYDROCHLORIDE – PCT only – Specialist – Special Authority see SA0879 below Cap 0.5 mg .......................................................................................CBS 100 Agrylin S29 Teva S29 ¾SA0879 Special Authority for Subsidy Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 The patient has primary thrombocythaemia; and 2 Either: 2.1 is at high risk (previous thromboembolic disease, bleeding or platelet count >1500/ml); or 2.2 is intolerant or refractory to hydroxyurea or interferon. Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months where the treatment remains appropriate and the patient is beneﬁting from treatment. Note: It is recommended that treatment with anagrelide be initiated only on the recommendation of a haematologist. ARSENIC TRIOXIDE – PCT only – Specialist Inj 10 mg ......................................................................................4,817.00 10 AFT S29 BLEOMYCIN SULPHATE – PCT only – Specialist Inj 15,000 iu ....................................................................................120.00 Inj 1,000 iu for ECP ............................................................................9.28 1 1,000 iu

DBL Bleomycin

Sulfate

Baxter Velcade Velcade Baxter

BORTEZOMIB – PCT only – Specialist – Special Authority see SA1127 on the next page Inj 1 mg ...........................................................................................540.70 1 Inj 3.5 mg .....................................................................................1,892.50 1 Inj 1 mg for ECP .............................................................................594.77 1 mg

152

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

¾SA1127 Special Authority for Subsidy Initial application — (Treatment naive multiple myeloma/amyloidosis) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 15 months for applications meeting the following criteria: Both: 1 Either: 1.1 The patient has treatment-naive symptomatic multiple myeloma; or 1.2 The patient has treatment-naive symptomatic systemic AL amyloidosis *; and 2 Maximum of 9 treatment cycles. Note: Indications marked with * are Unapproved Indications. Initial application — (Relapsed/refractory multiple myeloma/amyloidosis) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 8 months for applications meeting the following criteria: All of the following: 1 Either: 1.1 The patient has relapsed or refractory multiple myeloma; or 1.2 The patient has relapsed or refractory systemic AL amyloidosis *; and 2 The patient has received only one prior front line chemotherapy for multiple myeloma or amyloidosis; and 3 The patient has not had prior publicly funded treatment with bortezomib; and 4 Maximum of 4 treatment cycles. Note: Indications marked with * are Unapproved Indications. Renewal — (Relapsed/refractory multiple myeloma/amyloidosis) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 8 months for applications meeting the following criteria: Both: 1 The patient’s disease obtained at least a partial response from treatment with bortezomib at the completion of cycle 4; and 2 Maximum of 4 further treatment cycles (making a total maximum of 8 consecutive treatment cycles). Notes: Responding relapsed/refractory multiple myeloma patients should receive no more than 2 additional cycles of treatment beyond the cycle at which a conﬁrmed complete response was ﬁrst achieved. A line of therapy is considered to comprise either: a) a known therapeutic chemotherapy regimen and supportive treatments; or b) a transplant induction chemotherapy regimen, stem cell transplantation and supportive treatments. Refer to datasheet for recommended dosage and number of doses of bortezomib per treatment cycle. COLASPASE [L-ASPARAGINASE] – PCT only – Specialist Inj 10,000 iu ....................................................................................102.32 1 Leunase Inj 10,000 iu for ECP ......................................................................102.32 10,000 iu OP Baxter DACARBAZINE – PCT only – Specialist Inj 200 mg .........................................................................................48.00 Inj 200 mg for ECP ...........................................................................48.00 DACTINOMYCIN [ACTINOMYCIN D] – PCT only – Specialist Inj 0.5 mg ..........................................................................................13.52 Inj 0.5 mg for ECP ............................................................................13.52 DAUNORUBICIN – PCT only – Specialist Inj 2 mg per ml, 10 ml .....................................................................118.72 Inj 20 mg for ECP ...........................................................................118.72 DOCETAXEL – PCT only – Specialist Inj 20 mg ...........................................................................................48.75 460.00 Inj 80 mg .........................................................................................195.00 1,650.00 Inj 1 mg for ECP .................................................................................2.63 1 200 mg OP 1 0.5 mg OP 1 20 mg OP 1 1 1 mg

Hospira Baxter Cosmegen Baxter Pﬁzer Baxter Docetaxel Ebewe Taxotere Docetaxel Ebewe Taxotere Baxter

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

153

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

DOXORUBICIN – PCT only – Specialist Inj 10 mg ...........................................................................................10.00 Inj 50 mg ...........................................................................................40.00

1 1

Doxorubicin Ebewe DBL Doxorubicin DBL Doxorubicin

S29 S29

Inj 100 mg .........................................................................................80.00 Inj 200 mg .......................................................................................150.00 Inj 1 mg for ECP .................................................................................0.88 EPIRUBICIN – PCT only – Specialist Inj 2 mg per ml, 5 ml .........................................................................25.00 Inj 2 mg per ml, 25 ml .......................................................................39.38 87.50 Inj 2 mg per ml, 50 ml .......................................................................58.20 125.00 Inj 2 mg per ml, 100 ml .....................................................................94.50 210.00 Inj 1 mg for ECP .................................................................................0.82 ETOPOSIDE Cap 50 mg – PCT – Retail pharmacy-Specialist ...........................340.73 Cap 100 mg – PCT – Retail pharmacy-Specialist .........................340.73 Inj 20 mg per ml, 5 ml – PCT – Retail pharmacy-Specialist ............25.00 612.20 Inj 1 mg for ECP – PCT only – Specialist ..........................................0.30 ETOPOSIDE PHOSPHATE – PCT only – Specialist Inj 100 mg (of etoposide base) .........................................................40.00 Inj 1 mg (of etoposide base) for ECP .................................................0.47 HYDROXYUREA – PCT – Retail pharmacy-Specialist Cap 500 mg ......................................................................................31.76 IDARUBICIN HYDROCHLORIDE – PCT only – Specialist Cap 5 mg ........................................................................................115.00 Cap 10 mg ......................................................................................144.50 Inj 5 mg ...........................................................................................100.00 Inj 10 mg .........................................................................................200.00 Inj 1 mg for ECP ...............................................................................22.20 MESNA – PCT only – Specialist Tab 400 mg .....................................................................................210.65 Tab 600 mg .....................................................................................314.40 Inj 100 mg per ml, 4 ml ...................................................................137.04 Inj 100 mg per ml, 10 ml .................................................................314.66 Inj 1 mg for ECP .................................................................................2.29 MITOMYCIN C – PCT only – Specialist Inj 5 mg .............................................................................................72.75 Inj 1 mg for ECP ...............................................................................16.13

1 1 1 mg 1 1

Doxorubicin Ebewe Doxorubicin Ebewe Adriamycin Doxorubicin Ebewe Baxter Epirubicin Ebewe DBL Epirubicin

Hydrochloride

Epirubicin Ebewe DBL Epirubicin

Hydrochloride

Epirubicin Ebewe DBL Epirubicin

Hydrochloride

1 mg 20 10 1 10 1 mg 1 1 mg 100 1 1 1 1 1 mg 50 50 15 15 100 mg 1 1 mg

Epirubicin Ebewe Baxter Vepesid Vepesid Mayne Vepesid Baxter Etopophos Baxter Hydrea Zavedos Zavedos Zavedos Zavedos Baxter Uromitexan Uromitexan Uromitexan Uromitexan Baxter Arrow Baxter

154

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

MITOZANTRONE – PCT only – Specialist Inj 2 mg per ml, 5 ml .......................................................................110.00 Inj 2 mg per ml, 10 ml .....................................................................100.00 Inj 2 mg per ml, 12.5 ml ..................................................................407.50 Inj 1 mg for ECP .................................................................................5.65 PACLITAXEL – PCT only – Specialist Inj 30 mg .........................................................................................137.50 Inj 100 mg .........................................................................................91.67 Inj 150 mg .......................................................................................137.50

1 1 1 1 mg 5 1 1

Mitozantrone Ebewe Mitozantrone Ebewe Onkotrone Baxter Paclitaxel Ebewe Paclitaxel Actavis Paclitaxel Ebewe Anzatax Paclitaxel Actavis Paclitaxel Ebewe Anzatax Paclitaxel Actavis Paclitaxel Ebewe Paclitaxel Ebewe Baxter Nipent S29 Natulan S29 Temaccord Temaccord Temaccord Temaccord

Inj 300 mg .......................................................................................275.00

Inj 600 mg .......................................................................................550.00 Inj 1 mg for ECP .................................................................................1.02 PENTOSTATIN [DEOXYCOFORMYCIN] – PCT only – Specialist Inj 10 mg ...........................................................................................CBS PROCARBAZINE HYDROCHLORIDE – PCT only – Specialist Cap 50 mg ......................................................................................225.00 TEMOZOLOMIDE – Special Authority see SA1063 below – Retail pharmacy Cap 5 mg ..........................................................................................16.00 Cap 20 mg ........................................................................................72.00 Cap 100 mg ....................................................................................350.00 Cap 250 mg ....................................................................................820.00

1 1 mg 1 50 5 5 5 5

¾SA1063 Special Authority for Subsidy Initial application only from a relevant specialist. Approvals valid for 10 months for applications meeting the following criteria: All of the following: 1 Either: 1.1 Patient has newly diagnosed glioblastoma multiforme; or 1.2 Patient has newly diagnosed anaplastic astrocytoma*; and 2 Temozolomide is to be (or has been) given concomitantly with radiotherapy; and 3 Following concomitant treatment temozolomide is to be used for a maximum of six cycles of 5 days treatment, at a maximum dose of 200 mg/m2 . Notes: Indication marked with a * is an Unapproved Indication. Temozolomide is not subsidised for the treatment of relapsed glioblastoma multiforme. Reapplications will not be approved. Studies of temozolomide show that its beneﬁt is predominantly in those patients with a good performance status (WHO grade 0 or 1 or Karnofsky score >80), and in patients who have had at least a partial resection of the tumour. THALIDOMIDE – PCT only – Specialist – Special Authority see SA1124 on the next page Cap 50 mg ......................................................................................504.00 28 Thalomid Cap 100 mg .................................................................................1,008.00 28 Thalomid

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

155

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

¾SA1124 Special Authority for Subsidy Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Either: 1 The patient has multiple myeloma; or 2 The patient has systemic AL amyloidosis*. Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid without further renewal unless notiﬁed where the patient has obtained a response from treatment during the initial approval period. Notes: Prescription must be written by a registered prescriber in the thalidomide risk management programme operated by the supplier. Maximum dose of 400 mg daily as monotherapy or in a combination therapy regimen. Indication marked with * is an Unapproved Indication. TRETINOIN Cap 10 mg – PCT – Retail pharmacy-Specialist ...........................435.90 100 Vesanoid VINBLASTINE SULPHATE Inj 10 mg – PCT – Retail pharmacy-Specialist................................27.50 137.50 Inj 1 mg for ECP – PCT only – Specialist ..........................................3.05 VINCRISTINE SULPHATE Inj 1 mg per ml, 1 ml – PCT – Retail pharmacy-Specialist ............108.00 Inj 1 mg per ml, 2 ml – PCT – Retail pharmacy-Specialist ............116.00 Inj 1 mg for ECP – PCT only – Specialist ........................................15.77 VINORELBINE – PCT only – Specialist – Special Authority see SA1013 below Inj 10 mg per ml, 1 ml .......................................................................12.85 42.00 Inj 10 mg per ml, 5 ml .......................................................................64.25 210.00 Inj 1 mg for ECP .................................................................................1.45 1 5 1 mg 5 5 1 mg 1 1 1 mg

Mayne Mayne Baxter Hospira Hospira Baxter Navelbine Vinorelbine Ebewe Navelbine Vinorelbine Ebewe Baxter

¾SA1013 Special Authority for Subsidy Initial application — (Hodgkin’s Disease) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: All of the following: 1 The patient has Hodgkin’s Disease*; and 2 Any of the following: 2.1 Disease has failed to respond to second-line salvage chemotherapy treatment; or 2.2 Disease has relapsed following transplant; or 2.3 The patient is unsuitable for, or intolerant to, second-line salvage chemotherapy or high dose chemotherapy and transplant; and 3 Vinorelbine to be given for a maximum of 6 treatment cycles. Initial application — (T-Cell Lymphoma) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 The patient has T-cell Lymphoma*; and 2 Vinorelbine to be given for a maximum of 6 treatment cycles. Initial application — (Other indications) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Any of the following: 1 The patient has metastatic breast cancer; or continued. . .

156

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

continued. . . 2 The patient has non-small cell lung cancer (stage IIIa, or above); or 3 All of the following: 3.1 The patient has stage IB-IIIA non-small cell lung cancer; and 3.2 Vinorelbine is to be given as adjuvant treatment in combination with cisplatin; and 3.3 The patient has good performance status (WHO/ECOG grade 0-1). Renewal — (Other indications) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Either: 1 The patient requires continued therapy; or 2 The tumour has relapsed and requires re-treatment. Note: Indications marked with a * are Unapproved Indications.

Protein-tyrosine Kinase Inhibitors

DASATINIB – Special Authority see SA0976 below Tab 20 mg ....................................................................................3,774.06 Tab 50 mg ....................................................................................6,214.20 Tab 70 mg ....................................................................................7,692.58 Tab 100 mg ..................................................................................6,214.20 60 60 60 30

Sprycel Sprycel Sprycel Sprycel

¾SA0976 Special Authority for Subsidy Special Authority approved by the CML/GIST Co-ordinator Notes: Application details may be obtained from PHARMAC’s website http://www.pharmac.govt.nz, and prescriptions should be sent to: The CML/GIST Co-ordinator Phone: (04) 460 4990 PHARMAC Facsimile: (04) 916 7571 PO Box 10 254 Email: mary.chesterﬁeld@pharmac.govt.nz Wellington Special Authority criteria for CML - access by application a) Funded for patients with diagnosis (conﬁrmed by a haematologist) of a chronic myeloid leukaemia (CML) in blast crisis, accelerated phase, or in chronic phase. b) Maximum dose of 140 mg/day for accelerated or blast phase, and 100 mg/day for chronic phase CML. c) Subsidised for use as monotherapy only. d) Initial approvals valid seven months. e) Subsequent approval(s) are granted on application and are valid for six months. The ﬁrst reapplication (after seven months) should provide details of the haematological response. The third reapplication should provide details of the cytogenetic response after 14-18 months from initiating therapy. All other reapplications should provide details of haematological response, and cytogenetic response if such data is available. Applications to be made and subsequent prescriptions can be written by a haematologist or an oncologist. Note: Dasatinib is indicated for the treatment of adults with chronic, accelerated or blast phase CML with resistance or intolerance to prior therapy including imatinib. Guideline on discontinuation of treatment for patients with CML a) Prescribers should consider discontinuation of treatment if, after 6 months from initiating therapy, a patient did not obtain a haematological response as deﬁned as any one of the following three levels of response: 1) complete haematologic response (as characterised by an absolute neutrophil count (ANC) > 1.5 × 109 /L, platelets > 100 × 109 /L, absence of peripheral blood (PB) blasts, bone marrow (BM) blasts < 5% (or FISH Ph+ 0-35% metaphases), and absence of extramedullary disease); or 2) no evidence of leukaemia (as characterised by an absolute neutrophil count (ANC) > 1.0 × 109 /L, platelets > 20 × 109 /L, absence of peripheral blood (PB) blasts, bone marrow (BM) blasts < 5% (or FISH Ph+ 0-35% metaphases), and absence of extramedullary disease); or continued. . .

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

157

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

continued. . . 3) return to chronic phase (as characterised by BM and PB blasts < 15%, BM and PB blasts and promyelocytes < 30%, PB basophils < 20% and absence of extramedullary disease other than spleen and liver). b) Prescribers should consider discontinuation of treatment if, after 18 months from initiating therapy, a patient did not obtain a major cytogenetic response deﬁned as 0-35% Ph+ metaphases. ERLOTINIB HYDROCHLORIDE – Retail pharmacy-Specialist – Special Authority see SA1044 below Tab 100 mg ..................................................................................3,100.00 30 Tarceva Tab 150 mg ..................................................................................3,950.00 30 Tarceva ¾SA1044 Special Authority for Subsidy Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months for applications meeting the following criteria: All of the following: 1 Patient has advanced, unresectable, Non Small Cell Lung Cancer (NSCLC); and 2 Patient has documented disease progression following treatment with ﬁrst line platinum based chemotherapy; and 3 Erlotinib is to be given for a maximum of 3 months. Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months where radiological assessment (preferably including CT scan) indicates NSCLC has not progressed. GEFITINIB – Retail pharmacy-Specialist Tab 250 mg – Special Authority see SA1226 below....................1,700.00 30 Iressa ¾SA1226 Special Authority for Subsidy Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months for applications meeting the following criteria: Either: 1 All of the following: 1.1 Patient has treatment naive locally advanced, or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC); and 1.2 There is documentation conﬁrming that disease expresses activating mutations of EGFR tyrosine kinase; and 1.3 Geﬁtinib is to be given for a maximum of 3 months; or 2 The patient received geﬁtinib treatment prior to 1 August 2012 and radiological assessment (preferably including CT scan) indicates NSCLC has not progressed. Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months where radiological assessment (preferably including CT scan) indicates NSCLC has not progressed. IMATINIB MESYLATE – Special Authority see SA0643 below Tab 100 mg ..................................................................................2,400.00 60 Glivec ¾SA0643 Special Authority for Subsidy Special Authority approved by the CML/GIST Co-ordinator Notes: Application details may be obtained from PHARMAC’s website http://www.pharmac.govt.nz, and prescriptions should be sent to: The CML/GIST Co-ordinator Phone: (04) 460 4990 PHARMAC Facsimile: (04) 916 7571 PO Box 10 254 Email: mary.chesterﬁeld@pharmac.govt.nz Wellington Special Authority criteria for CML – access by application a) Funded for patients with diagnosis (conﬁrmed by a haematologist) of a chronic myeloid leukaemia (CML) in blast crisis, accelerated phase, or in chronic phase. b) Maximum dose of 600 mg/day for accelerated or blast phase, and 400 mg/day for chronic phase CML. c) Subsidised for use as monotherapy only. d) Initial approvals valid seven months. continued. . .

158

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

continued. . . e) Subsequent approval(s) are granted on application and are valid for six months. The ﬁrst reapplication (after seven months) should provide details of the haematological response. The third reapplication should provide details of the cytogenetic response after 14-18 months from initiating therapy. All other reapplications should provide details of haematological response, and cytogenetic response if such data is available. Applications to be made and subsequent prescriptions can be written by a haematologist or an oncologist. Guideline on discontinuation of treatment for patients with CML a) Prescribers should consider discontinuation of treatment if after 6 months from initiating therapy a patient did not obtain a haematological response as deﬁned as any one of the following three levels of response: 1) complete haematologic response (as characterised by an absolute neutrophil count (ANC) > 1.5 × 109 /L, platelets > 100 × 109 /L, absence of peripheral blood (PB) blasts, bone marrow (BM) blasts < 5% (or FISH Ph+ 0-35% metaphases), and absence of extramedullary disease); or 2) no evidence of leukaemia (as characterised by an absolute neutrophil count (ANC) > 1.0 × 109 /L, platelets > 20 × 109 /L, absence of peripheral blood (PB) blasts, bone marrow (BM) blasts < 5% (or FISH Ph+ 0-35% metaphases), and absence of extramedullary disease); or 3) return to chronic phase (as characterised by BM and PB blasts < 15%, BM and PB blasts and promyelocytes < 30%, PB basophils < 20% and absence of extramedullary disease other than spleen and liver). b) Prescribers should consider discontinuation of treatment if after 18 months from initiating therapy a patient did not obtain a major cytogenetic response deﬁned as 0-35% Ph+ metaphases. Special Authority criteria for GIST – access by application a) Funded for patients: 1) with a diagnosis (conﬁrmed by an oncologist) of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST); and 2) who have immunohistochemical documentation of c-kit (CD117) expression by the tumour. b) Maximum dose of 400 mg/day. c) Applications to be made and subsequent prescriptions can be written by an oncologist. d) Initial and subsequent applications are valid for one year. The re-application criterion is an adequate clinical response to the treatment with imatinib (prescriber determined). LAPATINIB DITOSYLATE – Special Authority see SA1191 below – Retail pharmacy Tab 250 mg ..................................................................................1,899.00 70 Tykerb ¾SA1191 Special Authority for Subsidy Initial application — (metastatic breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Either: 1 All of the following: 1.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and 1.2 The patient has not previously received trastuzumab treatment for HER 2 positive metastatic breast cancer; and 1.3 Lapatinib not to be given in combination with trastuzumab; and 1.4 Lapatinib to be discontinued at disease progression; or 2 All of the following: 2.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and 2.2 The patient started trastuzumab for metastatic breast cancer but discontinued trastuzumab within 3 months of starting treatment due to intolerance; and 2.3 The cancer did not progress whilst on trastuzumab; and 2.4 Lapatinib not to be given in combination with trastuzumab; and 2.5 Lapatinib to be discontinued at disease progression. continued. . .

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

159

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

continued. . . Renewal — (metastatic breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: All of the following: 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and 2 The cancer has not progressed at any time point during the previous 12 months whilst on lapatinib; and 3 Lapatinib not to be given in combination with trastuzumab; and 4 Lapatinib to be discontinued at disease progression. PAZOPANIB – Special Authority see SA1190 below – Retail pharmacy Tab 200 mg ..................................................................................1,334.70 30 Votrient Tab 400 mg ..................................................................................2,669.40 30 Votrient ¾SA1190 Special Authority for Subsidy Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria: All of the following: 1 The patient has metastatic renal cell carcinoma; and 2 Any of the following: 2.1 The patient is treatment naive; or 2.2 The patient has only received prior cytokine treatment; or 2.3 Both: 2.3.1 The patient has discontinued sunitinib within 3 months of starting treatment due to intolerance; and 2.3.2 The cancer did not progress whilst on sunitinib; and 3 The patient has good performance status (WHO/ECOG grade 0-2); and 4 The disease is of predominant clear cell histology; and The patient has intermediate or poor prognosis deﬁned as: 5 Any of the following: 5.1 Lactate dehydrogenase level > 1.5 times upper limit of normal; or 5.2 Haemoglobin level < lower limit of normal; or 5.3 Corrected serum calcium level > 10 mg/dL (2.5 mmol/L); or 5.4 Interval of < 1 year from original diagnosis to the start of systemic therapy; or 5.5 Karnofsky performance score of ≤ 70; or 5.6 ≥ 2 sites of organ metastasis; and 6 Pazopanib to be used for a maximum of 3 months. Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 No evidence of disease progression; and 2 The treatment remains appropriate and the patient is beneﬁting from treatment. Notes: Pazopanib treatment should be stopped if disease progresses. Poor prognosis patients are deﬁned as having at least 3 of criteria 5.1-5.6. Intermediate prognosis patients are deﬁned as having 1 or 2 of criteria 5.1-5.6. SUNITINIB – Special Authority see SA1200 on the next page – Retail pharmacy Cap 12.5 mg ................................................................................2,315.38 28 Sutent Cap 25 mg ...................................................................................4,630.77 28 Sutent Cap 50 mg ...................................................................................9,261.54 28 Sutent

160

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

¾SA1200 Special Authority for Subsidy Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria: All of the following: 1 The patient has metastatic renal cell carcinoma; and 2 Any of the following: 2.1 The patient is treatment naive; or 2.2 The patient has only received prior cytokine treatment; or 2.3 The patient has only received prior treatment with an investigational agent within the conﬁnes of a bona ﬁde clinical trial which has Ethics Committee approval; or 2.4 Both: 2.4.1 The patient has discontinued pazopanib within 3 months of starting treatment due to intolerance; and 2.4.2 The cancer did not progress whilst on pazopanib; and 3 The patient has good performance status (WHO/ECOG grade 0-2); and 4 The disease is of predominant clear cell histology; and The patient has intermediate or poor prognosis deﬁned as: 5 Any of the following: 5.1 Lactate dehydrogenase level > 1.5 times upper limit of normal; or 5.2 Haemoglobin level < lower limit of normal; or 5.3 Corrected serum calcium level > 10 mg/dL (2.5 mmol/L); or 5.4 Interval of < 1 year from original diagnosis to the start of systemic therapy; or 5.5 Karnofsky performance score of ≤ 70; or 5.6 ≥ 2 sites of organ metastasis; and 6 Sunitinib to be used for a maximum of 2 cycles. Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 No evidence of disease progression; and 2 The treatment remains appropriate and the patient is beneﬁting from treatment. Notes: Sunitinib treatment should be stopped if disease progresses. Poor prognosis patients are deﬁned as having at least 3 of criteria 5.1-5.6. Intermediate prognosis patients are deﬁned as having 1 or 2 of criteria 5.1-5.6

Endocrine Therapy

For GnRH ANALOGUES – refer to HORMONE PREPARATIONS, Trophic Hormones, page 81 BICALUTAMIDE – Special Authority see SA0941 below – Retail pharmacy Tab 50 mg .........................................................................................10.00 28

Bicalaccord

¾SA0941 Special Authority for Subsidy Initial application from any medical practitioner. Approvals valid without further renewal unless notiﬁed where the patient has advanced prostate cancer. FLUTAMIDE – Retail pharmacy-Specialist Tab 250 mg .......................................................................................55.00 100 Flutamin MEGESTROL ACETATE – Retail pharmacy-Specialist Tab 160 mg .......................................................................................57.92 (Megace Tab 160 mg to be delisted 1 February 2013) 30

Apo-Megestrol Megace

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

161

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

OCTREOTIDE (SOMATOSTATIN ANALOGUE) – Special Authority see SA1016 below – Retail pharmacy Inj 50 µg per ml, 1 ml ........................................................................19.24 5 Octreotide MaxRx Inj 100 µg per ml, 1 ml ......................................................................36.38 5 Octreotide MaxRx Inj 500 µg per ml, 1 ml ....................................................................131.25 5 Octreotide MaxRx Inj LAR 10 mg preﬁlled syringe ...................................................1,772.50 1 Sandostatin LAR Inj LAR 20 mg preﬁlled syringe ...................................................2,358.75 1 Sandostatin LAR Inj LAR 30 mg preﬁlled syringe ...................................................2,951.25 1 Sandostatin LAR ¾SA1016 Special Authority for Subsidy Initial application — (Malignant Bowel Obstruction) from any relevant practitioner. Approvals valid for 2 months for applications meeting the following criteria: All of the following: 1 The patient has nausea* and vomiting* due to malignant bowel obstruction*; and 2 Treatment with antiemetics, rehydration, antimuscarinic agents, corticosteroids and analgesics for at least 48 hours has failed; and 3 Octreotide to be given at a maximum dose 1500 µg daily for up to 4 weeks. Note: Indications marked with * are Unapproved Indications. Renewal — (Malignant Bowel Obstruction) from any relevant practitioner. Approvals valid for 3 months where the treatment remains appropriate and the patient is beneﬁting from treatment. Initial application — (Acromegaly) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 The patient has acromegaly; and 2 Any of the following: 2.1 Treatment with surgery, radiotherapy and a dopamine agonist has failed; or 2.2 Treatment with octreotide is for an interim period while awaiting the effects of radiotherapy and a dopamine agonist has failed; or 2.3 The patient is unwilling, or unable, to undergo surgery and/or radiotherapy. Renewal — (Acromegaly) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 IGF1 levels have decreased since starting octreotide; and 2 The treatment remains appropriate and the patient is beneﬁting from treatment. Note: In patients with Acromegaly octreotide treatment should be discontinued if IGF1 levels have not decreased after 3 months treatment. In patients treated with radiotherapy octreotide treatment should be withdrawn every 2 years, for 1 month, for assessment of remission. Octreotide treatment should be stopped where there is biochemical evidence of remission (normal IGF1 levels) following octreotide treatment withdrawal for at least 4 weeks Initial application — (Other Indications) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 VIPomas and Glucagonomas - for patients who are seriously ill in order to improve their clinical state prior to deﬁnitive surgery; or 2 Both: 2.1 Gastrinoma; and 2.2 Either: 2.2.1 Patient has failed surgery; or 2.2.2 Patient in metastatic disease after H2 antagonists (or proton pump inhibitors) have failed; or 3 Both: 3.1 Insulinomas; and continued. . .

162

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

continued. . . 3.2 Surgery is contraindicated or has failed; or 4 For pre-operative control of hypoglycaemia and for maintenance therapy; or 5 Both: 5.1 Carcinoid syndrome (diagnosed by tissue pathology and/or urinary 5HIAA analysis); and 5.2 Disabling symptoms not controlled by maximal medical therapy. Note: The use of octreotide in patients with ﬁstulae, oesophageal varices, miscellaneous diarrhoea and hypotension will not be funded as a Special Authority item Renewal — (Other Indications) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is beneﬁting from treatment. TAMOXIFEN CITRATE F Tab 10 mg .........................................................................................10.80 100 Genox F Tab 20 mg ...........................................................................................8.75 100 Genox

Aromatase Inhibitors

ANASTROZOLE F Tab 1 mg ...........................................................................................26.55 30

Aremed Arimidex DP-Anastrozole Aromasin Letraccord Letara

EXEMESTANE F Tab 25 mg .........................................................................................22.57 LETROZOLE F Tab 2.5 mg ..........................................................................................4.85 26.55

30 30

Immunosuppressants Cytotoxic Immunosuppressants

AZATHIOPRINE – Retail pharmacy-Specialist F Tab 50 mg – For azathioprine oral liquid formulation refer, page 182 .................................................................................... 18.45 F Inj 50 mg ...........................................................................................60.00

100 1

Imuprine Imuran

MYCOPHENOLATE MOFETIL – Special Authority see SA1041 on the next page – Retail pharmacy Dispensing pharmacy should check which brand to dispense with the prescriber if prescribed generically. Tab 500 mg .......................................................................................60.00 50 Ceptolate Myaccord 70.00 Cellcept Cap 250 mg ......................................................................................30.00 50 Ceptolate 60.00 100 Myaccord 70.00 Cellcept Powder for oral liq 1 g per 5 ml – Subsidy by endorsement ............285.00 165 ml OP Cellcept Mycophenolate powder for oral liquid is subsidised only for patients unable to swallow tablets and capsules, and when the prescription is endorsed accordingly.

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

163

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

¾SA1041 Special Authority for Subsidy Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid without further renewal unless notiﬁed for applications meeting the following criteria: Either: 1 Transplant recipient; or 2 Both: Patients with diseases where 2.1 Steroids and azathioprine have been trialled and discontinued because of unacceptable side effects or inadequate clinical response; and 2.2 Either: Patients with diseases where 2.2.1 Cyclophosphamide has been trialled and discontinued because of unacceptable side effects or inadequate clinical response; or 2.2.2 Cyclophosphamide treatment is contraindicated.

Immune Modulators

ANTITHYMOCYTE GLOBULIN (EQUINE) – PCT only – Specialist Inj 50 mg per ml, 5 ml ..................................................................2,137.50 BACILLUS CALMETTE-GUERIN (BCG) VACCINE – PCT only – Specialist Subsidised only for bladder cancer. Inj 2-8 × 100 million CFU ...............................................................187.37 RITUXIMAB – PCT only – Specialist – Special Authority see SA1152 below Inj 100 mg per 10 ml vial .............................................................1,075.50 Inj 500 mg per 50 ml vial .............................................................2,688.30 Inj 1 mg for ECP .................................................................................5.64 5

ATGAM

1 2 1 1 mg

OncoTICE Mabthera Mabthera Baxter

¾SA1152 Special Authority for Subsidy Initial application — (Post-transplant) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 The patient has B-cell post-transplant lymphoproliferative disorder*; and 2 To be used for a maximum of 8 treatment cycles. Note: Indications marked with * are Unapproved Indications. Initial application — (Indolent, Low-grade lymphomas) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 9 months for applications meeting the following criteria: Either: 1 Both: 1.1 The patient has indolent low grade NHL with relapsed disease following prior chemotherapy; and 1.2 To be used for a maximum of 6 treatment cycles; or 2 Both: 2.1 The patient has indolent, low grade lymphoma requiring ﬁrst-line systemic chemotherapy; and 2.2 To be used for a maximum of 6 treatment cycles. Note: ’Indolent, low-grade lymphomas’ includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia. Initial application — (Aggressive CD20 positive NHL) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Either: 1 All of the following: 1.1 The patient has treatment naive aggressive CD20 positive NHL; and continued. . .

164

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

continued. . . 1.2 To be used with a multi-agent chemotherapy regimen given with curative intent; and 1.3 To be used for a maximum of 8 treatment cycles; or 2 Both: 2.1 The patient has aggressive CD20 positive NHL with relapsed disease following prior chemotherapy; and 2.2 To be used for a maximum of 6 treatment cycles. Note: ’Aggressive CD20 positive NHL’ includes large B-cell lymphoma and Burkitt’s lymphoma/leukaemia Initial application — (Chronic Lymphocytic Leukaemia) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: All of the following: 1 The patient has progressive Binet stage A, B or C chronic lymphocytic leukaemia (CLL) requiring treatment; and 2 The patient is rituximab treatment naive; and 3 Either: 3.1 The patient is chemotherapy treatment naive; or 3.2 Both: 3.2.1 The patient’s disease has relapsed following no more than three prior lines of chemotherapy treatment; and 3.2.2 The patient has had a treatment-free interval of 12 months or more if previously treated with ﬂudarabine and cyclophosphamide chemotherapy; and 4 The patient has good performance status; and 5 The patient has good renal function (creatinine clearance ≥ 30 ml/min); and 6 The patient does not have chromosome 17p deletion CLL; and 7 Rituximab to be administered in combination with ﬂudarabine and cyclophosphamide for a maximum of 6 treatment cycles; and 8 It is planned that the patient receives full dose ﬂudarabine and cyclophosphamide (orally or dose equivalent intravenous administration). Note: ’Chronic lymphocytic leukaemia (CLL)’ includes small lymphocytic lymphoma. A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments. ’Good performance status’ means ECOG score of 0-1, however, in patients temporarily debilitated by their CLL disease symptoms a higher ECOG (2 or 3) is acceptable where treatment with rituximab is expected to improve symptoms and improve ECOG score to <2. Renewal — (Post-transplant) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 9 months for applications meeting the following criteria: All of the following: 1 The patient has had a rituximab treatment-free interval of 12 months or more; and 2 The patient has B-cell post-transplant lymphoproliferative disorder*; and 3 To be used for no more than 6 treatment cycles. Note: Indications marked with * are Unapproved Indications. Renewal — (Indolent, Low-grade lymphomas) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 9 months for applications meeting the following criteria: All of the following: 1 The patient has had a rituximab treatment-free interval of 12 months or more; and 2 The patient has indolent, low-grade NHL with relapsed disease following prior chemotherapy; and 3 To be used for no more than 6 treatment cycles. Note: ’Indolent, low-grade lymphomas’ includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia. Renewal — (Aggressive CD20 positive NHL) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: All of the following: 1 The patient has had a rituximab treatment-free interval of 12 months or more; and 2 The patient has relapsed refractory/aggressive CD20 positive NHL; and 3 To be used with a multi-agent chemotherapy regimen given with curative intent; and 4 To be used for a maximum of 4 treatment cycles. Note: ’Aggressive CD20 positive NHL’ includes large B-cell lymphoma and Burkitt’s lymphoma/leukaemia

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

165

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

TRASTUZUMAB – PCT only – Specialist – Special Authority see SA1192 below Inj 150 mg vial .............................................................................1,350.00 Inj 440 mg vial .............................................................................3,875.00 Inj 1 mg for ECP .................................................................................9.36

1 1 1 mg

Herceptin Herceptin Baxter

¾SA1192 Special Authority for Subsidy Initial application — (metastatic breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Either: 1 All of the following: 1.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and 1.2 The patient has not previously received lapatinib treatment for HER 2 positive metastatic breast cancer; and 1.3 Trastuzumab not to be given in combination with lapatinib; and 1.4 Trastuzumab to be discontinued at disease progression; or 2 All of the following: 2.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and 2.2 The patient started lapatinib treatment for metastatic breast cancer but discontinued lapatinib within 3 months of starting treatment due to intolerance; and 2.3 The cancer did not progress whilst on lapatinib; and 2.4 Trastuzumab not to be given in combination with lapatinib; and 2.5 Trastuzumab to be discontinued at disease progression. Renewal — (metastatic breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: All of the following: 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and 2 The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab; and 3 Trastuzumab not to be given in combination with lapatinib; and 4 Trastuzumab to be discontinued at disease progression. Initial application — (early breast cancer*) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 15 months for applications meeting the following criteria: All of the following: 1 The patient has early breast cancer expressing HER 2 IHC 3+ or ISH + (including FISH or other current technology); and 2 Maximum cumulative dose of 106 mg/kg (12 months’ treatment); and 3 Any of the following: 3.1 9 weeks’ concurrent treatment with adjuvant chemotherapy is planned; or 3.2 12 months’ concurrent treatment with adjuvant chemotherapy is planned; or 3.3 12 months’ sequential treatment following adjuvant chemotherapy is planned; or 3.4 Other treatment regimen, in association with adjuvant chemotherapy, is planned. Renewal — (early breast cancer*) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: All of the following: 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and 2 The patient received prior adjuvant trastuzumab treatment for early breast cancer; and 3 Any of the following: 3.1 All of the following: 3.1.1 The patient has not previously received lapatinib treatment for metastatic breast cancer; and continued. . .

166

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

continued. . . 3.1.2 Trastuzumab not to be given in combination with lapatinib; and 3.1.3 Trastuzumab to be discontinued at disease progression; or 3.2 All of the following: 3.2.1 The patient started lapatinib treatment for metastatic breast cancer but discontinued lapatinib within 3 months of starting treatment due to intolerance; and 3.2.2 The cancer did not progress whilst on lapatinib; and 3.2.3 Trastuzumab not to be given in combination with lapatinib; and 3.2.4 Trastuzumab to be discontinued at disease progression; or 3.3 All of the following: 3.3.1 The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab; and 3.3.2 Trastuzumab not to be given in combination with lapatinib; and 3.3.3 Trastuzumab to be discontinued at disease progression. Note: * For patients with relapsed HER-2 positive disease who have previously received adjuvant trastuzumab for early breast cancer.

Other Immunosuppressants

CYCLOSPORIN Cap 25 mg ........................................................................................59.50 Cap 50 mg ......................................................................................118.54 Cap 100 mg ....................................................................................237.08 Oral liq 100 mg per ml ....................................................................198.13 SIROLIMUS – Special Authority see SA0866 below – Retail pharmacy Tab 1 mg .........................................................................................813.00 Tab 2 mg ......................................................................................1,626.00 Oral liq 1 mg per ml ........................................................................487.80 50 50 50 50 ml OP 100 100 60 ml OP

Neoral Neoral Neoral Neoral Rapamune Rapamune Rapamune

¾SA0866 Special Authority for Subsidy Initial application from any medical practitioner. Approvals valid without further renewal unless notiﬁed where the drug is to be used for rescue therapy for an organ transplant recipient. Notes: Rescue therapy deﬁned as unresponsive to calcineurin inhibitor treatment as deﬁned by refractory rejection; or intolerant to calcineurin inhibitor treatment due to any of the following: G GFR<30 ml/min; or G Rapidly progressive transplant vasculopathy; or G Rapidly progressive obstructive bronchiolitis; or G HUS or TTP; or G Leukoencepthalopathy; or G Signiﬁcant malignant disease TACROLIMUS – Special Authority see SA0669 below – Retail pharmacy Cap 0.5 mg .....................................................................................214.00 100 Prograf Cap 1 mg ........................................................................................428.00 100 Prograf Cap 5 mg – For tacrolimus oral liquid formulation refer, page 182 ........................................................................................1,070.00 50 Prograf ¾SA0669 Special Authority for Subsidy Initial application only from a relevant specialist. Approvals valid without further renewal unless notiﬁed where the patient is an organ transplant recipient. Note: Subsidy applies for either primary or rescue therapy.

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

167

RESPIRATORY SYSTEM AND ALLERGIES

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

Antiallergy Preparations

BEE VENOM ALLERGY TREATMENT – Special Authority see SA0053 below – Retail pharmacy Maintenance kit - 6 vials 120 µg freeze dried venom, 6 diluent 1.8 ml ....................................................................................... 285.00 1 OP Albay Treatment kit - 1 vial 550 µg freeze dried venom, 1 diluent 9 ml, 3 diluent 1.8 ml ............................................................... 285.00 1 OP Albay ¾SA0053 Special Authority for Subsidy Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 RAST or skin test positive; and 2 Patient has had severe generalised reaction to the sensitising agent. Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is beneﬁting from treatment. WASP VENOM ALLERGY TREATMENT – Special Authority see SA0053 below – Retail pharmacy Treatment kit (Paper wasp venom) - 1 vial 550 µg freeze dried polister venom, 1 diluent 9 ml, 1 diluent 1.8 ml ....................... 285.00 1 OP Albay Treatment kit (Yellow jacket venom) - 1 vial 550 µg freeze dried vespula venom, 1 diluent 9 ml, 1 diluent 1.8 ml .............. 285.00 1 OP Albay ¾SA0053 Special Authority for Subsidy Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 RAST or skin test positive; and 2 Patient has had severe generalised reaction to the sensitising agent. Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is beneﬁting from treatment.

Antihistamines

CETIRIZINE HYDROCHLORIDE F Tab 10 mg ...........................................................................................1.59 F‡ Oral liq 1 mg per ml ............................................................................3.52 CHLORPHENIRAMINE MALEATE F‡ Oral liq 2 mg per 5 ml .........................................................................8.06 DEXTROCHLORPHENIRAMINE MALEATE F Tab 2 mg .............................................................................................1.01 (4.93) 2.02 (7.99) F‡ Oral liq 2 mg per 5 ml .........................................................................1.77 (10.29) FEXOFENADINE HYDROCHLORIDE F Tab 60 mg ...........................................................................................4.34 (11.53) F Tab 120 mg .........................................................................................4.74 (11.53) 14.22 (29.81) 100 200 ml 500 ml 20 Polaramine 40 Polaramine 100 ml Polaramine 20 Telfast 10 Telfast 30 Telfast

Zetop Cetirizine - AFT Histafen

168

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

RESPIRATORY SYSTEM AND ALLERGIES

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

LORATADINE F Tab 10 mg ...........................................................................................2.09 F Oral liq 1 mg per ml ............................................................................3.10 PROMETHAZINE HYDROCHLORIDE F Tab 10 mg ...........................................................................................1.99 F Tab 25 mg ...........................................................................................2.99 F‡ Oral liq 5 mg per 5 ml .........................................................................3.10 F Inj 25 mg per ml, 2 ml – Up to 5 inj available on a PSO ...................11.00 TRIMEPRAZINE TARTRATE ‡ Oral liq 30 mg per 5 ml .......................................................................2.79 (8.06)

100 100 ml 50 50 100 ml 5 100 ml OP

Loraclear Hayfever

Relief

Lorapaed Allersoothe Allersoothe Promethazine

Winthrop Elixir

Mayne

Vallergan Forte

Inhaled Corticosteroids

BECLOMETHASONE DIPROPIONATE Aerosol inhaler, 100 µg per dose CFC-free ......................................12.50 Aerosol inhaler, 250 µg per dose CFC-free ......................................22.67 Aerosol inhaler, 50 µg per dose CFC-free ..........................................8.54 BUDESONIDE Powder for inhalation, 100 µg per dose ............................................17.00 Powder for inhalation, 200 µg per dose ............................................15.20 19.00 Powder for inhalation, 400 µg per dose ............................................25.60 32.00 FLUTICASONE Aerosol inhaler, 50 µg per dose CFC-free ..........................................7.50 Powder for inhalation, 50 µg per dose ................................................7.50 Powder for inhalation, 100 µg per dose ..............................................7.50 Aerosol inhaler, 125 µg per dose CFC-free ......................................13.60 Aerosol inhaler, 250 µg per dose CFC-free ......................................27.20 Powder for inhalation, 250 µg per dose ............................................13.60 200 dose OP 200 dose OP 200 dose OP 200 dose OP 200 dose OP

Beclazone 100 Beclazone 250 Beclazone 50 Pulmicort

Turbuhaler

Budenocort Pulmicort

Turbuhaler

200 dose OP

Budenocort Pulmicort

Turbuhaler

120 dose OP 60 dose OP 60 dose OP 120 dose OP 120 dose OP 60 dose OP

Flixotide Flixotide Accuhaler Flixotide Accuhaler Flixotide Flixotide Flixotide Accuhaler

Inhaled Long-acting Beta-adrenoceptor Agonists

Prescribing Guideline for Inhaled Long-Acting Beta-Adrenoceptor Agonists The addition of inhaled long-acting beta-adrenoceptor agonists (LABAs) to inhaled corticosteroids is recommended: G For younger children (aged under 12 years) where asthma is poorly controlled despite using inhaled corticosteroids for at least three months at total daily doses of 200 µg beclomethasone or budesonide (or 100 µg ﬂuticasone). G For adults and older children (aged 12 years and over) where asthma is poorly controlled despite using inhaled corticosteroids for at least three months at total daily doses of 400 µg beclomethasone or budesonide (or 200 µg ﬂuticasone). Note: Further information on the place of inhaled corticosteroids and inhaled LABAs in the management of asthma can be found in the New Zealand guidelines for asthma in adults (www.nzgg.org.nz) and in the New Zealand guidelines for asthma in children aged 1-15 (www.paediatrics.org.nz).

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

169

RESPIRATORY SYSTEM AND ALLERGIES

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

EFORMOTEROL FUMARATE – See prescribing guideline on the preceding page Powder for inhalation, 6 µg per dose, breath activated ....................10.32 60 dose OP (16.90) Powder for inhalation, 12 µg per dose, and monodose device .........20.64 60 dose (35.80) SALMETEROL – See prescribing guideline on the preceding page Aerosol inhaler CFC-free, 25 µg per dose .......................................26.46 Powder for inhalation, 50 µg per dose, breath activated ..................26.46 120 dose OP 60 dose OP

Oxis Turbuhaler Foradil

Serevent Serevent Accuhaler

Inhaled Corticosteroids with Long-Acting Beta-Adrenoceptor Agonists

¾SA1179 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 All of the following: 1.1 Patient is a child under the age of 12; and 1.2 Has been treated with inhaled corticosteroids of at least 400 µg per day beclomethasone or budesonide, or 200 µg per day ﬂuticasone; and 1.3 The prescriber considers that the patient would receive additional clinical beneﬁt from switching to a combination product; or 2 All of the following: 2.1 Patient is over the age of 12; and 2.2 Has been treated with inhaled corticosteroids of at least 800 µg per day beclomethasone or budesonide, or 500 µg per day ﬂuticasone; and 2.3 The prescriber considers that the patient would receive additional clinical beneﬁt from switching to a combination product. Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is beneﬁting from treatment. BUDESONIDE WITH EFORMOTEROL – Special Authority see SA1179 above – Retail pharmacy Aerosol inhaler 100 µg with eformoterol fumarate 6 µg ...................26.49 120 dose OP Vannair Powder for inhalation 100 µg with eformoterol fumarate 6 µg ..........55.00 120 dose OP Symbicort Turbuhaler 100/6 Aerosol inhaler 200 µg with eformoterol fumarate 6 µg ...................31.25 120 dose OP Vannair Powder for inhalation 200 µg with eformoterol fumarate 6 µg ..........60.00 120 dose OP Symbicort Turbuhaler 200/6 Powder for inhalation 400 µg with eformoterol fumarate 12 µg – No more than 2 dose per day ..................................................60.00 60 dose OP Symbicort Turbuhaler 400/12 FLUTICASONE WITH SALMETEROL – Special Authority see SA1179 above – Retail pharmacy Aerosol inhaler 50 µg with salmeterol 25 µg ....................................37.48 120 dose OP Aerosol inhaler 125 µg with salmeterol 25 µg ..................................49.69 120 dose OP Powder for inhalation 100 µg with salmeterol 50 µg – No more than 2 dose per day...........................................................37.48 60 dose OP Powder for inhalation 250 µg with salmeterol 50 µg – No more than 2 dose per day...........................................................49.69 60 dose OP

Seretide Seretide Seretide Accuhaler Seretide Accuhaler

170

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

RESPIRATORY SYSTEM AND ALLERGIES

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

Beta-Adrenoceptor Agonists

SALBUTAMOL ‡ Oral liq 2 mg per 5 ml .........................................................................1.20 1.99 Infusion 1 mg per ml, 5 ml ..............................................................118.38 (130.21) Inj 500 µg per ml, 1 ml – Up to 5 inj available on a PSO..................12.90 90 ml 150 ml 10 Ventolin 5

Broncolin S29 Salapin Ventolin Ventolin

Inhaled Beta-Adrenoceptor Agonists

SALBUTAMOL Aerosol inhaler, 100 µg per dose CFC free – Up to 1000 dose available on a PSO.......................................................................3.80 (6.00) Nebuliser soln, 1 mg per ml, 2.5 ml – Up to 30 neb available on a PSO......................................................................................3.52 Nebuliser soln, 2 mg per ml, 2.5 ml – Up to 30 neb available on a PSO......................................................................................3.70 TERBUTALINE SULPHATE Powder for inhalation, 250 µg per dose, breath activated ................22.00

200 dose OP

Respigen Salamol

Ventolin

20 20 200 dose OP

Asthalin Asthalin Bricanyl Turbuhaler

Inhaled Anticholinergic Agents Inhaled Anticholinergic agents

IPRATROPIUM BROMIDE Aerosol inhaler, 20 µg per dose CFC-free ........................................16.20 Nebuliser soln, 250 µg per ml, 1 ml – Up to 40 neb available on a PSO......................................................................................3.79 Nebuliser soln, 250 µg per ml, 2 ml – Up to 40 neb available on a PSO......................................................................................4.06 200 dose OP 20 20

Atrovent Univent Univent Spiriva

TIOTROPIUM BROMIDE – Special Authority see SA1193 below – Retail pharmacy Powder for inhalation, 18 µg per dose ..............................................70.00 30 dose

¾SA1193 Special Authority for Subsidy Initial application only from a general practitioner or relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 To be used for the long-term maintenance treatment of bronchospasm and dyspnoea associated with COPD; and 2 In addition to standard treatment, the patient has trialled a short acting bronchodilator of at least 40 µg ipratropium q.i.d for one month; and 3 Either: The patient’s breathlessness according to the Medical Research Council (UK) dyspnoea scale is: 3.1 Grade 4 (stops for breath after walking about 100 meters or after a few minutes on the level); or 3.2 Grade 5 (too breathless to leave the house, or breathless when dressing or undressing); and Applicant must state recent measurement of: 4 All of the following: continued. . .

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

171

RESPIRATORY SYSTEM AND ALLERGIES

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

continued. . . 4.1 Actual FEV1 (litres); and 4.2 Predicted FEV1 (litres); and 4.3 Actual FEV1 as a % of predicted (must be below 60%); and 5 Either: 5.1 Patient is not a smoker (for reporting purposes only); or 5.2 Patient is a smoker and has been offered smoking cessation counselling; and 6 The patient has been offered annual inﬂuenza immunisation. Renewal only from a general practitioner or relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Patient is compliant with the medication; and 2 Patient has experienced improved COPD symptom control (prescriber determined); and Applicant must state recent measurement of: 3 All of the following: 3.1 Actual FEV1 (litres); and 3.2 Predicted FEV1 (litres); and 3.3 Actual FEV1 as a % of predicted.

Inhaled Beta-Adrenoceptor Agonists with Anticholinergic Agents

SALBUTAMOL WITH IPRATROPIUM BROMIDE Aerosol inhaler, 100 µg with ipratropium bromide, 20 µg per dose CFC-free ...........................................................................12.19 Nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg per vial, 2.5 ml – Up to 20 neb available on a PSO ........................... 4.29

200 dose OP 20

Duolin HFA Duolin

Leukotriene Receptor Antagonists

MONTELUKAST – Special Authority see SA1227 below – Retail pharmacy Prescribing Guideline: Clinical evidence indicates that the effectiveness of montelukast is strongest when montelukast is used in short treatment courses. Tab 4 mg ...........................................................................................18.48 28 Singulair Tab 5 mg ...........................................................................................18.48 28 Singulair Tab 10 mg .........................................................................................18.48 28 Singulair

¾SA1227 Special Authority for Subsidy Initial application — (Pre-school wheeze) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 To be used for the treatment of intermittent severe wheezing (possibly viral) in children under 5 years; and 2 The patient has trialled inhaled corticosteroids at a dose of up to 400 µg per day beclomethasone or budesonide, or 200 µg per day ﬂuticasone for at least one month; and 3 The patient continues to have at least three severe exacerbations at least one of which required hospitalisation (deﬁned as in-patient stay or prolonged Emergency Department treatment) in the past 12 months. Renewal — (Pre-school wheeze) from any relevant practitioner. Approvals valid for 1 year where the treatment remains appropriate and the patient is beneﬁting from treatment. Initial application — (exercise-induced asthma) from any relevant practitioner. Approvals valid without further renewal unless notiﬁed for applications meeting the following criteria: Both: continued. . .

172

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

RESPIRATORY SYSTEM AND ALLERGIES

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

continued. . . 1 Patient is being treated with maximal asthma therapy, including inhaled corticosteroids and long-acting beta-adrenoceptor agonists; and 2 Patient continues to experience frequent episodes of exercise-induced bronchoconstriction. Initial application — (aspirin desensitisation) only from a clinical immunologist or allergist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 Patient is undergoing aspirin desensitisation therapy under the supervision of a clinical immunologist or allergist; and 2 Patient has moderate to severe aspirin-exacerbated respiratory disease or Samter’s triad; and 3 Nasal polyposis, conﬁrmed radiologically or surgically; and 4 Documented aspirin or NSAID allergy conﬁrmed by aspirin challenge or a clinical history of severe reaction to aspirin or NSAID where challenge would be considered dangerous.

Mast Cell Stabilisers Mast cell stabilisers

NEDOCROMIL Aerosol inhaler, 2 mg per dose CFC-free .........................................28.07 SODIUM CROMOGLYCATE Powder for inhalation, 20 mg per dose .............................................17.94 Aerosol inhaler, 5 mg per dose CFC-free .........................................28.07 112 dose OP 50 dose 112 dose OP

Tilade Intal Spincaps Intal Forte CFC Free

Methylxanthines

AMINOPHYLLINE F Inj 25 mg per ml, 10 ml – Up to 5 inj available on a PSO .................53.75 THEOPHYLLINE F Tab long-acting 250 mg ....................................................................21.51 F‡ Oral liq 80 mg per 15 ml ...................................................................15.50 5 100 500 ml

DBL Aminophylline Nuelin-SR Nuelin

Mucolytics

DORNASE ALFA – Special Authority see SA0611 below – Retail pharmacy Nebuliser soln, 2.5 mg per 2.5 ml ampoule ....................................250.00 6

Pulmozyme

¾SA0611 Special Authority for Subsidy Special Authority approved by the Cystic Fibrosis Advisory Panel Notes: Application details may be obtained from PHARMAC’s website http://www.pharmac.govt.nz or: The Co-ordinator, Cystic Fibrosis Advisory Panel Phone: (04) 460 4990 PHARMAC, PO Box 10 254 Facsimile: (04) 916 7571 Wellington Email: CFPanel@pharmac.govt.nz Prescriptions for patients approved for treatment must be written by respiratory physicians or paediatricians who have experience and expertise in treating cystic ﬁbrosis. SODIUM CHLORIDE Not funded for use as a nasal drop. Soln 7% ............................................................................................23.50 90 ml OP Biomed

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

173

RESPIRATORY SYSTEM AND ALLERGIES

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

Nasal Preparations Allergy Prophylactics

BECLOMETHASONE DIPROPIONATE Metered aqueous nasal spray, 50 µg per dose ..................................2.35 (4.00) Metered aqueous nasal spray, 100 µg per dose ................................2.46 (4.81) BUDESONIDE Metered aqueous nasal spray, 50 µg per dose ..................................2.35 (4.00) Metered aqueous nasal spray, 100 µg per dose ................................2.61 (4.81) FLUTICASONE PROPIONATE Metered aqueous nasal spray, 50 µg per dose ................................13.34 IPRATROPIUM BROMIDE Aqueous nasal spray, 0.03% ..............................................................4.03 SODIUM CROMOGLYCATE Nasal spray, 4% ................................................................................15.85 200 dose OP Alanase 200 dose OP Alanase 200 dose OP Butacort Aqueous 200 dose OP Butacort Aqueous 120 dose OP

Flixonase Hayfever

& Allergy

15 ml OP 22 ml OP

Univent Rex

Respiratory Devices

MASK FOR SPACER DEVICE a) Up to 20 dev available on a PSO b) Only on a PSO c) Only for children aged six years and under Size 2 ..................................................................................................2.99 PEAK FLOW METER a) Up to 10 dev available on a PSO b) Only on a PSO Low range .........................................................................................11.44 Normal range ....................................................................................11.44 SPACER DEVICE a) Up to 20 dev available on a PSO b) Only on a PSO 230 ml (single patient) ........................................................................4.72 800 ml .................................................................................................8.50

EZ-ﬁt Paediatric

Mask

1 1

Breath-Alert Breath-Alert

1 1

Space Chamber

Plus

Volumatic

SPACER DEVICE AUTOCLAVABLE a) Up to 5 dev available on a PSO b) Only on a PSO 230 ml (autoclavable) – Subsidy by endorsement.............................11.60 1 Space Chamber Available where the prescriber requires a spacer device that is capable of sterilisation in an autoclave and the PSO is endorsed accordingly.

174

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

RESPIRATORY SYSTEM AND ALLERGIES

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

Respiratory Stimulants

CAFFEINE CITRATE Oral liq 20 mg per ml (10 mg base per ml) .......................................14.85 25 ml OP

Biomed

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

175

SENSORY ORGANS

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

Ear Preparations

ACETIC ACID WITH 1, 2- PROPANEDIOL DIACETATE AND BENZETHONIUM For Vosol ear drops with hydrocortisone powder refer, page 185 Ear drops 2% with 1, 2-Propanediol diacetate 3% and benzethonium chloride 0.02% ..................................................... 6.97 CHLORAMPHENICOL Ear drops 0.5% ...................................................................................2.20 FLUMETASONE PIVALATE Ear drops 0.02% with clioquinol 1% ...................................................4.46

35 ml OP 5 ml OP 7.5 ml OP

Vosol Chloromycetin Locacorten-Viaform

ED’s

Locorten-Vioform

TRIAMCINOLONE ACETONIDE WITH GRAMICIDIN, NEOMYCIN AND NYSTATIN Ear drops 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 µg per g ............................................ 5.16 7.5 ml OP

Kenacomb

Ear/Eye Preparations

DEXAMETHASONE WITH FRAMYCETIN AND GRAMICIDIN Ear/Eye drops 500 µg with framycetin sulphate 5 mg and gramicidin 50 µg per ml ............................................................... 4.50 (9.27) FRAMYCETIN SULPHATE Ear/Eye drops 0.5% ............................................................................4.13 (8.65)

8 ml OP Sofradex 8 ml OP Soframycin

Eye Preparations

Eye preparations are only funded for use in the eye. The exception is pilocarpine eye drops 1%, 2% and 4% which are subsidised for oral use pursuant to the Standard Formulae.

Anti-Infective Preparations

ACICLOVIR F Eye oint 3% ......................................................................................37.53 CHLORAMPHENICOL Eye oint 1% ........................................................................................2.37 Eye drops 0.5% ..................................................................................1.20 4.5 g OP 4 g OP 10 ml OP

Zovirax Chlorsig Chlorafast

CIPROFLOXACIN Eye Drops 0.3% ................................................................................12.43 5 ml OP Ciloxan For treatment of bacterial keratitis or severe bacterial conjunctivitis resistant to chloramphenicol. FUSIDIC ACID Eye drops 1% .....................................................................................4.50 5 g OP Fucithalmic GENTAMICIN SULPHATE Eye drops 0.3% ................................................................................11.40 PROPAMIDINE ISETHIONATE F Eye drops 0.1% ..................................................................................2.97 (7.99) 5 ml OP 10 ml OP Brolene

Genoptic

176

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

SENSORY ORGANS

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

TOBRAMYCIN Eye oint 0.3% ...................................................................................10.45 Eye drops 0.3% ................................................................................11.48

3.5 g OP 5 ml OP

Tobrex Tobrex

Corticosteroids and Other Anti-Inﬂammatory Preparations

DEXAMETHASONE F Eye oint 0.1% .....................................................................................5.86 F Eye drops 0.1% ..................................................................................4.50 DEXAMETHASONE WITH NEOMYCIN AND POLYMYXIN B SULPHATE F Eye oint 0.1% with neomycin sulphate 0.35% and polymyxin B sulphate 6,000 u per g .............................................................5.39 F Eye drops 0.1% with neomycin sulphate 0.35% and polymyxin B sulphate 6,000 u per ml ......................................................4.50 DICLOFENAC SODIUM F Eye drops 1 mg per ml .....................................................................13.80 FLUOROMETHOLONE F Eye drops 0.1% ..................................................................................4.05 LEVOCABASTINE Eye drops 0.5 mg per ml ....................................................................8.71 (10.34) LODOXAMIDE TROMETAMOL Eye drops 0.1% ..................................................................................8.71 PREDNISOLONE ACETATE F Eye drops 0.12% ................................................................................4.50 F Eye drops 1% .....................................................................................4.50 SODIUM CROMOGLYCATE Eye drops 2% .....................................................................................1.18 3.5 g OP 5 ml OP

Maxidex Maxidex

3.5 g OP 5 ml OP 5 ml OP 5 ml OP 4 ml OP

Maxitrol Maxitrol Voltaren Ophtha FML

Livostin 10 ml OP 5 ml OP 5 ml OP 5 ml OP

Lomide Pred Mild Pred Forte Rexacrom

Glaucoma Preparations - Beta Blockers

BETAXOLOL HYDROCHLORIDE F Eye drops 0.25% ..............................................................................11.80 F Eye drops 0.5% ..................................................................................7.50 LEVOBUNOLOL F Eye drops 0.25% ................................................................................7.00 F Eye drops 0.5% ..................................................................................7.00 TIMOLOL MALEATE F Eye drops 0.25% ................................................................................2.08 F Eye drops 0.25%, gel forming ............................................................3.30 F Eye drops 0.5% ..................................................................................2.08 F Eye drops 0.5%, gel forming ..............................................................3.78 5 ml OP 5 ml OP 5 ml OP 5 ml OP 5 ml OP 2.5 ml OP 5 ml OP 2.5 ml OP

Betoptic S Betoptic Betagan Betagan Arrow-Timolol Timoptol XE Arrow-Timolol Timoptol XE

Glaucoma Preparations - Carbonic Anhydrase Inhibitors

ACETAZOLAMIDE F Tab 250 mg – For acetazolamide oral liquid formulation refer, page 182 .................................................................................... 17.03 BRINZOLAMIDE F Eye Drops 1% .....................................................................................9.77

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

100 5 ml OP

Diamox Azopt 177

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

SENSORY ORGANS

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

DORZOLAMIDE HYDROCHLORIDE F Eye drops 2% .....................................................................................9.77 (13.95) DORZOLAMIDE HYDROCHLORIDE WITH TIMOLOL MALEATE F Eye drops 2% with timolol maleate 0.5% .........................................15.50

5 ml OP Trusopt 5 ml OP

Cosopt

Glaucoma Preparations - Prostaglandin Analogues

BIMATOPROST – Retail pharmacy-Specialist F Eye drops 0.03% ..............................................................................18.50 LATANOPROST – Retail pharmacy-Specialist F Eye drops 50 µg per ml, 2.5 ml ..........................................................1.99 TRAVOPROST – Retail pharmacy-Specialist F Eye drops 0.004% ............................................................................19.50 3 ml OP 2.5 ml OP 2.5 ml OP

Lumigan Hysite Travatan

Glaucoma Preparations - Other

BRIMONIDINE TARTRATE F Eye Drops 0.2% .................................................................................6.45 (AFT Eye Drops 0.2% to be delisted 1 October 2012) BRIMONIDINE TARTRATE WITH TIMOLOL MALEATE F Eye drops 0.2% with timolol maleate 0.5% ......................................18.50 PILOCARPINE F Eye drops 1% .....................................................................................4.26 F Eye drops 2% .....................................................................................5.35 F Eye drops 4% .....................................................................................7.99 F Eye drops 2% single dose – Special Authority see SA0895 below – Retail pharmacy ...........................................................31.95 (32.72) 5 ml OP 15 ml OP 15 ml OP 15 ml OP 20 dose Minims 5 ml OP

AFT Arrow-Brimonidine

Combigan Isopto Carpine Isopto Carpine Isopto Carpine

¾SA0895 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Patient has to use an unpreserved solution due to an allergy to the preservative; or 2 Patient wears soft contact lenses. Note: Minims for a general practice are considered to be “tools of trade” and are not approved as special authority items. Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is beneﬁting from treatment.

Mydriatics and Cycloplegics

ATROPINE SULPHATE F Eye drops 1% ...................................................................................17.36 CYCLOPENTOLATE HYDROCHLORIDE F Eye drops 1% .....................................................................................8.76 HOMATROPINE HYDROBROMIDE F Eye drops 2% .....................................................................................7.18 TROPICAMIDE F Eye drops 0.5% ..................................................................................7.15 F Eye drops 1% .....................................................................................8.66 15 ml OP 15 ml OP 15 ml OP 15 ml OP 15 ml OP

Atropt Cyclogyl Isopto Homatropine Mydriacyl Mydriacyl

178

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

SENSORY ORGANS

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

Preparations for Tear Deﬁciency

For acetylcysteine eye drops refer, page 185 HYPROMELLOSE F Eye drops 0.3% ..................................................................................2.62 F Eye drops 0.5% ..................................................................................2.00 (3.92) POLYVINYL ALCOHOL F Eye drops 1.4% ..................................................................................2.68 F Eye drops 3% .....................................................................................3.75 TYLOXAPOL F Eye drops 0.25% ................................................................................8.63

15 ml OP 15 ml OP

Poly-Tears

Methopt

15 ml OP 15 ml OP 15 ml OP

Vistil Vistil Forte Enuclene

Other Eye Preparations

NAPHAZOLINE HYDROCHLORIDE F Eye drops 0.1% ..................................................................................4.15 PARAFFIN LIQUID WITH SOFT WHITE PARAFFIN F Eye oint with soft white parafﬁn ..........................................................3.63 PARAFFIN LIQUID WITH WOOL FAT LIQUID F Eye oint 3% with wool fat liq 3% .........................................................3.63 PHENYLEPHRINE HYDROCHLORIDE F Eye drops 0.12% ................................................................................4.47 15 ml OP 3.5 g OP 3.5 g OP 15 ml OP

Naphcon Forte Lacri-Lube Poly-Visc Prefrin

‡ safety cap FThree months or six months, as applicable, dispensed all-at-once

LThree months supply may be dispensed at one time if endorsed “certiﬁed exemption” by the prescriber.

179

VARIOUS

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

Various

May only be claimed once per patient. PHARMACY SERVICES F Brand switch fee ................................................................................4.50 a) The Pharmacode for BSF Rizamelt is 2405849 b) The Pharmacode for BSF Ursosan is 2405857 (BSF Rizamelt Brand switch fee to be delisted 1 November 2012) (BSF Ursosan Brand switch fee to be delisted 1 November 2012)

1 fee

BSF Rizamelt BSF Ursosan

180

fully subsidised [HP4] refer page 9

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

SECTION C: EXTEMPORANEOUSLY COMPOUNDED PRODUCTS & GALENICALS

INTRODUCTION

The following extemporaneously compounded products are eligible for subsidy:

G G G G

The “Standard Formulae”. Oral liquid mixtures for patients unable to swallow subsidised solid dose oral formulations. The preparation of syringe drivers when prescribed by a general practitioner. Dermatological preparations a) One or more subsidised dermatological galenical(s) in a subsidised dermatological base. b) Dilution of proprietary Topical Corticosteroid-Plain preparations with a dermatological base (Retail pharmacy-specialist). c) Menthol crystals only in the following bases: Aqueous cream Urea cream 10% Wool fat with mineral oil lotion Hydrocortisone 1% with wool fat and mineral oil lotion Glycerol, parafﬁn and cetyl alcohol lotion.

Glossary

Dermatological base: The products listed in the Barrier creams and Emollients section and the Topical Corticosteroids-Plain section of the Pharmaceutical Schedule are classiﬁed as dermatological bases for the purposes of extemporaneous compounding and are the bases to which the dermatological galenicals can be added. Also the dermatological bases in the Barrier Creams and Emollients section of the Pharmaceutical Schedule can be used for diluting proprietary Topical Corticosteroid-Plain preparations. The following products are dermatological bases:

G G G G G G G G G G G

Aqueous cream Cetomacrogol cream BP Collodion ﬂexible Emulsifying ointment BP Hydrocortisone with wool fat and mineral oil lotion Oil in water emulsion Urea cream 10% White soft parafﬁn Wool fat with mineral oil lotion Zinc and castor oil ointment BP Proprietary Topical Corticosteroid-Plain preparations

Dermatological galenical: Dermatological galenicals will only be subsidised when added to a dermatological base. More than one dermatological galenical can be added to a dermatological base. The following are dermatological galenicals:

G G G G G

Coal tar solution BP - up to 10% Hydrocortisone powder - up to 5% Menthol crystals Salicylic acid powder Sulphur precipitated powder

Standard formulae: Standard formulae are a list of fomulae for ECPs that are subsidised. Their ingredients are listed under the appropriate therapeutic heading in Section B of the Pharmaceutical Schedule and also in Section C.

181

Explanatory notes

Oral liquid mixtures Oral liquid mixtures are subsidised for patients unable to swallow subsidised solid oral dose forms where no suitable alternative proprietary formulation is subsidised. Suitable alternatives include dispersible and sublingual formulations, oral liquid formulations or rectal formulations. Before extemporaneously compounding an oral liquid mixture, other alternatives such as dispersing the solid dose form (if appropriate) or crushing the solid dose form in jam, honey or soft foods such as yoghurt should be explored. The Emixt website www.pharminfotech.co.nz has evidence-based formulations which are intended to standardise compounded oral liquids within New Zealand. Pharmaceuticals with standardised formula for compounding in Ora products Acetazolamide 25 mg/ml Allopurinol 20 mg/ml Amlodipine 1 mg/ml Azathioprine 50 mg/ml Baclofen 10 mg/ml Carvedilol 1 mg/ml Clopidogrel 5 mg/ml Diltiazem hydrochloride 12 mg/ml Dipyridamole 10 mg/ml Domperidone 1 mg/ml Enalapril 1 mg/ml *Note this is a DCS formulation PHARMAC endorses the recommendations of the Emixt website and encourages New Zealand pharmacists to use these formulations when compounding is appropriate. The Emixt website also provides stability and expiry data for compounded products. For the majority of products compounded with Ora-Blend, Ora-Blend SF, Ora-Plus, Ora-Sweet or Ora-Sweet SF a four week expiry is appropriate. Please note that no oral liquid mixture will be eligible for Subsidy unless all the requirements of Section B and C of the Schedule applicable to that pharmaceutical are met. Some community pharmacies may not have appropriate equipment to compound all of the listed products, please use appropriate clinical judgement. Subsidy for extemporaneously compounded oral liquid mixtures is based on: qs Solid dose form qs Preservative Suspending agent qs Water to 100% or qs Solid dose form Ora-Blend, Ora-Blend SF, Ora-Plus, Ora-Sweet and/or Ora-Sweet SF to 100% Prescribers may prescribe or pharmacists may add extra non-subsidised ingredients such as ﬂavouring and colouring agents, but these extra ingredients will not be reimbursed. The subsidised ingredients in the formula will be reimbursed and a compounding fee paid. The majority of extemporaneously compounded oral liquid mixtures should contain a preservative and suspending agent. G Ora-Blend, Ora-Blend SF, Ora-Plus, Ora-Sweet and Ora-Sweet SF when used correctly are an appropriate preservative and suspending agent. G Methylcellulose 3% is considered a suitable suspending agent and compound hydroxybenzoate solution or methyl hydroxybenzoate 10% solution are considered to be suitable preservatives. Usually 1 ml of these preservative solutions is added to 100 ml of oral liquid mixture. Some solid oral dose forms are not appropriate for compounding into oral liquid mixtures and should therefore not be used/considered for extemporaneously compounded oral liquid mixtures. This includes long-acting solid dose formulations, enteric coated tablets or capsules, sugar coated tablets, hard gelatin capsules and chemotherapeutic agents. Flecainide 20 mg/ml Gabapentin 100 mg/ml Gabapentin (Neurontin) 100 mg/ml Hydrocortisone 1 mg/ml Labetolol 10 mg/ml Levetiracetam 100 mg/ml Levodopa with carbidopa (5 mg levodopa + 1.25 mg carbidopa)/ml Metoprolol tartrate 10 mg/ml Nitrofurantoin 10 mg/ml Pyrazinamide 100 mg/ml Rifabutin 20 mg/ml Sildenaﬁl 2 mg/ml Sotalol 15 mg/ml Sulphasalazine 100 mg/ml Tacrolimus 1 mg/ml Terbinaﬁne 25 mg/ml Ursodeoxycholic acid 50 mg/ml Valganciclovir 60 mg/ml* Verapamil hydrochloride 50 mg/ml

182

EXTEMPORANEOUSLY COMPOUNDED PRODUCTS & GALENICALS

The following practices will not be subsidised: G Where a Standard Formula exists in the Pharmaceutical Schedule for a solid dose form, compounding the solid dose form in Ora-Blend, Ora-Blend SF, Ora-Plus, Ora-Sweet and/or Ora-Sweet SF. G Mixing one or more proprietary oral liquids (eg an antihistamine with pholcodine linctus). G Extemporaneously compounding an oral liquid with more than one solid dose chemical. G Mixing more than one extemporaneously compounded oral liquid mixture. G Mixing one or more extemporaneously compounded oral liquid mixtures with one or more proprietary oral liquids. G The addition of a chemical/powder/agent/solution to a proprietary oral liquid or extemporaneously compounded oral mixture. Standard formulae A list of standard formulae is contained in this section. All ingredients associated with a standard formula will be subsidised and an appropriate compounding fee paid. Prescribers may prescribe or pharmacists may add extra non-subsidised ingredients, but these extra ingredients will not be reimbursed. The subsidised ingredients in the formula will be reimbursed and a compounding fee paid. Dermatological Preparations Proprietary topical corticosteroid preparations may be diluted with a dermatological base (see page 181) from the Barrier Creams and Emollients section of the Pharmaceutical Schedule (Retail pharmacy-Specialist). Dilution of proprietary topical corticosteroid preparations should only be prescribed for withdrawing patients off higher strength proprietary topical corticosteroid products where there is no suitable proprietary product of a lower strength available or an extemporaneously compounded product with up to 5% hydrocortisone is not appropriate. (In general proprietary topical corticosteroid preparations should not be diluted because dilution effects can be unpredictable and may not be linear, and usually there is no stability data available for diluted products). One or more dermatological galenicals may be added to a dermatological base (including proprietary topical corticosteroid preparations). Prescribers may prescribe or pharmacists may add extra non-subsidised ingredients, but these extra ingredients will not be reimbursed. The subsidised ingredients in the formula will be reimbursed and a compounding fee paid. The addition of dermatological galenicals to diluted proprietary Topical Corticosteroids-Plain will not be subsidised. The ﬂow diagram on the next page may assist you in deciding whether or not a dermatological ECP is subsidised.

183

EXTEMPORANEOUSLY COMPOUNDED PRODUCTS & GALENICALS

Dermatological ECPs

Is it subsidised?

Does the formula contain a subsidised dermatological base? Yes Is there only one dermatological base (e.g. aqueous cream)? Yes Is the galenical(s) a subsidised dermatological galenical? Yes Is the second base a proprietary topical corticosteroid-plain? No Is prescription written by a specialist or on the recommendation of a specialist? Entire product is NSS

Yes

Entire product is NSS

This part of the product is subsidised

Yes

Has a non-subsidised ingredient been added: e.g. glycerol?

Has a dermatological galenical or other non-subsidised ingredient been added? Yes

Yes

The non-subsidised ingredient is not subsidised but the rest is

The dermatological galenicals & non-subsidised ingredients are NSS

184

EXTEMPORANEOUSLY COMPOUNDED PRODUCTS & GALENICALS

Standard Formulae

ACETYLCYSTEINE EYE DROPS Acetylcysteine inj 200 mg per ml, 10 ml qs Suitable eye drop base qs ASPIRIN AND CHLOROFORM APPLICATION Aspirin Soluble tabs 300 mg 12 tabs Chloroform to 100 ml CODEINE LINCTUS PAEDIATRIC (3 mg per 5 ml) Codeine phosphate 60 mg Glycerol 40 ml Preservative qs Water to 100 ml CODEINE LINCTUS DIABETIC (15 mg per 5 ml) Codeine phosphate 300 mg Glycerol 40 ml Preservative qs Water to 100 ml FOLINIC MOUTHWASH Calcium folinate 15 mg tab 1 tab Preservative qs Water to 500 ml (Preservative should be used if quantity supplied is for more than 5 days. Maximum 500 ml per prescription.) MAGNESIUM HYDROXIDE MIXTURE Magnesium hydroxide paste Methyl hydroxybenzoate Water METHADONE MIXTURE Methadone powder Glycerol Water 275 g 1.5 g 770 ml qs qs to 100 ml

OMEPRAZOLE SUSPENSION Omeprazole capules or powder Sodium bicarbonate powder BP Water PHENOBARBITONE ORAL LIQUID Phenobarbitone Sodium Glycerol BP Water

qs 8.4 g to 100 ml 1g 70 ml to 100 ml

PHENOBARBITONE SODIUM PAEDIATRIC ORAL LIQUID (10 mg per ml) Phenobarbitone Sodium 400 mg Glycerol BP 4 ml Water to 40 ml PILOCARPINE ORAL LIQUID Pilocarpine 4% eye drops qs Preservative qs Water to 500 ml (Preservative should be used if quantity supplied is for more than 5 days.) SALIVA SUBSTITUTE FORMULA Methylcellulose 5g Preservative qs Water to 500 ml (Preservative should be used if quantity supplied is for more than 5 days. Maximum 500 ml per prescription.) SODIUM CHLORIDE ORAL LIQUID Sodium chloride inj 23.4%, 20 ml qs Water qs (Only funded if prescribed for treatment of hyponatraemia) VOSOL EAR DROPS WITH HYDROCORTISONE POWDER 1% Hydrocortisone powder 1% Vosol Ear Drops to 35 ml

METHYL HYDROXYBENZOATE 10% SOLUTION Methyl hydroxybenzoate 10 g Propylene glycol to 100 ml (Use 1 ml of the 10% solution per 100 ml of oral liquid mixture)

185

EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS AND GALENICALS

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

Extemporaneously Compounded Preparations and Galenicals

ACETYLCYSTEINE – Retail pharmacy-Specialist Inj 200 mg per ml, 10 ml .................................................................178.00 137.06 (255.35) Inj 200 mg per ml, 30 ml .................................................................219.00 (Hospira Inj 200 mg per ml, 10 ml to be delisted 1 October 2012) BENZOIN Tincture compound BP .......................................................................2.44 (5.10) 24.42 (38.00) CHLOROFORM – Only in combination Only in aspirin and chloroform application. Chloroform BP ..................................................................................25.50 10

Martindale

Acetylcysteine Hospira

Acetadote

50 ml PSM 500 ml PSM

500 ml

PSM

CODEINE PHOSPHATE – Safety medicine; prescriber may determine dispensing frequency Powder – Only in combination .........................................................12.62 5g (25.46) Douglas 63.09 25 g (90.09) Douglas a) Only in extemporaneously compounded codeine linctus diabetic or codeine linctus paediatric. b) ‡ Safety cap for extemporaneously compounded oral liquid preparations. COLLODION FLEXIBLE Collodion ﬂexible ..............................................................................19.30 100 ml PSM COMPOUND HYDROXYBENZOATE – Only in combination Only in extemporaneously compounded oral mixtures. Soln ..................................................................................................34.18 GLYCERIN WITH SODIUM SACCHARIN – Only in combination Only in combination with Ora-Plus. Suspension .......................................................................................36.80 GLYCERIN WITH SUCROSE – Only in combination Only in combination with Ora-Plus. Suspension .......................................................................................36.80 GLYCEROL F Liquid – Only in combination ...........................................................17.86 Only in extemporaneously compounded oral liquid preparations. MAGNESIUM HYDROXIDE Paste ................................................................................................22.61

100 ml

David Craig

473 ml

Ora-Sweet SF

473 ml 2,000 ml

Ora-Sweet healthE

500 g

PSM

186

fully subsidised

[HP3], [HP4] refer page 9

EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS AND GALENICALS

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

METHYL HYDROXYBENZOATE Powder ................................................................................................8.00 8.98 METHYLCELLULOSE Powder ..............................................................................................14.00 (17.72) Suspension – Only in combination ..................................................36.80

25 g

PSM Midwest ABM

MidWest

100 g 473 ml

Ora-Plus Ora-Blend SF Ora-Blend MidWest MidWest

METHYLCELLULOSE WITH GLYCERIN AND SODIUM SACCHARIN – Only in combination Suspension .......................................................................................36.80 473 ml METHYLCELLULOSE WITH GLYCERIN AND SUCROSE – Only in combination Suspension .......................................................................................36.80 473 ml

PHENOBARBITONE SODIUM Powder – Only in combination .........................................................52.50 10 g 325.00 100 g a) Only in children up to 12 years b) ‡ Safety cap for extemporaneously compounded oral liquid preparations. PROPYLENE GLYCOL Only in extemporaneously compounded methyl hydroxybenzoate 10% solution. Liq .....................................................................................................10.50 500 ml 11.25 12.00 (ABM Liq to be delisted 1 September 2012) SODIUM BICARBONATE Powder BP – Only in combination .....................................................8.95 500 g 9.80 (29.50) Only in extemporaneously compounded omeprazole and lansoprazole suspension. SYRUP (PHARMACEUTICAL GRADE) – Only in combination Only in extemporaneously compounded oral liquid preparations. Liq .....................................................................................................21.75 2,000 ml WATER Tap – Only in combination .................................................................0.00 1 ml

PSM Midwest ABM

Midwest

David Craig

Midwest Tap water

fully subsidised

[HP3], [HP4] refer page 9

187

SECTION D: SPECIAL FOODS

EXPLANATORY NOTES

The list of special foods to which Subsidies apply is contained in this section. The list of available products, guidelines for use, subsidies and charges is reviewed as required. Applications for new listings and changes to subsidies and access criteria will be considered by the special foods sub-committee of PTAC which meets as and when required. In all cases, subsidies are available by Special Authority only. This means that, unless a patient has a valid Special Authority number for their special food requirements, they must pay the full cost of the products themselves. Eligibility for Special Authority Special Authorities will be approved for patients meeting conditions speciﬁed under the Conditions and Guidelines for each product. In some cases there are also limits to how products can be prescribed (for example quantity, use or duration). Only those brands, presentations and ﬂavours of special foods listed in this section are subsidised. Who can apply for Special Authority? Only from a dietitian, relevant specialist or a vocationally registered general practitioner. Reapplications: Only from a dietitian, relevant specialist or a vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or a vocationally registered general practitioner. Other general practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and the date contacted. All applications must be made on an ofﬁcial form available from the PHARMAC website www.pharmac.govt.nz. All applications must include speciﬁc details as requested on the form relating to the application. Applications must be forwarded to: Ministry of Health Sector Services Private Bag 3015 WHANGANUI 4540 Freefax 0800 100 131 Initial Applications: Subsidies and manufacturer’s surcharges The Subsidies for some special foods are based on the lowest priced product within each group. Where this is so, or where special foods are otherwise not fully subsidised, a manufacturer’s surcharge may be payable by the patient. The manufacturer’s surcharge is the difference between the price of the product and the subsidy attached to it and may be subject to mark-ups applied at a pharmacy level. As a result the manufacturer’s surcharge may vary. Fully subsidised alternatives are available in most cases (as indicated by a tick in the left hand column). Patients should only have to pay a co-payment on these products. Where are special foods available from? Distribution arrangements for special foods vary from region to region. Special foods are available from hospital pharmacies providing an outpatient dispensing service as well as retail pharmacies in the Northern, Midland and Central (including Nelson and Blenheim) regions. Deﬁnitions Failure to thrive Growth deﬁciency An inability to gain or maintain weight resulting in physiological impairment. Where the weight of the child is less than the ﬁfth or possibly third percentile for their age, with evidence of malnutrition

188

SPECIAL FOODS

Dietitian Prescribing Prescriptions from Dietitians will be only valid for subsidy where they are for special foods, as listed in this section, or where they are for the following products: ASCORBIC ACID Tab 100 mg CALCIUM CARBONATE Tab eff 1.75 g (1 g elemental) Tab 1.25 g (500 mg elemental) COMPOUND ELECTROLYTES Powder for soln for oral use 4.4 g DEXTROSE WITH ELECTROLYTES Soln with electrolytes FERROUS FUMARATE Tab 200 mg (65 mg elemental) FERROUS FUMARATE WITH FOLIC ACID Tab 310 mg (100 mg elemental) with folic acid 350 µg FERROUS SULPHATE Tab long-acting 325 mg (105 mg elemental) Oral liq 30 mg per 1 ml (6 mg elemental per 1 ml) FERROUS SULPHATE WITH FOLIC ACID Tab long-acting 325 mg (105 mg elemental) with folic acid 350 µg FOLIC ACID Tab 0.8 mg MULTIVITAMINS Powder PANCREATIC ENZYME Cap EC 10,000 BP u lipase, 9,000 BP u amylase and 210 BP u protease POTASSIUM BICARBONATE Tab eff 315 mg with sodium acid phosphate 1.937 g and sodium bicarbonate 350 mg POTASSIUM CHLORIDE Tab eff 548 mg (14 m eq) with chloride 285 mg (8 m eq) Tab long-acting 600 mg POTASSIUM IODATE Tab 256 µg (150 µg elemental iodine) PYRIDOXINE HYDROCHLORIDE Tab 25 mg Tab 50 mg SODIUM CHLORIDE Inj 23.4%, 20 ml SODIUM FLUORIDE Tab 1.1 mg (0.5 mg elemental) THIAMINE HYDROCHLORIDE Tab 50 mg VITAMIN A WITH VITAMINS D AND C Soln 1000 u with Vitamin D 400 u and ascorbic acid 30 mg per 10 drops VITAMIN B COMPLEX Tab, strong, BPC VITAMINS Tab (BPC cap strength) Cap (fat soluble vitamins A, D, E, K)

189

SPECIAL FOODS

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

Nutrient Modules Carbohydrate

¾SA1090 Special Authority for Subsidy Initial application — (Cystic ﬁbrosis or renal failure) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria: Either: 1 cystic ﬁbrosis; or 2 chronic renal failure or continuous ambulatory peritoneal dialysis (CAPD) patient. Initial application — (Indications other than cystic ﬁbrosis or renal failure) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Any of the following: 1 cancer in children; or 2 cancers affecting alimentary tract where there are malabsorption problems in patients over the age of 20 years; or 3 failure to thrive; or 4 growth deﬁciency; or 5 bronchopulmonary dysplasia; or 6 premature and post premature infant; or 7 inborn errors of metabolism. Renewal — (Cystic ﬁbrosis or renal failure) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian,relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is beneﬁting from treatment; and 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted. Renewal — (Indications other than cystic ﬁbrosis or renal failure) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is beneﬁting from treatment; and 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted. CARBOHYDRATE SUPPLEMENT – Special Authority see SA1090 above – Hospital pharmacy [HP3] Powder ................................................................................................5.29 400 g OP Polycal 1.30 368 g OP (12.00) Moducal

Carbohydrate And Fat

¾SA1091 Special Authority for Subsidy Initial application — (Cystic ﬁbrosis) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 infant aged four years or under; and 2 cystic ﬁbrosis. Initial application — (Indications other than cystic ﬁbrosis) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both: continued. . .

190

fully subsidised

[HP3], [HP4] refer page 9

SPECIAL FOODS

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

continued. . . 1 infant aged four years or under; and 2 Any of the following: 2.1 cancer in children; or 2.2 failure to thrive; or 2.3 growth deﬁciency; or 2.4 bronchopulmonary dysplasia; or 2.5 premature and post premature infants. Renewal — (Cystic ﬁbrosis) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is beneﬁting from treatment; and 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted. Renewal — (Indications other than cystic ﬁbrosis) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is beneﬁting from treatment; and 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted. CARBOHYDRATE AND FAT SUPPLEMENT – Special Authority see SA1091 on the preceding page – Hospital pharmacy [HP3] Powder (neutral) ...............................................................................60.31 400 g OP Duocal Super Soluble Powder

Fat

¾SA1092 Special Authority for Subsidy Initial application — (Inborn errors of metabolism) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years where the patient has inborn errors of metabolism. Initial application — (Indications other than inborn errors of metabolism) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Any of the following: 1 failure to thrive where other high calorie products are inappropriate or inadequate; or 2 growth deﬁciency; or 3 bronchopulmonary dysplasia; or 4 fat malabsorption; or 5 lymphangiectasia; or 6 short bowel syndrome; or 7 infants with necrotising enterocolitis; or 8 biliary atresia. Renewal — (Inborn errors of metabolism) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is beneﬁting from treatment; and 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted. continued. . .

fully subsidised

[HP3], [HP4] refer page 9

191

SPECIAL FOODS

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

continued. . . Renewal — (Indications other than inborn errors of metabolism) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is beneﬁting from treatment; and 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted. FAT SUPPLEMENT – Special Authority see SA1092 on the preceding page – Hospital pharmacy [HP3] Emulsion (neutral) ............................................................................12.30 200 ml OP Calogen 30.75 500 ml OP Calogen Emulsion (strawberry) .......................................................................12.30 200 ml OP Calogen Oil .....................................................................................................28.73 250 ml OP Liquigen 30.00 500 ml OP MCT oil (Nutricia)

Protein

¾SA1093 Special Authority for Subsidy Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Either: 1 protein losing enteropathy; or 2 high protein needs (eg burns). Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is beneﬁting from treatment; and 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted. PROTEIN SUPPLEMENT – Special Authority see SA1093 above – Hospital pharmacy [HP3] Powder ................................................................................................7.90 225 g OP Protifar 8.95 227 g OP Resource Beneprotein Powder (vanilla) ................................................................................12.90 275 g OP Promod

Oral Supplements/Complete Diet (Nasogastric/Gastrostomy Tube Feed) Respiratory Products

¾SA1094 Special Authority for Subsidy Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year where the patient has CORD and hypercapnia. Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is beneﬁting from treatment; and 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted. CORD ORAL FEED 1.5KCAL/ML – Special Authority see SA1094 above – Hospital pharmacy [HP3] Liquid ..................................................................................................1.66 237 ml OP Pulmocare

192

fully subsidised

[HP3], [HP4] refer page 9

SPECIAL FOODS

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

Diabetic Products

¾SA1095 Special Authority for Subsidy Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year where the patient is a type I or and II diabetic who is suffering weight loss and malnutrition that requires nutritional support. Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is beneﬁting from treatment; and 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted. DIABETIC ENTERAL FEED 1KCAL/ML – Special Authority see SA1095 above – Hospital pharmacy [HP3] Liquid ..................................................................................................7.50 1,000 ml OP Diason RTH Glucerna Select RTH DIABETIC ORAL FEED 1KCAL/ML – Special Authority see SA1095 above – Hospital pharmacy [HP3] Liquid (strawberry) ..............................................................................1.50 200 ml OP Diasip Liquid (vanilla) ....................................................................................1.50 200 ml OP Diasip 1.88 250 ml OP Glucerna Select 1.78 237 ml OP (2.10) Resource Diabetic

Fat Modiﬁed Products

¾SA1096 Special Authority for Subsidy Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Either: 1 Patient has metabolic disorders of fat metabolism; or 2 Patient has chylothorax. Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is beneﬁting from treatment; and 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted. FAT MODIFIED FEED – Special Authority see SA1096 above – Hospital pharmacy [HP3] Powder ..............................................................................................60.48 400 g OP Monogen

High Protein Products

¾SA1097 Special Authority for Subsidy Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Anorexia and weight loss; and 2 Either: 2.1 decompensating liver disease without encephalopathy; or 2.2 protein losing gastro-enteropathy. continued. . .

fully subsidised

[HP3], [HP4] refer page 9

193

SPECIAL FOODS

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

continued. . . Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is beneﬁting from treatment; and 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted. HIGH PROTEIN ORAL FEED 1KCAL/ML – Special Authority see SA1097 on the preceding page – Hospital pharmacy [HP3] Liquid ..................................................................................................1.90 200 ml OP Fortimel Regular

Paediatric Products For Children Awaiting Liver Transplant

¾SA1098 Special Authority for Subsidy Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years where the patient is a child (up to 18 years) who is awaiting liver transplant. Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is beneﬁting from treatment; and 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted. ENTERAL/ORAL FEED 1KCAL/ML – Special Authority see SA1098 above – Hospital pharmacy [HP3] Powder ..............................................................................................78.97 400 g OP Generaid Plus

Paediatric Products For Children With Chronic Renal Failure

¾SA1099 Special Authority for Subsidy Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years where the patient is a child (up to 18 years) with chronic renal failure. Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is beneﬁting from treatment; and 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted. ENTERAL/ORAL FEED 1KCAL/ML – Special Authority see SA1099 above – Hospital pharmacy [HP3] Liquid ................................................................................................54.00 400 g OP Kindergen

Paediatric Products

¾SA1224 Special Authority for Subsidy Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Child is aged one to ten years; and 2 Any of the following: 2.1 the child is being fed via a tube or a tube is to be inserted for the purposes of feeding; or 2.2 any condition causing malabsorption; or 2.3 failure to thrive; or continued. . .

194

fully subsidised

[HP3], [HP4] refer page 9

SPECIAL FOODS

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

continued. . . 2.4 increased nutritional requirements. Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is beneﬁting from treatment; and 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted. PAEDIATRIC ENTERAL FEED 1KCAL/ML – Special Authority see SA1224 on the preceding page – Hospital pharmacy [HP3] Liquid ..................................................................................................2.68 500 ml OP Nutrini RTH Pediasure RTH PAEDIATRIC ENTERAL FEED WITH FIBRE 1.5KCAL/ML – Special Authority see SA1224 on the preceding page – Hospital pharmacy [HP3] Liquid ..................................................................................................6.00 500 ml OP Nutrini Energy Multi Fibre Nutrini Energy RTH PAEDIATRIC ORAL FEED 1.5KCAL/ML – Special Authority see SA1224 on the preceding page – Hospital pharmacy [HP3] Liquid (strawberry) ..............................................................................1.60 200 ml OP Fortini Liquid (vanilla) ....................................................................................1.60 200 ml OP Fortini PAEDIATRIC ORAL FEED 1KCAL/ML – Special Authority see SA1224 on the preceding page – Hospital pharmacy [HP3] Liquid (chocolate) ...............................................................................1.07 200 ml OP Pediasure Liquid (strawberry) ..............................................................................1.07 200 ml OP Pediasure Liquid (vanilla) ....................................................................................1.07 200 ml OP Pediasure 1.27 237 ml OP Pediasure PAEDIATRIC ORAL FEED WITH FIBRE 1.5KCAL/ML – Special Authority see SA1224 on the preceding page – Hospital pharmacy [HP3] Liquid (chocolate) ...............................................................................1.60 200 ml OP Fortini Multi Fibre Liquid (strawberry) ..............................................................................1.60 200 ml OP Fortini Multi Fibre Liquid (vanilla) ....................................................................................1.60 200 ml OP Fortini Multi Fibre

Renal Products

¾SA1101 Special Authority for Subsidy Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years where the patient has acute or chronic renal failure. Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is beneﬁting from treatment; and 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted. RENAL ORAL FEED 2KCAL/ML – Special Authority see SA1101 above – Hospital pharmacy [HP3] Liquid ..................................................................................................2.43 200 ml OP Nepro (strawberry) Nepro (vanilla) 2.88 237 ml OP (3.31) NovaSource Renal Liquid (apricot) ....................................................................................2.88 125 ml OP Renilon 7.5 Liquid (caramel) ..................................................................................2.88 125 ml OP Renilon 7.5

fully subsidised

[HP3], [HP4] refer page 9

195

SPECIAL FOODS

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

Specialised And Elemental Products

¾SA1102 Special Authority for Subsidy Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Any of the following: 1 malabsorption; or 2 short bowel syndrome; or 3 enterocutaneous ﬁstulas; or 4 pancreatitis. Notes: Each of these products is highly specialised and would be prescribed only by an expert for a speciﬁc disorder. The alternative is hospitalisation. Elemental 028 Extra is more expensive than other products listed in this section and should only be used where the alternatives have been tried ﬁrst and/or are unsuitable. Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is beneﬁting from treatment; and 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted. ENTERAL/ORAL ELEMENTAL FEED 1KCAL/ML – Special Authority see SA1102 above – Hospital pharmacy [HP3] Powder ................................................................................................4.40 79 g OP Vital HN 7.50 76 g OP Alitraq ORAL ELEMENTAL FEED 0.8KCAL/ML – Special Authority see SA1102 above – Hospital pharmacy [HP3] Liquid (grapefruit) ...............................................................................9.50 250 ml OP Elemental 028 Extra Liquid (pineapple & orange) ...............................................................9.50 250 ml OP Elemental 028 Extra Liquid (summer fruit) ..........................................................................9.50 250 ml OP Elemental 028 Extra ORAL ELEMENTAL FEED 1KCAL/ML – Special Authority see SA1102 above – Hospital pharmacy [HP3] Powder (unﬂavoured) .........................................................................4.50 80.4 g OP Vivonex TEN SEMI-ELEMENTAL ENTERAL FEED 1KCAL/ML – Special Authority see SA1102 above – Hospital pharmacy [HP3] Liquid ................................................................................................12.04 1,000 ml OP Peptisorb

Undyalised End Stage Renal Failure

¾SA1103 Special Authority for Subsidy Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years where the patient has undialysed end stage renal failure. Note: Where possible, the requirements for oral supplementation should be established in conjunction with assessment by a dietitian. Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is beneﬁting from treatment; and 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted. RENAL ORAL FEED 1KCAL/ML – Special Authority see SA1103 above – Hospital pharmacy [HP3] Liquid ..................................................................................................3.80 237 ml OP Suplena

196

fully subsidised

[HP3], [HP4] refer page 9

SPECIAL FOODS

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

Paediatric Products For Children With Low Energy Requirements

¾SA1196 Special Authority for Subsidy Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Child aged one to eight years; and 2 The child has a low energy requirement but normal protein and micronutrient requirements. Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is beneﬁting from treatment; and 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted. PAEDIATRIC ENTERAL FEED WITH FIBRE 0.75 KCAL/ML – Special Authority see SA1196 above – Hospital pharmacy [HP3] Liquid ..................................................................................................4.00 500 ml OP Nutrini Low Energy Multi Fibre

Standard Supplements

¾SA1228 Special Authority for Subsidy Initial application — (Children) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The patient is under 18 years of age; and 2 Any of the following: 2.1 The patient has a condition causing malabsorption; or 2.2 The patient has failure to thrive; or 2.3 The patient has increased nutritional requirements; and 3 Nutrition goal has been set (eg reach a speciﬁc weight or BMI). Renewal — (Children) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The patient is under 18 years of age; and 2 The treatment remains appropriate and the patient is beneﬁting from treatment; and 3 A nutrition goal has been set (eg reach a speciﬁc weight or BMI). Initial application — (Adults) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 months for applications meeting the following criteria: All of the following: 1 Any of the following: Patient is Malnourished 1.1 Patient has a body mass index (BMI) of less than 18.5 kg/m2; or 1.2 Patient has unintentional weight loss greater than 10% within the last 3-6 months; or 1.3 Patient has a BMI of less than 20 kg/m2 and unintentional weight loss greater than 5% within the last 3-6 months; and 2 Any of the following: Patient has not responded to ﬁrst-line dietary measures over a 4 week period by: 2.1 Increasing their food intake frequency (eg snacks between meals); or 2.2 Using high-energy foods (e.g. milkshakes, full fat milk, butter, cream, cheese, sugar etc); or 2.3 Using over the counter supplements (e.g. Complan); and continued. . .

fully subsidised

[HP3], [HP4] refer page 9

197

SPECIAL FOODS

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

continued. . . 3 A nutrition goal has been set (e.g. to reach a speciﬁc weight or BMI). Renewal — (Adults) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 A nutrition goal has been set (eg reach a speciﬁc weight or BMI); and 2 Any of the following: Patient is Malnourished 2.1 Patient has a body mass index (BMI) of less than 18.5 kg/m2; or 2.2 Patient has unintentional weight loss greater than 10% within the last 3-6 months; or 2.3 Patient has a BMI of less than 20 kg/m2 and unintentional weight loss greater than 5% within the last 3-6 months. Initial application — (Adults transitioning from hospital Discretionary Community Supply) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 The patient has had up to a 30 day supply of a 1.0 or a 1.5 kcal/ml Standard Oral Supplement; and 2 A nutrition goal has been set (eg reach a speciﬁc weight or BMI); and 3 Any of the following: Patient is Malnourished 3.1 Patient has a body mass index (BMI) of less than 18.5 kg/m2; or 3.2 Patient has unintentional weight loss greater than 10% within the last 3-6 months; or 3.3 Patient has a BMI of less than 20 kg/m2 and unintentional weight loss greater than 5% within the last 3-6 months. Initial application — (Short-term medical condition) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Any of the following: 1 Is being feed via a nasogastric tube or a nasogastric tube is to be inserted for feeding; or 2 Malignancy and is considered likely to develop malnutrition as a result; or 3 Is undergoing a bone marrow transplant; or 4 Tempomandibular surgery; or 5 Both: 5.1 Pregnant; and 5.2 Any of the following: 5.2.1 Patient is in early pregnancy (<13 weeks) and has severe clinical hyperemesis gravidarum requiring admission to hospital and is unlikely to meet her nutritional requirements due to continuing hyperemesis gravidarum; or 5.2.2 Patient has clinical hyperemesis gravidarum continuing past 13 weeks and either there is concern that the patient is unlikely to meet the Institute of Medicine’s (1990) recommended weight gain guidelines for pregnancy or the patient’s weight has not increased past her booking/pre-pregnancy weight; or 5.2.3 Patient is having multiple births and is under the care of an obstetric team who consider the nutritional needs of the patient are not being meet. Renewal — (Short-term medical condition) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Any of the following: 1 Is being fed via a nasogastric tube; or 2 Malignancy and is considered likely to develop malnutrition as a result; or 3 Has undergone a bone marrow transplant; or 4 Tempomandibular surgery; or 5 Both: 5.1 Pregnant; and continued. . .

198

fully subsidised

[HP3], [HP4] refer page 9

SPECIAL FOODS

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

continued. . . 5.2 Any of the following: 5.2.1 Patient is in early pregnancy (<13 weeks) and has severe clinical hyperemesis gravidarum requiring admission to hospital and is unlikely to meet her nutritional requirements due to continuing hyperemesis gravidarum; or 5.2.2 Patient has clinical hyperemesis gravidarum continuing past 13 weeks and either there is concern that the patient is unlikely to meet the Institute of Medicine’s (1990) recommended weight gain guidelines for pregnancy or the patient’s weight has not increased past her booking/pre-pregnancy weight; or 5.2.3 Patient is having multiple births and is under the care of an obstetric team who consider the nutritional needs of the patient are not being meet. Initial application — (Long-term medical condition) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notiﬁed for applications meeting the following criteria: Any of the following: 1 Is being fed via a tube or a tube is to be inserted for the purpose of feeding (not nasogastric tube - refer to speciﬁc medical condition criteria); or 2 Cystic Fibrosis; or 3 Liver disease; or 4 Chronic Renal failure; or 5 Inﬂammatory bowel disease; or 6 Chronic obstructive pulmonary disease with hypercapnia; or 7 Short bowel syndrome; or 8 Bowel ﬁstula; or 9 Severe chronic neurological conditions; or 10 Epidermolysis bullosa; or 11 AIDS (CD4 count < 200 cells/mm3 ); or 12 Chronic pancreatitis. Renewal — (Chronic disease OR tube feeding for patients who have previously been funded under Special Authority forms SA0702 or SA0583) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notiﬁed for applications meeting the following criteria: Any of the following: 1 Is being fed via a tube or a tube is to be inserted for the purpose of feeding (not nasogastric tube - refer to speciﬁc medical condition criteria); or 2 Cystic Fibrosis; or 3 Liver disease; or 4 Chronic Renal failure; or 5 Inﬂammatory bowel disease; or 6 Chronic obstructive pulmonary disease with hypercapnia; or 7 Short bowel syndrome; or 8 Bowel ﬁstula; or 9 Severe chronic neurological conditions. ENTERAL FEED 1.5KCAL/ML – Special Authority see SA1228 on page 197 – Hospital pharmacy [HP3] Liquid ..................................................................................................7.00 1,000 ml Nutrison Energy

fully subsidised

[HP3], [HP4] refer page 9

199

SPECIAL FOODS

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

ENTERAL FEED 1KCAL/ML – Special Authority see SA1228 on page 197 – Hospital pharmacy [HP3] Liquid ..................................................................................................1.24 250 ml OP Isosource Standard Osmolite 2.65 500 ml OP Nutrison Standard RTH 5.29 1,000 ml OP Nutrison Standard RTH Isosource Standard RTH 2.65 500 ml OP Osmolite RTH 5.29 1,000 ml OP Osmolite RTH ENTERAL FEED WITH FIBRE 1 KCAL/ML – Special Authority see SA1228 on page 197 – Hospital pharmacy [HP3] Liquid ..................................................................................................1.32 237 ml OP Jevity 2.65 500 ml OP Nutrison Multi Fibre 5.29 1,000 ml OP Nutrison Multi Fibre 2.65 500 ml OP Jevity RTH 5.29 1,000 ml OP Jevity RTH ENTERAL FEED WITH FIBRE 1.5KCAL/ML – Special Authority see SA1228 on page 197 – Hospital pharmacy [HP3] Liquid ..................................................................................................1.75 250 ml OP Ensure Plus HN 7.00 1,000 ml OP Ensure Plus RTH Nutrison Energy Multi Fibre ORAL FEED (POWDER) – Special Authority see SA1228 on page 197 – Hospital pharmacy [HP3] Powder (chocolate) ...........................................................................10.22 900 g OP Sustagen Hospital Formula 13.00 Ensure Powder (vanilla) ..................................................................................9.50 900 g OP Fortisip 10.22 Sustagen Hospital Formula 13.00 Ensure

200

fully subsidised

[HP3], [HP4] refer page 9

SPECIAL FOODS

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

ORAL FEED 1.5KCAL/ML – Special Authority see SA1228 on page 197 – Hospital pharmacy [HP3] Additional subsidy by endorsement is available for patients being bolus fed through a feeding tube. The prescription must be endorsed accordingly. Liquid (banana) – Higher subsidy of $1.26 per 200 ml with Endorsement ................................................................................0.72 200 ml OP (1.26) Ensure Plus (1.26) Fortisip Liquid (chocolate) – Higher subsidy of up to $1.33 per 237 ml with Endorsement.........................................................................0.72 200 ml OP (1.26) Ensure Plus 0.85 237 ml OP (1.33) Ensure Plus 0.72 200 ml OP (1.26) Fortisip Liquid (fruit of the forest) – Higher subsidy of $1.26 per 200 ml with Endorsement.........................................................................0.72 200 ml OP (1.26) Ensure Plus Liquid (strawberry) – Higher subsidy of up to $1.33 per 237 ml with Endorsement.............................................................0.72 200 ml OP (1.26) Ensure Plus 0.85 237 ml OP (1.33) Ensure Plus 0.72 200 ml OP (1.26) Fortisip Liquid (toffee) – Higher subsidy of $1.26 per 200 ml with Endorsement.....................................................................................0.72 200 ml OP (1.26) Fortisip Liquid (tropical fruit) – Higher subsidy of $1.26 per 200 ml with Endorsement.........................................................................0.72 200 ml OP (1.26) Fortisip Liquid (vanilla) – Higher subsidy of up to $1.33 per 237 ml with Endorsement.........................................................................0.72 200 ml OP (1.26) Ensure Plus 0.85 237 ml OP (1.33) Ensure Plus 0.72 200 ml OP (1.26) Fortisip ORAL FEED WITH FIBRE 1.5 KCAL/ML – Special Authority see SA1228 on page 197 – Hospital pharmacy [HP3] Additional subsidy by endorsement is available for patients being bolus fed through a feeding tube. The prescription must be endorsed accordingly. Liquid (chocolate) – Higher subsidy of $1.26 per 200 ml with Endorsement ................................................................................0.72 200 ml OP (1.26) Fortisip Multi Fibre Liquid (strawberry) – Higher subsidy of $1.26 per 200 ml with 200 ml OP Endorsement ................................................................................0.72 (1.26) Fortisip Multi Fibre Liquid (vanilla) – Higher subsidy of $1.26 per 200 ml with Endorsement ................................................................................0.72 200 ml OP (1.26) Fortisip Multi Fibre

fully subsidised

[HP3], [HP4] refer page 9

201

SPECIAL FOODS

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

Adult Products High Calorie

¾SA1195 Special Authority for Subsidy Initial application — (Cystic ﬁbrosis) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria: All of the following: 1 Cystic ﬁbrosis; and 2 other lower calorie products have been tried; and 3 patient has substantially increased metabolic requirements. Initial application — (Indications other than cystic ﬁbrosis) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 Any of the following: 1.1 any condition causing malabsorption; or 1.2 failure to thrive; or 1.3 increased nutritional requirements; or 1.4 ﬂuid restricted; and 2 other lower calorie products have been tried; and 3 patient has substantially increased metabolic requirements or is ﬂuid restricted. Renewal — (Cystic ﬁbrosis) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is beneﬁting from treatment; and 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted. Renewal — (Indications other than cystic ﬁbrosis) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is beneﬁting from treatment; and 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted. ENTERAL FEED 2KCAL/ML – Special Authority see SA1195 above – Hospital pharmacy [HP3] Liquid ..................................................................................................5.50 500 ml OP Nutrison Concentrated ORAL FEED 2KCAL/ML – Special Authority see SA1195 above – Hospital pharmacy [HP3] Additional subsidy by endorsement is available for patients being bolus fed through a feeding tube. The prescription must be endorsed accordingly. Liquid (vanilla) – Higher subsidy of $2.25 per 237 ml with Endorsement ................................................................................ 1.14 237 ml OP (2.25) Two Cal HN

Food Thickeners

¾SA1106 Special Authority for Subsidy Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year where the patient has motor neurone disease with swallowing disorder. continued. . .

202

fully subsidised

[HP3], [HP4] refer page 9

SPECIAL FOODS

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

continued. . . Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is beneﬁting from treatment; and 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted. FOOD THICKENER – Special Authority see SA1106 on the preceding page – Hospital pharmacy [HP3] Powder ................................................................................................7.25 380 g OP Karicare Food Thickener

Gluten Free Foods

The funding of gluten free foods is no longer being actively managed by PHARMAC from 1 April 2011. This means that we are no longer considering the listing of new products, or making subsidy, or other changes to the existing listings. As a result we anticipate that the range of funded items will reduce over time. Management of Coeliac disease with a gluten free diet is necessary for good outcomes. A range of gluten free options are available through retail outlets. ¾SA1107 Special Authority for Subsidy Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notiﬁed for applications meeting the following criteria: Either: 1 Gluten enteropathy has been diagnosed by biopsy; or 2 Patient suffers from dermatitis herpetiformis. GLUTEN FREE BAKING MIX – Special Authority see SA1107 above – Hospital pharmacy [HP3] Powder ................................................................................................2.81 1,000 g OP (5.15) Healtheries Simple Baking Mix GLUTEN FREE BREAD MIX – Special Authority see SA1107 above – Hospital pharmacy [HP3] Powder ................................................................................................3.93 1,000 g OP (7.32) 4.77 (8.71) 3.51 (10.87) GLUTEN FREE FLOUR – Special Authority see SA1107 above – Hospital pharmacy [HP3] Powder ................................................................................................5.62 2,000 g OP (18.10)

NZB Low Gluten Bread Mix Bakels Gluten Free Health Bread Mix Horleys Bread Mix

Horleys Flour

fully subsidised

[HP3], [HP4] refer page 9

203

SPECIAL FOODS

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

GLUTEN FREE PASTA – Special Authority see SA1107 on the preceding page – Hospital pharmacy [HP3] Buckwheat Spirals ..............................................................................2.00 250 g OP (3.11) Orgran Corn and Vegetable Shells .................................................................2.00 250 g OP (2.92) Orgran Corn and Vegetable Spirals ................................................................2.00 250 g OP (2.92) Orgran Rice and Corn Lasagne Sheets .........................................................1.60 200 g OP (3.82) Orgran Rice and Corn Macaroni .....................................................................2.00 250 g OP (2.92) Orgran Rice and Corn Penne .........................................................................2.00 250 g OP (2.92) Orgran Rice and Maize Pasta Spirals .............................................................2.00 250 g OP (2.92) Orgran Rice and Millet Spirals ........................................................................2.00 250 g OP (3.11) Orgran Rice and corn spaghetti noodles ........................................................2.00 375 g OP (2.92) Orgran Vegetable and Rice Spirals ................................................................2.00 250 g OP (2.92) Orgran Italian long style spaghetti ..................................................................2.00 220 g OP (3.11) Orgran

Foods And Supplements For Inborn Errors Of Metabolism

¾SA1108 Special Authority for Subsidy Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notiﬁed for applications meeting the following criteria: Any of the following: 1 Dietary management of homocystinuria; or 2 Dietary management of maple syrup urine disease; or 3 Dietary management of phenylketonuria (PKU); or 4 For use as a supplement to the Ketogenic diet in patients diagnosed with epilepsy.

Supplements For Homocystinuria

AMINOACID FORMULA WITHOUT METHIONINE – Special Authority see SA1108 above – Hospital pharmacy [HP3] Powder ............................................................................................461.94 500 g OP XMET Maxamum

Supplements For MSUD

AMINOACID FORMULA WITHOUT VALINE, LEUCINE AND ISOLEUCINE – Special Authority see SA1108 above – Hospital pharmacy [HP3] Powder ............................................................................................300.54 500 g OP MSUD Maxamaid 437.22 MSUD Maxamum

204

fully subsidised

[HP3], [HP4] refer page 9

SPECIAL FOODS

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

Supplements For PKU

AMINOACID FORMULA WITHOUT PHENYLALANINE – Special Authority see SA1108 on the preceding page – Hospital pharmacy [HP3] Tabs ..................................................................................................99.00 75 OP Phlexy 10 Sachets (pineapple/vanilla) 29 g ...................................................330.10 30 OP Minaphlex Sachets (tropical) ............................................................................324.00 30 Phlexy 10 Infant formula ..................................................................................174.72 400 g OP PKU Anamix Infant Powder (orange) .............................................................................221.00 500 g OP XP Maxamaid 320.00 XP Maxamum Powder (unﬂavoured) .....................................................................221.00 500 g OP XP Maxamaid 320.00 XP Maxamum Liquid (berry) ....................................................................................13.10 125 ml OP PKU Anamix Junior LQ 15.65 62.5 ml OP PKU Lophlex LQ 10 31.20 125 ml OP PKU Lophlex LQ 20 Liquid (citrus) ....................................................................................15.65 62.5 ml OP PKU Lophlex LQ 10 31.20 125 ml OP PKU Lophlex LQ 20 Liquid (forest berries) ........................................................................30.00 250 ml OP Easiphen Liquid Liquid (orange) .................................................................................13.10 125 ml OP PKU Anamix Junior LQ 15.65 62.5 ml OP PKU Lophlex LQ 10 31.20 125 ml OP PKU Lophlex LQ 20 Liquid (unﬂavoured) ..........................................................................13.10 125 ml OP PKU Anamix Junior LQ (Minaphlex Sachets (pineapple/vanilla) 29 g to be delisted 1 November 2012)

Foods

LOW PROTEIN BAKING MIX – Special Authority see SA1108 on the preceding page – Hospital pharmacy [HP3] Powder ................................................................................................8.22 500 g OP Loproﬁn Mix LOW PROTEIN PASTA – Special Authority see SA1108 on the preceding page – Hospital pharmacy [HP3] Animal shapes ..................................................................................11.91 500 g OP Loproﬁn Lasagne ..............................................................................................5.95 250 g OP Loproﬁn Low protein rice pasta ......................................................................11.91 500 g OP Loproﬁn Macaroni .............................................................................................5.95 250 g OP Loproﬁn Penne ...............................................................................................11.91 500 g OP Loproﬁn Spaghetti ..........................................................................................11.91 500 g OP Loproﬁn Spirals ...............................................................................................11.91 500 g OP Loproﬁn

Infant Formulae For Premature Infants

PREMATURE BIRTH FORMULA – Special Authority see SA1221 below – Hospital pharmacy [HP3] Liquid ..................................................................................................0.75 100 ml OP S26LBW Gold RTF ¾SA1221 Special Authority for Subsidy Note: Subsidy for patients approved prior to 1 July 2012. Approvals vaild for 6 months. No new approvals will be granted from 1 July 2012. PRETERM POST-DISCHARGE INFANT FORMULA – Special Authority see SA1198 on the next page – Hospital pharmacy [HP3] Powder ..............................................................................................15.25 400 g OP S-26 Gold Premgro

fully subsidised

[HP3], [HP4] refer page 9

205

SPECIAL FOODS

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

¾SA1198 Special Authority for Subsidy Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 The infant was born before 33 weeks gestation or weighed less than 1.5 kg at birth; and 2 Either: 2.1 The infant has faltering growth (downward crossing of percentiles); or 2.2 The infant is not maintaining, or is considered unlikely to maintain, adequate growth on standard infant formula.

For Williams Syndrome

¾SA1110 Special Authority for Subsidy Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year where the patient is an infant suffering from Williams Syndrome and associated hypercalcaemia. Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is beneﬁting from treatment; and 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted. LOW CALCIUM INFANT FORMULA – Special Authority see SA1110 above – Hospital pharmacy [HP3] Powder ..............................................................................................44.40 400 g OP Locasol

Gastrointestinal and Other Malabsorptive Problems

AMINO ACID FORMULA – Special Authority see SA1219 below – Hospital pharmacy [HP3] Powder ................................................................................................6.00 48.5 g OP 53.00 400 g OP Powder (tropical) ...............................................................................53.00 Powder (unﬂavoured) .......................................................................53.00 400 g OP 400 g OP

Powder (vanilla) ................................................................................53.00

400 g OP

Vivonex Pediatric Neocate Neocate LCP Neocate Advance Elecare Elecare LCP Neocate Advance Neocate Gold Elecare Neocate Advance

¾SA1219 Special Authority for Subsidy Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria: Any of the following: 1 Extensively hydrolysed formula has been reasonably trialled and is inappropriate due to documented severe intolerance or allergy or malabsorption; or 2 History of anaphylaxis to cows milk protein formula or dairy products; or 3 Eosinophilic oesophagitis. Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 An assessment as to whether the infant can be transitioned to a cows milk protein, soy, or extensively hydrolysed infant formula has been undertaken; and continued. . .

206

fully subsidised

[HP3], [HP4] refer page 9

SPECIAL FOODS

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

continued. . . 2 The outcome of the assessment is that the infant continues to require an amino acid infant formula; and 3 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted. EXTENSIVELY HYDROLYSED FORMULA – Special Authority see SA1220 below – Hospital pharmacy [HP3] Powder ..............................................................................................15.21 450 g OP Pepti Junior Gold ¾SA1220 Special Authority for Subsidy Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria: Any of the following: 1 Both: 1.1 Cows milk formula is inappropriate due to severe intolerance or allergy to its protein content; and 1.2 Either: 1.2.1 Soy milk formula has been trialled without resolution of symptoms; or 1.2.2 Soy milk formula is considered clinically inappropriate or contraindicated; or 2 Severe malabsorption; or 3 Short bowel syndrome; or 4 Intractable diarrhea; or 5 Biliary atresia; or 6 Cholestatic liver diseases causing malsorption; or 7 Chylous ascite; or 8 Chylothorax; or 9 Cystic ﬁbrosis; or 10 Proven fat malabsorption; or 11 Severe intestinal motility disorders causing signiﬁcant malabsorption; or 12 Intestinal failure. Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 An assessment as to whether the infant can be transitioned to a cows milk protein or soy infant formula has been undertaken; and 2 The outcome of the assessment is that the infant continues to require an extensively hydrolysed infant formula; and 3 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted. Renewal — (Step Down from Amino Acid Formula) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 The infant is currently receiving funded amino acid formula; and 2 The infant is to be trialled on, or transitioned to, an extensively hydrolysed formula; and 3 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and the date contacted.

Ketogenic Diet

¾SA1197 Special Authority for Subsidy Initial application only from a metabolic physician or paediatric neurologist. Approvals valid for 3 months where the patient has intractable epilepsy, pyruvate dehydrogenase deﬁciency or glucose transported type-1 deﬁciency and other conditions requiring a ketogenic diet. Renewal only from a metabolic physician or paediatric neurologist. Approvals valid for 2 years where the patient is on a ketogenic diet and the patient is beneﬁting from the diet.

fully subsidised

[HP3], [HP4] refer page 9

207

SPECIAL FOODS

Subsidy (Manufacturer’s Price) $ Fully Subsidised Per Brand or Generic Manufacturer

HIGH FAT FORMULA WITH VITAMINS, MINERALS AND TRACE ELEMENTS AND LOW IN PROTEIN AND CARBOHYDRATE – Special Authority see SA1197 on the preceding page – Retail pharmacy Powder (vanilla) ................................................................................35.50 300 g OP KetoCal

208

fully subsidised

[HP3], [HP4] refer page 9

SECTION E PART I PRACTITIONER’S SUPPLY ORDERS Pharmaceuticals and quantities that may be obtained on a Practitioner’s Supply Order

ADRENALINE Inj 1 in 1,000, 1 ml ...................................................... 5 Inj 1 in 10,000, 10 ml .................................................. 5 AMINOPHYLLINE Inj 25 mg per ml, 10 ml ............................................... 5 AMIODARONE HYDROCHLORIDE Inj 50 mg per ml, 3 ml ................................................. 5 AMOXYCILLIN Cap 250 mg .............................................................. 30 Grans for oral liq 125 mg per 5 ml ..................... 200 ml Grans for oral liq 250 mg per 5 ml ..................... 200 ml Inj 1 g.......................................................................... 5 AMOXYCILLIN CLAVULANATE Tab amoxycillin 500 mg with potassium clavulanate 125 mg ..............................................30 Grans for oral liq amoxycillin 125 mg with potassium clavulanate 31.25 mg per 5 ml................................................................ 200 ml Grans for oral liq amoxycillin 250 mg with potassium clavulanate 62.5 mg per 5 ml................................................................ 200 ml ASPIRIN Tab dispersible 300 mg............................................. 30 ATROPINE SULPHATE Inj 600 µg, 1 ml........................................................... 5 AZITHROMYCIN Tab 500 mg – Subsidy by endorsement – See note on page 84 ..............................................8 BENDROFLUAZIDE Tab 2.5 mg – See note on page 55......................... 150 BENZATHINE BENZYLPENICILLIN Inj 1.2 mega u per 2.3 ml ............................................ 5 BENZTROPINE MESYLATE Inj 1 mg per ml, 2 ml ................................................... 5 BENZYLPENICILLIN SODIUM (PENICILLIN G) Inj 600 mg ................................................................... 5 CEFTRIAXONE SODIUM Inj 500 mg – Subsidy by endorsement – See note on page 83 .....................................................5 Inj 1 g – Subsidy by endorsement – See note on page 83 .....................................................5 CHARCOAL Oral liq 50 g per 250 ml ..................................... 250 ml CHLORPROMAZINE HYDROCHLORIDE Tab 10 mg ................................................................. 30 Tab 25 mg ................................................................. 30 Tab 100 mg ............................................................... 30 Inj 25 mg per ml, 2 ml ................................................. 5 CIPROFLOXACIN Tab 250 mg ................................................................. 5 Tab 500 mg ................................................................. 5 CO-TRIMOXAZOLE Tab trimethoprim 80 mg and sulphamethoxazole 400 mg..................................30 Oral liq trimethoprim 40 mg and sulphamethoxazole 200 mg per 5 ml................................................................ 200 ml COMPOUND ELECTROLYTES Powder for soln for oral use 4.4 g ............................. 10 CONDOMS 49 mm..................................................................... 144 52 mm..................................................................... 144 52 mm extra strength.............................................. 144 53 mm..................................................................... 144 53 mm (chocolate) .................................................. 144 53 mm (strawberry)................................................. 144 53 mm extra strength.............................................. 144 54 mm, shaped ....................................................... 144 55 mm..................................................................... 144 56 mm..................................................................... 144 56 mm, shaped ....................................................... 144 60 mm..................................................................... 144 DEXAMETHASONE Tab 1 mg – Retail pharmacy-Specialist .................... 30 Tab 4 mg – Retail pharmacy-Specialist .................... 30 DEXAMETHASONE SODIUM PHOSPHATE Inj 4 mg per ml, 1 ml – See note on page 76.............. 5 Inj 4 mg per ml, 2 ml – See note on page 76.............. 5 DEXTROSE Inj 50%, 10 ml ............................................................. 5 Inj 50%, 90 ml ............................................................. 5 DIAPHRAGM 65 mm – See note on page 70 ................................... 1 70 mm – See note on page 70 ................................... 1 75 mm – See note on page 70 ................................... 1 80 mm – See note on page 70 ................................... 1 continued. . .

fully subsidised brand available Please refer to Section A for a deﬁnition, and conditions of supply, of Practitioner’s Supply Orders.

209

PRACTITIONER’S SUPPLY ORDERS

(continued) DIAZEPAM Inj 5 mg per ml, 2 ml – Subsidy by endorsement – See note on page 126 ...................5 Rectal tubes 5 mg....................................................... 5 Rectal tubes 10 mg..................................................... 5 DICLOFENAC SODIUM Inj 25 mg per ml, 3 ml ................................................. 5 Suppos 50 mg........................................................... 10 DIGOXIN Tab 62.5 µg............................................................... 30 Tab 250 µg................................................................ 30 DOXYCYCLINE HYDROCHLORIDE Tab 50 mg ................................................................. 30 Tab 100 mg ............................................................... 30 ERGOMETRINE MALEATE Inj 500 µg per ml, 1 ml................................................ 5 ERYTHROMYCIN ETHYL SUCCINATE Tab 400 mg ............................................................... 30 Grans for oral liq 200 mg per 5 ml ..................... 200 ml Grans for oral liq 400 mg per 5 ml ..................... 200 ml ERYTHROMYCIN STEARATE Tab 250 mg ............................................................... 30 ETHINYLOESTRADIOL WITH DESOGESTREL Tab 20 µg with desogestrel 150 µg .......................... 63 Tab 20 µg with desogestrel 150 µg and 7 inert tab ................................................................84 Tab 30 µg with desogestrel 150 µg .......................... 63 Tab 30 µg with desogestrel 150 µg and 7 inert tab ................................................................84 ETHINYLOESTRADIOL WITH LEVONORGESTREL Tab 50 µg with levonorgestrel 125 µg and 7 inert tab ................................................................84 Tab 30 µg with levonorgestrel 150 µg ...................... 63 Tab 30 µg with levonorgestrel 150 µg and 7 inert tab ................................................................84 Tab 20 µg with levonorgestrel 100 µg and 7 inert tab ................................................................84 ETHINYLOESTRADIOL WITH NORETHISTERONE Tab 35 µg with norethisterone 1 mg ......................... 63 Tab 35 µg with norethisterone 1 mg and 7 inert tab ................................................................84 Tab 35 µg with norethisterone 500 µg...................... 63 Tab 35 µg with norethisterone 500 µg and 7 inert tab ................................................................84 FLUCLOXACILLIN SODIUM Cap 250 mg .............................................................. 30 Grans for oral liq 125 mg per 5 ml ..................... 200 ml Grans for oral liq 250 mg per 5 ml ..................... 200 ml Inj 1 g.......................................................................... 5 FLUPENTHIXOL DECANOATE Inj 20 mg per ml, 1 ml ................................................. 5 Inj 20 mg per ml, 2 ml ................................................. 5 Inj 100 mg per ml, 1 ml ............................................... 5 FLUPHENAZINE DECANOATE Inj 12.5 mg per 0.5 ml, 0.5 ml ..................................... 5 Inj 25 mg per ml, 1 ml ................................................. 5 Inj 100 mg per ml, 1 ml ............................................... 5 FUROSEMIDE Tab 40 mg ................................................................. 30 Inj 10 mg per ml, 2 ml ................................................. 5 GLUCAGON HYDROCHLORIDE Inj 1 mg syringe kit...................................................... 5 GLYCERYL TRINITRATE Tab 600 µg.............................................................. 100 Aerosol spray, 400 µg per dose..................... 250 dose HALOPERIDOL Tab 500 µg................................................................ 30 Tab 1.5 mg ................................................................ 30 Tab 5 mg ................................................................... 30 Oral liq 2 mg per ml ........................................... 200 ml Inj 5 mg per ml, 1 ml ................................................... 5 HALOPERIDOL DECANOATE Inj 50 mg per ml, 1 ml ................................................. 5 Inj 100 mg per ml, 1 ml ............................................... 5 HYDROCORTISONE Inj 50 mg per ml, 2 ml ................................................. 5 HYDROXOCOBALAMIN Inj 1 mg per ml, 1 ml ................................................... 6 HYOSCINE N-BUTYLBROMIDE Inj 20 mg, 1 ml ............................................................ 5 INTRA-UTERINE DEVICE IUD............................................................................ 40 IPRATROPIUM BROMIDE Nebuliser soln, 250 µg per ml, 1 ml.......................... 40 Nebuliser soln, 250 µg per ml, 2 ml.......................... 40 IVERMECTIN Tab 3 mg – See note on page 64............................ 100 continued. . .

210

fully subsidised brand available Please refer to Section A for a deﬁnition, and conditions of supply, of Practitioner’s Supply Orders.

PRACTITIONER’S SUPPLY ORDERS

(continued) LEVONORGESTREL Tab 30 µg.................................................................. 84 Tab 1.5 mg .................................................................. 5 LIGNOCAINE Gel 2%, 10 ml urethral syringe – Subsidy by endorsement – See note on page 120 ...................5 LIGNOCAINE HYDROCHLORIDE Inj 1%, 5 ml ................................................................. 5 Inj 2%, 5 ml ................................................................. 5 Inj 1%, 20 ml ............................................................... 5 Inj 2%, 20 ml ............................................................... 5 LIGNOCAINE WITH CHLORHEXIDINE Gel 2% with chlorhexidine 0.05%, 10 ml urethral syringes – Subsidy by endorsement – See note on page 120 ...................5 LOPERAMIDE HYDROCHLORIDE Tab 2 mg ................................................................... 30 Cap 2 mg .................................................................. 30 MASK FOR SPACER DEVICE Size 2 – See note on page 174 ................................ 20 MEDROXYPROGESTERONE ACETATE Inj 150 mg per ml, 1 ml syringe................................... 5 METOCLOPRAMIDE HYDROCHLORIDE Inj 5 mg per ml, 2 ml ................................................... 5 METRONIDAZOLE Tab 200 mg ............................................................... 30 MORPHINE SULPHATE Inj 5 mg per ml, 1 ml – Only on a controlled drug form ................................................................5 Inj 10 mg per ml, 1 ml – Only on a controlled drug form ................................................................5 Inj 15 mg per ml, 1 ml – Only on a controlled drug form ................................................................5 Inj 30 mg per ml, 1 ml – Only on a controlled drug form ................................................................5 NALOXONE HYDROCHLORIDE Inj 400 µg per ml, 1 ml................................................ 5 NICOTINE Patch 7 mg – See note on page 145 ........................ 28 Patch 14 mg – See note on page 145 ...................... 28 Patch 21 mg – See note on page 145 ...................... 28 Lozenge 1 mg – See note on page 145.................. 216 Lozenge 2 mg – See note on page 145.................. 216 Gum 2 mg (Classic) – See note on page 145......... 384 Gum 2 mg (Fruit) – See note on page 145 ............. 384 Gum 2 mg (Mint) – See note on page 145 ............. 384 Gum 4 mg (Classic) – See note on page 145......... 384 Gum 4 mg (Fruit) – See note on page 145 ............. 384 Gum 4 mg (Mint) – See note on page 145 ............. 384 NORETHISTERONE Tab 350 µg................................................................ 84 Tab 5 mg ................................................................... 30 NORETHISTERONE WITH MESTRANOL Tab 1 mg with mestranol 50 µg and 7 inert tab .........84 OXYTOCIN Inj 5 iu per ml, 1 ml ..................................................... 5 Inj 10 iu per ml, 1 ml ................................................... 5 Inj 5 iu with ergometrine maleate 500 µg per ml, 1 ml...................................................................5 PARACETAMOL Tab 500 mg ............................................................... 30 Oral liq 120 mg per 5 ml .................................... 200 ml Oral liq 250 mg per 5 ml .................................... 100 ml PEAK FLOW METER Low range ................................................................. 10 Normal range............................................................ 10 PETHIDINE HYDROCHLORIDE Inj 50 mg per ml, 1 ml – Only on a controlled drug form ................................................................5 Inj 50 mg per ml, 2 ml – Only on a controlled drug form ................................................................5 PHENOXYMETHYLPENICILLIN (PENICILLIN V) Cap potassium salt 250 mg ...................................... 30 Grans for oral liq 125 mg per 5 ml ..................... 200 ml Grans for oral liq 250 mg per 5 ml ..................... 200 ml PHENYTOIN SODIUM Inj 50 mg per ml, 2 ml ................................................. 5 Inj 50 mg per ml, 5 ml ................................................. 5 PHYTOMENADIONE Inj 2 mg per 0.2 ml ...................................................... 5 Inj 10 mg per ml, 1 ml ................................................. 5 PIPOTHIAZINE PALMITATE Inj 50 mg per ml, 1 ml ................................................. 5 Inj 50 mg per ml, 2 ml ................................................. 5 PREDNISOLONE SODIUM PHOSPHATE Oral liq 5 mg per ml – See note on page 77 ........................................................... 30 ml PREDNISONE Tab 5 mg ................................................................... 30 continued. . .

fully subsidised brand available Please refer to Section A for a deﬁnition, and conditions of supply, of Practitioner’s Supply Orders.

211

PRACTITIONER’S SUPPLY ORDERS

(continued) PREGNANCY TESTS - HCG URINE Cassette........................................................... 200 test PROCAINE PENICILLIN Inj 1.5 mega u ............................................................. 5 PROCHLORPERAZINE Tab 5 mg ................................................................... 30 Inj 12.5 mg per ml, 1 ml .............................................. 5 PROMETHAZINE HYDROCHLORIDE Inj 25 mg per ml, 2 ml ................................................. 5 SALBUTAMOL Inj 500 µg per ml, 1 ml................................................ 5 Aerosol inhaler, 100 µg per dose CFC free .......................................................... 1000 dose Nebuliser soln, 1 mg per ml, 2.5 ml .......................... 30 Nebuliser soln, 2 mg per ml, 2.5 ml .......................... 30 SALBUTAMOL WITH IPRATROPIUM BROMIDE Nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg per vial, 2.5 ml ............................20 SILVER SULPHADIAZINE Crm 1%................................................................ 250 g SODIUM BICARBONATE Inj 8.4%, 50 ml ............................................................ 5 Inj 8.4%, 100 ml .......................................................... 5 SODIUM CHLORIDE Inf 0.9% – See note on page 44 ...................... 2000 ml Inj 0.9%, 5 ml – See note on page 44......................... 5 Inj 0.9%, 10 ml – See note on page 44....................... 5 SPACER DEVICE 230 ml (single patient) .............................................. 20 800 ml ....................................................................... 20 SPACER DEVICE AUTOCLAVABLE 230 ml (autoclavable) – Subsidy by endorsement – See note on page 174 ...................5 TRIMETHOPRIM Tab 300 mg ............................................................... 30 VERAPAMIL HYDROCHLORIDE Inj 2.5 mg per ml, 2 ml ................................................ 5 WATER Puriﬁed for inj, 5 ml – See note on page 44................ 5 Puriﬁed for inj, 10 ml – See note on page 44.............. 5 Puriﬁed for inj, 20 ml – See note on page 44.............. 5 ZUCLOPENTHIXOL DECANOATE Inj 200 mg per ml, 1 ml ............................................... 5

212

fully subsidised brand available Please refer to Section A for a deﬁnition, and conditions of supply, of Practitioner’s Supply Orders.

SECTION E PART II: RURAL AREAS

Rural Areas for Practitioner’s Supply Orders

NORTH ISLAND Northland DHB Dargaville Hikurangi Kaeo Kaikohe Kaitaia Kawakawa Kerikeri Mangonui Maungaturoto Moerewa Ngunguru Paihia Rawene Ruakaka Russell Tutukaka Waipu Whangaroa Waitemata DHB Helensville Huapai Kumeu Snells Beach Waimauku Warkworth Wellsford Auckland DHB Great Barrier Island Oneroa Ostend Counties Manukau DHB Tuakau Waiuku Waikato DHB Coromandel Huntly Kawhia Matamata Morrinsville Ngatea Otorohanga Paeroa Pauanui Beach Putaruru Raglan Tairua Taumarunui Te Aroha Te Kauwhata Te Kuiti Tokoroa Waihi Whangamata Whitianga Bay of Plenty DHB Edgecumbe Katikati Kawerau Murupara Opotiki Taneatua Te Kaha Waihi Beach Whakatane Lakes DHB Mangakino Turangi Tairawhiti DHB Ruatoria Te Araroa Te Karaka Te Puia Springs Tikitiki Tokomaru Bay Tolaga Bay Taranaki DHB Eltham Inglewood Manaia Oakura Okato Opunake Patea Stratford Waverley Hawkes Bay DHB Chatham Islands Waipawa Waipukurau Wairoa Whanganui DHB Bulls Marton Ohakune Raetihi Taihape Waiouru MidCentral DHB Dannevirke Foxton Levin Otaki Pahiatua Shannon Woodville Wairarapa DHB Carteron Featherston Greytown Martinborough SOUTH ISLAND Nelson/Marlborough DHB Havelock Mapua Motueka Murchison Picton Takaka Wakeﬁeld West Coast DHB Dobson Greymouth Hokitika Karamea Reefton South Westland Westport Whataroa Canterbury DHB Akaroa Amberley Amuri Cheviot Darﬁeld Diamond Harbour Hanmer Springs Kaikoura Leeston Lincoln Methven Oxford Rakaia Rolleston Rotherham Templeton Waikari

South Canterbury DHB Fairlie Geraldine Pleasant Point Temuka Twizel Waimate

Southern DHB Alexandra Balclutha Cromwell Gore Kurow Lawrence Lumsden Mataura Milton Oamaru Oban Otautau Outram Owaka Palmerston Queenstown Ranfurly Riverton Roxburgh Tapanui Te Anau Tokonui Tuatapere Wanaka Winton

fully subsidised brand available Please refer to Section A for a deﬁnition, and conditions of supply, of Practitioner’s Supply Orders.

213

SECTION F: COMMUNITY PHARMACEUTICALS DISPENSING PERIOD EXEMPTIONS SECTION F: PART I

A Community Pharmaceutical identiﬁed with a F within the other sections of the Pharmaceutical Schedule: a) is exempt from any requirement to dispense in Monthly Lots; b) will only be subsidised if it is dispensed in a 90 Day Lot unless it is under the Dispensing Frequency Rule. A Community Pharmaceutical that is an oral contraceptive and that is identiﬁed with a F within the other sections of the Pharmaceutical Schedule: a) is exempt from any requirement to dispense in Monthly Lots; b) will only be subsidised if it is dispensed in a 180 Day Lot unless it is is under the Dispensing Frequency Rule.

SECTION F: PART II: CERTIFIED EXEMPTIONS AND ACCESS EXEMPTIONS TO MONTHLY DISPENSING

A Community Pharmaceutical, other than a Community Pharmaceutical identiﬁed with a F within the other sections of the Pharmaceutical Schedule, may be dispensed in a 90 Day Lot if: a) the Community Pharmaceutical is identiﬁed with a L within the other sections of the Pharmaceutical Schedule and the prescriber/pharmacist has endorsed/annotated the Prescription item(s) on the Prescription to which the exemption applies “certiﬁed exemption”. In endorsing/annotating the Prescription items for a certiﬁed exemption, the prescriber/pharmacist is certifying that: i) the patient wished to have the medicine dispensed in a quantity greater than a Monthly Lot; and ii) the patient has been stabilised on the same medicine for a reasonable period of time; and iii) the prescriber has reason to believe the patient will continue on the medicine and is compliant. b) a patient, who has difﬁculty getting to and from a pharmacy, signs the back of the Prescription to qualify for an Access Exemption. In signing the Prescription, the patient or his or her nominated representative must also certify which of the following criteria they meet: i) have limited physical mobility; ii) live and work more than 30 minutes from the nearest pharmacy by their normal form of transport; iii) are relocating to another area; iv) are travelling extensively and will be out of town when the repeat prescriptions are due.

SECTION F: PART III: FLEXIBLE AND VARIABLE DISPENSING PERIODS FOR PHARMACY

A Community Pharmaceutical, other than a Community Pharmaceutical identiﬁed with a F within the other sections of the Pharmaceutical Schedule, may be dispensed in variable dispensing periods under the following conditions: a) for stock management where the original pack(s) result in dispensing greater than 30 days supply, b) to synchronise a patients medication where multiple medicines result in uneven supply periods, note if dispensing a medicine other than a Pharmaceutical identiﬁed with a F please refer to Section F; Part II Note – the total quantity and dispensing period can not exceed the total quantity and period prescribed on the prescription.

214

SECTION F

The following Community Pharmaceuticals are identiﬁed with a L within the other sections of the Pharmaceutical Schedule and may be dispensed in a 90 Day Lot if endorsed as a certiﬁed exemption in accordance with paragraph (a) in Section F Part II above. ALIMENTARY TRACT AND METABOLISM INSULIN ASPART INSULIN ASPART INSULIN GLARGINE INSULIN GLULISINE INSULIN ISOPHANE INSULIN ISOPHANE WITH INSULIN NEUTRAL INSULIN LISPRO INSULIN LISPRO WITH INSULIN LISPRO PROTAMINE INSULIN NEUTRAL CARDIOVASCULAR SYSTEM AMIODARONE HYDROCHLORIDE Tab 100 mg Cordarone-X Tab 200 mg Cordarone-X DISOPYRAMIDE PHOSPHATE FLECAINIDE ACETATE Tab 50 mg Tab 100 mg Cap long-acting 100 mg Cap long-acting 200 mg Tambocor Tambocor Tambocor CR Tambocor CR ENTACAPONE GABAPENTIN GABAPENTIN (NEURONTIN) LACOSAMIDE LAMOTRIGINE LISURIDE HYDROGEN MALEATE PERGOLIDE PRAMIPEXOLE HYDROCHLORIDE ROPINIROLE HYDROCHLORIDE HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES DESMOPRESSIN Nasal drops 100 µg per Minirin ml Nasal spray 10 µg per Desmopressin-PH&T dose TOLCAPONE TOPIRAMATE VIGABATRIN NERVOUS SYSTEM AMANTADINE HYDROCHLORIDE APOMORPHINE HYDROCHLORIDE MUSCULOSKELETAL SYSTEM PYRIDOSTIGMINE BROMIDE

PROPAFENONE HYDROCHLORIDE

215

SECTION G: SAFETY CAP MEDICINES

Pharmacists are required, under the Code of Ethics of the Pharmacy Council of New Zealand, to endeavour to use safety caps when dispensing any of the medicines listed in Section G in an oral liquid formulation pursuant to a prescription or Practitioner’s Supply Order. This includes all proprietary and extemporaneously compounded oral liquid preparations of those pharmaceuticals listed in Section G of the Pharmaceutical Schedule. These medicines will be identiﬁed throughout Section B of the Pharmaceutical Schedule with the symbol ‘‡’.

Exemptions

Oral liquid preparations of the pharmaceuticals listed in Section G of the Pharmaceutical Schedule will be dispensed in a container with a safety cap unless: G the practitioner has endorsed the Prescription or Practitioner’s Supply Order, stating that, the Pharmaceutical is not to be dispensed in a container with a safety cap; or G the Contractor has annotated the Prescription or Practitioner’s Supply Order stating that, because of inﬁrmity of the particular person, the Pharmaceutical to be used by that person should not be dispensed in a container with a safety cap; or G the Pharmaceutical is packaged in an Original Pack so designed that on the professional judgement of the Contractor, transfer to a container with a safety cap would be inadvisable or a retrograde procedure.

Reimbursment

Pharmacists will be reimbursed according to their agreement. Where an additional fee is paid on safety caps it will be paid on all dispensings of oral liquid preparations for those pharmaceuticals listed in Section G of the Pharmaceutical Schedule unless the practitioner has endorsed or the contractor has annotated the Prescription or Practitioner’s Supply Order that a safety cap has not been supplied.

Safety Caps (NZS 5825:1991)

20 mm.................................. .Clic-Loc, United Closures & Plastics PLC, England Kerr, Cormack Packaging, Sydney, under licence to Kerr USA 24 mm.................................. .Clic-Loc, United Closures & Plastics PLC, England Clic-Loc, ACI Closures under license to Owens-Illinois Kerr, Cormack Packaging, Sydney, under licence to Kerr USA 28 mm.................................. .Clic-Loc, United Closures & Plastics PLC, England Clic-Loc, ACI Closures under license to Owens-Illinois Kerr, Cormack Packaging, Sydney, under licence to Kerr USA PDL Squeezlok PDL FG

216

SAFETY CAP MEDICINES

ALIMENTARY TRACT AND METABOLISM FERROUS SULPHATE Oral liq 30 mg per 1 ml Ferodan (6 mg elemental per 1 ml) CARDIOVASCULAR SYSTEM AMILORIDE Oral liq 1 mg per ml Biomed CAPTOPRIL Oral liq 5 mg per ml CHLOROTHIAZIDE Oral liq 50 mg per ml DIGOXIN Oral liq 50 µg per ml FUROSEMIDE Oral liq 10 mg per ml SPIRONOLACTONE Oral liq 5 mg per ml Capoten Biomed Lanoxin Lasix Biomed CLOBAZAM Tab 10 mg Frisium (Extemporaneously compounded oral liquid preparations) CLONAZEPAM Oral drops 2.5 mg per ml

Rivotril

DIAZEPAM Tab 2 mg Arrow-Diazepam Tab 5 mg Arrow-Diazepam (Extemporaneously compounded oral liquid preparations) ETHOSUXIMIDE Oral liq 250 mg per 5 ml

Zarontin

LORAZEPAM Tab 1 mg Ativan Tab 2.5 mg Ativan (Extemporaneously compounded oral liquid preparations) LORMETAZEPAM Tab 1 mg Noctamid (Extemporaneously compounded oral liquid preparations) METHADONE HYDROCHLORIDE Oral liq 2 mg per ml Biodone Oral liq 5 mg per ml Biodone Forte Oral liq 10 mg per ml Biodone Extra Forte MORPHINE HYDROCHLORIDE Oral liq 1 mg per ml RA-Morph Oral liq 2 mg per ml RA-Morph Oral liq 5 mg per ml RA-Morph Oral liq 10 mg per ml RA-Morph NITRAZEPAM Tab 5 mg Nitrados (Extemporaneously compounded oral liquid preparations) OXAZEPAM Tab 10 mg Ox-Pam Tab 15 mg Ox-Pam (Extemporaneously compounded oral liquid preparations) OXYCODONE HYDROCHLORIDE Oral liq 5 mg per 5 ml OxyNorm PARACETAMOL Oral liq 120 mg per 5 ml Oral liq 250 mg per 5 ml PHENYTOIN SODIUM Oral liq 30 mg per 5 ml Ethics Paracetamol Paracare Double Strength Dilantin

HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES LEVOTHYROXINE Tab 25 µg Synthroid Tab 50 µg Eltroxin Goldshield Synthroid Tab 100 µg Eltroxin Goldshield Synthroid (Extemporaneously compounded oral liquid preparations) MUSCULOSKELETAL SYSTEM IBUPROFEN Oral liq 100 mg per 5 ml Fenpaed QUININE SULPHATE Tab 300 mg Q 300 (Extemporaneously compounded oral liquid preparations) NERVOUS SYSTEM ALPRAZOLAM Tab 250 µg Arrow-Alprazolam Tab 500 µg Arrow-Alprazolam Tab 1 mg Arrow-Alprazolam (Extemporaneously compounded oral liquid preparations) CARBAMAZEPINE Oral liq 100 mg per 5 ml

Tegretol

217

SAFETY CAP MEDICINES

SODIUM VALPROATE Oral liq 200 mg per 5 ml SALBUTAMOL Oral liq 2 mg per 5 ml

Epilim S/F Liquid Epilim Syrup

TEMAZEPAM Tab 10 mg Normison (Extemporaneously compounded oral liquid preparations) TRIAZOLAM Tab 125 µg Hypam Tab 250 µg Hypam (Extemporaneously compounded oral liquid preparations) RESPIRATORY SYSTEM AND ALLERGIES CETIRIZINE HYDROCHLORIDE Oral liq 1 mg per ml Cetirizine - AFT CHLORPHENIRAMINE MALEATE Oral liq 2 mg per 5 ml Histafen DEXTROCHLORPHENIRAMINE MALEATE Oral liq 2 mg per 5 ml Polaramine PROMETHAZINE HYDROCHLORIDE Oral liq 5 mg per 5 ml Promethazine Elixir Winthrop

Ventolin Salapin Broncolin Nuelin

THEOPHYLLINE Oral liq 80 mg per 15 ml

TRIMEPRAZINE TARTRATE Oral liq 30 mg per 5 ml Vallergan Forte EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS AND GALENICALS CODEINE PHOSPHATE Powder Douglas (Extemporaneously compounded oral liquid preparations) METHADONE HYDROCHLORIDE Powder AFT (Extemporaneously compounded oral liquid preparations) PHENOBARBITONE SODIUM Powder MidWest (Extemporaneously compounded oral liquid preparations)

218

INDEX Generic Chemicals and Brands

- Symbols 3TC .................................................95 -AA-Lices ............................................66 A-Scabies .......................................66 Abacavir sulphate ...........................95 Abacavir sulphate with lamivudine ................................. 95 Abilify ............................................132 ABM Hydroxocobalamin .................37 Acarbose ........................................30 Accu-Chek Ketur-Test .....................31 Accu-Chek Performa ................31, 32 Accupril ...........................................49 Accuretic 10 ....................................49 Accuretic 20 ....................................49 Acetadote .....................................186 Acetazolamide ..............................177 Acetic acid with 1, 2- propanediol diacetate and benzethonium .......................... 176 Acetic acid with hydroxyquinoline and ricinoleic acid ...................... 73 Acetylcysteine ...............................186 Aci-Jel .............................................73 Aciclovir Infection ......................................92 Sensory ....................................176 Acidex .............................................26 Acipimox .........................................45 Acitretin ...........................................66 Aclasta ..........................................116 Aclin ..............................................103 Act-HIB .........................................100 Actinomycin D ...............................153 Actrapid ..........................................29 Actrapid Penﬁll ................................29 Acupan .........................................121 Adalat 10 ........................................53 Adalat Oros .....................................53 Adalimumab ..................................104 Adapalene ......................................58 Adeﬁn XL ........................................53 Adefovir dipivoxil .............................90 Adrenaline ......................................56 Adriamycin ....................................154 ADT Booster ...................................99 Advantan ........................................62 AFT-Leﬂunomide ..........................103 AFT-Pyrazinamide ..........................89 Agents Affecting the Renin-Angiotensin System .........48 Agents for Parkinsonism and Related Disorders .................... 119 Agents Used in the Treatment of Poisonings ................................. 39 Agrylin ..........................................152 Alanase .........................................174 Albay .............................................168 Albustix ...........................................75 Aldara .............................................68 Alendronate sodium ......................114 Alendronate sodium with cholecalciferol .......................... 114 Alfacalcidol .....................................37 Alginic acid .....................................26 Alitraq ...........................................196 Alkeran .........................................147 Allersoothe ....................................169 Allopurinol .....................................118 Alpha Adrenoceptor Blockers .........48 Alpha-Keri Lotion ............................63 Alphamox ........................................85 Alprazolam ....................................137 Alu-Tab ...........................................26 Aluminium hydroxide ......................26 Amantadine hydrochloride ............119 Ambrisentan ...................................56 Amiloride ........................................55 Amiloride with frusemide ................55 Amiloride with hydrochlorothiazide ................... 55 Aminophylline ...............................173 Amiodarone hydrochloride ..............50 Amirol ...........................................123 Amisulpride ...................................132 Amitrip ..........................................123 Amitriptyline ..................................123 Amlodipine ......................................53 Amorolﬁne ......................................59 Amoxycillin ......................................85 Amoxycillin clavulanate ..................86 Amphotericin B ...............................36 Amsacrine ....................................152 Amsidine .......................................152 Amyl nitrite ......................................56 Anabolic Agents ..............................76 Anaesthetics .................................120 Anagrelide hydrochloride ..............152 Analgesics ....................................121 Anastrozole ...................................163 Andriol Testocaps ...........................77 Androderm ......................................77 Antabuse ......................................145 Antacids and Antiﬂatulants .............26 Anten ............................................124 Anthelmintics ..................................83 Antiacne Preparations ....................58 Antiallergy Preparations ...............168 Antianaemics ..................................40 Antiandrogen Oral Contraceptives ........................... 73 Antiarrhythmics ...............................50 Antibacterials ..................................83 Antibacterials Topical ......................59 Anticholinesterases ......................102 Antidepressants ............................123 Antidiarrhoeals ................................26 Antiepilepsy Drugs .......................126 Antiﬁbrinolytics, Haemostatics and Local Sclerosants ............... 41 Antifungals ......................................88 Antifungals Topical ..........................59 Antihaemorrhoidals .........................28 Antihistamines ..............................168 Antihypotensives .............................51 Antimalarials ...................................89 Antimigraine Preparations ............130 Antinaus ........................................132 Antinausea and Vertigo Agents ..................................... 131 Antipruritic Preparations .................60 Antipsychotics ...............................132 Antiretrovirals ..................................93 Antiretrovirals - Additional Therapies ................................... 96 Antirheumatoid Agents .................103 Antispasmodics and Other Agents Altering Gut Motility ....................................... 28 Antithrombotic Agents ....................41 Antithymocyte globulin (equine) ................................... 164 Antitrichomonal Agents ..................89 Antituberculotics and Antileprotics ............................... 89 Antiulcerants ...................................28 Antivirals .........................................90 Anxiolytics .....................................137 Anzatax .........................................155 Apidra .............................................30 Apidra SoloStar ..............................30 Apo-Allopurinol .............................118 Apo-Amlodipine ..............................53 Apo-Bromocriptine ........................119 Apo-Cimetidine ...............................28

219

INDEX Generic Chemicals and Brands

Apo-Clarithromycin Alimentary ..................................28 Infection ......................................84 Apo-Clomipramine ........................123 Apo-Clopidogrel ..............................41 Apo-Doxazosin ...............................48 Apo-Folic Acid ................................40 Apo-Gliclazide ................................30 Apo-Megestrol ..............................161 Apo-Metformin ................................31 Apo-Moclobemide .........................125 Apo-Nadolol ....................................52 Apo-Nicotinic Acid ..........................45 Apo-Oxybutynin ..............................75 Apo-Pindolol ...................................52 Apo-Prazo .......................................48 Apo-Prednisone ..............................77 Apo-Primidone ..............................129 Apo-Propranolol ..............................53 Apo-Pyridoxine ...............................37 Apo-Risperidone ...........................134 Apo-Selegiline ..............................119 Apo-Thiamine .................................37 Apo-Timol .......................................53 Apo-Zopiclone ..............................140 Apomine .......................................119 Apomorphine hydrochloride .........119 Aprepitant .....................................131 Apresoline .......................................56 Aquasun 30+ ..................................68 Aqueous cream ..............................63 Aratac .............................................50 Arava ............................................103 Aremed .........................................163 Arimidex ........................................163 Aripiprazole ...................................132 Aristocort ........................................62 Aromasin ......................................163 Arrow-Alprazolam .........................137 Arrow-Azithromycin ........................84 Arrow-Bendroﬂuazide .....................55 Arrow-Brimonidine ........................178 Arrow-Cabergoline ..........................82 Arrow-Calcium ................................38 Arrow-Citalopram ..........................125 Arrow-Diazepam ...........................137 Arrow-Enalapril ...............................48 Arrow-Etidronate ...........................114 Arrow-Lamotrigine ........................128 Arrow-Lisinopril ...............................48 Arrow-Losartan & Hydrochlorothiazide ................... 50 Arrow-Meloxicam ..........................103 Arrow-Morphine LA ......................122 Arrow-Nifedipine XR .......................53 Arrow-Norﬂoxacin ...........................99 Arrow-Ornidazole ............................89 Arrow-Ranitidine .............................29 Arrow-Roxithromycin ......................85 Arrow-Sertraline ...........................125 Arrow-Simva 10mg .........................46 Arrow-Simva 20mg .........................46 Arrow-Simva 40mg .........................46 Arrow-Simva 80mg .........................46 Arrow-Sumatriptan ........................130 Arrow-Testosterone ........................77 Arrow-Timolol ...............................177 Arrow-Topiramate .........................129 Arrow-Tramadol ............................121 Arrow-Venlafaxine XR ...................126 Arrowcare .....................................102 Arsenic trioxide .............................152 Arthrexin .......................................103 Asacol .............................................27 Asamax ...........................................27 Ascorbic acid ..................................37 Aspec 300 .....................................121 Aspen Adrenaline ...........................56 Aspen Ceftriaxone ..........................83 Aspirin Blood ..........................................41 Nervous ....................................121 Asthalin .........................................171 Atacand ..........................................50 Atazanavir sulphate ........................96 Atenolol ...........................................51 Atenolol Tablet USP ........................51 ATGAM .........................................164 Ativan ............................................137 Atomoxetine ..................................140 Atorvastatin ....................................45 Atropine sulphate Alimentary ..................................28 Sensory ....................................178 Atropt ............................................178 Atrovent ........................................171 Auranoﬁn ......................................103 Ava 20 ED .......................................72 Ava 30 ED .......................................72 Avanza ..........................................125 Avelox .............................................87 Avomine ........................................132 Avonex ..........................................139 Azathioprine .................................163 Azithromycin ...................................84 Azol .................................................82 Azopt ............................................177 AZT .................................................95 -BB-D Micro-Fine ...............................32 B-D Ultra Fine .................................33 B-D Ultra Fine II ..............................33 B-PlexADE ......................................37 Bacillus Calmette-Guerin (BCG) vaccine .................................... 164 Bacillus Calmette-Guerin vaccine ...................................... 99 Baclofen ........................................118 Bactroban .......................................59 Bakels Gluten Free Health Bread Mix ........................................... 203 Baraclude .......................................90 Barrier Creams and Emollients .................................. 63 Batrafen ..........................................59 BCG Vaccine ..................................99 Beclazone 100 ..............................169 Beclazone 250 ..............................169 Beclazone 50 ................................169 Beclomethasone dipropionate ..................... 169, 174 Bee venom allergy treatment ................................. 168 Bendroﬂuazide ................................55 Benhex ...........................................64 Benzathine benzylpenicillin ............86 Benzoin .........................................186 Benztrop .......................................120 Benztropine mesylate ...................120 Benzydamine hydrochloride ...........36 Benzylpenicillin sodium (penicillin G) ............................................... 86 Beta Adrenoceptor Blockers ...........51 Beta Cream ....................................61 Beta Ointment .................................61 Beta Scalp ......................................67 Beta-Adrenoceptor Agonists .........171 Betadine .........................................64 Betadine Skin Prep .........................64 Betaferon ......................................139 Betagan ........................................177 Betahistine dihydrochloride ..........131 Betaloc CR .....................................52 Betamethasone dipropionate ..........61 Betamethasone dipropionate with calcipotriol .......................... 66 Betamethasone sodium phosphate with betamethasone acetate ............. 76

220

INDEX Generic Chemicals and Brands

Betamethasone valerate ...........61, 67 Betamethasone valerate with clioquinol .................................... 62 Betamethasone valerate with fusidic acid ................................. 62 Betaxolol hydrochloride ................177 Betnovate .......................................61 Betnovate-C ....................................62 Betoptic .........................................177 Betoptic S .....................................177 Bezaﬁbrate .....................................45 Bezalip Retard ................................45 Bicalaccord ...................................161 Bicalutamide .................................161 Bicillin LA ........................................86 BiCNU ...........................................147 Bimatoprost ..................................178 Biodone ........................................122 Biodone Extra Forte ......................122 Biodone Forte ...............................122 Bisacodyl ........................................35 Bisoprolol fumarate .........................51 BK Lotion ........................................63 Bleomycin sulphate ......................152 Blood glucose diagnostic test meter ......................................... 31 Blood glucose diagnostic test strip ............................................ 32 Bonjela ............................................36 Boostrix ..........................................99 Bortezomib ...................................152 Bosentan ........................................56 Bosvate ...........................................51 Breath-Alert ..................................174 Brevinor 1/21 ..................................72 Brevinor 1/28 ..................................72 Brevinor 21 .....................................72 Bricanyl Turbuhaler .......................171 Brimonidine tartrate ......................178 Brimonidine tartrate with timolol maleate .................................... 178 Brinzolamide .................................177 Brolene .........................................176 Bromocriptine mesylate ................119 Broncolin .......................................171 Brufen ...........................................102 Brufen SR .....................................102 BSF Rizamelt ................................180 BSF Ursosan ................................180 Buccastem ....................................132 Budenocort ...................................169 Budesonide Alimentary ..................................26 Respiratory .......................169, 174 Budesonide with eformoterol .............................. 170 Bumetanide ....................................54 Buprenorphrine with naloxone .................................. 144 Bupropion hydrochloride ...............145 Burinex ...........................................54 Buscopan ........................................28 Buspirone hydrochloride ...............137 Busulphan .....................................147 Butacort Aqueous .........................174 -CCabergoline ....................................82 Cafergot ........................................130 Caffeine citrate .............................175 Cal-d-Forte .....................................37 Calamine ........................................60 Calcipotriol ......................................66 Calcitonin ......................................114 Calcitriol ..........................................37 Calcium carbonate ..........................38 Calcium carbonate with aminoacetic acid ........................ 26 Calcium Channel Blockers .............53 Calcium Disodium Versenate .........39 Calcium folinate ............................148 Calcium Folinate Ebewe ...............148 Calcium gluconate ..........................38 Calcium polystyrene sulphonate ................................. 44 Calcium Resonium .........................44 Calogen ........................................192 Calsource .......................................38 Camptosar ....................................151 Candesartan ...................................50 Candestar .......................................50 Canesten ........................................59 Capecitabine .................................148 Capoten ..........................................48 Capsaicin ........................................69 Captopril .........................................48 Carafate ..........................................29 Carbamazepine ............................127 Carbimazole ...................................80 Carboplatin ...................................147 Carboplatin Ebewe .......................147 Carbosorb-X ...................................39 Cardinol ..........................................53 Cardinol LA .....................................53 Cardizem CD ..................................54 CareSens ........................................32 CareSens II .....................................31 CareSens POP ...............................31 Carmustine ...................................147 Carvedilol .......................................51 Catapres .........................................54 Catapres-TTS-1 ..............................54 Catapres-TTS-2 ..............................54 Catapres-TTS-3 ..............................54 CeeNU ..........................................147 Cefaclor monohydrate ....................83 Cefaclor Sandoz .............................83 Cefalexin Sandoz ............................84 Cefazolin sodium ............................83 Cefoxitin sodium .............................83 Ceftriaxone sodium ........................83 Cefuroxime axetil ............................83 Cefuroxime sodium .........................83 Celestone Chronodose ...................76 Celiprolol .........................................51 Cellcept .........................................163 Celol ...............................................51 Centrally Acting Agents ..................54 Cephalexin ABM .............................84 Cephalexin monohydrate ................84 Ceptolate ......................................163 Cerezyme .......................................35 Cetirizine - AFT ............................168 Cetirizine hydrochloride ................168 Cetomacrogol .................................63 Champix .......................................145 Charcoal .........................................39 Chemotherapeutic Agents ............147 Chlorafast .....................................176 Chlorambucil .................................147 Chloramphenicol ...........................176 Chlorhexidine gluconate Alimentary ..................................36 Dermatological ...........................62 Chloroform ....................................186 Chloromycetin ...............................176 Chlorothiazide .................................55 Chlorpheniramine maleate ...........168 Chlorpromazine hydrochloride ........................... 133 Chlorsig ........................................176 Chlorthalidone ................................55 Chlorvescent ..................................44 Cholecalciferol ................................37 Cholestyramine with aspartame ................................. 45 Choline salicylate with cetalkonium chloride .................. 36 Cholvastin .......................................46 Ciclopirox olamine ..........................59

221

INDEX Generic Chemicals and Brands

Cilazapril .........................................48 Cilazapril with hydrochlorothiazide ................... 49 Cilicaine ..........................................86 Cilicaine VK ....................................86 Ciloxan ..........................................176 Cimetidine .......................................28 Cipﬂox .............................................87 Ciproﬂoxacin Infection ......................................87 Sensory ....................................176 Cisplatin ........................................147 Cisplatin Ebewe ............................147 Citalopram hydrobromide .............125 Cladribine .....................................149 Clarithromycin Alimentary ..................................28 Infection ......................................84 Clexane ..........................................42 Climara 100 ....................................78 Climara 50 ......................................78 Clindamycin ....................................87 Clindamycin ABM ...........................87 Clobazam .....................................127 Clobetasol propionate ...............61, 67 Clobetasone butyrate .....................61 Clomazol Dermatological ...........................59 Genito-Urinary ............................74 Clomiphene citrate ..........................82 Clomipramine hydrochloride .........123 Clonazepam .........................126–127 Clonidine .........................................54 Clonidine hydrochloride Cardiovascular ...........................54 Nervous ....................................130 Clopidogrel .....................................41 Clopine .........................................133 Clopixol .................................135, 136 Clotrimazole Dermatological ...........................59 Genito-Urinary ............................74 Clozapine ......................................133 Clozaril .........................................133 Co-Renitec ......................................49 Co-trimoxazole ...............................87 Coal tar ...........................................67 Coal tar with allantoin, menthol, phenol and sulphur .................... 67 Coal tar with salicylic acid and sulphur ....................................... 67 Coco-Scalp .....................................67 Codeine phosphate Extemporaneous ......................186 Nervous ....................................121 Cogentin .......................................120 Colaspase [L-asparaginase] .........153 Colchicine .....................................118 Colestid ...........................................45 Colestipol hydrochloride .................45 Colgout .........................................118 Colifoam .........................................27 Colistin sulphomethate ...................87 Colistin-Link ....................................87 Collodion ﬂexible ..........................186 Colofac ...........................................28 Coloxyl ............................................34 Combigan .....................................178 Combivir .........................................96 Compound electrolytes ...................44 Compound hydroxybenzoate ..................... 186 Comtan .........................................119 Concerta .......................................142 Condoms ........................................70 Condyline ........................................68 Contraceptives - Hormonal .............71 Contraceptives Non-hormonal ............................ 70 Copaxone .....................................139 Corangin .........................................55 Cordarone-X ...................................50 Corticosteroids and Related Agents for Systemic Use ........... 76 Corticosteroids Topical ...................61 Cosmegen ....................................153 Cosopt ..........................................178 Coumadin .......................................43 Coversyl ..........................................49 Creon 10000 ...................................33 Creon Forte ....................................33 Crixivan ...........................................96 Crotamiton ......................................60 Crystacide ......................................59 Curam .............................................86 Curam Duo .....................................86 Cyclizine hydrochloride .................131 Cyclizine lactate ............................131 Cycloblastin ..................................147 Cyclogyl ........................................178 Cyclopentolate hydrochloride ........................... 178 Cyclophosphamide .......................147 Cyclosporin ...................................167 Cyklokapron ....................................41 Cyproterone acetate .......................77 Cyproterone acetate with ethinyloestradiol ......................... 73 Cytarabine ....................................149 Cytotec ...........................................28 Cytoxan ........................................147 -DD-Penamine ..................................103 d4T .................................................95 Dabigatran ......................................43 Dacarbazine .................................153 Dactinomycin [Actinomycin D] ............................................. 153 Daivobet .........................................66 Daivonex .........................................66 Daktarin Alimentary ..................................36 Dermatological ...........................60 Dalacin C ........................................87 Danazol ..........................................82 Danthron with poloxamer ................35 Dantrium .......................................118 Dantrolene sodium .......................118 Daonil .............................................30 Dapa-Tabs ......................................55 Dapsone .........................................89 Darunavir ........................................96 Dasatinib .......................................157 Daunorubicin ................................153 DBL Aminophylline .......................173 DBL Bleomycin Sulfate .................152 DBL Carboplatin ...........................147 DBL Doxorubicin ...........................154 DBL Doxorubicin S29 ...................154 DBL Epirubicin Hydrochloride .......................... 154 DBL Ergometrine ............................74 DBL Gemcitabine .........................150 DBL Leucovorin Calcium ..............148 DBL Methotrexate .........................152 DBL Morphine Sulphate ...............122 DBL Pethidine Hydrochloride .......................... 123 DBL Tobramycin .............................88 DDI .................................................95 De-Worm ........................................83 Deca-Durabolin Orgaject ................76 Deferiprone .....................................47 Deoxycoformycin ..........................155 Depo-Medrol ...................................76 Depo-Medrol with Lidocaine ...........76 Depo-Provera .................................73 Depo-Testosterone .........................77

222

INDEX Generic Chemicals and Brands

Deprim ............................................87 Dermol ......................................61, 67 Desferrioxamine mesylate ..............47 Desmopressin .................................81 Desmopressin-PH&T ......................81 Detection of Substances in Urine .......................................... 75 Dexamethasone Hormone ....................................76 Sensory ....................................177 Dexamethasone sodium phosphate .................................. 76 Dexamethasone with framycetin and gramicidin ......................... 176 Dexamethasone with neomycin and polymyxin b sulphate .........177 Dexamphetamine sulphate ...........141 Dextrochlorpheniramine maleate .................................... 168 Dextrose .........................................43 Dextrose with electrolytes ...............44 DHC Continus ...............................121 Diabetes .........................................29 Diabetes Management ...................31 Diamide Relief ................................26 Diamox .........................................177 Diaphragm ......................................70 Diasip ............................................193 Diason RTH ..................................193 Diastop ...........................................26 Diazepam .............................126, 137 Dibenyline .......................................48 Diclax SR ......................................102 Diclofenac Sandoz ........................102 Diclofenac sodium Musculoskeletal System ...........102 Sensory ....................................177 Didanosine [DDI] ............................95 Differin ............................................58 Difﬂam ............................................36 Diﬂucan ...........................................88 Diﬂucortolone valerate ....................61 Digestives Including Enzymes .................................... 33 Digoxin ............................................50 Dihydrocodeine tartrate ................121 Dilantin ..........................................129 Dilantin Infatab ..............................129 Dilatrend .........................................51 Diltiazem hydrochloride ..................54 Dilzem .............................................54 Dimetriose ......................................82 Dipentum ........................................27 Diphenoxylate hydrochloride with atropine sulphate ....................... 26 Diphtheria and tetanus vaccine ...................................... 99 Diphtheria, tetanus and pertussis vaccine ...................................... 99 Diphtheria, tetanus, pertussis and polio vaccine ....................... 99 Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus inﬂuenzae type B vaccine ...................................... 99 Diprosone .......................................61 Diprosone OV .................................61 Dipyridamole ...................................41 Disinfecting and Cleansing Agents ....................................... 62 Disipal ...........................................120 Disopyramide phosphate ................51 Disulﬁram ......................................145 Diuretics ..........................................54 Diurin 40 .........................................55 Dixarit ...........................................130 DM Ject ..........................................33 Docetaxel ......................................153 Docetaxel Ebewe ..........................153 Docusate sodium ............................34 Docusate sodium with sennosides ................................ 34 Domperidone ................................131 Donepezil hydrochloride ...............143 Donepezil-Rex ..............................143 Dopergin .......................................119 Dopress ........................................124 Dornase alfa .................................173 Dorzolamide hydrochloride ...........178 Dorzolamide hydrochloride with timolol maleate ........................ 178 Dostinex ..........................................82 Dothiepin hydrochloride ................124 Doxazosin mesylate .......................48 Doxepin hydrochloride ..................124 Doxine ............................................86 Doxorubicin ...................................154 Doxorubicin Ebewe .......................154 Doxy-50 ..........................................86 Doxycycline hydrochloride ..............86 DP Lotion ........................................63 DP Lotn HC ....................................62 DP-Anastrozole ............................163 Dr Reddy’s Atorvastatin ..................45 Dr Reddy’s Olanzapine .........133, 136 Dr Reddy’s Omeprazole .................29 Dr Reddy’s Ondansetron ..............131 Dr Reddy’s Pantoprazole ................29 Dr Reddy’s Pramipexole ...............119 Dr Reddy’s Quetiapine .................134 Dr Reddy’s Risperidone ................134 Dr Reddy’s Terbinaﬁne ...................89 Drugs Affecting Bone Metabolism .............................. 113 Dulcolax ..........................................35 Duocal Super Soluble Powder ..................................... 191 Duolin ...........................................172 Duolin HFA ...................................172 Durex Conﬁdence ...........................70 Durex Extra Safe ............................70 Durex Select Flavours ....................70 Duride .............................................55 Dynacirc-SRO .................................53 -EE-Mycin ...........................................85 Ear Preparations ...........................176 Ear/Eye Preparations ...................176 Easiphen Liquid ............................205 Econazole nitrate ............................60 Efavirenz .........................................95 Efexor XR .....................................126 Efﬁent .............................................41 Eformoterol fumarate ....................170 Efudix ..............................................68 Egopsoryl TA ..................................67 Elecare .........................................206 Elecare LCP .................................206 Electral ............................................44 Elemental 028 Extra .....................196 Eligard ............................................81 Elocon .............................................62 Eloxatin .........................................148 Eltroxin ............................................80 Emend Tri-Pack ............................131 EMLA ............................................120 Emtricitabine ...................................95 Emtriva ...........................................95 Emulsifying ointment ......................63 Enalapril .........................................48 Enalapril with hydrochlorothiazide ................... 49 Enbrel ...........................................108 Endocrine Therapy .......................161 Endoxan .......................................147 Enfuvirtide ......................................96 Enoxaparin sodium .........................42 Ensure ..........................................200 Ensure Plus ..................................201

223

INDEX Generic Chemicals and Brands

Ensure Plus HN ............................200 Ensure Plus RTH ..........................200 Entacapone ..................................119 Entecavir .........................................90 Entocort CIR ...................................26 Enuclene .......................................179 Epilim ............................................129 Epilim Crushable ..........................129 Epilim IV .......................................129 Epilim S/F Liquid ...........................129 Epilim Syrup .................................129 Epirubicin ......................................154 Epirubicin Ebewe ..........................154 Eprex ..............................................40 ERA ................................................85 Ergometrine maleate ......................74 Ergotamine tartrate with caffeine .................................... 130 Erlotinib hydrochloride ..................158 Erythrocin IV ...................................85 Erythromycin ethyl succinate ..........85 Erythromycin lactobionate ..............85 Erythromycin stearate ....................85 Erythropoietin alpha .......................40 Erythropoietin beta .........................40 Escitalopram .................................125 Estradot ..........................................78 Estrofem .........................................78 Etanercept ....................................108 Ethambutol hydrochloride ...............89 Ethics Aspirin ................................121 Ethics Aspirin EC ............................41 Ethics Paracetamol .......................121 Ethinyloestradiol .............................79 Ethinyloestradiol with desogestrel ................................ 71 Ethinyloestradiol with levonorgestrel ............................ 72 Ethinyloestradiol with norethisterone ............................ 72 Ethosuximide ................................127 Etidronate disodium ......................114 Etopophos ....................................154 Etoposide ......................................154 Etoposide phosphate ....................154 Etravirine ........................................95 Eumovate .......................................61 Evista ............................................115 Exemestane ..................................163 Extemporaneously Compounded Preparations and Galenicals ................................ 186 Eye Preparations ..........................176 EZ-ﬁt Paediatric Mask ..................174 Ezetimibe ........................................46 Ezetimibe with simvastatin .............46 Ezetrol ............................................46 -FFamotidine ......................................28 Famox .............................................28 Felo 10 ER ......................................53 Felo 5 ER ........................................53 Felodipine .......................................53 Femtran 100 ...................................78 Femtran 50 .....................................78 Fenpaed .......................................102 Fentanyl ........................................121 Fentanyl citrate .............................122 Ferodan ..........................................38 Ferriprox .........................................47 Ferro-F-Tabs ...................................38 Ferro-tab .........................................38 Ferrograd ........................................38 Ferrograd F .....................................38 Ferrous fumarate ............................38 Ferrous fumarate with folic acid ............................................ 38 Ferrous sulphate .............................38 Ferrous sulphate with folic acid ............................................ 38 Ferrum H ........................................39 Fexofenadine hydrochloride .........168 Fibalip .............................................45 Fibro-vein ........................................41 Finasteride ......................................74 Fine Ject .........................................32 Flagyl ..............................................89 Flagyl-S ..........................................89 Flamazine .......................................59 Flecainide acetate ..........................51 Fleet Phosphate Enema .................35 Flixonase Hayfever & Allergy ...................................... 174 Flixotide ........................................169 Flixotide Accuhaler .......................169 Florinef ...........................................76 Fluanxol ........................................135 Fluarix ...........................................100 Flucloxacillin sodium .......................86 Flucloxin .........................................86 Fluconazole ....................................88 Fludara .........................................149 Fludara Oral ..................................149 Fludarabine Ebewe .......................149 Fludarabine phosphate .................149 Fludrocortisone acetate ..................76 Fluids and Electrolytes ...................43 Flumetasone pivalate ...................176 Fluocortolone caproate with ﬂuocortolone pivalate and cinchocaine ................................ 28 Fluorometholone ...........................177 Fluorouracil Ebewe .......................150 Fluorouracil sodium Dermatological ...........................68 Oncology ..................................150 Fluox .............................................125 Fluoxetine hydrochloride ...............125 Flupenthixol decanoate ................135 Fluphenazine decanoate ..............135 Flutamide ......................................161 Flutamin ........................................161 Fluticasone ...................................169 Fluticasone propionate .................174 Fluticasone with salmeterol ..........170 Fluvax ...........................................100 FML ..............................................177 Foban .............................................59 Folic acid ........................................40 Food Thickeners ...........................202 Foods And Supplements For Inborn Errors Of Metabolism .............................. 204 Foradil ...........................................170 Forteo ...........................................115 Fortimel Regular ...........................194 Fortini ...........................................195 Fortini Multi Fibre ..........................195 Fortisip ..................................200, 201 Fortisip Multi Fibre ........................201 Fosamax .......................................114 Fosamax Plus ...............................114 Framycetin sulphate .....................176 FreeStyle Lite ...........................31, 32 Freestyle Optium ......................31, 32 Freestyle Optium Ketone ................31 Frisium ..........................................127 Frumil ..............................................55 Frusemide-Claris ............................55 Fucicort ...........................................62 Fucidin ............................................87 Fucithalmic ...................................176 Fungilin ...........................................36 Furosemide .....................................55 Fusidic acid Dermatological ...........................59 Infection ......................................87 Sensory ....................................176 Fuzeon ............................................96

224

INDEX Generic Chemicals and Brands

-GGabapentin ...................................127 Gabapentin (Neurontin) ................128 Gamma benzene hexachloride .............................. 64 Gardasil ........................................100 Gastrosoothe ..................................28 Gaviscon Double Strength ..............26 Gaviscon Infant ...............................26 Geﬁtinib ........................................158 Gemcitabine Actavis 1000 ............150 Gemcitabine Actavis 200 ..............150 Gemcitabine Ebewe .....................150 Gemcitabine hydrochloride ...........150 Gemﬁbrozil .....................................45 Gemzar .........................................150 Generaid Plus ...............................194 Genoptic .......................................176 Genotropin ......................................81 Genox ...........................................163 Gentamicin sulphate Infection ......................................87 Sensory ....................................176 Gestrinone ......................................82 Ginet 84 ..........................................73 Glatiramer acetate ........................139 Glibenclamide .................................30 Gliclazide ........................................30 Glipizide ..........................................30 Glivec ............................................158 Glucagen Hypokit ...........................29 Glucagon hydrochloride ..................29 Glucerna Select ............................193 Glucerna Select RTH ....................193 Glucobay ........................................30 Gluten Free Foods ........................203 Glycerin with sodium saccharin ................................. 186 Glycerin with sucrose ...................186 Glycerol Alimentary ..................................35 Extemporaneous ......................186 Glyceryl trinitrate ............................55 Glytrin .............................................55 Gold Knight .....................................70 Gopten ............................................49 Goserelin acetate ...........................81 Gutron .............................................51 Gynaecological Anti-infectives ............................ 73 -HHabitrol .........................................145 Haemophilus inﬂuenzae type B vaccine .................................... 100 Haldol ...........................................135 Haldol Concentrate .......................135 Haloperidol ...................................133 Haloperidol decanoate .................135 Hamilton Sunscreen .......................68 HBvaxPro .....................................100 healthE Fatty Cream .......................63 Healtheries Simple Baking Mix ........................................... 203 Hemastix .........................................75 Heparin sodium ..............................42 Heparinised saline ..........................42 Hepatitis B vaccine .......................100 Hepsera ..........................................90 Herceptin ......................................166 Hexamine hippurate .......................99 Hiprex .............................................99 Histafen ........................................168 Holoxan ........................................147 Homatropine hydrobromide ..........178 Horleys Bread Mix ........................203 Horleys Flour ................................203 Hormone Replacement Therapy Systemic .................................... 77 Humalog .........................................30 Humalog Mix 25 ..............................30 Humalog Mix 50 ..............................30 Human papilomavirus vaccine .................................... 100 Humira ..........................................104 HumiraPen ....................................104 Humulin 30/70 ................................30 Humulin NPH ..................................30 Humulin R .......................................29 Hybloc .............................................52 Hydralazine .....................................56 Hydrea ..........................................154 Hydrocortisone Dermatological ...........................61 Hormone ....................................76 Hydrocortisone acetate ..................27 Hydrocortisone butyrate ...........61, 67 Hydrocortisone with cinchocaine ................................ 28 Hydrocortisone with miconazole ................................ 62 Hydrocortisone with natamycin and neomycin ............................ 62 Hydrocortisone with wool fat and mineral oil .................................. 62 Hydroderm Lotion ...........................63 Hydrogen peroxide Alimentary ..................................36 Dermatological ...........................59 Hydroxocobalamin ..........................37 Hydroxychloroquine sulphate .........89 Hydroxyurea .................................154 Hygroton .........................................55 Hyoscine (scopolamine) ...............131 Hyoscine hydrobromide ................131 Hyoscine N-butylbromide ...............28 Hypam ..........................................140 Hyperuricaemia and Antigout ................................... 118 Hypnovel .......................................140 Hypromellose ................................179 Hysite ............................................178 -IIbiamox ...........................................85 Ibuprofen ......................................102 Idarubicin hydrochloride ...............154 Ifosfamide .....................................147 Iloprost ............................................57 Imatinib mesylate ..........................158 Imiglucerase ...................................35 Imipramine hydrochloride .............124 Imiquimod .......................................68 Immune Modulators ........................97 Immunosuppressants ...................163 Imuprine .......................................163 Imuran ..........................................163 Indapamide .....................................55 Indinavir ..........................................96 Indomethacin ................................103 Infanrix-hexa ...................................99 Infanrix-IPV .....................................99 Infant Formulae ............................205 Inﬂuenza vaccine ..........................100 Inhaled Anticholinergic Agents ..................................... 171 Inhaled Corticosteroids .................169 Inhaled Long-acting Beta-adrenoceptor Agonists ................................... 169 Inhibace Plus ..................................49 Innovacon hCG One Step Pregnancy Test .......................... 74 Insulin aspart ............................29–30 Insulin glargine ...............................30 Insulin glulisine ...............................30 Insulin isophane ..............................30 Insulin isophane with insulin neutral ........................................ 30

225

INDEX Generic Chemicals and Brands

Insulin lispro ....................................30 Insulin lispro with insulin lispro protamine ................................... 30 Insulin neutral .................................29 Insulin pen needles .........................32 Insulin syringes, disposable with attached needle ......................... 33 Intal Forte CFC Free .....................173 Intal Spincaps ...............................173 Intelence .........................................95 Interferon alpha-2a .........................97 Interferon alpha-2b .........................97 Interferon beta-1-alpha .................139 Interferon beta-1-beta ...................139 Intra-uterine device .........................71 Intron-A ...........................................97 IPOL .............................................101 Ipratropium bromide .............171, 174 Iressa ............................................158 Irinotecan ......................................151 Irinotecan-Rex ..............................151 Iron Overload ..................................47 Iron polymaltose .............................39 Isentress .........................................96 Ismo 20 ...........................................55 Isoniazid .........................................89 Isoprenaline hydrochloride .............56 Isoptin .............................................54 Isopto Carpine ..............................178 Isopto Homatropine ......................178 Isosorbide mononitrate ...................55 Isosource Standard ......................200 Isosource Standard RTH ..............200 Isotretinoin ......................................58 Isradipine ........................................53 Isuprel .............................................56 Itch-Soothe .....................................60 Itraconazole ....................................88 Itrazole ............................................88 Ivermectin .......................................64 -JJadelle ............................................73 Jevity ............................................200 Jevity RTH ....................................200 -KKaletra ............................................96 Karicare Food Thickener ..............203 Kemadrin ......................................120 Kenacomb ....................................176 Kenacort-A ......................................77 Kenacort-A40 ..................................77 KetoCal .........................................208 Ketoconazole Dermatological ...........................67 Infection ......................................88 Ketogenic Diet ..............................207 Ketone blood beta-ketone electrodes .................................. 31 Ketoprofen ....................................102 Ketostix ...........................................31 Kindergen .....................................194 Kivexa .............................................95 Klacid ..............................................84 Kliogest ...........................................79 Kliovance ........................................79 Konakion MM ..................................41 Konsyl-D .........................................34 -LL-asparaginase .............................153 Labetalol .........................................52 Lacosamide ..................................128 Lacri-Lube ....................................179 Lactulose ........................................35 Laevolac .........................................35 Lamictal ........................................128 Lamivudine ...............................91, 95 Lamotrigine ...................................128 Lanoxin ...........................................50 Lanoxin PG .....................................50 Lansoprazole ..................................29 Lantus .............................................30 Lantus SoloStar ..............................30 Lanvis ...........................................152 Lanzol Relief ...................................29 Lapatinib Ditosylate ......................159 Largactil ........................................133 Lasix ...............................................55 Latanoprost ...................................178 Lax-Tab ...........................................35 Laxatives ........................................34 Laxofast 120 ...................................34 Laxofast 50 .....................................34 Laxsol .............................................34 Leﬂunomide ..................................103 Letara ...........................................163 Letraccord .....................................163 Letrozole .......................................163 Leukeran FC .................................147 Leukotriene Receptor Antagonists .............................. 172 Leunase ........................................153 Leuprorelin ......................................81 Leustatin .......................................149 Levetiracetam ...............................129 Levetiracetam-Rex ........................129 Levlen ED .......................................72 Levobunolol ..................................177 Levocabastine ..............................177 Levodopa with benserazide ..........119 Levodopa with carbidopa ..............119 Levomepromazine ........................133 Levonorgestrel Genito-Urinary ............................73 Hormone ....................................79 Levothyroxine ..................................80 Lifestyles Flared .............................70 Lignocaine ....................................120 Lignocaine hydrochloride ..............120 Lignocaine with chlorhexidine ........................... 120 Lignocaine with prilocaine ............120 Lincocin ..........................................87 Lincomycin ......................................87 Lipazil .............................................45 Lipid Modifying Agents ...................45 Lipitor ..............................................45 Liquigen ........................................192 Lisinopril .........................................48 Lisuride hydrogen maleate ...........119 Litak ..............................................149 Lithicarb FC ..................................133 Lithium carbonate .........................133 Livostin .........................................177 Locacorten-Viaform ED’s ..............176 Locasol .........................................206 Loceryl ............................................59 Locoid .......................................61, 67 Locoid Crelo ...................................61 Locoid Lipocream ...........................61 Locorten-Vioform ..........................176 Lodoxamide trometamol ...............177 Loette .............................................72 Logem ...........................................128 Lomide ..........................................177 Lomustine .....................................147 Loperamide hydrochloride ..............26 Lopinavir with ritonavir ....................96 Lopresor .........................................52 Loproﬁn .........................................205 Loproﬁn Mix ..................................205 Loraclear Hayfever Relief .............169 Lorapaed ......................................169 Loratadine .....................................169 Lorazepam ....................................137 Lormetazepam .............................140 Losartan .........................................50 Lostaar ............................................50 Lovir ................................................92

226

INDEX Generic Chemicals and Brands

Loxalate ........................................125 Loxamine ......................................125 Lucrin Depot ...................................81 Lucrin Depot PDS ...........................81 Ludiomil ........................................124 Lumigan ........................................178 Lycinate ..........................................55 Lyderm ............................................66 -Mm-Captopril .....................................48 m-Cefuroxime .................................83 m-Eslon ........................................122 M-M-R II ........................................101 m-Mometasone ...............................62 Mabthera ......................................164 Macrogol 3350 ................................35 Madopar 125 ................................119 Madopar 250 ................................119 Madopar 62.5 ...............................119 Madopar Dispersible .....................119 Madopar HBS ...............................119 Magnesium hydroxide ...................186 Magnesium sulphate Alimentary ..................................39 Dermatological ...........................69 Malathion ........................................66 Maprotiline hydrochloride .............124 Marevan ..........................................43 Marine Blue Lotion SPF 30+ ..........68 Marquis Black .................................70 Marquis Conforma ..........................70 Marquis Protecta ............................70 Marquis Selecta ..............................70 Marquis Sensolite ...........................70 Marquis Supalite .............................70 Marquis Titillata ..............................70 MarquisTantiliza ..............................70 Martindale Acetylcysteine .............186 Marvelon 21 ....................................71 Marvelon 28 ....................................71 Mask for spacer device .................174 Mast Cell Stabilisers .....................173 Maxidex ........................................177 Maxitrol .........................................177 MCT oil (Nutricia) .........................192 Measles, mumps and rubella vaccine .................................... 101 Mebendazole ..................................83 Mebeverine hydrochloride ..............28 Medrol .............................................76 Medroxyprogesterone acetate Genito-Urinary ............................73 Hormone ..............................79–80 Mefenamic acid ............................102 Megace .........................................161 Megestrol acetate .........................161 Meloxicam ....................................103 Melphalan .....................................147 Meningococcal A, C, Y and W-135 vaccine ......................... 101 Menomune ....................................101 Menthol ...........................................60 Mercaptopurine ............................151 Mercilon 21 .....................................71 Mercilon 28 .....................................71 Mesalazine .....................................27 Mesna ...........................................154 Mestinon .......................................102 Metabolic Disorder Agents .............35 Metamide ......................................131 Metformin hydrochloride .................31 Methadone hydrochloride Extemporaneous ......................186 Nervous ....................................122 Methatabs .....................................122 Methoblastin .................................152 Methopt .........................................179 Methotrexate .................................152 Methotrexate Ebewe .....................152 Methyl hydroxybenzoate ...............187 Methylcellulose .............................187 Methylcellulose with glycerin and sodium saccharin .................... 187 Methylcellulose with glycerin and sucrose .................................... 187 Methyldopa .....................................54 Methylphenidate hydrochloride ........................... 142 Methylphenidate hydrochloride extended-release ..................... 142 Methylprednisolone ........................76 Methylprednisolone aceponate .................................. 62 Methylprednisolone acetate ............76 Methylprednisolone acetate with lignocaine .................................. 76 Methylprednisolone sodium succinate ................................... 77 Methylxanthines ............................173 Metoclopramide hydrochloride ........................... 131 Metoclopramide hydrochloride with paracetamol ..................... 130 Metopirone ......................................82 Metoprolol - AFT CR .......................52 Metoprolol succinate .......................52 Metoprolol tartrate ..........................52 Metronidazole .................................89 Metyrapone .....................................82 Miacalcic .......................................114 Mianserin hydrochloride ...............124 Micolette .........................................35 Miconazole .....................................36 Miconazole nitrate Dermatological ...........................60 Genito-Urinary ............................74 Micreme ..........................................74 Micreme H ......................................62 Microgynon 20 ED ..........................72 Microgynon 30 ................................72 Microgynon 30 ED ..........................72 Microgynon 50 ED ..........................72 Microlut ...........................................73 Midazolam ....................................140 Midodrine ........................................51 Minaphlex .....................................205 Minerals ..........................................38 Minidiab ..........................................30 Minirin .............................................81 Mino-tabs ........................................86 Minocycline hydrochloride ..............86 Minomycin ......................................86 Minor Skin Infections ......................64 Mirena .............................................79 Mirtazapine ...................................125 Misoprostol .....................................28 Mitomycin C ..................................154 Mitozantrone .................................155 Mitozantrone Ebewe .....................155 Mixtard 30 .......................................30 Moclobemide ................................125 Modaﬁnil .......................................143 Modavigil ......................................143 Modecate ......................................135 Moducal ........................................190 Moduretic ........................................55 Mogine ..........................................128 Mometasone furoate .......................62 Monofeme .......................................72 Monogen .......................................193 Montelukast ..................................172 Morphine hydrochloride ................122 Morphine sulphate ........................122 Morphine tartrate ..........................123 Motetis ..........................................120 Motilium ........................................131 Mouth and Throat ...........................36 Movicol ...........................................35 Moxiﬂoxacin ....................................87

227

INDEX Generic Chemicals and Brands

MSUD Maxamaid .........................204 MSUD Maxamum .........................204 Mucilaginous laxatives ....................34 Mucilaginous laxatives with stimulants .................................. 34 Mucilax ...........................................34 Mucolytics .....................................173 MultiADE .........................................38 Multiload Cu 375 .............................71 Multiload Cu 375 SL .......................71 Multiple Sclerosis Treatments ............................... 138 Multivitamins ...................................37 Mupirocin ........................................59 Muscle Relaxants .........................118 Myaccord ......................................163 Myambutol ......................................89 Mycobutin .......................................89 Mycophenolate mofetil ..................163 Mycostatin ......................................60 Mydriacyl ......................................178 Mylan Atenolol ................................51 Mylan Fentanyl Patch ...................121 Mylanta P ........................................26 Myleran .........................................147 Myloc CR ........................................52 Myocrisin ......................................103 Myometrial and Vaginal Hormone Preparations .............................. 74 -NNadolol ...........................................52 Nalcrom ..........................................27 Naloxone hydrochloride ................144 Naltraccord ...................................145 Naltrexone hydrochloride ..............145 Nandrolone decanoate ...................76 Naphazoline hydrochloride ...........179 Naphcon Forte ..............................179 Naprosyn SR 1000 .......................102 Naprosyn SR 750 .........................102 Naproxen ......................................102 Nardil ............................................124 Nasal Preparations .......................174 Natulan .........................................155 Nausicalm .....................................131 Navelbine ......................................156 Navoban .......................................132 Nedocromil ...................................173 Nefopam hydrochloride ................121 Neo-Mercazole ...............................80 Neocate ........................................206 Neocate Advance .........................206 Neocate Gold ................................206 Neocate LCP ................................206 Neoral ...........................................167 NeoRecormon ................................40 Neostigmine ..................................102 Neotigason .....................................66 Nepro (strawberry) ........................195 Nepro (vanilla) ..............................195 Nerisone .........................................61 Neulactil ........................................134 NeuroKare ......................................38 Neurontin ......................................128 Nevirapine ......................................95 Nicotine .........................................145 Nicotinic acid ..................................45 Nifedipine ........................................53 Nifuran ............................................99 Nilstat Alimentary ..................................36 Genito-Urinary ............................74 Infection ......................................88 Nipent ...........................................155 Nitrados ........................................140 Nitrates ...........................................55 Nitrazepam ...................................140 Nitroderm TTS ................................55 Nitrofurantoin ..................................99 Nizoral ............................................88 Noctamid ......................................140 Nodia ..............................................26 Noﬂam 250 ...................................102 Noﬂam 500 ...................................102 Non-steroidal Anti-inﬂammatory Drugs (NSAIDs) ....................... 102 Nordette 28 .....................................72 Norethisterone Genito-Urinary ............................73 Hormone ....................................80 Norethisterone with mestranol ................................... 72 Norﬂex ..........................................118 Norﬂoxacin ......................................99 Noriday 28 ......................................73 Norimin ...........................................72 Norinyl-1/28 ....................................72 Normacol Plus ................................34 Normison ......................................140 Norpress .......................................124 Nortriptyline hydrochloride ............124 Norvir ..............................................96 NovaSource Renal .......................195 Novatretin .......................................66 NovoFine ........................................32 NovoMix 30 FlexPen .......................29 NovoRapid ......................................30 NovoRapid Penﬁll ...........................30 Nozinan ........................................133 Nuelin ...........................................173 Nuelin-SR .....................................173 Nupentin .......................................127 Nutraplus ........................................63 Nutrient Modules ..........................190 Nutrini Energy Multi Fibre .............195 Nutrini Energy RTH ......................195 Nutrini Low Energy Multi Fibre ........................................ 197 Nutrini RTH ...................................195 Nutrison Concentrated .................202 Nutrison Energy ............................199 Nutrison Energy Multi Fibre ..........200 Nutrison Multi Fibre ......................200 Nutrison Standard RTH ................200 Nyefax Retard .................................53 Nystatin Alimentary ..................................36 Dermatological ...........................60 Genito-Urinary ............................74 Infection ......................................88 NZB Low Gluten Bread Mix ..........203 -OOctreotide (somatostatin analogue) ................................. 162 Octreotide MaxRx .........................162 Oestradiol .......................................78 Oestradiol valerate .........................78 Oestradiol with norethisterone ............................ 79 Oestriol Genito-Urinary ............................74 Hormone ....................................79 Oestrogens .....................................79 Oestrogens with medroxyprogesterone ................ 79 Oil in water emulsion ......................63 Olanzapine ...........................133, 136 Olanzapine pamoate monohydrate ............................ 135 Olanzine .......................................133 Olanzine-D ....................................136 Olbetam ..........................................45 Olsalazine .......................................27 Omeprazole ....................................29 Omezol Relief .................................29 On Call Advanced .....................31, 32 OncoTICE .....................................164 Ondansetron .................................131 One-Alpha ......................................37

228

INDEX Generic Chemicals and Brands

Onkotrone .....................................155 Ora-Blend .....................................187 Ora-Blend SF ................................187 Ora-Plus .......................................187 Ora-Sweet ....................................186 Ora-Sweet SF ...............................186 Orabase ..........................................36 Oracort ...........................................36 Oral Supplements/Complete Diet (Nasogastric/Gastrostomy Tube Feed) .............................. 192 Oratane ...........................................58 Orgran ..........................................204 Ornidazole ......................................89 Orphenadrine citrate .....................118 Orphenadrine hydrochloride .........120 Ortho All-ﬂex ...................................70 Ortho-tolidine ..................................75 Oruvail SR ....................................102 Osmolite .......................................200 Osmolite RTH ...............................200 Ospamox ........................................85 Ospamox Paediatric Drops .............85 Other Endocrine Agents .................82 Other Oestrogen Preparations .............................. 79 Other Progestogen Preparations .............................. 79 Other Skin Preparations .................68 Ovestin Genito-Urinary ............................74 Hormone ....................................79 Ox-Pam ........................................138 Oxaliplatin .....................................148 Oxaliplatin Actavis 100 .................148 Oxaliplatin Actavis 50 ...................148 Oxaliplatin Ebewe .........................148 Oxazepam ....................................138 Oxis Turbuhaler ............................170 Oxybutynin ......................................75 Oxycodone hydrochloride .............123 OxyContin .....................................123 OxyNorm ......................................123 Oxypentifylline ................................56 Oxytocin ..........................................74 Ozole ..............................................88 -PPacifen ..........................................118 Paciﬁc Buspirone ..........................137 Paclitaxel ......................................155 Paclitaxel Actavis ..........................155 Paclitaxel Ebewe ..........................155 Paediatric Seravit ...........................37 Pamidronate disodium ..................115 Pamisol .........................................115 Panadol ........................................121 Pancreatic enzyme .........................33 Pantocid IV .....................................29 Pantoprazole ...................................29 Panzytrat ........................................33 Papaverine hydrochloride ...............56 Paracare .......................................121 Paracare Double Strength ............121 Paracetamol .................................121 Paracetamol + Codeine (Relieve) .................................. 123 Paracetamol with codeine ............123 Parafast ........................................121 Parafﬁn ...........................................64 Parafﬁn liquid with soft white parafﬁn ..................................... 179 Parafﬁn liquid with wool fat liquid ........................................ 179 Paraldehyde ..................................126 Paramax .......................................130 Parasiticidal Preparations ...............64 Parnate .........................................124 Paroxetine hydrochloride ..............125 Paxam ..........................................127 Pazopanib .....................................160 Peak ﬂow meter ............................174 Pedialyte - Bubblegum ....................44 Pedialyte - Fruit ...............................44 Pedialyte - Plain ..............................44 Pediasure .....................................195 Pediasure RTH .............................195 Pegasys ..........................................98 Pegasys RBV Combination Pack ........................................... 98 Pegylated interferon alpha-2a .........98 Penicillamine ................................103 PenMix 30 .......................................30 PenMix 40 .......................................30 PenMix 50 .......................................30 Pentasa ..........................................27 Pentostatin [Deoxycoformycin] ................... 155 Pepti Junior Gold ..........................207 Peptisoothe .....................................29 Peptisorb ......................................196 Pergolide ......................................119 Perhexiline maleate ........................54 Pericyazine ...................................134 Perindopril ......................................49 Permax .........................................119 Permethrin ......................................66 Persantin ........................................41 Pethidine hydrochloride ................123 Pevaryl ............................................60 Pexsig .............................................54 Pharmacy Services ......................180 Phenelzine sulphate .....................124 Phenobarbitone ............................129 Phenobarbitone sodium ................187 Phenoxybenzamine hydrochloride ............................. 48 Phenoxymethylpenicillin (Penicillin V) ............................... 86 Phentolamine mesylate ..................48 Phenylephrine hydrochloride ........................... 179 Phenytoin sodium .................126, 129 Phlexy 10 ......................................205 Phosphate-Sandoz .........................44 Phytomenadione .............................41 Pilocarpine ....................................178 Pimafucort ......................................62 Pindolol ...........................................52 Pinetarsol ........................................67 Pinorax ...........................................35 Pinorax Forte ..................................35 Pioglitazone ....................................31 Piportil ..........................................136 Pipothiazine palmitate ..................136 Pizaccord ........................................31 Pizotifen ........................................130 PKU Anamix Infant .......................205 PKU Anamix Junior LQ .................205 PKU Lophlex LQ 10 ......................205 PKU Lophlex LQ 20 ......................205 Plaquenil .........................................89 Plendil ER .......................................53 Pneumococcal (PCV13) vaccine .................................... 101 Pneumococcal polysaccharide vaccine .................................... 101 Pneumococcal vaccine .................101 Pneumovax 23 ..............................101 Podophyllotoxin ..............................68 Polaramine ....................................168 Poliomyelitis vaccine .....................101 Poloxamer .......................................34 Poly-Tears .....................................179 Poly-Visc .......................................179 Polycal ..........................................190 Polyvinyl alcohol ...........................179 Ponstan ........................................102 Postinor-1 .......................................73 Potassium bicarbonate ...................44

229

INDEX Generic Chemicals and Brands

Potassium chloride ...................43–44 Potassium citrate ............................75 Potassium iodate ............................38 Povidone iodine ..............................64 Pradaxa ..........................................43 Pramipexole hydrochloride ...........119 Prasugrel ........................................41 Pravastatin ......................................46 Prazosin hydrochloride ...................48 Pred Forte ....................................177 Pred Mild ......................................177 Prednisolone acetate ....................177 Prednisolone sodium phosphate .................................. 77 Prednisone .....................................77 Prefrin ...........................................179 Pregnancy Tests - hCG Urine .........74 Premarin .........................................79 Premia 2.5 Continuous ...................79 Premia 5 Continuous ......................79 Prevenar 13 ..................................101 Prezista ...........................................96 Priadel ..........................................133 Primidone .....................................129 Primolut N .......................................80 Probenecid ...................................118 Probenecid-AFT ...........................118 Procaine penicillin ...........................86 Procarbazine hydrochloride ..........155 Prochlorperazine ..........................132 Proctosedyl .....................................28 Procyclidine hydrochloride ............120 Prodopa ..........................................54 Prograf ..........................................167 Progynova ......................................78 Promethazine hydrochloride .........169 Promethazine theoclate ................132 Promethazine Winthrop Elixir ......................................... 169 Promod .........................................192 Propafenone hydrochloride ............51 Propamidine isethionate ...............176 Propranolol .....................................53 Propylene glycol ...........................187 Propylthiouracil ...............................80 Protamine sulphate .........................42 Protaphane .....................................30 Protaphane Penﬁll ..........................30 Protifar ..........................................192 Provera .....................................79, 80 PSO ......................................209–212 Psoriasis and Eczema Preparations .............................. 66 PTU ................................................80 Pulmicort Turbuhaler ....................169 Pulmocare ....................................192 Pulmozyme ...................................173 Purinethol .....................................151 Pyrazinamide ..................................89 Pyridostigmine bromide ................102 PyridoxADE ....................................37 Pyridoxine hydrochloride ................37 Pytazen SR .....................................41 -QQ 300 ............................................118 Questran-Lite ..................................45 Quetapel .......................................134 Quetiapine ....................................134 Quinapril .........................................49 Quinapril with hydrochlorothiazide ................... 49 Quinine sulphate ...........................118 -RRA-Morph .....................................122 Raloxifene hydrochloride ..............115 Raltegravir potassium .....................96 Ranbaxy-Cefaclor ...........................83 Ranitidine hydrochloride .................29 Rapamune ....................................167 Redipred .........................................77 Regitine ..........................................48 Renilon 7.5 ...................................195 Resonium-A ....................................45 Resource Beneprotein ..................192 Resource Diabetic ........................193 Respigen ......................................171 Respiratory Devices .....................174 Respiratory Stimulants .................175 ReTrieve .........................................58 Retrovir ...........................................95 Rex Medical ....................................74 Rexacrom .....................................177 Reyataz ..........................................96 Ridal .............................................134 Ridaura .........................................103 Ridaura s29 ..................................103 Rifabutin .........................................89 Rifadin ............................................89 Rifampicin .......................................89 Riﬁnah ............................................89 Riodine ...........................................64 Risperdal ......................................134 Risperdal Consta ..........................136 Risperdal Quicklet ........................136 Risperidone ..........................134, 136 Risperon .......................................134 Ritalin ............................................142 Ritalin LA ......................................142 Ritalin SR ......................................142 Ritonavir .........................................96 Rituximab ......................................164 Rivacol ............................................36 Rivaroxaban ....................................43 Rivotril ...................................126, 127 Rizamelt ........................................130 Rizatriptan ....................................130 Rocaltrol solution ............................37 Roferon-A .......................................97 Ropin ............................................119 Ropinirole hydrochloride ...............119 Roxithromycin .................................85 Rubifen .........................................142 Rubifen SR ...................................142 Rythmodan .....................................51 Rytmonorm .....................................51 -SS-26 Gold Premgro .......................205 S26LBW Gold RTF .......................205 Sabril ............................................129 Salamol .........................................171 Salapin ..........................................171 Salazopyrin .....................................27 Salazopyrin EN ...............................27 Salbutamol ....................................171 Salbutamol with ipratropium bromide .................................... 172 Salicylic acid ...................................67 Salmeterol ....................................170 Sandomigran ................................130 Sandostatin LAR ...........................162 SC Proﬁ-Fine ..................................32 Scalp Preparations .........................67 Scopoderm TTS ...........................131 Sebizole ..........................................67 Sedatives and Hypnotics ..............140 Selegiline hydrochloride ...............119 Senna .............................................35 Senokot ..........................................35 SensoCard ......................................32 Serenace ......................................133 Seretide ........................................170 Seretide Accuhaler .......................170 Serevent .......................................170 Serevent Accuhaler ......................170 Serophene ......................................82 Seroquel .......................................134 Sertraline ......................................125 Sevredol .......................................122

230

INDEX Generic Chemicals and Brands

Sex Hormones Non Contraceptive ............................ 77 Shield 49 .........................................70 Shield Blue .....................................70 Shield XL ........................................70 Sildenaﬁl .........................................57 Silver sulphadiazine ........................59 Simethicone ....................................26 Simvastatin .....................................46 Sindopa ........................................119 Sinemet ........................................119 Sinemet CR ..................................119 Singulair ........................................172 Sirolimus .......................................167 Siterone ..........................................77 Slow-Lopresor ................................52 Sodibic ............................................44 Sodium acid phosphate ..................35 Sodium alginate ..............................26 Sodium aurothiomalate .................103 Sodium bicarbonate Blood ....................................43–44 Extemporaneous ......................187 Sodium calcium edetate .................39 Sodium carboxymethylcellulose .............. 36 Sodium chloride Blood ..........................................44 Respiratory ...............................173 Sodium citrate with sodium lauryl sulphoacetate ............................ 35 Sodium citro-tartrate .......................75 Sodium cromoglycate Alimentary ..................................27 Respiratory .......................173–174 Sensory ....................................177 Sodium ﬂuoride ..............................38 Sodium nitroprusside ......................31 Sodium polystyrene sulphonate ................................. 45 Sodium tetradecyl sulphate ............41 Sodium valproate ..........................129 Sofradex .......................................176 Soframycin ....................................176 Solian ............................................132 Solifenacin succinate ......................75 Solox ...............................................29 Solu-Cortef .....................................76 Solu-Medrol ....................................77 Somatropin .....................................81 Sotacor ...........................................53 Sotalol .............................................53 Space Chamber ............................174 Space Chamber Plus ....................174 Spacer device ...............................174 Spacer device autoclavable ..........174 Span-K ............................................44 Spiriva ...........................................171 Spironolactone ................................55 Spirotone ........................................55 Sprycel .........................................157 Staphlex ..........................................86 Stavudine [d4T] ..............................95 Stelazine .......................................135 Stemetil .........................................132 Stesolid .........................................126 Stimulants/ADHD Treatments ............................... 140 Stocrin ............................................95 Stomahesive ...................................36 Strattera ........................................140 Stromectol ......................................64 Suboxone .....................................144 Sucralfate .......................................29 Sulindac ........................................103 Sulphasalazine ...............................27 Sulphur ...........................................67 Sumatriptan ..................................130 Sunitinib ........................................160 Sunscreens .....................................68 Sunscreens, proprietary .................68 Suplena ........................................196 Surgam .........................................103 Sustagen Hospital Formula ..........200 Sustanon Ampoules .......................77 Sutent ...........................................160 Symbicort Turbuhaler 100/6 .........170 Symbicort Turbuhaler 200/6 .........170 Symbicort Turbuhaler 400/12 ..................................... 170 Symmetrel ....................................119 Sympathomimetics .........................56 Synacthen .......................................77 Synacthen Depot ............................77 Synermox .......................................86 Synﬂorix ........................................101 Synthroid ........................................80 Syntocinon ......................................74 Syntometrine ..................................74 Syrup (pharmaceutical grade) ...................................... 187 -TTacrolimus ....................................167 Tambocor ........................................51 Tambocor CR ..................................51 Tamoxifen citrate ...........................163 Tamsulosin hydrochloride ...............74 Tamsulosin-Rex ..............................74 Tap water ......................................187 Tar with triethanolamine lauryl sulphate and ﬂuorescein ............ 67 Tarceva .........................................158 Tasmar ..........................................119 Taxotere ........................................153 Tegretol .........................................127 Tegretol CR ...................................127 Telfast ...........................................168 Temaccord ....................................155 Temazepam ..................................140 Temozolomide ..............................155 Tenofovir disoproxil fumarate ..........92 Tenoxicam ....................................103 Terazosin hydrochloride ..................48 Terbinaﬁne ......................................89 Terbutaline sulphate .....................171 Teriparatide ...................................115 Testosterone ...................................77 Testosterone cypionate ...................77 Testosterone esters ........................77 Testosterone undecanoate .............77 Tetrabenazine ...............................120 Tetrabromophenol ...........................75 Tetracosactrin .................................77 Teva ..............................................152 Thalidomide ..................................155 Thalomid .......................................155 Theophylline .................................173 Thiamine hydrochloride ..................37 THIO-TEPA ...................................148 Thioguanine ..................................152 Thiotepa ........................................148 Thymol glycerin ..............................36 Thyroid and Antithyroid Agents ....................................... 80 Tiaprofenic acid ............................103 Tilade ............................................173 Tilcotil ...........................................103 Timolol maleate Cardiovascular ...........................53 Sensory ....................................177 Timoptol XE ..................................177 Tiotropium bromide .......................171 Titralac ............................................26 TMP ................................................88 Tobramycin Infection ......................................88 Sensory ....................................177 Tobrex ...........................................177 Tofranil ..........................................124

231

INDEX Generic Chemicals and Brands

Tolcapone .....................................119 Tolvon ...........................................124 Topamax .......................................129 Topiramate ....................................129 Total parenteral nutrition (TPN) ......................................... 44 TPN ................................................44 Tracleer ...........................................56 Tramadol hydrochloride ................121 Trandate ..........................................52 Trandolapril .....................................49 Tranexamic acid ..............................41 Tranylcypromine sulphate .............124 Trastuzumab .................................166 Travatan ........................................178 Travoprost .....................................178 Treatments for Dementia ..............143 Treatments for Opioid Overdose ................................. 144 Treatments for Substance Dependence ............................ 144 Trental 400 ......................................56 Tretinoin Dermatological ...........................58 Oncology ..................................156 Triamcinolone acetonide Alimentary ..................................36 Dermatological ...........................62 Hormone ....................................77 Triamcinolone acetonide with gramicidin, neomycin and nystatin Dermatological ...........................62 Sensory ....................................176 Triazolam ......................................140 Trichozole .......................................89 Triclosan .........................................63 Triﬂuoperazine hydrochloride ........................... 135 Trimeprazine tartrate ....................169 Trimethoprim ...................................88 Trisequens ......................................79 Trisul ...............................................87 Trophic Hormones ..........................81 Tropicamide ..................................178 Tropisetron ....................................132 Trusopt ..........................................178 Two Cal HN ...................................202 Tykerb ...........................................159 Tyloxapol .......................................179 -UUltraproct ........................................28 Univent .................................171, 174 Ural .................................................75 Urea ................................................63 Urex Forte .......................................55 Urinary Agents ................................74 Urinary Tract Infections ...................99 Uromitexan ...................................154 Ursodeoxycholic acid ......................33 Ursosan ..........................................33 -VVaccinations ...................................99 Valaciclovir ......................................92 Vallergan Forte .............................169 Valtrex .............................................92 Vancomycin hydrochloride ..............88 Vannair .........................................170 Varenicline tartrate .......................145 Various .........................................180 Vasodilators ....................................56 Vasopressin Agonists .....................81 Velcade .........................................152 Venlafaxine ...................................126 Ventavis ..........................................57 Ventolin .........................................171 Vepesid .........................................154 Veracol ............................................83 Verapamil hydrochloride .................54 Vergo 16 .......................................131 Vermox ...........................................83 Verpamil SR ...................................54 Vesanoid .......................................156 Vesicare ..........................................75 Viaderm KC ....................................62 Viagra .............................................57 Videx EC .........................................95 Vigabatrin .....................................129 Vimpat ..........................................128 Vinblastine sulphate .....................156 Vincristine sulphate ......................156 Vinorelbine ....................................156 Vinorelbine Ebewe ........................156 Viramune ........................................95 Viramune Suspension ....................95 Viread .............................................92 Vistil ..............................................179 Vistil Forte ....................................179 Vitabdeck ........................................38 Vitadol C .........................................37 Vital HN ........................................196 Vitala-C ...........................................37 Vitamin A with vitamins D and C ................................................ 37 Vitamin B complex ..........................37 Vitamins ....................................37–38 Vivonex Pediatric ..........................206 Vivonex TEN .................................196 Volibris ............................................56 Voltaren ........................................102 Voltaren D .....................................102 Voltaren Ophtha ............................177 Volumatic ......................................174 Vosol .............................................176 Votrient .........................................160 Vytorin ............................................46 -WWarfarin sodium ..............................43 Wart Preparations ...........................68 Wasp venom allergy treatment ................................. 168 Water Blood ..........................................44 Extemporaneous ......................187 Wool fat with mineral oil ..................63 -XXarelto ............................................43 Xeloda ..........................................148 XMET Maxamum ..........................204 XP Maxamaid ...............................205 XP Maxamum ...............................205 Xylocaine ......................................120 Xylocaine Viscous ........................120 -ZZantac .............................................29 Zapril ..............................................48 Zarator ............................................45 Zarontin ........................................127 Zavedos ........................................154 Zefﬁx ...............................................91 Zeldox ...........................................135 Zerit ................................................95 Zetop ............................................168 Ziagen .............................................95 Zidovudine [AZT] ............................95 Zidovudine [AZT] with lamivudine ................................. 96 Zinacef ............................................83 Zinc and castor oil ..........................63 Zinc sulphate ..................................39 Zincaps ...........................................39 Zinnat ..............................................83 Ziprasidone ...................................135 Zithromax ........................................84 Zoladex ...........................................81 Zoledronic acid .............................116 Zopiclone ......................................140 Zostrix HP .......................................69 Zovirax ..........................................176

232

INDEX Generic Chemicals and Brands

Zuclopenthixol decanoate .............136 Zuclopenthixol hydrochloride ........................... 135 Zyban ............................................145 Zyprexa .........................................133 Zyprexa Relprevv ..........................135 Zyprexa Zydis ...............................136

233

Only

annually for hard copy Schedule and Updates

$55

www. schedule. co.nz

today

to receive electronic and/or hard copy

Pharmaceutical Management Agency Level 9, 40 Mercer Street, PO Box 10-254, Wellington 6143, New Zealand Phone: 64 4 460 4990 - Fax: 64 4 460 4995 - www.pharmac.govt.nz Freephone Information line (9am-5pm weekdays) 0800 66 00 50 ISSN 1172-9376 (Print) ISSN 1179-3686 (Online)

PHARMAC is the Government agency responsible for deciding which medicines are subsidised for New Zealanders. It manages spending on pharmaceuticals for the District Health Boards, and ensures that a comprehensive list of medicines (the Pharmaceutical Schedule) is subsidised for New Zealanders, and that the list of medicines continues to grow to meet the needs of patients.

Metadata

Title

Pharmaceutical Schedule - effective 1 August 2012

Abstract

Pharmaceutical Management Agency Update New Zealand Pharmaceutical Schedule Effective 1 August 2012 Cumulative for May, June, July and August 2012 Section H for August 2012 Only annually for hard copy Schedule and Updates $55 www. schedule. co.nz today Register to…

Page 1

Note

This text has been extracted from the source PDF document.

Also available as plain text.

Please contact webmaster to discuss alternative format options.